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Glucocorticoids are one of the most frequently prescribed families of drugs. In addition to their 
anti-inflammatory efficacy, their use is complicated by many side effects, including sleep 
disturbance and memory impairment for which the underlying mechanism is unknown. In this 
thesis, I show that the therapeutic glucocorticoid methylprednisolone (MPL) disrupts the 
circadian regulation of the core clock genes Period1, Period2 and Bmal1 in the master clock, 
the suprachiasmatic nucleus (SCN). I also found that the Type II corticosteroid receptor mRNA 
is expressed in the SCN. RNAseq of whole hippocampi revealed a significant dysregulation of 
clock genes in the MPL treated rats. I demonstrate that locomotor activity is altered in the 
presence of MPL and that sleep architecture during the 6h memory consolidation period of a 
novel object location task is altered, leading to memory impairment. I therefore conclude that 
MPL acts directly on the SCN to dysregulate the central clock, leading to disrupted peripheral 
clocks and circadian rhythms, resulting in altered sleep and impaired hippocampal-dependent 
memory. These data reveal a novel role for glucocorticoids in the regulation of the master clock 
in the SCN and provides a potential mechanism to understand glucocorticoid related sleep 
disturbances and memory impairment in patients treated chronically with long acting synthetic 
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1.1 Circadian rhythms  
 
The daily rotation of the earth, as well as its annual revolution around the sun provides 
daily and seasonal changes to the photoperiod, with significant changes in light intensity, 
temperature and the availability of food observed across this period. Most organisms, 
certainly mammalian, have evolved to contain an innate clock that drives behaviour to the 
circadian (latin circa = around, dia = day) period, enabling the anticipation to, and 
accommodation of the fluctuating environment. Hormone secretion, body temperature, 
behavioural activity and sleep have all been shown to have clear circadian rhythm 
(Weitzman 1976; Refinetti & Menaker 1992). Breeding animals, and for example sheep, 
exhibit differences in their behaviour, reproductive physiology, and metabolism, across 
seasons (Arens et al. 2007; Baldock et al. 1988).  Rodents show altered patterns of 
behavioural activity when exposed to changing day lengths and light patterns (Edmonds & 
Adler 1977).  Daily fluctuations have influence on almost all aspects of physiology and 
behaviour, as the rest-wake cycle i.e. behavioural activity, cardiovascular activity and 
metabolism all exhibit circadian rhythmicity (Huikuri et al. 1992; Huang et al. 2011). The 
hippocampus, a brain region important for the consolidation of memory and processing of 
sleep, changes volume with circadian and seasonal timing (Miller et al. 2015), as does the 
size and shape of the pupil of the eye (Loving et al. 1996). These systems are driven by the 
molecular clock, through changes in light intensity, hormone levels, and metabolic 
processes to name a few.       
 
1.1.2. Organisation of the suprachiasmatic nucleus 
 
The suprachiasmatic nucleus (SCN) of the hypothalamus is the master regulator of the 
mammalian circadian clock. Circadian rhythmicity of the SCN persists not only within the 
animal, but also in vitro in both hypothalamic slice and cell culture preparation (Inouye & 
Kawamura 1982; Yamaguchi et al. 2003). In the hypothalamic slice, SCN neurons fire at 
rates of approximately 24 hours, with peak firing occurring during the animal’s subjective 
activity period (Welsh et al. 1995). In cell culture, vasopressin (AVP) and vasoactive 
intestinal peptide (VIP) are secreted in a circadian oscillation, although this period ranged 




Lesions of the SCN abolish circadian rhythmicity of locomotor activity, neuroendocrine 
secretion and core body temperature. However, locomotor activity and body temperature 
rhythms were restored when SCN transplants were placed into the third ventricle (Silver et 
al. 1996). The period of the restored rhythm was set to the timing of the transplanted SCN, 
demonstrating that its periodicity is an intrinsic phenomenon that is not, in part, driven by 
inputs from other brain areas or external cues. 
 
The SCN has been described in many mammalian species, including the rat, human and 
guinea pig. In the rat, the SCN is the cluster of densely packed neurons in both cerebral 
hemispheres separated by the periventricular stratum and third ventricle, located in the 
rostral, ventral hypothalamus, which is bordered by the optic chiasm and supraoptic 




The retina, midbrain raphe (MR) and intergeniculate leaf (IGL) drive the regulation of the 
core clock within the SCN via dense projections, predominantly to the core (Levine et al. 
1986; Dudley et al. 1999; Moore et al. 2002). The retinal input to the SCN has been 
extensively studied. Varying light cycles, light intensity and applying different 
wavelengths of the light spectrum have shown that the SCN is regulated by the light-dark 
cycle (Rea et al. 1993; Meijer & De Vries 1995). The SCN’s response to light is further 
modulated by serotonergic input, with neurons of the midbrain raphe projecting to and 
innervating the core and shell of the SCN, although dominance of the core is observed (Rea 
et al. 1994; Moga & Moore 1997; Meyer-Bernstein & Morin 1996). Intrinsically 
photosensitive retinal ganglion cells (ipRGCs) transmit directly to the SCN via the 
retinohypothalamic tract (RHT) (Berson et al. 2002). The RHT, conveys direct input from 
melanopsin containing ipRGCs in the eye to the SCN, with the projections terminating 
predominantly at neurons in the SCN core, however some connections directly activate 
neurons of the shell (Hattar et al. 2002; Baver et al. 2008). Non-photic entrainment of the 
circadian rhythm is mediated by the IGL, which although is an area that receives input from 
the retina, targets the SCN via the geniculohypothalamic tract (GHT) (Harrington 1997). 
The RHT is crucial to driving circadian rhythms via light/dark signals and although the role 
of the IGL-GHT pathway in light/dark signal entrainment is not fully understood, rats with 
lesions of the IGL entrain normally to the light-dark cycle, but when in the presence of a 
 4 
skeleton photoperiod (SPP), they exhibit free running rhythms, indicating that the IGL is 
important for entraining circadian rhythms (Edelstein & Amir 1999). 
 
Axonal projections from the pretectum group along the lateral border of the SCN, 
terminating in both the core and shell, and can therefore innervate the whole SCN 
(Mikkelsen & Vrang 1994). The infralimbic cortex projects only to the SCN shell (Hurley 
et al. 1991), whereas afferent cell populations, including the PVN and subparaventricular 
zone (sPVZ) innervate the entire SCN (Watts & Swanson 1987; Moga et al. 1995).  
 
Serotonin-containing fibres located predominantly within the core of the SCN receive 
dense serotonergic innervation. The median raphe nuclei are most likely responsible for 
this innervation as in a previous study, the SCN lacked axonal labelling after a biotinylated 
dextran (BDX) injection placed centrally in the dorsal raphe nucleus (Moga & Saper 1994). 
Serotonin significantly decreases in the SCN following midbrain median raphe lesions, 
however not after lesioning the dorsal raphe nucleus. The dorsal raphe nucleus innervates 
the SCN, although the median raphe is dominant (van de Kar & Lorens 1979). 
 
The SCN is further innervated from retinorecipient areas including the IGL and pretectum 
(Mikkelsen 1990). The projection from the IGL terminates in the lateral core of the SCN, 
where neuropeptide Y-immunoreactivity (NPY) was reported (Card & Moore 1988).  NPY-
immunoreactive neurons of the IGL project directly to the SCN (Harrington et al. 1987). 
Free running animals infused with NPY into the SCN present with a phase shift in the 
circadian rhythmicity of locomotor activity (Albers & Ferris 1984).  
 
This result was similar to that of phase shifts from non-photic stimuli that induce locomotor 
activity, further evidencing that the GHT mediates non-photic entrainment of the SCN 
(Reeth & Turek 1989).  
 
Dense projections from the paraventricular thalamus (PVT) are sent to the SCN, innovating 
both the core and shell (Moga & Moore 1997). However, lesions of the PVT do not alter 
the free-running circadian behaviour of locomotor activity, suggesting it is not crucial for 
circadian rhythm generation (Ebling et al. 1992).  
 
 5 
The hypothalamic input to the SCN arises from many nuclei. Hypothalamic cell groups 
project largely to the SCN shell, and therefore avoid the VIP/GRP-expressing cell 
population in the SCN core (Moga & Moore 1997). Tracer studies indicated that axonal 
labelling to the SCN shell was sparse, signifying that the hypothalamic inputs to the SCN 
are possibly of little importance to circadian function. However, with such a vast number 
of inputs terminating in the shell from these areas, indicates that the hypothalamus must 
play a crucial role in the regulation of the SCN (Van den Pol 1980).  
 
Preoptic projections to the SCN originate from within the medial preoptic area (MPOA), 
(median and medial preoptic nuclei) and the anteroventral periventricular nucleus (Moga 
& Moore 1997). Gonadotropin-releasing hormone (GnRH)-immunoreactive fibres in the 
SCN overlap with the preoptic terminal field, providing a role for GnRH as a 
neuromodulator of the preoptic projection to the SCN (van der Beek et al. 1997). This is 
supported as the lamina terminalis and medial preoptic area, both of which project directly 
to the SCN, contain GnRH-immunoreactive cells (Kawano & Daikoku 1981; van der Beek 
1996). The ventral medial hypothalamus (VMH), which controls feeding and 
thermoregulation, preferentially targets the SCN shell (Bernardis 1973), similarly to the 
majority of other hypothalamic afferents, however these projections are relatively minor 
whereas the SCN sends a reciprocal projection to the VMH, driving the circadian 
rhythmicity of body temperature (Krieger 1980). The dorsomedial hypothalamus (DMH), 
which is involved in feeding and body weight regulation projects densely to the SCN 
region, yet only a minor input was shown to the SCN shell (Thompson et al. 1996).  
 
Whereas most hypothalamic nuclei project to the SCN shell, the sPVZ and 
tuberomammillary nucleus (TMN) both innervate the core and shell of the SCN (Watts & 
Swanson 1987; Moga & Moore 1997). The sPVZ can be further subdivided into the dorsal 
and ventral subdivisions and relays signals to the SCN to drive body temperature and 
locomotor activity and sleep regulation, respectively, whereas the TMN controls arousal, 
memory and sleep (Blandina et al. 2012). The TMN is the neuronal source of histamine in 
the mammalian brain and histaminergic terminals are evident in the SCN and appear evenly 
distributed across the core and shell (Inagaki et al. 1988; Panula et al. 1989). The 
histaminergic input may be involved in circadian timing and rhythms. Free-running rats 
exhibit a pronounced phase delay in locomotor activity and drinking behaviour following 
histamine administration at the onset of the active period (Itowi et al. 1990). Interestingly, 
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histamine administration didn’t cause a phase advance in these animals if given during the 
late subjective night. 
 
1.1.2.2 Cell types and neurotransmission 
 
The rat SCN can be divided into two major subdivisions, the ventral ‘core’ and dorsal 
‘shell’, characterised based on cytoarchitecture and neuropeptide immunoreactivity (Antle 
& Silver 2005; Gamble et al. 2007; Ibata et al. 1989; Kiss et al. 2008). The core expresses 
vasoactive intestinal peptide (VIP) and gastrin-releasing peptide (GRP) immunoreactive 
cells (Abrahamson & Moore 2001; Antle & Silver 2005), whereas the shell expresses 
vasopressin (AVP) immunoreactive cells (Moore et al. 2002). VIP-expressing neurons 
release VIP and GABA in the SCN to critically regulate the circadian cycle and the 
synchrony of other SCN neurons and their synapses, controlling the firing rate of target 
neurons (Castel & Morris 2000).  
 
VIP expression has been assessed in different areas, and a clear circadian rhythm of 
expression is evident in the cerebral spinal fluid (CSF), characterising it as a humoral output 
of the SCN (Kruisbrink et al. 1987). However, it was confirmed to act as a humoral factor 
as infusion of VIP into the ventricular system didn’t alter daily sleep/wake cycles 
(Kruisbrink et al. 1987). It is however the only SCN output shown to be secreted this way 
in vivo, primarily as a result of the circadian firing rate of VIP-expressing neurons of the 
SCN core. Further evidence indicating the importance of the humoral output of the SCN 
was shown when Silver et al. 1996, transplanted a SCN with a semi-permeable membrane 
into the third ventricle of SCN lesioned rats, restoring circadian rhythm to locomotor 
activity, implying that diffusible factors emanate from the SCN to control peripheral clock 
driven systems as well as via neural connectivity. Other factors, including prokineticin-2 
(PK2) (Zhou & Cheng 2005) and transforming growth factor-alpha (TGF) (Kramer et al. 
2005) have been identified as humoral outputs of the SCN that inhibit locomotor activity, 
however there are currently no SCN factors shown to promote arousal or feeding activity, 
as instead the SCN appears to drive other nuclei to induce these behaviours.   
 
AVP-expressing neurons, confined mainly in the shell of the SCN, are critical for 
interneuronal coupling between the core and shell to regulate circadian behavioural 
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rhythms (Mieda et al. 2015). A targeted Bmal1 deletion of AVP-expressing neurons 
showed a marked increase in the free-running period as well as a significant increase in the 
total activity period. When these mice were subjected to a jet-lag paradigm, exposing them 
to an abrupt 8-hour phase advance, the Bmal1(-/-) mice reentrained to the light cycle faster 
than their controls, indicating that Bmal1-dependent oscillations in AVP-expressing 
neurons are vital to modulate the coupling of the SCN network. A functional lesion of AVP 
in the SCN using a cytotoxic antibody altered AVP expression in the parvocellular region 
of the PVN, a major site of SCN hypothalamic efference, which lead to the conclusion that 
the SCN and AVP were able to disrupt corticosterone release (Gomez et al. 1997). 
 
GRP-expressing neurons, located predominantly in the core of the SCN with VIP-
expressing neurons, are able to phase reset SCN neurons via spike-dependent and 
independent mechanisms, however Per1 localisation was key to mediating these 
downstream events in the neurons of the SCN (Gamble et al. 2007). Treatment with GRP 
to rat and hamster SCN slices during the subjective day did not alter the peak time of SCN 
firing, however when GRP was applied to these cultures during the subjective night, it 
phase delayed the SCN firing peak, with this result being completely blocked using the 
GRP specific receptor antagonist (Mcarthur et al. 2000), indicating the importance of GRP 
in a time of day specific manner.   
 
The SCN transplantation work of Silver et al. 1996 demonstrated that as well as humoral 
activation of circadian driven systems, intact neural projections from the SCN are required 
for full circadian control of biological systems, as although this study reinstated locomotor 
activity circadian rhythm, it did not reinstate neuroendocrine rhythms, such as the circadian 
release of corticosterone, with this system requiring the activation of VIP-projecting 
neurons to the paraventricular nucleus, enabling the release of corticotropin-releasing 
hormone (CRH) to be secreted, activating the hypothalamic-pituitary-adrenal axis (HPA) 
(Waite et al. 2012).   
 
1.1.2.3 Circuitry and projections 
 
Projections from the SCN show that the outflow control is predominantly limited to the 
medial hypothalamus (Berk & Finkelstein 1981) as most SCN projections target areas 
containing interneurons, such as the medial preoptic area (MPOA), the dorsomedial 
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hypothalamus (DMH), and the paraventricular nucleus (PVN) (Saper et al. 2005; Watts & 
Swanson 1987). Direct connections have also been observed in neurons containing 
corticotropin-releasing hormone (CRH), thyrotropin-releasing hormone (TRH), thyroid 
hormones (TH) and GnRH neurons (Kalsbeek & Buijs 2002; de la Iglesia et al. 2003).  
 
The first description of circadian timing involved in SCN and neuroendocrine control, 
showed that VIP-expressing neurons of the SCN project to the PVN/DMH area, controlling 
the secretion of corticosterone from the adrenal cortex, in the later well-described 
hypothalamus-pituitary-adrenal (HPA) axis (Lightman & Conway-Campbell 2010). This 
daily rhythm of corticosterone release is controlled by at least two SCN transmitters, as 
VIP released in the DMH is able to inhibit the activity of the HPA axis at the beginning of 
the inactive period (Smith & Vale 2006). However, VIP and GRP also stimulate 
adrenocorticotropin hormone (ACTH) and corticosterone release prior to the onset of the 
active period (Oliva et al. 1982; Olsen et al. 1992). The circadian release of corticosterone 
is also regulated by the polysynaptic projection from the SCN to the adrenal gland, via 
preautonomic neurons in the PVN and spinal cord that act on the splanchnic nerve, allowing 
the SCN to directly influence the sensitivity of the adrenal cortex to ACTH (Ulrich-Lai et 
al. 2006).    
 
The SCN relies on hormones binding to their specific receptors and for neurons to deliver 
their message to drive rhythmicity on targeted tissues (Reul & Kloet 1985). The circadian 
secretion of corticosterone provides evidence for this, as the SCN utilises hormones and 
neurons to precisely drive the secretion of CORT via direct input to neuroendocrine 
neurons to control the release of ACTH from the anterior pituitary, as well as maintaining 
the control of adrenal sensitivity for ACTH via the autonomic nervous system (Herman & 
Cullinan 1997). This is not limited to the HPA axis, as the SCN also increases the sensitivity 
of insulin prior to wakening, causing an increase in glucose intake in muscle, whilst also 
increasing glucose production in the liver to ensure sufficient glucose availability for the 
active period ahead (Coomans et al. 2013).  
 
The neuroendocrine rhythms driven by the SCN, are further connected to the circadian 
release of melatonin from the pineal gland via sympathetic innervation (Moore 1995). The 
pineal gland sends multisynaptic projections to the SCN and PVN. Projections were also 
observed in preganglionic sympathetic neurons of the spinal cord, as well as noradrenalin-
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containing neurons of the superior cervical ganglion (Moore & Klein 1974). The release of 
melatonin from the pineal gland can be altered by manipulating the GABAergic 
transmission in the PVN, and GABAergic neurons in the SCN mediate direct inhibitory 
effects of light on melatonin release (Kalsbeek et al. 1999). SCN lesions significantly blunt 
the circadian rhythmicity of melatonin secretion in the pineal gland (Perreau-Lenz et al. 
2003).    
 
The daily rhythms of body temperature and cardiovascular activity are under the control of 
the autonomic nervous system located in the brain stem, however they are under the 
circadian control of the SCN (Honma et al. 1988; Schroeder et al. 2011). A balance of 
GABA and glutamate in the PVN, DMH and the MPOA are necessary for cardiovascular 
and body temperature to function in circadian cycling (De Novellis et al. 1995; Chen et al. 
2003). The GABA/glutamate balance is important for regulating the sleep/wake regulatory 
system (Sherin et al. 1996), driven primarily by the VLPO.  
 
1.1.3 Molecular mechanism 
 
Whole transcriptomic sequencing has showed that the circadian clock drives rhythmic 
expression of almost half of the protein coding transcriptome (43%) (Zhang et al. 2014). 
The molecular clock has been extensively studied, with the 2017 Nobel Prize for 
Physiology or Medicine going to Michael W. Young, Michael Rosbash and Jeffrey C. Hall 
for their early studies on the molecular clock (Hall 1983; Young et al. 1985; Rosbash & 
Hall 1985) and its importance in Drosophila and has now been studied further in other 
animals. Further characterisation of the molecular clock has been carried out since its 
discovery, with a striking result indicating that it remains robust and consistent across 
different cell types and importantly, across different species (Ko & Takahashi 2006). 
 
A set of core clock genes generate circadian gene expression. In mammalian physiology, 
these core genes interact in two major transcriptional feedback loops (Reppert & Weaver 
2002; Witkovsky et al. 2003; Kriegsfeld et al. 2003; Goto & Denlinger 2002; Kume et al. 
1999; Gekakis et al. 1998; Rudic et al. 2004; Cho et al. 2012; Sato et al. 2004; Etchegaray 
et al. 2009; DeBruyne et al. 2006).  
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The primary transcriptional feedback loop (Figure 1.1) includes two master heterodimer 
transcription factors, Circadian Locomotor Output Cycles Kaput (CLOCK) and Brain and 
Muscle ARNT-Like 1 (BMAL1). This basic helix-loop-helix Per-Arnt-Single-minded 
(bHLH-PAS) transcription factor rhythmically activates the expression of its 
transcriptional repressors PERIOD (Per1, Per2 and Per3) and CRYPTOCHROME (Cry1 
and Cry2) by binding at the enhancer box (E-box) cis-regulatory sequences of these target 
genes. CLOCK and BMAL1 drive rhythmic gene expression regulating biological 
functions. Rhythmic binding of the CLOCK:BMAL1 dimer on the DNA promotes 
rhythmic chromatin opening and remodelling allowing for further transcription factors to 
bind, contributing to genome-wide effects of transcriptional output of the heterodimer. 
Following the accumulation of PER and CRY proteins, these dimerise and translocate into 
the nucleus and act as the negative arm of the molecular clock, blocking the activity of the 
CLOCK:BMAL1 dimer by binding to the complex, inhibiting transcription of its own, and 




Figure 1.1 The primary loop of the molecular clock. CLOCK:BMAL1 heterodimers 
bind to E-box elements facilitating the transcription of PER and CRY genes. The translated 
proteins translocate into the nucleus and target the CLOCK:BMAL1 heterodimers, 
downregulating further transcription of their own gene. Adapted from Udoh et al. 2015.  
 













The second transcriptional feedback loop (Figure 1.2), the accessory loop, similarly 
induced by CLOCK:BMAL1 heterodimers, activates the transcription of the retinoic acid-
related orphan nuclear receptors, REV-ERB and ROR. Subsequently, these REV-ERB 
and ROR proteins translocate into the nucleus and competitively bind to the retinoic acid-
related orphan receptor response elements (ROREs) which are present on the Bmal1 
promoter. ROR,  and , as well as REV-ERB and  regulate the transcription of Bmal1 
through ROREs; RORs promote the expression of Bmal1, whereas REV-ERB repress the 
expression of Bmal1.    
 
Figure 1.2 The accessory loop of the molecular clock. CLOCK:BMAL1 heterodimers 
bind to E-box elements facilitating the transcription of Ror and Rev-erb. The translated 
proteins translocate into the nucleus where ROR bind at RRE sites to facilitate Bmal1 
transcription, whereas REV-ERB bind to suppress the transcription of Bmal1. Adapted 
from Udoh et al. 2015. 
   
This complex autoregulatory system takes ~24h to complete a cycle and therefore 
constitutes the circadian molecular clock. The precise timing of this system is governed by 
post-translational modifications including phosphorylation and ubiquitination (Yoshitane 
et al. 2009; Stojkovic et al. 2014), affecting the stability and nuclear translocation 
accessibility of the core clock components to regulate their own activity. In mammals, 


















protein turnover (Zheng et al. 2014; Lee et al. 2011). A mutation to both CK1 and CK1 
proved this, as the circadian period was significantly altered, with a decrease in total time 
detected (Etchegaray et al. 2009). CK1 and CK1 are therapeutic targets in humans due 
to their activity being linked with familial advanced sleep phase syndrome (FASPS), which 
manifests as a daily biological clock that is phase-advanced 3-4 hours (Jones et al. 1999). 
The mouse Clock gene has histone acetyltransferase (HAT) activity driving the rhythmic 
expression of the core clock and its output genes, targeting specific histone subunits (Doi 
et al. 2006). Clock also acetylates Bmal1 at Lys537 and appears to be essential for clock 
function, as it was shown to be rhythmic in liver and appeared to be required to inactivate 
Bmal1 transcriptional activity (Hirayama et al. 2007). Deacetylation of these components 
also occur. Sirtuin1 (Silent mating type information regulation 2, homolog) 1 (Sirt1), is a 
circadian deacetylase that interacts with Clock and is involved in the rhythmic acetylation 
pattern of Bmal1-Lys537 (Nakahata et al. 2008; Belden & Dunlap 2008). However, 
although rhythmic binding of SIRT1 to BMAL1:CLOCK occurs, a lack of activity was 
shown, however SIRT1 oscillatory acetylation of PER2 increases its stability (Asher et al. 
2008). In addition to the posttranslational processes of phosphorylation and acetylation, 
BMAL1 is modified by SUMOylation (small ubiquitin-like modifier) to enhance 
transcriptional activity (Lee et al. 2008).  
  
Figure 1.3 The interacting primary and accessory loop of the molecular clock. ROR 
binds at RREs upstream of the Bmal1 gene to facilitate the transcription and translation of 
BMAL1. REV-ERB competitively binds at RREs to block the transcription of Bmal1. 
CLOCK:BMAL1 dimers bind at E-box elements upstream of Per, Cry, Rev-erb and Ror 
to facilitate their transcription. PER and CRY proteins competitively bind at the E-box 






















  1.1.3.1 PERIOD 
 
The PER proteins were first isolated in 1971 by Konopka and Benzer but later sequenced 
by Rosbash and colleagues in 1984   are a core component of the primary loop of the 
circadian clock which were first identified in Drosophila. They are instrumental in signal 
conduction in the negative feedback involved in circadian core clock oscillations. The 
mammalian PER proteins bind to the CLOCK:BMAL1 dimer to suppress the transcription 
of its own gene and to regulate the expression of other CCGs. The Per genes have been 
extensively studied, not only because of their role within the circadian clock, but also 
because of their importance in other systems, including suppressing tumour proliferation 
and development (Yang et al. 2009), to the necessity of Per for the formation of long-term 
memory (LTM) (Sakai et al. 2004). Per2 has been linked with preferred alcohol intake in 
mice (Spanagel et al. 2005), and alcohol consumption itself being shown to shorten the free 
running period (Hofstetter et al. 2003). Per targeted mice, in the case of Per1ldc/ldc and 
Per2ldc/ldc, (lysine decarboxylase) exhibit an altered phase of locomotor activity and core 
body temperature rhythms relative to the light/dark cycle, as well as deficits to long term 
memory (Rawashdeh et al. 2014a). However, total sleep period was maintained in these 
animals, suggesting that only the distribution of sleep, and not the circadian period may be 
affected by this mutation.    
 
Classically, Per gene expression is driven by the dimerization of the bHLH transcription 
factors CLOCK:BMAL1 or CLOCK:NPAS2 dimerising and binding to E-box enhancer 
elements upstream of the Per transcriptional start site (TSS). As PER proteins accumulate 
within the cytoplasm, they are regulated by phosphorylation and their association with 
CRY proteins encoded by the Cry genes. PER and CRY translocate into the nucleus where 
they negatively regulate their own transcriptional output, blocking the activity of the 
CLOCK:BMAL1 dimer at the E-box. However, more recently it has been shown that Per 
gene expression can be driven independent of the classically known mechanism, as 
exposure to glucocorticoids can increase Per transcriptional levels independent of circadian 
cues (Reddy et al. 2012).  
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Figure 1.4 Classical pathways facilitating the transcriptional and translational output 
of Per gene. (a) CLOCK:BMAL1 dimers bind to E-box elements upstream of Per gene. 
(b) Ligand bound glucocorticoid receptors bind to GREs upstream of the Per gene 
transcriptional start site.  
 
PER function is not only necessary for retaining clock function but is also functionally 
important in other biological processes. For instance, PER regulates cell growth and acts 
as tumour suppressors, although this hasn’t yet been determined as a result of dysregulation 
of the master clock, known to be within the suprachiasmatic nucleus of the hypothalamus 
(SCN), or ‘local’ clock dysregulation as this was shown in breast, endometrial and 
pancreatic cell lines (Chen et al. 2005; Yeh et al. 2005; Relles et al. 2013).  
 
PER is also important in facilitating long-term memory formation, in particular in the 
hippocampus, although in this study, dysregulation to other core clock components did not 
exhibit similar effects (Sakai et al. 2004). In Per1(-/-) mice, clock gene expression in 
peripheral tissue is delayed, and subsequently, locomotor activity and feeding rhythms 
were altered, with a shortened free-running period reported. However, in these Per1(-/-) 
E-box
GRE










animals, the oscillatory expression of the clock genes in the SCN, as well as immediate 
early genes in response to light remained unaffected (Cermakian et al. 2001).   
 
Disruption to sleep and its effects on glucose homeostasis are well documented (Knutson 
2007), as the molecular clock regulates metabolic processes in the liver, and disruption to 
this peripheral clock leads to obesity and metabolic syndrome (Turek et al. 2005; Tong & 
Yin 2013). In particular, Per1/Per2(-/-) mice display a blunted metabolic response to food 
intake, leptin levels and adipose transcription (Husse et al. 2012).  Furthermore, in humans, 
a mutation to the Per2 gene has been linked to FASPS (Toh et al. 2001). Whereas in 
contrast, delayed sleep phase syndrome (DSPS) patients, who exhibit sleep-onset insomnia 
has been linked with a specific haplotype of the Per3 gene (Hida et al. 2015). These data 
reiterate the importance of the Per gene and that alterations to it can increase one’s 
susceptibility to sleep disorders, supported further by altered sleep patterns exhibited in 




BMAL1 was first identified in 1997 (Hogenesch et al. 1997; Ikeda & Nomura 1997). 
BMAL1 and CLOCK function as activators of the molecular clock, promoting the 
transcription of Per, Cry, Rev-erb and Ror. CLOCK:BMAL1 dimers bind at E-box sites on 
DNA to regulate gene expression during the initiation of transcription (Xiong et al. 2016). 
The CLOCK:BMAL1 dimer recruits histone modifying enzymes including 
acetyltransferases p300 and CBP to mediate the acetylation of H3K9 and H3K27 as well 
as the histone methyltransferases, Myeloid/Lymphoid Or Mixed Lineage Leukaemia 
(MLL1 and MLL3), to promote the tri-methylation of H3K4 to influence chromatin 
modification at the core clock gene promotor and enhancer regions (Koike et al. 2012; 
Valekunja et al. 2013; Katada & Sassone-Corsi 2010). The rhythmic binding of 
CLOCK:BMAL1 to DNA also promotes rhythmic nucleosomal removal, generating a 
chromatin landscape accessible for transcription factor binding at its enhancer region. The 
CLOCK:BMAL1 dimer recruits transcriptional co-activators such as RNA Polymerase II 
to initiate core clock transcription (Menet et al. 2014; Le Martelot et al. 2012).         
 
BMAL1 binding to E-box elements drives the expression of Per and Cry in the primary 
loop of the molecular clock. However, Bmal1 gene expression is driven primarily by the 
 16 
secondary loop, or accessory loop, which consists of REV-ERBs and RORs, that act as 
transcriptional repressors and activators, respectively (Patel et al. 2016; Ono et al. 2015). 
Bmal1(-/-) disrupts the circadian rhythm of activity, whilst also accelerating aging resulting 
in a shortened lifespan. These animals also exhibit increases in total sleep period, yet 
fragmented, with an attenuated sleep-wakefulness rhythm noted (Kondratov et al. 2006; 




CLOCK dimerises with BMAL1 and binds to E-box elements on DNA to facilitate the 
transcription of Per and Cry genes. Along with Casein kinase 1 (CK1), it is the only other 
clock mechanism gene that is not rhythmic but is instead constitutively active in the SCN, 
however oscillates at a circadian frequency in peripheral tissues (Patel et al. 2016). The 
CLOCK protein is essential in regulating the negative feedback circuitry that generates the 
circadian oscillations observed in the molecular clock, but also for the rhythmic 
transcriptional profile of the transcription factor D-box binding protein (DBP) (Ripperger 
et al. 2000). CLOCK binds to an E-box motif within the enhancer regions of the first and 
second intron of the Dbp gene (Yamaguchi et al. 2000). This same E-box motif has been 
identified in the promoter region of the Per1 gene, however CLOCK binding to this 
element has not yet been described (Ripperger & Schibler 2006). ClockΔ19/Δ19 mice, 
produce a dominant-negative CLOCK protein which is therefore defective in 
transcriptional activation activity (King et al. 1997), exhibit a decrease in total sleep period 
whilst also presenting with small increases in rapid eye movement (REM) sleep (Naylor et 




CRYTOCHROME (CRY), a major component of the primary loop of the molecular clock 
was first identified in Arabidopsis (Ahmad & Cashmore 1993), before being described in 
the fly (Emery et al. 1998; Stanewsky et al. 1998). They are blue light responsive and are 
found to be highly expressed in the ganglion cells and inner nuclear area of the retina where 
they target the SCN to rhythmically cycle, and more recently shown to express across 
different tissues in the brain and body (Thompson et al. 2003; Sancar 2004; Levy et al. 
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2007). However, CRY is not a photopigment in mammals. CRY1 and CRY2 are essential 
clock components that along with PERIOD, inhibit the activity of the CLOCK:BMAL1 
dimer to prevent their own transcription. However, following the accumulation of PER and 
CRY, the subsequent proteasomal degradation of CRY and PER proteins cease this 
inhibition, allowing the molecular cycle to restart.  
 
The co-expression of Cry1 and Cry2 are required for periodic molecular and behavioural 
circadian rhythmicity. However, individual knockout models of Cry1 and Cry2 present 
with opposing circadian phenotypes, where the Cry1(-/-) mice circadian period is shortened 
but Cry2(-/-) mice lengthened (Horst et al. 1999), eluding to the requirement of a functional 
Cry1 and Cry2, to retain circadian oscillations to 24h. This was further examined in vitro, 
with these studies corroborating what was observed in vivo, and enhanced further in these 
cells when presented with Fbxl3Afh, a stabiliser of CRY protein (Anand et al. 2013). Further 
support for its requirement was shown as Cry1/2(-/-) mice become arrhythmic (Horst et al. 
1999). In the liver, CRY inhibits the P300 induced increase in CLOCK:BMAL1 driven 
transcription, through REV-ERB activity, leading to a delay in Cry1 mRNA rhythm, in 
relation to Per1 rhythm (Etchegaray et al. 2003; Sato et al. 2004) Interestingly, although 
Cry1(-/-) and Cry2(-/-) mice exhibited differences in circadian period, both presented with 
increased baseline levels of NREM and consolidation of NREM sleep episodes, compared 
to wildtype (Wisor et al. 2002), but also lacked the compensatory response in the sleep 




Neuronal PAS domain 2 (NPAS2) and CLOCK have overlapping roles in the molecular 
clock. NPAS2 was discovered in 1997 (Zhou et al. 1997). In the SCN, CLOCK:BMAL1 
or NPAS2:BMAL1 heterodimers bind to E-box elements located in the regulatory regions 
of Per and Cry genes to activate their transcription. Targeting this dimer, Clock(-/-)/Npas2(-
/-) mice become arrhythmic, however when Clock(-/-) mice were assessed, both the SCN and 
peripheral tissues exhibited a stable, autonomous circadian rhythm, eluding to NPAS2 
compensating for the loss of CLOCK in these animals (DeBruyne et al. 2007; Landgraf et 
al. 2016).     
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1.1.3.6 Retinoic acid-related orphan receptors 
 
Proteins of this orphan receptor family bind to REV-ERB/ROR (RRE) elements in 
responsive genes such as Bmal1. RRE binding of REV-ERB and REV-ERB 
transcriptionally repress Bmal1, whereas RRE binding of ROR, ROR and ROR 




REV-ERB and  synchronise with ROR,  and  to protect the circadian clock and 
regulate metabolic function. They regulate the oscillations in Bmal1 expression by binding 
to the RRE at the Bmal1 promoter region, suppressing its expression during periods when 
REV-ERB is elevated (Bugge et al. 2012). Further modulation of the molecular clock 
occurs through REV-ERB, as Npas2 and Clock gene expression is regulated by this 
transcription factor. A RRE was identified in the first intron of the Clock gene, and 
suppression of Reverb leads to an elevation in Clock mRNA production (Crumbley & 
Burris 2011). Reverb mRNA expression is also controlled by negative feedback 
downregulation of its own gene, with the Reverb gene promoter containing a functional 
RRE binding site (Raspé et al. 2002).  
 
In the SCN and in liver tissue, the circadian expression of Reverb mRNA is in antiphase 
to circadian Bmal1 mRNA, potentially identifying its role as a transcriptional repressor of 
Bmal1 (Ueda et al. 2002). This was further supported as Reverb(-/-) mice exhibited high 
levels of Bmal1 mRNA expression, which also lacked circadian oscillations in expression 
(Preitner et al. 2002). The expression of Reverb mRNA is regulated by CLOCK:BMAL1 
dimers binding at E-box elements in its promoter region. This interconnection between the 
primary and accessory loops of the molecular clock indicates that Reverb is a major 
determinate of the circadian oscillations observed in Bmal1 mRNA expression, through its 








The retinoic acid-related orphan receptors (ROR) are closely related to REV-ERB, 
recognising similar response elements, however they differ by promoting opposing effects 
to that of REV-ERB, as they promote transcription, rather than suppress the transcription 
of its target genes.      
 
ROR competes with REV-ERB for activity on the same promoter element of Bmal1 to 
drive the transcription of this target gene, defining the accessory loop of the molecular 
clock (Guillaumond et al. 2005). BMAL1 RREs can drive the rhythmic expression of the 
molecular clock alone, indicating their positive transcriptional role, and also their role to 
repress the clock (Ueda et al. 2002). Ror and Ror gene expression is driven by 
CLOCK:BMAL1 regulation on the E-box element of its promoter region (Sato et al. 2004), 
and is robust in the SCN and remains under the control of the master clock in peripheral 
tissues (André et al. 1998; Kamphuis et al. 2005). Ror however is not expressed within 
the SCN but is robustly expressed in peripheral tissue (Hirose et al. 1994). However, it 
remains a vital component of the clock machinery in these tissues, as circadian oscillations 
of Ror have been observed in the liver (Medvedev et al. 1996). Peak mRNA levels of all 
three variants in the SCN and peripheral tissue coincide with the peak expression of Bmal1 
mRNA levels (Preitner et al. 2002; Ueda et al. 2002). Further stability to the molecular 
clock has been described, as ROR regulates Reverb expression, whereas REV-ERB is 
able to regulate its own transcription, providing evidence of extra regulatory processes in 
the molecular clock (Adelmant et al. 1996; Delerive et al. 2002).    
 
A frame shift deletion of Ror(staggerer) leads to a non-functional protein and significantly 
shortened locomotor behaviour whilst blunting corticosterone circadian rhythmicity 
(Frédéric et al. 2006). However, these mice were shown to retain normal clock rhythm 
within peripheral tissue, indicating a role for Ror as a major Bmal1 transactivator, as for 
example in the liver, all three Ror variants may contribute to the rhythmic activation of 
Bmal1 (Sato et al. 2004). Because Ror (staggerer) mice only change the circadian behaviour 
a small amount, a redundancy transactivation function between Ror and Ror could 
account for this small effect, at least within the SCN, as Ror is robustly expressed here, 
and because Ror(-/-) mice retain a circadian phenotype, albeit significantly lengthened 
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(André et al. 1998). Targeting the Ror or Ror gene in mice impairs circadian locomotor 
rhythm and feeding behaviour (Billon et al. 2017). ROR positively regulates Bmal1 
expression and is therefore vital to driving circadian rhythms (Akashi & Takumi 2005). A 
Ror/Ror(-/-) mouse could further identify if redundancy does occur in the single knockout 
animal.   
 
1.1.4 Targeting the molecular clock      
 
The molecular clock has been extensively studied, in particular in the mouse to understand 
the role of each component within the overall functionality of the clock. Below (Table 1.1) 
shows the core clock components with peak gene expression and behavioural phenotype 
following mutation (Ripperger & Merrow 2011; Peirson et al. 2006; Cermakian et al. 2001; 
Oishi et al. 2003; Meng et al. 2008; Guillaumond et al. 2005; DeBruyne et al. 2007; Preitner 





















Table 1.1 Effects of altering clock genes expression.  
Gene Transcript peak  Mutation Behavioural phenotype 
 SCN Peripheral   
Bmal1  16-24 22-02 Bmal1-/- Arrhythmic 
Clock Constitutive 21-03 ClockΔ19/Δ19  Arrhythmic 
   Clock-/- 23.5h  
Per1 4-12 10-16 Per1−/−, 
Per1brdm1, 
Per1ldc   
23-23.5h 
Per2 4-16 14-18 Per2brdm1  22.5h 
   Per2ldc  Arrhythmic 
Per3 4-16 10-14 Per3−/− 23.5h  
Cry1 8-16 14-18 Cry1−/−  23h  
Cry2 8-16 8-12 Cry2−/−  23h  
Reverb  2-6 4-10 Reverb−/− 23.5/  
Ror 6-10 Arrhythmic staggerer 23.5h  
Ror 4-8 18-22 Ror−/− 24.5h  
Ror Not SCN 16-20 Ror−/− - 
Npas2 Not SCN 0-4 Npas2−/− 23.8h  
Ck1 Constitutive Constitutive CK1εtaud 20hr  
Ck1 Constitutive Constitutive Csnk1δ−/+  23.5h 
 
 
1.1.5 Tissue specific clocks 
 
The molecular clock is a self-sustained, cell-autonomous system that is driven primarily by 
the master circadian regulator, the SCN, as well as in peripheral tissue and cell culture, to 
maintain their circadian rhythmicity (Welsh et al. 1995). There are variations in timing 
across different tissues, as for example, Clock mRNA cycles in peripheral tissue, but 
remains constitutively active within the SCN (Ripperger & Merrow 2011). Ror displays 
a robust circadian rhythm within the SCN, but only a slight oscillation has been observed 
in peripheral tissue. On the other hand, Ror, which is not expressed in the SCN, is rhythmic 
in peripheral tissue and is important in regulating the peripheral clock (Sato et al. 2004). 
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Interestingly, Ror(staggerer) mice, which should affect the transcriptional output of Bmal1, 
maintain circadian rhythm in peripheral tissue, including the Bmal1 mRNA rhythm, 
suggesting that ROR proteins may contribute to the activation of the molecular clock in a 
tissue specific manner, as for instance, Bmal1(-/-) mice display a loss of circadian rhythm, 
decreased body weight, infertility and a shortened lifespan (Kondratov et al. 2006). This 
suggests that BMAL1 and other clock components are instrumental in a variety of 
functions, depending on the tissue in which they are expressed. Clock(-/-) mice also present 
with reduced lifespan and altered circadian profiles in a tissue specific manner (Dubrovsky 
et al. 2010). Clock(-/-) mice exhibit a dampened amplitude of Reverb mRNA oscillations 
in the SCN, whereas the amplitude of the transcript is markedly reduced in the liver. 
Interestingly, liver Per1 mRNA expression in these animals was also robustly rhythmic, 
however a delay in peak expression was observed compared to that of wild-type liver 
(DeBruyne et al. 2006), indicating that the transcription factors that promote circadian gene 
patterns, in the absence of Clock, are target gene and tissue specific. Further, Per2 mRNA 
rhythms also exhibit tissue specific disruption in ClockΔ19/Δ19 mutation. The circadian 
rhythmicity of Per2 persists in Clock mutant liver and muscle, with only slight changes in 
amplitude and peak phase, when compared to wild-type, however the Per2 transcript is 
severely blunted in Clock(-/-) kidney and heart (Turek et al. 2005).        
 
1.1.5.1 In the brain 
  
The master clock, located in the suprachiasmatic nucleus (SCN), is one of many nuclei that 
make up the hypothalamic region of the brain. Not only does the SCN contain robust clock 
machinery, the other nuclei of the hypothalamus do too, in turn driving circadian regulated 
processes, such as metabolism (Arcuate nucleus ARC), hormone secretion (Paraventricular 
nucleus PVN) and the sleep-wake cycle (Ventrolateral preoptic area VLPO) (Abe et al. 
2002; Lu et al. 2000; Lu et al. 2002). 
 
The SCN disseminates, via neural and humoral activation, to other brain regions to regulate 
those tissues in a circadian rhythmic manner (Guo et al. 2005; Silver et al. 1996). 
Established areas of the brain that are known to contain the clock components, but also 
drive circadian rhythm of these particular areas are vast, and include, but are not limited to, 
the hippocampus (HC), the perirhinal cortex (PrhC), the amygdala (AMY), bed nucleus of 
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the stria terminalis (BNST), pineal gland, frontal cortex, and brainstem (Uz et al. 2005; 
Lamont et al. 2005; Segall et al. 2006; Takekida et al. 2000; Kaneko et al. 2009).  
 
The SCN is known as the master clock in the body, regulating all tissues to remain in 
rhythm and controlling processes including locomotor activity, core body temperature and 
metabolic processes (Stephan & Zucker 1972; Ruby et al. 2002; Schwartz et al. 1983). The 
SCN has been extensively studied, both in vivo and in vitro to describe the components of 
the clock and to understand its importance on the rest of the body. The SCN’s major 
activator is through light, where photosensitive retinal ganglion cells activate the clock 
machinery in the SCN to signal rhythmic processes (Berson et al. 2002; Hattar et al. 2002). 
However, animals in constant dark retain circadian rhythmicity, through other key 
activators of rhythms, including hormone secretion and feeding rhythms (Hara et al. 2001; 
Balsalobre et al. 2000). Rats in constant light become arrhythmic in activity (Eastman & 
Rechtschaffen 1983). Lesions to the SCN produce arrhythmic activity similar to what is 
observed in constant light (Stephan & Zucker 1972), however following transplantation of 
a SCN into SCNx animals, activity periods and body temperature circadian rhythmicity 
returned (Silver et al. 1996) confirming its role in driving the circadian oscillations in 
animal behavioural output (Oishi et al. 1998b; Akhtar et al. 2002; Terazono et al. 2003).    
 
Molecular clocks peripheral to the SCN, but still within the brain have also been identified, 
in particular using transgenic animal models whose circadian rhythmicity can be measured 
in real-time (Weger et al. 2013). The olfactory bulb (OB) contains robust circadian 
rhythmicity (Granados-Fuentes et al. 2006), as well as the pineal gland and arcuate nucleus. 
Per1 in these peripheral clocks was delayed in comparison, with peak expression occurring 
during the night, whereas in the SCN it occurred in the late day. Interestingly, the 
expression of Per1 was assessed in the olfactory bulb following a SCN lesion, and the 
rhythmic activity of Per1 was not affected, indicating further regulatory systems target the 
OB to remain in rhythm (Granados-Fuentes et al. 2004; Abraham et al. 2005), eluding to 
the possibility that the SCN acts to synchronise individual peripheral brain oscillators, 
rather than necessarily driving circadian rhythmicity in these tissues.  
 
The reward system, which is composed of structures including the ventral tegmental area 
(VTA), the nucleus accumbens (NAc) and prefrontal cortex (PFC) can modify behaviour, 
learning capabilities and mood (Fields et al. 2007; Drevets et al. 1992; Mayberg et al. 2000). 
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Food, alcohol and cocaine all influence the reward system, with reward-related behaviours 
exhibiting a rhythmic period of ~24h, suggesting there is an interaction between circadian 
and reward systems in the brain (Abarca et al. 2002). Further to circadian effects on the 
reward pathway, seasonal patterns also influence addictive drug use and is often 
accompanied with depression (McGrath & Yahia 1993; Rosenwasser et al. 2005). People 
with genetically determined sleep disorders are also more prone to addiction (Shibley et al. 
2008).        
 
The mouse neocortex and cerebellar cortex display circadian oscillations of Per1, Per2, 
Cry1, Bmal1 and Rev-erb, however a 6h delay compared to the SCN was described, 
reflecting the known ‘master-slave’ relationship between SCN and peripheral clocks (Rath 
et al. 2014).   
 
The hippocampus is known to contain components of the molecular clock which are vital 
for daily processes including sleep and memory consolidation (Rawashdeh et al. 2016), as 
well as regulating neurogenesis (Bouchard-Cannon et al. 2013). Ultradian glucocorticoid 
exposure directs Per1 gene pulsing in the hippocampus (Conway-Campbell et al. 2010), 
providing a further mechanism that regulates core clock genes irrespective of SCN signal. 
Per1(-/-) mice display deficits to memory in a hippocampal specific task (Rawashdeh et al. 
2014b). Another area involved in memory consolidation through the action of recognition 
memory is the perirhinal cortex. Although unpublished, clock genes are expressed in this 
area, with data similar to that observed in the hippocampus, with a delay in phase compared 
to that of the SCN (Rozwaha 2017). 
 
Although clock genes are expressed in different brain regions, such as the prefrontal cortex, 
the olfactory bulb, and hypothalamic nuclei (Chen et al. 2016; Granados-Fuentes et al. 
2006), the rest of the brain has been overlooked. For instance, clock gene expression studies 
in the hippocampus is limited (Mure et al. 2018; Tam et al. 2017). Classically, peripheral 
clocks have been identified in regions outside of the brain, with an extensive publication 
list in organs such as the heart and liver. Further to this, skeletal muscle is also a commonly 
targeted area for clock gene function.       





Expression of clock genes Bmal1, Clock, Cry and Cry/2 and Per1, Per2, and Per3 in the 
heart is integral in priming the heart to anticipate and subsequently adapt to physiological 
alterations throughout the day (Young et al. 2001). Heart rate was assessed in infants 
ranging from 2 months to 15 years, with a significant circadian rhythm identified and the 
rhythm being most pronounced between high frequency periods in day and night. A rise in 
heart rate was also observed during night and was associated with sleep maturation (Massin 
et al. 2000). Per1 mRNA expression peaks at ZT12-16 in the heart, delayed in comparison 
to that of the master clock in the SCN, where Per1 mRNA expression peaks at ZT4-12, 
lending to a delay in response between these tissues. This was also evident in Cry1 mRNA 
expression, as in the SCN it peaked between ZT8-16, whereas in the heart it peaked at 
ZT14-18 (Peirson et al. 2006).      
 
1.1.5.3 Liver  
 
Clock gene expression and its role within the liver is well established, both in vivo and 
further characterised in vitro (Tong & Yin 2013; Zmrzljak et al. 2013; Peirson et al. 2006). 
Energy homeostasis is maintained in the liver in mammals, where glucose is broken down 
into smaller carbohydrates and gluconeogenesis reverses this reaction (Inoue et al. 2004). 
Although light is the most potent timing queue for entraining daily rhythms in the SCN and 
peripheral tissues, the liver is further circadian regulated by processes including feeding 
and hormone secretion (Davidson et al. 2003; Díaz-Muñoz et al. 2000), known as the food-
entrainable oscillator (FEO) or through HPA axis steroid secretion. SCN-disrupted animals 
still respond to rhythmic food availability (Krieger 1980) and lesions to the SCN do not 
affect food-anticipatory behaviours in these animals (Stephan et al. 1979).     
 
Glucocorticoids have been shown to alter the clock in the liver, whilst unaffecting the clock 
in the SCN. Dexamethasone, which binds to the glucocorticoid receptor (GR), phase shifts 
clock gene expression in the liver, and other peripheral tissues to the SCN, proposing the 
theory of differential expression of the GR across the liver and SCN accounting for this 
effect (Balsalobre et al. 2000; Reul & Kloet 1985; Reul & de Kloet 1986). Glucocorticoid 
signalling affects almost 60% of the rhythmic liver transcriptome (Reddy et al. 2007), and 
the importance of feeding time has been further described as having an effect on clock 
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rhythms, as restricted feeding induces changes to the phase of circadian gene expression of 
the liver and other peripheral organs, without affecting the SCN, demonstrating an 
uncoupling of peripheral clocks from the central clock (Damiola et al. 2000; Stokkan et al. 
2001). Food metabolites and hormones secreted upon feeding and fasting further regulate 
the circadian clock mechanism in the liver and other peripheral tissues, indicating an 
additional entraining signal for circadian rhythmicity in the liver (Schmutz et al. 2012). For 
instance, targeting Bmal1 in mice hepatic tissue only exhibit hypoglycaemia in their resting 
phase, whereas in a global knockout, the mice had normal resting blood sugar levels 
(Gatfield & Schibler 2008), therefore providing evidence that a failed synchrony between 
the SCN and hepatic clocks resulted in this hypoglycaemic state, suggesting that peripheral 
pacemakers in the liver, may ultimately determine metabolic function in response to 
environment inputs. Similarly, other peripheral clock tissues, such as the liver clock, is also 
delayed in comparison to the SCN with peak timing of Per1 and Cry1 at CT12 in the liver 
(Peirson et al. 2006).    
 
1.1.5.4 Skeletal Muscle    
 
The critical role that clock genes have in the liver and on metabolic processes, ultimately 
leads to the question of what peripheral and tissue-specific actions do these circadian 
regulators have in insulin-sensitive tissues. The skeletal muscle circadian transcriptome 
was described in 2007 (Miller et al. 2007), however it was previously shown that skeletal 
muscle activity rhythms can be reset by altering the timing of exercise/activity or by the 
timing of feeding, rendering it partially independent of the central clock (Maywood et al. 
1999).  
 
Bmal1(-/-) mice exhibit reduced activity, decreased muscle mass and accelerated aging 
(Laposky et al. 2005; Kondratov et al. 2006). However, a targeted Bmal1(-/-) in skeletal 
muscle only resulted in mice exhibiting a normal lifespan and increased muscle mass. The 
circadian activity of these animals was also unaltered, however an increase in the amplitude 
of activity during the active phase was observed (Dyar et al. 2014). Insulin-stimulated 
glucose uptake into skeletal muscle was substantially reduced, whereas whole-body 
glycemia remained unchanged. GLUT4, an insulin-regulated glucose transporter protein, 
was reduced to almost 50% in Bmal1(-\-) muscle, although the mRNA levels remained 
unchanged, indicative of a post-translational event causing this alteration. Targeting the 
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Bmal1 gene in skeletal muscle also altered the expression of other clock genes and clock-
controlled genes (Peek et al. 2017). A subtle difference is observed between the 
synchronicity of the SCN and skeletal muscle and may underlie the increased risk of type 
2 diabetes due to an impaired glucose disposal (Marcheva et al. 2010), and therefore 
targeting the clock therapeutically could be a possible method to treat insulin-resistant 
skeletal muscle commonly observed in metabolic dysfunction (DeFronzo & Tripathy 
2009).    
 
Per mRNA expression profiling of skeletal muscle showed that similarly again to the other 
peripheral tissue mentioned, peak expression occurred around ZT12. Interestingly in the 
same study, Cry1 had modest circadian oscillations, with a small increase in expression 
occurring early in the day cycle, at ZT0 (Yang et al. 2006).   
 
1.1.6 Diseases associated with altered clock 
 
The molecular clock drives most tissues in the body to regulate their activity to the daily 
period, whether it be entrainment by light, driving activity periods, to feeding, causing the 
release of glucose prompting gluconeogenesis to occur whilst stimulating muscle activity. 
The absence of a synchronised clock in animal models delivers alterations in activity, sleep, 
memory and metabolic processes. There are an increasing number of disease states in 
humans that are associated with circadian timing disruptions, however it is important to 
note that most studies have connected disease state with correlative evidence of gene 
variation which does not ultimately indicate causation. See table 1.2 (Zhao et al. 2016; 












Table 1.2 Diseases associated with affected genes of the clock.  
Gene Phenotype  
Per1 Abnormal apoptosis, abnormal behavioural sensitization to 
psychostimuli 
Per2 Cancer development, Increased alcohol intake, FASPS 
Per3 DSPS 
Bmal1 Altered sleep and metabolic syndrome 
Clock Altered sleep and metabolic syndrome 
Cry (1 and 2) Altered sleep  




1.2. Organisation of the HPA axis.  
 
Glucocorticoids are secreted from the adrenal gland in a circadian pattern of ultradian 
pulses governed by the circadian drive of the SCN. Adrenocorticotrophic hormone 
releasing factor (CRF) or corticotropin releasing hormone (CRH) and vasopressin (AVP) 
are secreted from the PVN in response to circadian cues but also in response to stress. These 
hormones in turn, stimulate the secretion of adrenocorticotrophic hormone (ACTH) from 












Figure 1.5 The HPA axis and its hormonal output over the day. A schematic of the 
HPA axis (A) and measurement of corticosterone in rat (B) and cortisol in human (C) over 
one day (Lightman & Conway-Campbell 2010; Henley et al. 2009).     
 
1.2.1 Paraventricular nucleus 
 
The paraventricular nucleus of the hypothalamus (PVN) is a group of densely packed 
neurons that are stimulated by physiological changes, such as the changing light/dark cycle 
and in the presence of a stress. The PVN contains CRF cell bodies which through axonal 
projections to the capillaries of the median eminence, secretes CRH directly into the portal 
system to act on the pituitary to regulate ACTH secretion. Neurons of the PVN project 
directly to the posterior pituitary where oxytocin is released, or to the brainstem and spinal 
cord, to regulate appetite and autonomic functions. The PVN is highly vascularised and is 
protected by the blood-brain barrier, however its neuroendocrine cells beyond it. The 
magnocellular neurosecretory cells’ axons extend into the posterior pituitary, as well as the 




median eminence. The PVN also projects to the brainstem and spinal cord via parvocellular 
preautonomic cells (Ter Horst et al. 1991).  
 
The magnocellular neurons secrete oxytocin (OT) and vasopressin (AVP), which are 
transported down the axonal projections and released from the neurosecretory nerve 
terminals residing in the posterior pituitary gland. Magnocellular neurons are also found in 
the supraoptic nucleus (SON) and secrete vasopressin, to enhance water reabsorption in the 
kidney (Erkut et al. 1998).  
 
The parvocellular neurons project to the median eminence, where they secrete CRH, AVP 
and TRH from nerve terminals at the primary capillary plexus of the hypophyseal portal 
system. The secretion of CRH and AVP from parvocellular neurons act synergistically to 
stimulate ACTH secretion from the anterior pituitary (Berk & Finkelstein 1981).    
 
The PVN, in addition to neuroendocrine neurons, also contains interneurons and 
populations of other neurons that project centrally to other brain regions. Parvocellular 
oxytocin secreting cells project to the brainstem and spinal cord, to suppress nociception, 
promoting analgesic effects (Eliava et al. 2016). Parvocellular vasopressin secreting cells 
project mainly to the hypothalamus, including the SCN, and the limbic system. 
Parvocellular CRH secreting neurons project to the amygdala, where an overexpression of 
CRH in this brain region, results in increased anxiety (Kalin 2018).   
 
1.2.2 Pituitary gland 
 
The pituitary gland is made up of three lobes (the anterior, intermediate and posterior lobes) 
that sits at the base of the brain in a protective bony enclosure. The lobes differ greatly; 
however, the release of hormones is governed by the hypothalamus.   
 
CRH, AVP and TRH are released by parvocellular neurosecretory cells into hypothalamic 
capillaries joining to infundibular blood vessels, that in turn leads to a second capillary bed 
in the anterior pituitary, constituting the hypothalamic-hypophyseal portal system. These 
hormones diffuse out of the second capillary bed and target anterior pituitary endocrine 
cells, regulating the release of ACTH. The anterior lobe is further subdivided into the pars 
tuberalis, pars intermedia and pars distalis. The anterior pituitary not only secretes ACTH, 
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it also contains cells that synthesise and secrete other hormones, such as human growth 
hormone (HGH), thyroid stimulating hormone (TSH), luteinising and follicle stimulating 
hormone (LH/FSH), as well as prolactin (PRL) (Childs et al. 1989).       
 
The posterior lobe of the pituitary develops as an extension of the hypothalamus, with 
hormones secreted from here being synthesised by cell bodies within the hypothalamic 
area. The posterior lobe contains glia (pituicytes) that store and secrete OT and AVP and 
this lobe can be subdivided into the pars nervosa and infundibulum stalk. The infundibulum 
stalk bridges the hypothalamic and hypophyseal systems and connects to the median 
eminence. The pars nervosa contains OT and AVP secretory cells. The magnocellular 
neurosecretory cells of the SON and PVN in the hypothalamus project axons down the 
infundibulum to terminals in the posterior pituitary where the storage and secretion of 
neurohypophyseal hormones OT and AVP into the neurohypophyseal capillaries occurs, 
and further into the systemic circulation (Bisset et al. 1973).  
 
The intermediate lobe is important in many animals but is not a distinctive structure in 
humans. In rodents, it is composed mainly of melanotrophs, endocrine cells that secrete 
alpha-melanocyte-stimulating hormone (alpha-MSH) and beta-endorphin. This area is 
poorly vascularised, and here pituitary melanotrophs are supplied by nerve fibres 
emanating from the hypothalamus (Lamacz et al. 1991). Pituitary melanotrophs synthesise 
proopiomelanocortin (POMC) and cell bodies targeted for POMC are located in the arcuate 
nucleus of the hypothalamus (ARC) and the nucleus of the solitary tract of the brainstem 
(NTS), both of which functionally drive appetite and food intake.    
 
1.2.3 Adrenal gland     
 
The adrenal gland is made up of three main zones (glomerulosa, fasciculata and reticularis) 
with each having a distinct function, producing mineralocorticoids, glucocorticoids and 
androgens, respectively. Although each zone has a specific mechanism of regulation, 
ACTH acts on all zones (Vinson 2016).  
 
The zona glomerulosa is the most superficial layer of the adrenal cortex. The 
mineralocorticoid aldosterone is released from this layer in response to increased potassium 
and renin levels, or decreased blood flow within the renin-angiotensin system.  
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The zona fasciculata, which sits between the glomerulosa and reticularis, is the primary 
producer of glucocorticoids. This layer produces androgens; however, the main source of 
androgen is from the zona reticularis. Adrenal tumours and hyperplasia in this region result 
in excess cortisol production and present as adrenal Cushing’s disease. In rodents, the 
fasciculata synthesises corticosterone instead of cortisol (humans), due to the lack of 
17alpha-hydroxylase.      
 
The zona reticularis is the innermost layer of the adrenal cortex and produce precursor 
androgens including dehydroepiandrosterone (DHEA). It is either further converted in the 
cortex to DHEA-S or enters the bloodstream and testis and ovaries to produce testosterone 
and oestrogens, respectively. ACTH partly regulates adrenal androgen secretion.  
 
1.3. The central nervous system 
 
The central nervous system comprises the brain and spinal cord in mammalian physiology. 
Decoding the chemical, electrical and genetic processes that account for brain output is one 
of the greatest challenges in modern biomedical research. The mammalian brain is the most 
developed brain of all animals, with distinct differences observed in the size of the 
neocortex, the area of the brain that processes higher learning, such as cognition and 
language (Amato et al. 2004; Benedict et al. 2006). The brain itself can be grossly 
simplified into four distinct regions; the cerebrum, the cerebellum, the limbic system and 




The brainstem, which consists of the midbrain, pons and medulla oblongata, is posterior in 
the brain and directly connects to the spinal cord. Autonomic regulation of cardiac and 
respiratory function occurs here (Harper et al. 2000), as well as the maintenance of 
consciousness and sleep (Steriade & McCarley 1990).  The midbrain can be further 
subdivided into the tectum, tegmentum, cerebral aqueduct, and cerebral peduncles in which 
the tectum comprises the inferior and superior colliculi, which receive input from auditory 
and visual cues, resulting in the head turning in the direction of either stimulus (Merzenich 
& Reid 1974; Sprague 1966). The tegmentum, which extends from the substantia nigra to 
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the cerebral aqueduct processes voluntary and involuntary movement, as well as arousal, 
self-consciousness and reward (Lammel et al. 2012; Sukhotinsky et al. 2005). The cerebral 
peduncles - structures at the front of the midbrain contain ascending and descending nerve 
tracts to assist in refining motor movements, using sensory and motor contact, respectively. 
Damage to this area results in unrefined motor skill, imbalance and poor proprioception 
(Hosp et al. 2011). The pons contains the end terminal of four cranial nerves, of which 
serve to regulate involuntary movements such as respiration, chewing and swallowing, and 
the secretion of saliva and tears (Meng et al. 2000). The medulla oblongata, the final 
subdivision of the brainstem is also responsible for autonomic actions, such as vomiting 
and sneezing (Martin et al. 1991) and it is the area of the brainstem that contains the centres 
for breathing, heart rate and blood pressure control (Verner et al. 2004).  
 
In addition to the role of the HPA axis on stress, the brainstem also plays a crucial role in 
regulating the adaptive response to stress through brainstem noradrenergic neurons, 
sympathetic adrenomedullary circuits and parasympathetic systems (Herman et al. 2016; 
Habib et al. 2001; Whitnall et al. 1993), primarily in response to alterations in homeostatic 
mechanisms, such as hypovolaemia and inflammatory challenges. The nucleus of the 
solitary tract (NTS) and ventral medulla (VM) target the PVN through noradrenergic, 
adrenergic and glucagon-like peptide 1 containing neurons to affect the HPA axis response 
(Sawchenko et al. 1993; Smith & Vale 2006). Neurons of the brainstem receive input from 
the vagus and sympathetic nervous system, as well as local inflammatory signals which 
then target the parvocellular cells of the PVN, dictating the activity of the HPA axis 




The cerebellum, which sits at the most caudal location of the brain structure above the 
brainstem is well known to play an important role in motor control in humans, where it 
distinguishes between actual and learned movement. Damage to the cerebellum results in 
deficits in fine motor skill, balance and posture (Ivry et al. 1988).  
 
However, in 1976 evidence for the importance of the cerebellum in emotion and emotional 
disorders, describing its importance in the Papez circuit was published, with follow up work 
indicating a functional role of the cerebellum in cognition and emotion (Schmahmann 
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1991). In cerebellar dysfunction, where motor activity is often affected, evidence for an 
increased risk in mental health disorders was reported, with schizophrenia and depression 
often observed (Schmahmann 2004).  
 
The cerebellum projects wholly to the limbic system, with observations in the 
hypothalamus, hippocampus, amygdala and basal ganglia, as well as to brainstem nuclei, 
substantia nigra and locus coeruleus (Heath & Harper 1974). Targeted lesions to the 
cerebellum in the monkey resulted in reduced aggressive behaviour, and stimulation of the 
cerebellum in rats resulted in limbic system activation (Peters 1971; Heath et al. 1978), 




The cerebrum, the largest part of the mammalian brain is a vast structure that contains the 
cerebral cortex, as well as subcortical structures including the amygdala, basal ganglia and 
hippocampus. The cerebrum, being such a major component controls a magnitude of 
different functions dependent on the location but is fundamental for, and not least of all, 
emotion, hearing, vision, personality, voluntary action and memory storage (Grol et al. 
2006; Gais et al. 2007).  
 
The HPA axis and the release of glucocorticoids can significantly affect different areas of 
the cerebrum. For instance, lesions to the central nucleus of the amygdala (CeA) or medial 
nucleus of the amygdala (MeA) results in HPA axis attenuation and reduction of the stress 
response in various stimuli (Dayas et al. 1999; Buller et al. 1998). However, as the 
projections from the CeA and MeA are limited (Gray et al. 1989; Prewitt & Herman 1998), 
they must affect the PVN via an indirect pathway, possibly through the bed nucleus of the 
stria terminalis (BNST), as projections from the CeA and MeA are GABAergic (Swanson 
& Petrovich 1998), and projections from the BNST to the PVN are GABAergic, resulting 
in HPA axis activation. This pathway could be disinhibitory, as the CORT response to 






1.3.4 Limbic system 
 
The limbic system has been extensively studied for its role in emotional processing and is 
located deep within the cerebrum, consisting of the hypothalamus, hippocampus, amygdala 
and the thalamus to name a few, which exists to support a variety of functions including 
reviewing and responding to emotional events, as well as being instrumental in behaviour 
responses and memory processing (Catani et al. 2013).  
 
Lesions of the anterior thalamic nuclei results in decreased expression of the neural 
plasticity marker zif268 in the subiculum as well as reductions to pCREB (Dumont et al. 
2012), indicating the role of the thalamus as part of the extended hippocampal system, 
crucially involved in memory processing. The amygdala (AMY) contributes heavily to 
fear-motivated learning, with manipulations to the region significantly affecting 
behavioural outcomes in the presence of fear conditioning (Fanselow & LeDoux 1999). 
Changes to firing rates of neurons have also been observed in the AMY, however the limbic 
system circuitry as a whole heavily influences this learning also (Quirk et al. 1997). As for 
instance, the basolateral amygdala (BLA) receives input from the neocortex, thalamus and 
hippocampus, projecting to the CeA to generate and coordinate with other limbic brain 
areas, inducing fear-related behaviour (Swanson & Petrovich 1998; Bolton et al. 2018).           
 
1.4. The Hippocampus 
 
The hippocampus (HC) is a structure of the brain that forms part of the limbic system and 
plays a key role in spatial navigation and episodic memory (O’Keefe & Speakman 1987). 
Both human and animal studies have found that stress impairs hippocampal-dependent 
memory tasks, altering the synaptic plasticity and firing properties of neurons involved in 
consolidation processes (Benoit et al. 2015).    
 
The ventral HC and ventral subiculum largely control the response to HPA axis activity, as 
CORT pellets implanted into these areas present with a flattened circadian CORT rhythm, 
but also because stimulation of the vHC inhibits HPA axis activity (Slusher 1966; Casady 
& Taylor 1976). The HC primarily exerts an inhibitory effect on the PVN, with gross HC 
lesions elevating basal CORT levels (Fendler et al. 1961; Knigge 1961). However, lesions 
to specific areas have differing effects on HPA axis activity. Lesioning the dorsal HC, the 
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main projection to the hypothalamus, disrupts the circadian CORT rhythm and elevates 
resting CORT levels (Fischette et al. 1980), whereas lesions to the hippocampus proper 
(i.e. CA1-3) prolong the CORT response to stress, indicating the HC is important in 
controlling the rhythm and inhibition of the HPA axis in response to stress and circadian 
timing.      
 
1.4.1 Input  
 
The afferent and efferent pathways of the HC are vast, signifying its importance in the 
regulation of many circuits and regions of the brain. The primary afferent pathway of the 
HC is the perforant pathway, which originates in the entorhinal cortex (EC) and synapses 
predominantly in the granular cells of the dentate gyrus (DG), a region of the hippocampus 
formation (Witter 2007). These fibres predominantly project from the lateral EC to the 
outer layers of the DG, whereas fibres projecting from the medial area of the EC project to 
deeper regions of the DG.  
 
The lateral and medial EC (MEC) process spatial information. The lateral EC (LEC) 
processes local spatial frameworks, whereas the medial EC processes global spatial 
frameworks (Knierim et al. 2014; Neunuebel et al. 2013). Lesioning of the LEC impairs 
local spatial framework tasks. Impaired memory was also observed during an object 
recognition task when involving multiple local stimuli but was unimpaired when 
recognising a single familiar object (Kuruvilla & Ainge 2017).  
 
Further afferent projections of the HC include the cingulate gyrus, the contralateral HC, the 
medial septal nuclei and the fornix (Fuhrmann et al. 2015; Hamani et al. 2011). The 
precommissural branch of the fornix connects to the septal nuclei and ventral striatum to 
link the reward pathway (Schultz & Engelhardt 2014), the preoptic nuclei to regulate body 
temperature (McKinley et al. 2015), the orbitofrontal cortex which processes decision 
making (Rushworth et al. 2011), and the anterior cingulate cortex which connects the 
limbic system to the prefrontal cortex, combining the emotional response to cognitive 
processing (Bush et al. 2000). The postcommissural branch of the fornix projects to the 
anterior nuclei of the thalamus, a key component of the hippocampal system for episodic 
memory as well to the mammillary bodies of the hypothalamus, which act as a relay for 
indirect hippocampal inputs to the thalamic anterior nuclei and are often referred to as a 
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constituent of an extension of the hippocampus (Aggleton & Brown 1999). The afferent 
pathways of the HC provide insight into the vast actions of this structure, and its importance 
in multiple systems and circuits of the brain, in particular the limbic system.        
 
1.4.2 Cell types and neuroanatomy 
 
The HC is often described as the hippocampus proper, and hippocampus formation. The 
hippocampus proper is composed of the Cornu Ammonis (CA) regions (CA1-3) only, 
whereas the hippocampus formation consists of the CA regions, the dentate gyrus (DG) 
and subiculum (SUB) (Grønli et al. 2006; Roelink 2000). Principal neurons of the 
trisynaptic circuit of the HC formation (DG – CA3 – CA1) fire spatially modulated spikes 
in a particular area of the environment to form a neural representation of its surroundings, 
supporting its involvement in spatial navigation and episodic memories (Buzsáki 2010; 
Leutgeb et al. 2005).  
 
The CA regions of the HC are structurally defined by their strata. The stratum oriens is 
composed of the cell bodies of inhibitory basket cells and the horizontal trilaminar cells – 
oriens, pyramidal and radiatum (Thal et al. 2000). The dendrites of pyramidal cells are 
located in the oriens, and receive information from pyramidal cells, septal fibres and 
commissural fibres of the contralateral HC (Lacaille et al. 1987). The stratum pyramidale 
is composed of the cell bodies of the pyramidal neurons, which are the principal excitatory 
neurons of the HC (Miles et al. 1996). Within the CA3 region, this stratum contains the 
synapses from mossy fibres which project through the stratum lucidum and is only found 
in the CA3 region where mossy fibres from the DG pass through this layer and synapse in 
the stratum pyramidale (Frotscher 1985). The stratum lacunosum contains Schaeffer 
collateral fibres as well as perforant path fibres from the EC. The stratum moleculare is the 
most superficial stratum in the HC, and where the perforant path fibres form synapses onto 
the distal, apical dendrites of pyramidal neurons (Andersen et al. 1966). Theta rhythm 
varies throughout the strata, and therefore the sulcus, which is a cell free area, is often used 






1.4.2.1 CA1 region   
 
The CA1 region of the hippocampus has been extensively studied for its role in memory 
processing. It receives external information from the EC, arriving at the most distal 
dendritic regions of principal neurons. Internal information, predominantly from the CA3 
region arrives at proximal perisomatic dendrites (Steward 1976; Megías et al. 2001; Suh et 
al. 2011; Witter et al. 2000). The CA1, CA3 and EC circuit drives the CA1 region to 
associate contextual and spatial information, therefore generating and maintaining context-
dependent spatial maps (Takahashi & Magee 2009; Wood et al. 2000; Markus et al. 1995; 
Frank et al. 2000; Leutgeb et al. 2005).    
 
In CA1 neurons, the glucocorticoid receptor is nuclear in the presence of glucocorticoids, 
and cytoplasmic in the absence of glucocorticoids (Conway-Campbell et al. 2010), 
presenting a rapid and transient effect of GCs on the GR at the level of these neurons. The 
expression of the molecular clock activators, CLOCK and BMAL1 in the CA1 region 
exhibit a significant circadian oscillation across the day and in the presence of a chronic 
unpredictable stress (CUS) paradigm, providing evidence for the role and importance of 
the molecular clock in depressive-like behaviour (Jiang & Salton 2013) in the hippocampus 
proper, and possibly, specifically in the CA1 region. Per1 expression within CA1 has been 
shown, with expression susceptible to differing conditions such as restricted feeding, which 
increasing the expression in the CA1 region (Feillet et al. 2008). The CA1 region, along 
with CA3 and DG have the highest level of Per1, Per2, Clock and Bmal1 (Shieh 2003; 
Segall & Amir 2010; Yamamoto et al. 2001), with these genes being rhythmic (Jilg et al. 
2009). Further, the expression profiles of clock genes, Per1, Per2 and Bmal1 are altered in 
the CA1 region following chronic mild stress (Christiansen et al. 2016).   
 
1.4.2.2 CA2 region 
 
The CA2 region of the hippocampus is the least studied area of the hippocampus, with little 
known about its functional properties and behavioural role. The region contains pyramidal 
neurons and although projections to the EC are sparse from CA2, clear and robust 
projections occur at CA1 and CA3 regions, with the densest projections observed in the 
stratum oriens (Hitti & Siegelbaum 2014). Hypothalamic input to CA2, specifically from 
the PVN offers mixed results, with projections observed (Cui et al. 2013) and not (Hitti & 
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Siegelbaum 2014) in this area, potentially indicating an inability from a methodological 
point of view to identify this projection. CA2 projections to the CA1 region are clear and 
robust, with CA1 stratum oriens and radiatum regions evoking robust monosynaptic 
postsynaptic potentials (mPSPs) in principal neurons of the region. However, a functional 
inactivation of the CA2 region does not alter activity or anxiety-like behaviour. Nor does 
it affect spatial memory as assessed using the Morris water maze (Morris 2008). 
 
Although the CA2 region has been shown to not affect spatial memory, it may play an 
important role in non-spatial tasks. Synaptic input was identified from the LEC, which 
delivers non-spatial memory (Hargreaves et al. 2005), as well as sub-cortical input from 
the median raphe nucleus which produces serotonin to act as an inhibitory relay onto the 
HPA axis (Hensler 2006) and the hypothalamic supramammillary nucleus (SuM) (Pan & 
McNaughton 2004). The SuM is instrumental in regulating the frequency in theta activity 
in the hippocampus, and therefore could influence hippocampal contributions to cognition 
and emotion (Pan & McNaughton 2002).   
 
Per1(-/-) mice exhibit deficits to hippocampal specific memory formation. The 
phosphorylation of CREB was severely diminished in the CA2 region of these animals, in 
particular at a time when CREB phosphorylation is elevated in wild types to promote the 
transcription of genes required for long-term memory formation (Rawashdeh et al. 2014b).    
 
1.4.2.3 CA3 region 
 
The CA3 region of the HC is located in the lateral portion of the hippocampus proper. 
Neurons in this region project to neurons of the CA1 region via the Schaeffer collateral 
pathway (Gruart et al. 2006).  
 
The region is composed primarily of pyramidal neurons, as well as inhibitory interneurons 
that synapse on pyramidal cells (Ishizuka et al. 1990). The most common inhibitory neuron 
of the CA3 region is the basket cell, which synapse on the cell bodies of CA3 pyramidal 
neurons, mediating somatic inhibition. Interneurons also synapse on the dendrites of the 
pyramidal neurons to inhibit dendritic activation (Buzsáki 2002). The pyramidal neurons 
receive excitatory input from the dentate granule neurons via the mossy fibre pathway and 
also through the perforant pathway input from the EC (Marchal & Mulle 2004; Lee & 
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Kesner 2004). Pyramidal neurons of the CA3 region project out of the ipsilateral HC via 
the alveus and fimbria of the fornix, which in turn project to the septal nuclei and 
contralateral HC (Li et al. 1994).  
 
The CA3 region is largely involved in memory processing but is also susceptible to seizures 
and neurodegeneration (Scharfman et al. 2000). The internal connectivity of the CA3 
region is denser than any other hippocampal region, with pyramidal neurons extensively 
making contacts with neighbouring excitatory and inhibitory neurons (Lei & McBain 
2004). It receives input from the EC either directly through the perforant path or indirectly 
from the DG via mossy fibres (Amaral & Dent 1981), with the mossy fibre pathway 
translating densely coded cortical signals into specific hippocampal code essential to the 
formation of memory.     
 
Per1, Per2 and Clock are expressed in the CA3 region, and exhibit clear circadian rhythm 
in timing with the SCN (O’Callaghan et al. 2012).  In Per1(-/-) mice, CREB activity is 
altered in the CA3 region, along with impaired spatial memory (Phan et al. 2011).  
 
1.4.2.4 Dentate gyrus  
 
The dentate gyrus (DG), similarly to the CA regions, is composed of a series of well-
defined strata – the molecular layer, the principal cell layer and the polymorphic layer. The 
DG contains dentate granule cells, of which the dendrites are located predominantly in the 
molecular layer of the three-layer structure (Kuhn et al. 1996). Fibres originating from the 
EC project down the perforant path to this layer.    
 
The principal cell layer is composed of densely packed granule cells. The cell body of the 
dentate pyramidal basket cell is often located within the border of the granule cell layer 
with the polymorphic layer. The polymorphic layer is composed mainly of mossy cells and 
interneurons. The axons of dentate granule cells pass through this layer to target the CA3 
region of the HC proper (Amaral & Lavenex 2007). The stratum granulosum contains the 
cell bodies of the dentate granule cells (Schlessinger et al. 1975). The stratum moleculare 
can be divided into the inner third and outer two thirds. Commissural fibres from the 
contralateral DG run through the inner third and form synapses (Gottlieb & Cowan 1973). 
Medial septum input terminates here, on proximal dendrites of the granule cells (Frey et al. 
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2003). The outer two thirds are located superficial to the HC sulcus and across from the 
stratum moleculare in the CA fields. Perforant path fibres project through here, making 
excitatory synapses onto the distal apical dendrites of granule cells (Witter 2007).    
 
The DG expresses the components of the molecular clock, with SCN and DG Per1 
expression in phase, however when corticosterone rhythm is blocked, the rhythm of Per1 
in the DG is suppressed (Gilhooley et al. 2011). The DG relies on an intact circadian CORT 
rhythm to exhibit effective stimulating anti-depressant drug effects, as blocking CORT 




The subiculum (SUB), which is encapsulated in the hippocampus formation terminology, 
is located caudal to the hippocampal formation, between the CA1 and subcortical regions 
including the EC and perirhinal cortex (PrhC). The plasticity of synaptic transmission and 
the functionality of the hippocampal-subicular axis is not as well understood as the 
pathways within the hippocampus proper.  
 
The ventral subiculum (vSUB) projects to the PVN inhibiting the activity of the HPA and 
hypothalamic-spinal-adrenal (HSA) axes, with lesion studies confirming this (Herman & 
Spencer 1998; Herman et al. 1995). There are multiple reciprocal connections between the 
SUB and other brain regions, including the hypothalamic nuclei. The ventral 
premammillary nucleus, the medial septal nuclei, as well as the anteroventral and 
anteromedial nuclei of the thalamus all project to the SUB (Köhler 1990; Risold & Swanson 
1997). The projections from the vSUB target the hypothalamus via the postcommissural 
fornix, the medial corticohypothalamic tract and the AMY, where these projections 
innervate the MPOA, the VMH and DMH, as well as the ventral premammillary and medial 
mammillary nuclei (Canteras & Swanson 1992).  
 
Inhibition of the HPA axis via the SUB is transynaptically mediated through GABAergic 
neurons that project to the PVN via neurons in the bed nucleus of the stria terminalis, the 
MPOA and the dorsomedial hypothalamus (Herman et al. 2003). Neurons of the median 
raphe nucleus project to the vSUB projecting area, indicating the role of SUB projections 
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to the PVN, which principally act to inhibit the HPA axis, limiting the response to stress 
(Herman et al. 1995). 
 
Long range projections from the SCN to the SUB have been reported, and GABAergic 
input along this projection is rhythmic (Kalsbeek et al. 2008). However, little data has 
examined the role of the clock mechanism within this region. SCN lesions to animals after 
training showed hippocampal-dependent memory deficits (Phan et al. 2011), providing 
evidence of the importance of the master clock and its connectivity with the SUB and wider 
hippocampal structure. Bmal1 is expressed in the SUB (Kondratova et al. 2010). The 
circadian input from the SCN to the HC via the SUB may regulate the excitability of the 
HC.  
 
Figure 1.6 The hippocampal interconnectivity between sub regions. Projections from 
the entorhinal cortex and subiculum synapse predominantly on granule cells in the dentate 
gyrus (DG) project to the CA3 region, which project further to the CA1 region. Projections 
from the CA1 region to the entorhinal cortex closes the hippocampal loop. EC – entorhinal 
cortex, SUB – subiculum, DG – Dentate gyrus, CA3 – Cornu Ammonis 3, CA1 – Cornu 
Ammonis 1, PP – perforant path, sc – Schaeffer collateral, Blue box – s.o. stratum oriens, 






1.4.3 Glucocorticoid response 
 
The HC is an area extensively studied, providing a bridge between stress and brain 
plasticity, and its interconnected brain regions, such as the AMY, prefrontal cortex (PFC), 
PVN and SCN and as the HC provides negative feedback to the HPA axis, the role of 
glucocorticoids in hippocampal processes have been extensively studied. The HC acts as 
the hub in the memory and navigation network, with research assessing what effect 
differing levels of GCs, and at different points of the activity of the HPA axis, have on 
memory processing.   
 
In 1985, the glucocorticoid (GR) and mineralocorticoid (MR) receptors were demonstrated 
in the HC (Reul & Kloet 1985), and following shortly after, the distribution and expression 
of these receptors were shown to vary depending upon their location. The dorsal subiculum 
and CA1 regions express both receptors, but with a 7-fold increase in MR expression 
compared to the GR. The dentate gyrus (DG) and CA3 region express both receptors 
equally and at a similar level to that of MR in the CA1 region (Reul & de Kloet 1986). The 
finding of GRs and MRs in the HC led to studies assessing glucocorticoid action on the 
brain, not only to regulate hypothalamic function, but also to influence neurological, 
cognitive and emotional functions throughout the brain. GCs facilitate memory processing 
during highly aversive memory testing paradigms, such as fear conditioning and passive 
avoidance tasks (Conrad et al. 1999; Conrad et al. 2004) but impair memory during less 
aversive memory tasks, such as during Y-maze and non-emotional declarative memory 
(Conrad et al. 1996). Immediate post-training injections of GC agonists in 
adrenalectomised (ADX) rats impair Y-maze performance , however GC antagonists given 
similarly also impair performance (Oitzl & de Kloet 1992), proposing that not only are 
glucocorticoids required for memory consolidation processes, but at a particular dose.  
 
In addition to the hippocampus expressing the GR and MR, it is also driven by the master 
regulator of the molecular clock to regulate neurogenesis by controlling cellular timing to 
~24h (Bouchard-Cannon et al. 2013). Per1 expression for instance, a major component of 
the molecular clock, is rhythmically expressed in the HC (Jilg et al. 2009) and can be driven 
by chemical or electrical seizure-inducing stimulations (Eun et al. 2011) but importantly, 
also with GC treatment (Conway-Campbell et al. 2010), where robust upregulation in the 
expression of Per1 mRNA and protein in the hippocampal formation is evident. 
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The 24hr cellular clock controls different aspects of hippocampal memory, however it’s 
the consolidation period that seems heavily dependent on hippocampal neurons (Wood et 
al. 2000). HC memory consolidation requires the phosphorylation of cAMP Response 
Element Binding (CREB) protein to promote the transcription of genes for long term 
memory formation (Williams et al. 2008; Morris & Gold 2012). PER1 regulates the 
phosphorylation of CREB in the HC in a time of day dependent manner, where PER1 and 
pP90RSK co-translocate into the nucleus as in for example Per1(-/-) mice, pP90RSK 
remains perinuclear and unable to phosphorylate nuclear CREB, indicating that the 
presence of PER1 in a time of day dependent manner drives the phosphorylation of CREB, 
offering a functional link between circadian rhythms, GC exposure and learning efficiency 
(Rawashdeh et al. 2016). 
 
1.4.4 Involvement in memory and sleep 
 
The hippocampus determines memory acquisition, consolidation and retrieval with 
hippocampal specific cellular and molecular dynamics driven by: the time of day, 
activation through the HPA axis and stress, and reliance on the output of the SCN (Ruby et 
al. 2008; Phan et al. 2011).  
 
During sleep, memories are vulnerable to manipulation, as a period of sleep is beneficial 
during the consolidation of memory stage (Stickgold et al. 2000; Graves et al. 2003). The 
critical signalling period, between 0.5h and 3h, occurs within the first few hours of post-
learning. Sleep loss or alterations to the sleep period during this time overlap with critical 
molecular signalling that promotes the gene transcription of proteins that consolidate labile 
memories into long-term memories, such as the activation of CREB (Ahmed & Frey 2005). 
Disruption to CREB activation during this early phase following behavioural testing can 
impair the consolidation of memories (Graves et al. 2003; Palchykova et al. 2006).  
 
Multiple systems contribute to the control of sleep, however as the molecular clock is 
instrumental in driving the circadian activity of tissues to day and night oscillations, it has 
been a target of research. PER1, along with PER2 have been shown to regulate the response 
of metabolism-associated transcripts that contribute to sleep disruption (Husse et al. 2012). 
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During sleep, both the nadir and major portion of GC secretion occur. In the earliest stages 
of sleep, GC levels are low, whereas as the night progresses, the first large pulse of GC 
occurs, in preparation for awakening. During the early hours of the sleep period, the 
majority of slow wave sleep (SWS) occurs, whereas in the second half of sleep, SWS is 
rare but rapid eye movement (REM) sleep predominates (Weitzman 1976), indicating an 
important interaction between the different sleep states and architecture with the activity of 
the HPA axis.  
 
It is well established that sleep quality deteriorates with aging, as decreased SWS and slow 
wave activity (SWA) are observed in the aged population (Garfinkel et al. 1995; Landolt 
et al. 1996). However, the relationship with CORT secretion needs to be assessed further 
as HPA axis activity affects sleep. An infusion of CRH during the sleep period decreases 
SWS, but increases the REM period (Ehlers et al. 1986; Marrosu et al. 1990). As CRH 
impairs sleep, but CORT promotes SWS, this is most likely due to its inhibitory effect on 
the HPA axis.  
 
1.5. Endogenous and Synthetic glucocorticoids 
 
1.5.1 Endogenous glucocorticoids 
 
Endogenous glucocorticoids are secreted from the adrenal cortex as an end product of the 
activation of the HPA axis. The axis consists of the paraventricular nucleus (PVN) of the 
hypothalamus, the anterior pituitary and the adrenal gland. The PVN is activated in the 
presence of circadian cues from the SCN, but also in the presence of a stressor. Activation 
leads to the secretion of CRH and AVP which in turn activates the secretion of ACTH from 
the anterior pituitary. ACTH drives the secretion of CORT from the adrenal gland.  
 
In the absence of a stressor, this system is driven by circadian cues, with 24hr profiling of 
endogenous glucocorticoids in blood exhibiting a clear daily rhythm. An ultradian rhythm 
is also described, explained by the feedback of CORT onto the anterior pituitary and PVN, 
preventing the release of ACTH and CRH, respectively. Peak CORT secretion occurs just 
prior to wakening, in preparation for the onset of activity, with the levels decreasing 






Figure 1.7 The HPA axis in Cushing’s disease. A measure of cortisol over a 24h period 
in a healthy individual (A) and from a patient diagnosed with Cushing’s disease (B). 
(Henley et al. 2009; Van Cauter & Refetoff 1985) 
 
Cushing’s disease can be characterised by excess levels of cortisol secretion, caused by a 
cortisol secreting adenoma in the cortex of the adrenal gland (~30%) or as a small benign 
tumour in the pituitary (70%). In these examples, the adrenal adenoma secretes cortisol at 
a high level irrespective of time of day, and negative feedback onto the pituitary from this 
high cortisol level, causes ACTH levels to remain low. However, a tumour of the pituitary 
produces excess levels of ACTH, in turn causing the adrenal gland to secrete prolonged, 
high levels of cortisol. Cushing’s symptoms are varied, but can include, excessive or 
sudden weight gain, a decrease in muscle mass and bone density, as well as cognitive 
dysfunction, sleep impairment and depression (Nieman et al. 2008).     
 
Although Cushing’s can be characterised as an adrenal or pituitary tumour that allows for 
the continuous secretion of cortisol, the most common cause of Cushing’s syndrome is 
glucocorticoid treatment. Steroids prescribed for a prolonged period of time, such as for 
asthma, arthritis or colitis, can induce similar effects to what is observed in patients with 
Cushing’s disease. The incidence of Cushing’s is 1 in 200,000, however the frequency is 
believed to be higher as the symptoms are so wide ranging, the diagnosis may not be 






1.5.2 Synthetic glucocorticoids  
 
Since the discovery of cortisone and cortisol in 1935 and the subsequent successful use of 
cortisone as a treatment of rheumatoid arthritis, glucocorticoids have been recognised to be 
beneficial in the treatment of many disorders (Barrow et al. 1951). 
 
Synthetic glucocorticoids are a commonly prescribed class of drugs that are used to treat a 
variety of conditions. They are administered as replacement therapy in patients with 
primary and secondary adrenal insufficiency, as well as for adrenal suppression therapy in 
congenital adrenal hyperplasia and glucocorticoid resistance. They are also used for a range 
of non-endocrine disorders, such as treating skin conditions like dermatitis and 
rheumatological diseases like systemic lupus erythematosus due to their 
immunosuppressive and anti-inflammatory properties. In the UK, nearly 2% of the adult 
population use oral GCs at any given time (Overman et al. 2013; van Staa et al. 2000). 
Dosing, route of delivery and timeline of treatment range significantly and depend on the 
severity, and responsiveness of the condition being treated.   
 
Methylprednisolone is Prednisolone with a methyl group attached at position 6 rendering 
it water soluble and can therefore be given intravenously and at very high doses over a 
short period of time. It was first given approval for medical use in 1955. It is primarily 
prescribed as an immunosuppressant, with clinical use ranging from alleviating skin 
inflammation, to organ transplantation and spinal cord injury inflammatory suppression 
(Tambe et al. 2010; Hurlbert 2000). In rat, the plasma corticosterone half-life is 15min 
(Sainio et al. 1988). In humans, plasma cortisol half-life is 66min (Weitzman et al. 1971) 
whereas the plasma methylprednisolone half-life ranged from 2.2 - 4.14h (Uhl et al. 2002; 
Sprague 1966; Al-Habet & Rogers 1989).   
     
Table 1.3 Steroid dosage and disease state. 
Dose mg per day Condition 
Low <10 Rheumatoid arthritis (Conn 2001) 
Medium 10-20 Ulcerative colitis, Crohn’s (Sandborn et al. 2012) 
High >20 Giant cell arteritis (Hayreh & Zimmerman 2003)   
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1.5.2.1 Side effects of synthetic glucocorticoid use 
 
As with most prescribed treatments, glucocorticoids do not come without side effects. Side 
effects of glucocorticoid treatment vary greatly, depending on the method of application, 
dose and period of treatment required. Low dose steroids, commonly found in asthma 
inhalers have few side effects, with the most common being hoarseness of the throat (Lévy 
et al. 2003). Whereas mid to high dose steroid use can result in more serious side effects, 
however these are more often prescribed in acute serious illness, rather than as long-term 
care (Bone et al. 1987; Short et al. 2000; Zorzon et al. 2005). However, following high dose 
glucocorticoid treatment, a patient study found evidence of mania and depression, as well 
as changes to cognitive function, assessed using verbal and declarative working memory 
tasks (Brown & Chandler 2001).    
 
1.6.  Corticosteroid receptor signalling and action 
 
The steroid hormone receptors are an evolutionary conserved subset of the nuclear receptor 
superfamily. Nuclear receptors are a group of proteins with sequence and structure 
similarity, with all possessing three major functional domains: the C-terminal ligand 
binding domain, a DNA binding domain and the N-terminal domain. Nuclear receptors are 
diverse in their functional output, controlling homeostasis, metabolism and development. 
These receptors are ligand activated transcription factors, and following activation by 
hormone binding, the receptors bind to regulatory DNA regions of target genes to initiate 
transcriptional activation or repression.   
 
1.6.1 Steroid receptor structure  
 
Steroid receptors have three important, functional regions: The N-terminal domain (NTD), 
which contains the activation function domain 1 (AF1), and acts in a ligand-independent 
manner. A central DNA binding domain (DBD) and a C-terminal ligand-binding domain 
(LBD), containing the ligand-dependent activation function 2 (AF2) site, which is tightly 
regulated by hormone binding. The LBD is connected to the NTD by a hinge region, 
enabling the receptors to act as ligand-activated transcription factors, binding to specific 
DNA sequences and recruiting other factors via the AF sites to evoke a high level of 
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transcriptional regulation (Carson-Jurica et al. 1990; Kumar & Thompson 1999; Kumar & 
Thompson 2005; Khan et al. 2011).  
 
The type 1 and type 2 corticosteroid receptors (GR and MR) were both cloned by 1987 
(Giguere et al. 1986; Arriza et al. 1987) and were found to be very similar in structure and 
function, which has led to research into MR versus GR specificity, in particular in tissues 
such as the hippocampus, where they are co-expressed.  
 
The LBD consists of 12 helices that fold into a globular structure, each consisting of three 
sets of helices forming the sides and top of the globule, creating a central hydrophobic 
pocket where the ligand can bind. For the glucocorticoid receptor (GR), this structure is 
held in an open configuration by the association of chaperone proteins such as heat shock 
proteins (HSPs).   
 
The DBD contains two zinc finger motifs which are responsible for recognition and binding 
to target regions of DNA known as glucocorticoid response elements (GREs). With GR, 
the first zinc finger comprises a P-box with a glycine, serine and valine that interact with 
specificity to the GRE. The second zinc finger is required for receptor dimerization, which 
for GR is vital for transactivation of target genes. In vitro studies have showed that GR 
binds as an inverted dimer to two 6bp palindromic sequences, separated by a 3bp spacer. 
These two zinc fingers can therefore work together to promote GR binding with the first 
zinc finger binding to the first half of the palindromic sequence, and the second zinc finger 
enabling the binding of another GR to the other half of the palindromic sequence. Binding 
of a homodimer to the GRE of specific genes can promote transactivation.  
 
The NTD is highly variable depending on the receptor but contains the ligand-independent 
activation function 1 site. AF1 in this region has been shown to communicate with 
coactivators, chromatin modulators as well as basal transcription factors including RNA 
polymerase II and TATA binding protein to initiate transcription. In the GR, the AF1 site 
remains relatively unfolded in the basal state, whilst it forms a significantly complex helical 
structure in response to binding to cofactors, including TBP and p160 coactivators (Khan 





Figure 1.8 Structure of the glucocorticoid receptor. (a) Gene encoding the 
glucocorticoid receptor. The receptor is encoded by 9 exons, with the encoding region 
indicated by peach coloured boxes. Alternative splicing of exon 9 produces the a and b 
isoforms. (b) The structure of the receptor. The NTD contains the major transactivation 
function domain AF-1. The DBD consists of two a-helices, coordinating two zinc atoms 
and is important for dimerization, nuclear translocation and binding to glucocorticoid 
response elements. The LBD and DBD are joined by a hinge region. The LBD undergoes 
a conformational change when it binds ligand, enabling the interaction with other 
coregulator proteins. Heat-shock proteins bind in this region and it also contains the 
activation function domain AF-2. The receptor is subject to post-translational modification, 
impacting on its function. Abbreviations: P, sites of phosphorylation on serine and 
threonine residues; U, site of ubiquitination; SUMO, sites of SUMOylation (post-
translational modification mediated by small, ubiquitin-related modifier proteins). Adapted 
from Rekers et al. 2016.    
 
1.6.2 Steroid receptor binding 
 
Endogenous mammalian GC actions are mediated via two corticosteroid receptors. The 
high affinity mineralocorticoid receptor (MR), originally termed the Type 1 corticosteroid 
receptor but now termed NR3C2 and the low affinity glucocorticoid receptor (GR), 





1.6.2.1 Binding affinities for CORT, MPL and DEX 
 
Glucocorticoids are secreted from the adrenal gland in a circadian pattern which is driven 
by ultradian pulses of increasing amplitude in anticipation of the active period. The 
endogenous Corticosterone, or cortisol in human, binds to the MR in a 10-fold greater 
affinity than that of the GR (Reul & Kloet 1985). During low levels of glucocorticoid 
secretion from the adrenal i.e. during the inactive phase, the MR remains occupied, but the 
GR is not. It is only during higher levels of circulating glucocorticoid that the GR becomes 
occupied, i.e. during the active phase, or during a stress response (Mifsud & Reul 2016). 
The ultradian rhythm of 1hr pulses of CORT release are also important to note. During the 
active phase, CORT will bind to the GR for ~20 minutes, before dissociating from the GR 
following GR:DNA binding (Conway-Campbell et al. 2012). This dissociation occurs as 
circulating CORT decreases in these individual pulses. Previously, the MR was believed to 
remain at near maximal ligand occupancy during the circadian peak and nadir (Reul & 
Kloet 1985; Reul & de Kloet 1986), however more recent evidence suggests that the MR, 
similarly to GR, is bound in a circadian pattern, at least on the Fkbp5, Per1 and Sgk1 gene, 
and that in the presence of an acute stressor, the binding of MR on Fkbp5 is further 
increased (Mifsud & Reul 2016).   
 
Methylprednisolone binds to the GR and MR with similar affinity to that of endogenous 
glucocorticoids. However, the binding period is significantly different, with 
methylprednisolone binding to the GR for ~6h. Dexamethasone, another glucocorticoid 
steroid significantly more potent than methylprednisolone binds to the GR for ~12h (E Earl 
et al. 2018).     
 
1.6.3 Expression of GR and MR 
 
GR is widely expressed throughout most cells and tissue types in the body. In the brain, 
GR has been found to be highly abundant in the hippocampus (HC) and medial prefrontal 
cortex (mPFC), as well as being expressed within the AMY, areas that are associated with 
memory and learning processes (Reul & de Kloet 1986). The pyramidal cells of the CA1 
and CA2 regions of the HC have been shown to express GR highly, as well as the granular 
cells of the DG (Van Eekelen et al. 1988).  High levels of GR have also been shown in the 
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cerebellar cortex, olfactory cortex, thalamus, hypothalamus, dorsal nucleus raphe and locus 
coeruleus (Ahima & Harlan 1990; Reul & Kloet 1985). 
 
MR is generally reported to exhibit a more restricted expression profile throughout the 
body, with notably high levels of expression in the kidney and adipose tissue (Edwards et 
al. 1988). In the brain MR expression has been reported in the PFC, the MeA and CeA, 
lateral septum, thalamic nuclei and hypothalamic nuclei (Diorio et al. 1993; Mitra et al. 
2009; Han et al. 2005).  However, the highest expression of MR has been reported in the 
CA1, CA2, CA3 and the DG of the hippocampus (Reul & de Kloet 1986). However, a 
recent study in the Parus major has shown that MR is prevalent across many areas of the 
brain including the locus coeruleus and the oculomotor nerve (Senft et al. 2016), therefore 
it may still remain to be seen how widespread MR expression is in humans and 
experimental rodents.  
 
In previous studies, the GR and MR were undetectable within the SCN, leading researchers 
to believe that glucocorticoid steroids do not bind and regulate within this highly significant 
brain area. However, these receptors are expressed in high abundance in the HC to detect 
circulating GCs and modulate the negative feedback inhibition of the HPA axis through 
stress and circadian variations of GCs (Buchanan et al. 2004). Blocking or deleting the GR 
in the HC diminished the inhibitory influence on the HPA axis, increased CORT levels and 
caused GC resistance to negative feedback inhibition of the axis (Boyle et al. 2005).    
 
1.7. Research statement 
 
Circadian rhythms and the genes that comprise the molecular clock are important for 
driving the daily changes to the environment that one is presented with. The molecular 
clock has been studied extensively, with affected change observed in psychiatric and mood-
related disorders, an increased risk in cardiovascular and diabetes diseases, as well as 
affective state changes to sleep and memory loss. However, the underlying mechanisms 
driving these changes remains unknown.  
 
Glucocorticoids, which are produced endogenously and driven by circadian cues target 
almost every area of the body, influencing a variety of physiological processes such as 
glucose metabolism, immune and inflammatory responses, and mental functions, such as 
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promoting memory processing. They maintain homeostatic mechanisms and are the major 
factor secreted in response to stress. However, glucocorticoids are the most important and 
most frequently prescribed class of anti-inflammatory drugs to this day, with almost 2% of 
the UK population being prescribed oral glucocorticoids at any given time, with little 
evidence to show what effects taking glucocorticoids has on the brain, when taken 
throughout the day. Unlike endogenous glucocorticoids which are rapidly metabolised in 
vivo to produce short lived pulses and associated GR activation, synthetic glucocorticoids, 
and in particular, Methylprednisolone, has a prolonged half-life (biological – 18-36h) in 
the circulation that activates the GR and MR for much longer than its endogenous 
counterpart. Methylprednisolone was synthetised from the endogenous glucocorticoid, 
Cortisol, and therefore binds to both the GR and MR with similar affinity.    
 
Patients who are prescribed synthetic glucocorticoids often complain of poor sleep, and 
evidence-based studies indicate an effect of memory impairment in patients prescribed 
glucocorticoids, however the mechanism causing this remains unknown.  
 
Glucocorticoids have been shown to promote the transcription of Period 1, a major 
component of the molecular clock, in the liver and hippocampus, with alterations to this 
gene causing memory deficits and sleep disturbances in the latter.   
 
1.8. Hypothesis and aims 
 
Therefore, using Methylprednisolone to blunt the endogenous secretion of glucocorticoid 
whilst maintaining high circulating levels of synthetic glucocorticoid, I hypothesise that 
prolonged activation of the glucocorticoid receptor in peripheral tissues to the master clock 
in the SCN, such as the hippocampus, would lead to dysregulation of the molecular clock, 
uncoupling the timing of the peripheral clock from the central clock, affecting sleep and 
memory processing.   
 
Chapter 3: Compare the expression of core clock genes in the SCN in response to MPL 
treatment to confirm a lack of effect of this synthetic glucocorticoid on the master clock 
 
Chapter 4: Assess the expression of core clock genes and glucocorticoid regulated genes in 
the hippocampus using RNAseq in response to treatment with MPL 
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Chapter 5: Measure locomotor activity and core body temperature in animals following 
MPL treatment 
 
Chapter 6: Measure brain activity, in particular during sleep, following a hippocampal 











































2.1. Animals and treatments 
 
Adult male Lister hooded rats (250-350g, 9-11 weeks) (Envigo, UK) were used in all 
experimental procedures. Animals were maintained in standard housing conditions under 
a 12:12 light/dark cycle. Food and water were available ad libitum. All procedures were 
carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 under 
PPL 30/3114 and PIL I04092F5F. 
  
2.1.1 Surgery under general anaesthesia 
 
Animals used in the described experiments were subjected to a combination of procedures 
detailed below.  Individual chapter methods sections provide exact details of the 
combination of surgeries and treatments applied for each experiment.  Rats were 
anaesthetised using a combination of gaseous isoflurane (Merial, UK) and medical grade 
air.  During all surgical procedures and recovery, body temperature was maintained using 
heat pads. Aseptic technique, sterilized drapes and autoclaved surgical tools were used 
throughout.    
 
2.1.2 Telemetry probe implantation 
 
Anaesthetised rats were placed on their front. A section of the mid-back was shaved and 
disinfected with Hibitane. A midline incision was made along the midline rostro-caudally 
to expose subcutaneous tissue and muscle sitting over the rib cage. Following identification 
of landmarks along the spine, an incision was made through the muscle wall and into the 
peritoneal cavity near to the liver. Blunt scissors stretched the incision site to allow for the 
implantation of the telemeter (PTD 4000 E-mitter, Starr Life Sciences Corp). The sterilised 
telemeter was inserted into the abdominal space and sutured to the muscle wall closing in 
the process. The midline skin incision was closed using individual suture knots. The wound 
was cleaned and treated with wound powder to aid healing.  
 
2.1.3 Antagonist implantation 
 
Following telemetry probe implantation, the rats received subcutaneous implantation of a 
slow-release pellet (Innovative Research of America, US) between the shoulder blades. At 
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the start of surgery, a section of the nape of the neck was shaved and disinfected with 
Hibitane. An incision along the midline of the back was made followed by blunt dissection 
to make a pocket for pellet placement. The slow-release pellet was placed under the skin 
far enough away from the incision site to cause adverse effects. When implanting the GR 
(Mifepristone (RU-486), cat no. X-999) and MR (Spironolactone, cat no. M-161) 
antagonists together, they were placed on opposing sides of the midline to prevent cross 
reaction. The wound was sutured using conventional techniques and wound powder was 
applied to aid healing.    
 
2.1.4 Local field potential drive implantation  
  
Rats were implanted with multi-site electrode arrays (EIB-36, Neurolynx, US) targeting 
the Prelimbic (PrL) area of the prefrontal cortex and the dorsal CA1 area of the 
hippocampus. A minimum of 1 week was allowed for recovery, during which the animals 
were handled daily and habituated to the behavioural arena and recording environment 5 
days prior to experiment start.  
 
2.1.5 Post-operative care 
 
Immediate post-operative pain relief was administered with 1mg subcutaneous Carprofen 
(Rimadyl, Pfizer, UK). Fluids were replaced by subcutaneous injection of 2.5ml of glucose 
saline (0.9% NaCl, 5% Glucose) (Braun, Germany). Following surgical recovery defined 
by reacquisition of the righting reflex, animals were transferred to clean housing ready for 
experimental procedures. 
 
2.1.6 Administration of drug 
  
Methylprednisolone (MPL) (Solu-Medrone, Pfizer, UK) solution was provided in drinking 
water ad libitum. Treatment lasted five days. MPL was made up in accordance with the 
supplier directions, then diluted with tap water to give a final concentration of 1mg/ml. To 
preserve stability of MPL, bottles were protected from light and drinking solution was 
replaced every two days. MPL was provided in drinking water to limit possible stress 
effects of administration via other routes such as oral gavage, and subcutaneous and 
intraperitoneal injections. As the biological half-life of MPL is 18-36h, multiple injections 
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would be required to retain elevated circulating glucocorticoid levels. Providing treatment 
ad libitum in drinking water was able to bypass such parameters. Rats were individually 
housed and drinking water was monitored daily to confirm drug administration. Body 
weight was also measured daily as a known measure of steroid therapy (Azcue et al. 1997).   
 
2.1.7 Death and Dissection 
 
For all experimental settings animals were anaesthetised using a combination of gaseous 
isoflurane and medical grade air and then decapitated. Brains were either rapidly dissected 
on ice for hippocampal isolation or whole brains frozen on dry ice for dissection on a 
cryostat. Hippocampal tissue was rapidly dissected and frozen in liquid Nitrogen. Blood 
was collected from the trunk into tubes containing Ethylenediaminetetraacetic acid 
(EDTA) and plasma was obtained following centrifugation at 4000rpm for 10 minutes at 
4C and stored at -20C until corticosterone was measured by radioimmunoassay. 
 
2.2. RNA extraction 
 
2.2.1 Sample preparation 
 
Whole brains were rapidly removed from the skull following decapitation. Hippocampal 
tissue was dissected immediately on ice and flash frozen in liquid nitrogen in preparation 
for RNA extraction. SCN tissue was sliced using a cryostat on whole brains that were 
frozen rapidly on dry ice.  
 
2.2.2 RNA quality assessment 
 
All extracted RNA samples were first assessed for RNA quality and quantity using a 
Nanodrop (ThermoScientific, US). Samples sent for RNA sequencing were further 






2.2.3 RNA extraction protocol 
 
2.2.3.1 Suprachiasmatic nucleus 
 
Frozen whole brains were given time to increase in temperature to be able to slice 
accurately within the cryostat. Object and chamber temperature were both set at -10C for 
slices 200µm thick to prevent tissue cracking. SCN coordinates were identified from The 
Rat Brain in Stereotaxic Coordinates (Paxinos & Watson 2007). Brains were sliced rostro-
caudally and the start of the SCN was identified at Bregma -0.92mm. Serial slices 200µm 
thick were taken and ceased at bregma -1.72, within the retrochiasmatic area. A single 1mm 
punch (Sample corer, 18035-01, Fine Science Tools, Germany) was taken from each of the 
four slices in the location of the SCN and stored in a 1.5mL eppendorf tube, kept on dry 
ice until transferred the RNA extraction protocol. 400µL of TRIzol (ThermoFisher 
Scientific, US) was added to each tube and vortexed at high speed for 2x10 seconds, with 
a rest period in between. Direct-zol total RNA extraction kit (Zymo Research, US) was 
used, following the manufacturer’s protocol, including the DNase digestion step. Samples 
were stored at -80C. 
       
2.2.3.2 Hippocampus    
 
Frozen whole hippocampal tissue was placed into individual tubes stored in dry ice. 1mL 
of TRIzol (ThermoFisher Scientific, US) was added to each tube and each sample was 
immediately homogenised using a mechanical homogeniser (Polytron PT-2100, 
Kinematica, Switzerland). Following complete homogenisation of sample, 300µL of 
chloroform (Sigma-Aldrich, UK) was added to each sample and mixed by inversion. 
Samples were spun for 15 minutes at 4C, >10,000rpm for phase separation. The aqueous 
phase was removed by pipette, avoiding the organic phase below and placed into a fresh 
1.5mL tube. Total RNA was extracted using the miRNeasy total RNA extraction kit 
protocol (Qiagen, US) following the manufacturer’s guide and included a DNase digestion 





2.2.4 cDNA synthesis 
 
RNA samples were measured for purity and quantity on a Nanodrop 2000C (ThermoFisher 
Scientific, US) and a total of 1g of RNA was used to synthesise cDNA using iScript cDNA 
synthesis kit (BioRad, US), as per the manufacturer’s protocol.  
 
2.3. RNA sequencing 
 
2.3.1 Sample preparation 
 
RNA sequencing of hippocampal tissue was carried out using TruSeq Stranded Total RNA 
kit and protocols (Illumina, US). A 1ug aliquot of total RNA from each hippocampus was 
prepared for RNA sequencing. 48 samples total. First, bioanalyzer traces were carried out 
on all samples for RNA quantity and quality check. RIN scores above 8.0 were deemed 
high enough quality to take through to RNA sequencing. Below is a workflow of the library 
preparation (Figure 2.1). 
Figure 2.1 Workflow of TruSeq sample preparation protocol. Adapted from Illumina 
TruSeq Stranded Total RNA Sample Preparation Guide.   
 
2.3.2 RNA sequencing protocol 
 
Following library preparation, the samples were run on a HiSeq 2500 machine (Illumina, 
US). 8 samples were run in each lane, in a paired end sequencing run, generating 
1ug of Total RNA
RiboZero Deplete 
and Fragment RNA
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approximately 300 million reads across the 8 samples. This equated to ~37.5million reads 
per sample.     
 
2.4. Quantitative Polymerase Chain Reaction 
  
Quantitative Polymerase Chain Reaction was used to assess mRNA transcript levels across 
time points and treatments using ThermoFisher Scientific reagents.  
 
2.4.1 Sample preparation and primer design 
 
Primers for RNA analysis were designed NCBI BLAST Primer design tool 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi) or taken from the literature for all Sybr Green 
assays. Primer length was designed to be between 60-150bp in length. Nuclease free water 
was added to each lyophilised primer to give a stock concentration of 100M. 20L of 
stock primer was added to 980L of nuclease free water, creating a working primer 
concentration of 2M. A standard curve for each primer was produced to assess primer 
efficiency and to validate the absence of primer dimers. Serial dilutions of cDNA for RNA 
analysis were prepared to provide a range of cycle threshold (Ct) values that were 
anticipated would cover the range of values expected to be produced by samples. Taqman 
primers were designed by Life Technologies (ThermoFisher Scientific, US).     
 
Table 2.1 mRNA primer sequences used for Sybr Green qPCR  
Gene Forward Primer Reverse Primer 
Per 1 CCTCGATGTAACGGCTTGTGT GTCCGAGTGGCCAGGATCT 
Per 2 CGAAGCGCCTCATTCCAGAG TGCTCATGTCCACGTCTTCC 
Cry 1 AGAGGACGCACAGAGTGTTG CCTCCCGCATGCTTTCGTAT 
Cry 2 CTGCGTCTACATCCTCGACC GCAGTAGGAACCTCCATCGG 
Bmal1 TGCCACTGACTACCAAGAAAGT GGGCCTCCCTTGCATTTTTG 
Clock CACAAGGCATGTCACAGTTTCA TCTATCATGCGTGTCCGCTG 
Npas2 CCGCCTCTCCTTACTGCTTA AGAGGCTCTCTTTGCTCTATCC 
Rev-erb CCCTGGCATGACCAAGAGTC TGAAGAAGCCCTTACAGCCT 
Ror GGGATCAAACCCGAACCCAT GCAAGGTGTTCTAGTTCCGC 
Act CGCGAGTACAACCTTCTTGC CGTCATCCATGGCGAACTGG 
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Table 2.2 mRNA primer accession codes for Taqman qPCR  
Gene Accession code 
Period 1 Rn01325256_m1 




Table 2.3 Reaction quantities for Sybr Green qPCR 
Reaction component Volume per well (µL) 
Fast Sybr®Green Master mix 5 
Forward Primer 1.5 
Reverse Primer 1.5 
Nuclease-free water 1 
cDNA sample 1 
Total Reaction volume 10 
 
Table 2.4 Reaction quantities for Taqman qPCR 
Reaction component Volume per well (µL) 
Taqman Mastermix (2x) 5 
Taqman Assay (20x) 0.5 
Nuclease-free water 3.5 
cDNA sample 1 
Total Reaction volume 10  
  
2.4.2 qPCR reaction 
 
qPCR determined the approximate levels of mRNA transcripts in RNA samples. 
Experiments were performed using 96-well plates (Applied Biosystems, Life 
Technologies, UK) with a 10µL final reaction per well (Tables 2.3 and 2.4). Each PCR 
reaction contained 1µL of cDNA. Samples were pipetted in duplicate and a no template 
control (NTC) was added to each plate to assess for contamination. MicroAmp Optical 
Adhesive film (Applied Biosystems, Life Technologies, UK) was used to seal plates. Plates 
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were spun to ensure samples were at the bottom of each well prior to amplification. A 
StepOnePlus PCR machine (Applied Biosystems, Life Technologies, UK) was used. The 
Taqman and Sybr®Green qPCR runs consisted of an initial 95C holding stage for 20 
seconds, followed by 40 cycles of 95C (1 second) and 60C (20 second). However, the 
Sybr®Green run also contained a melt curve step, consisting of 40 cycles of 95C (15 
seconds) and 60C (1 minute), with a final denaturing step of 95C (15 seconds).          
  
2.5. Radioimmunoassay for Corticosterone 
 
Using an automated gamma counter (PerkinElmer, US), a CORT radioimmunoassay was 
carried out to assess CORT levels in blood samples collected from trunk blood.  
 
An 11-point standard curve of known CORT concentrations was prepared in B-buffer 
(25mM tri-sodium citrate, 50mM sodium dihydrogen orthophosphate, 1mg/mL bovine 
serum albumin: pH3). Plasma obtained either from the automated blood sampler or trunk 
blood was diluted in triplicate at a ratio of either 1:10 or 1:50 in B-buffer, respectively. A 
specific CORT antibody (kindly provided by G. Makara, Institute of Experimental 
Medicine, Budapest, Hungary) was diluted at a ratio of 1:50 in B-buffer and 50l added to 
100uL standards, unknown samples, and Quality Control (QC20 and QC100) tubes. Tracer 
(Izotop, Institute of Isotopes, Hungary) was diluted in B-buffer to give total counts of 
3750cpm in 50l and added to all tubes (50l/tube). Tubes were incubated overnight at 
4C.  
 
Charcoal suspension (5g charcoal added to 0.5g Dextran T70 dissolved in 1L B-buffer) was 
prepared and 500l added to all tubes and briefly vortexed. Blocks were centrifuged at 
4000rpm at 4C and the resulting supernatant aspirated off. Unknown samples were 








2.6. Behavioural Testing 
  
2.6.1 Telemetry recording 
  
Animals were individually housed for telemetry recordings due to technical reasons. Cages 
were placed upon signal receivers (ER-4000 receiver, Starr Life Sciences Corp, US) which 
were connected to a computer that recorded data collection using the VitalView software 
package (Starr Life Sciences Corp, US), from 24 hours post-surgery, into 10-minute 
epochs. Four of eight animals were implanted with telemeters. All received either vehicle 
or MPL in drinking water, or MPL with either GR (X-999, Innovative Research of 
America, US) or MR (M-161, Innovative Research of America, US) antagonism, or a 
combination of both. MPL treatment started 1 day following surgery. Locomotor activity 
and body temperature recording continued for 5 days.  
 
2.6.2 Novel Object Location task 
 
The novel object location task, a hippocampal specific memory task, was used in 




Exploration occurred in an open-top arena (50 x 90 x 100cm) made of wood. The walls 
inside the arena were black in colour and floor covered in sawdust. An overhead camera 
and video recorder were used to monitor behaviour for analysis at a later date. The objects 
presented as stimuli were constructed from Duplo blocks and varied in shape, size and 




After acclimatising to the facility and being handled for a week prior to experimental start, 
the animals were habituated to the arena without stimuli for 10 minutes daily for 5 days 




2.6.2.3 Novel Object Location task 
 
The task comprised of an acquisition and test phase separated by a 6h delay. During the 
acquisition phase, each rat was placed into the arena at the same position facing the wall. 
The arena contained identical objects in the far side corners of the arena, 10cm away from 
the walls to allow full access around the object. The rats were allowed to investigate the 
objects for 4 minutes and then returned to the sleep box until the test phase. In between 
each animal, the objects were cleaned with ethanol and the sawdust reset. The test phase 
lasted 3 minutes and consisted of one of the objects being moved to the opposite corner 
with the other object remaining in its original position. The position of the object was 
counter balanced between rats. Throughout the task, the rat was tethered for 
electrophysiology recordings. 
 
2.6.3 Electrophysiology recordings 
 
Electrical signal was acquired using a Digital Lynx 4 SX system (Neuralynx, USA) and 
recording using the PC software Cheetah (Neuralynx, USA). All behavioural and sleep 
recordings were carried out during the active period of the rat. The rats were placed in a 
sound-attenuating chamber for a 2h recording, followed by a 4min object location sample 
phase experiment in a behavioural arena. The rats were placed back into the sound-
attenuating chamber for a further 6h recording. Following the 6h delay period, the rats were 
replaced into the behavioural arena with one of the objects moved to a novel location. In 
order to measure the rats movement, a video recording was captured above the sound-
attenuating chamber and above the behavioural arena. These movement data were used 
alongside the electrophysiology data to manually score arousal state in 10sec epochs. 
Epochs was scored as wake if movement was high. Non-rapid eye movement (NREM) was 
scored if there was low movement and ripples and slow-waves on the local field potential 
(LFP) drive. After the final experiment, animals were deeply anaesthetised with sodium 
pentobarbital (60mg/kg). A positive current of 30M was passed through each channel in 
order to create a lesion at the tip of the electrode before the rat was perfused transcardially 
with 0.9% saline (Braun, Germany) followed by 4% paraformaldehyde (Sigma-Aldrich, 
UK). Brains were dissected and stored for 48h in paraformaldehyde before being 
transferred to 30% sucrose. 50m coronal sections were cut using a freezing microtome 
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and Nissl-stained with thionin. Lesions were identified as a darkened ring of damaged 
tissue and checked for correct location using the rat brain atlas (Paxinos & Watson 2007). 
n = 5 per group.   
 
2.7. Statistical Analyses 
  
GraphPad Prism version 7 (GraphPad software Inc., US) was used to analyse data by One-
way or Two-way ANOVA with suitable post-hoc test. T-tests were also carried out in 
Prism. For each result, the statistical test used is stated. The mean and standard error of the 
mean (SEM) were also calculated.  
 
2.7.1 Whole genome RNA sequencing 
 
High-throughput RNA sequencing raw data were uploaded to Galaxy, an open access portal 
for next-generation sequencing analysis (www.galaxyproject.org). For each condition, a N 
of 4 was used in each group, and three lanes of data were collected for each sample. A 
workflow was run to generate a BAM file (Sequence aligned data file) (Figure 2.2). The 
BAM files from each of the three lanes were merged. The merged BAM files were then 
analysed for gene expression differences using CuffDiff analysis. The CuffDiff parameters 
included geometric library organisation, pooled dispersion estimation and the false 
discovery rate was set at 0.05. Minimum alignment count – 10, multi-read correct, bias 
correction and CuffLinks effective length correction. Differential gene expression was 
calculated from fragments per kilobase per million mapped reads (FKPM) values. 
Differential expression was assessed between all time points and across both treatment 
groups using CuffDiff, a statistical package widely used which encompasses a test 
statistical model of T = E[log(y)]/Var[log(y)], where y is the ratio of the normalized counts 
between two conditions, and this ratio approximately follows a normal distribution, which 
is why a t-test is used to calculate the P-value. Multiple hypothesis correction was carried 
out using the Benjamini-Hochberg test, which lowers the false discovery rate using the 
formula (i/m)Q, where i = individual P value, m = total number of tests and Q is the false 
discovery rate. Data deemed statistically significant by the programme were FDR < 0.05. 
supraHex analysis was used to aid visualisation of expression patterns in the data (Fang & 
Gough 2014).    
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Figure 2.2 Schematic of the differential gene expression pipeline 
(www.Galaxyproject.org). 
 
2.7.2 quantitative PCR  
 
StepOne Software (Life Technologies, UK) was used to analyse all samples.  Baselines and 
thresholds were defined and set automatically.  The corresponding data file was exported 
to Microsoft Excel for further analysis. 
 
All Sybr Green data were analysed using the standard curve method. All Taqman data were 
analysed using the Ct method.  actin was used as an endogenous control throughout. 
Fold change was determined relative to ZT2 samples. Analysis methods described below: 
 
Standard curve analysis: 
 
1. The numbers generated from the standard curve for each duplicate for the gene of 
interest (GOI) and endogenous control (ECon) was obtained  
2. An average of the ZT2 GOI and ECon values were obtained (Ct calibrator) 
3. The value from each GOI and ECon was divided with result from step 2 
4. The output from step 3 was divided (GOI/ECon) for each sample 
5. An average of the duplicate sample was taken, giving fold change data 
Input dataset 1 (FOR)







In this library mate-paired? Paired-end
Mean inner distance between mate pairs = 300
St. Dev for distance between mate pairs = 100
Report discordant pair alignment = Yes
Use a built-in reference genome = Rn6
Tophat settings
Max realign edit distance = 1000
Max edit distance = 2
Library type = FR First strand
Final read mismatches = 2
Use bowtie –n mode = no
Anchor length (at least 3) = 8
Minimum intron length = 70
Maximum intron length = 500000
Allow indel search = Yes
Max insertion length = 3
Max deletion length = 3
Maximum number of alignments allowed = 20
Minimum intron length that may be found during split-segment search = 50
Maximum intron length that may be found during split-segment search = 500000
Number of mismatches allowed in each segment = 2
Minimum length of read segments = 25
Use own junctions = no
Use coverage search = no
Use microexon search = no
Do fusion search = no
Set bowtie2 settings = no
Specify read group = no
Default job resource parameters 
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Ct analysis:  
 
1. The Ct values generated for the gene of interest (GOI) and endogenous control 
(ECon) was obtained  
2. An average of the ZT2 GOI and ECon values were obtained 
3. The Ct of each sample of the ECon was subtracted from the GOI (Ct) 
4. Ct = 2-(Ct - Ct calibrator) produced relative expression across samples 
 
Normalised data were further analysed using GraphPad Prism (Version 7.0; GraphPad 
Software, Inc., USA). All graphs are expressed as mean ± SEM unless otherwise stated. 
Specific analysis methods used are described with each result. Calculated values of P<0.05 
were considered statistically significant. 
  
2.7.3 Locomotor activity and core body temperature 
 
Locomotor activity and core body temperature data were collected in 10-minute epochs 
using VitalView software (Starr Life Sciences Corp, US). MATLAB (v2016b, MathWorks, 
US) was used to analyse and plot the data using an in-house script consisting of Wavelet 
transform spectral analysis and Lomb-Scargle Periodogram. Rhythms are commonly 
assessed in biology, with varying analysis packages and techniques to understand rhythmic 
periods in a dataset. Often, actograms are used to analyse locomotor activity however these 
datasets are generally large, consisting of 2+ weeks of data (Leise et al. 2013). However, 
due to the experimental design, LA and cBT were recorded for only 5 days, which is an 
insufficient period length to run with actogram programs. Therefore, wavelet transform 
was utilised to assess periodicity. It has been used for many years in the field of physical 
sciences but is relatively new to the field of circadian biology. It is a technique that 
processes rhythmic signals, or wavelets, in a dataset. This is a unique property to this signal 
processing technique, as these signals can be symmetric or non-symmetric, high or low 
frequency, and be identified in regular or irregular datasets (Hoang Dang 2014). It allows 
for discrete identification of rhythms, or independent frequencies within a dataset, and in 
conjunction with using the Lomb-Scargle periodogram, which detects rhythmic signals 
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based upon a least squares fit of sinusoidal data (Hocke 1998) from sample data with zero 
mean, allows for period length to be measured.  
 
The wavelet transform analysis subsequently identified wavelets, or rhythmic signals 
within the data as a measure of time. The Lomb-Scargle periodogram fits the detrended 
data under the pretense that it is sinusoidal, using the least squares fit method. The script 




All sleep electrophysiology data were analysed using MATLAB (v2016b, MathWorks, 
US). In order to measure the animals movement, a video recording was captured above the 
sound-attenuating chamber. These movement data were used alongside the 
electrophysiology data to manually score arousal state in 10 second epochs. Epochs were 
scored as wake if movement was high. Non-rapid eye movement sleep (NREM) was scored 
if there was low movement and ripples and slow-waves were recorded on the LFP (Delta 
wave; 0.5-2Hz). Ripples were characterized by sharp bursts of neural activity within slow 
waves. Rapid eye movement sleep (REM) was scored as low levels of movement and theta 
waves on the LFP (Theta wave; 6-10Hz). All analysis was carried out using in-house scripts 
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The molecular clock is a robust mechanism that drives the daily rhythm of cells and tissues 
in preparation for daily environmental changes. This clock is present in all mammalian 
cells tested, however the central clock, located in the SCN, drives peripheral clocks, such 
as those found in the rest of the brain, skeletal muscle, liver and heart, to remain in rhythm 
(Gillette & Tischkau 1999). Light input to the SCN via the retinohypothalamic tract is the 
master entraining signal of daily rhythms (Foster & Hankins 2007; LeGates et al. 2014), 
however, skeletal muscle and liver can be further regulated by food intake and activity 
periods (Hodge et al. 2015).  
 
The importance of circadian rhythms is vast, determining sleeping and feeding patterns, 
whilst also controlling brain activity, hormone production and cell regeneration (Xie et al. 
2015; Welsh et al. 1985; Qian et al. 2012). Sleep-wake disorders, which affects a large 
proportion of the UK, are believed to be caused by alterations in the SCN clock timing, its 
entraining systems, or due to a misalignment of the internal clock rhythm with the external 
environment. Recently, a dissociation between central and peripheral clocks has been 
linked to depression and mental illness in patients (Partonen et al. 2007; Soria et al. 2010; 
Jagannath et al. 2013). It has furthermore been suggested that an altered clock, which is 
observed in patients with Alzheimer’s may be an underlying cause of the disease as the 
sleep/wake cycle regulates the production of amyloid-beta peptide and an alteration to this 
cycle may therefore increase the levels of this peptide in the brain (Bellanti et al. 2017).   
 
Glucocorticoids are the most commonly prescribed class of drugs in the UK today, with 
2% of the population prescribed oral glucocorticoids at any given time (Overman et al. 
2013), with a third reporting continued use of longer than five years. Prolonged use of 
glucocorticoid steroids can lead to several detrimental side effects. A significant number of 
long-term users complain of alterations to their daily activity, sleep period, and impairment 
to memory (Keenan et al. 1996; Coluccia et al. 2008). Side effects observed during 
glucocorticoid therapy are vast, predominantly targeting endocrine systems and metabolic 
systems but they also affect the central nervous system with patients often complaining of 
changes to mood, with a proportion of these reporting bouts of depression, and in severe 
cases, mania (Naber et al. 1996). Therefore, it is important to understand the molecular 
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mechanisms that underlie these severe side effects, a fundamentally important question in 
glucocorticoid research.   
 
The effect of glucocorticoids on the central clock within the SCN has previously been 
assessed, using the potent GR specific agonist, Dexamethasone (Balsalobre et al. 2000). 
No change to the rhythm and timing of the molecular clock or any of its components was 
observed in the SCN, however a phase shift in mRNA expression of the components of the 
molecular clock in the liver, kidney and heart were noted. As glucocorticoids act through 
binding to their cognate receptors, these results were somewhat expected, as previously, 
binding assays targeting the GR and MR could not detect their expression in the SCN (Reul 
& Kloet 1985). In contrast, GR and MR were found to be expressed highly in the HC and 
liver, regions that have since been extensively studied.  
 
The GR and MR reside in the cell cytoplasm and upon binding to ligand, translocate into 
the nucleus, where they bind to specific sequences on DNA called glucocorticoid response 
elements (GREs) to facilitate the recruitment of transcription factors to promote the 
transcription of glucocorticoid regulated genes. In peripheral tissues to the SCN, such as 
the hippocampus and liver, glucocorticoids binding through its receptors, promote the 
expression of the major clock gene Per1, through the glucocorticoid binding site upstream 
of the Per1 transcriptional start site (Reddy et al. 2012). Therefore, in this first chapter, the 
rhythmic expression of Per1, Per2 and one of its transcriptional activators Bmal1, were 
assessed in the SCN following treatment with the glucocorticoid and mineralocorticoid 
agonist Methylprednisolone. Based upon previous findings, no difference was expected 
between the rhythms of the central clock with steroid treatment, even though Per1 is a 
glucocorticoid sensitive and regulated gene (Conway-Campbell et al. 2010; Balsalobre et 
al. 2000), because of a lack of GR in this brain area. Instead the daily rhythm and clock 
machinery was expected to remain in time and rhythm with the controls, driven by the 
major regulator of the clock, the light/dark cycle.   
 
Although the potent glucocorticoid agonist Dexamethasone does not affect clock gene 
expression in the SCN, the well-known glucocorticoid MPL has not been assessed. In this 
chapter, I assessed the effect of MPL on clock gene expression in the SCN, to identify if 





3.2.1 Animal housing and Home Office  
 
96 adult male Lister Hooded rats (250-300g; 9-11 weeks) were obtained from Harlan 
Laboratories, now Envigo (Bicester, UK) and maintained under standard housing 
conditions with a 12:12 light/dark cycle. Food and water were available ad libitum. Rats 
were given an initial period to acclimatise to the facility. All procedures were carried out 
in accordance with the UK Home Office guidelines and the UK Animals (Scientific 
Procedures) Act under PPL 30/3114 and PIL I04092F5F.    
 
3.2.2 Experimental design 
 
Rats were housed in pairs for experimental purposes and were habituated to the 
experimenter for five days prior to the start of experimental procedures and during to 
eliminate effects of stress. Methylprednisolone (1mg/ml in drinking water (Demski-Allen 
2014) (20mg/per day)) treatment lasted five days. Following five days treatment, the 
animals (n=8 per time and treatment) were killed at zeitgeber (ZT) times 2, 6, 10, 14, 18 
and 22. Whole brains were frozen on dry ice and stored at -80C for subsequent RNA 
expression studies. Trunk blood was collected to assess the levels of circulating 
endogenous glucocorticoid in the blood at the time of kill. Group size was determined by 
literature review.   
 
3.2.3 RNA extraction and qPCR  
 
Suprachiasmatic nucleus coordinates were assessed (Paxinos & Watson 2007) and coronal 
sections (4 x 200um) were cut on a cryostat. The SCN was removed using a 1mm 
micropunch. Total RNA was extracted using Direct-zol Miniprep reagents (Zymo 
Research, USA). RNA quality and concentration was assessed using a Nanodrop 
(ThermoFisher Scientific, USA). cDNA was synthesised using the iScript cDNA synthesis 
kit (Biorad, USA). All gene expression assays were carried out using inventoried Taqman 
assays (ThermoFisher Scientific, USA) using a 7500 thermal cycler (ABI systems, USA) 
to assess expression. Period1 (Rn01325256_m1), Period2 (Rn1427704_m1) and Bmal1 
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(Rn00577590_m1). Brains were dissected and all molecular biology techniques were 
blinded to the experimenter. 
  
3.2.4 Radioimmunoassay (RIA) 
 
Trunk blood was collected at all time points and treatment immediately following 
decapitation. Corticosterone levels were measured following an in-house corticosterone 





3.3.1 Assessment of corticosterone levels in blood in control and MPL treated rats  
 
The hypothalamic-pituitary-adrenal (HPA) axis regulates corticosterone secretion from the 
adrenal gland in a circadian profile, driven by activation of the PVN from the SCN. This 
circadian profile is highly conserved across species with the highest levels of CORT 
secreted prior to the onset of the active period. The secretion and presence of CORT is vital 
for many processes, including driving gluconeogenesis in the liver, preparing glucose 
uptake in skeletal muscle for the active period, whilst also driving the consolidation of 
memories and promoting sleep processes, including REM and NREM sleep (Yabaluri & 
Bashyam 2010; Van Cauter et al. 2000; Tatomir et al. 2014). Glucocorticoids are known to 
regulate gene expression, in particular in the liver, where synchronisation of 60% of the 
circadian transcriptome occurs (Reddy et al. 2007). The HPA axis however, can be 
interrupted in the presence of a stressor, where a transient spike of CORT is released from 
the adrenal gland in response to a stress response, to initiate glucocorticoid target systems 
into action. Although the hypothesis was that glucocorticoids would not affect gene 
expression in the SCN, it was still important, for completeness, to assess circulating levels 
of corticosterone in the blood at each time point and treatment to ensure that the molecular 
clock was not affected by stimuli outside of a circadian paradigm, for instance, through 
stress. Using known reference points, from our lab and others, levels deemed ‘stress’ and 
not part of the ‘normal’ CORT levels could be assessed measuring CORT levels in the 
blood. It was also important to confirm that the MPL treated animals were HPA axis 

















Figure 3.1 RIA of the circadian corticosterone profile in control animals and reduced 
corticosterone levels with MPL treatment. In control animals, circulating CORT is 
circadian, as expected from previously published data. Circulating CORT levels in MPL 
treated animals are significantly blunted, with no circadian profile observed and no 
significant difference observed across time points. All data represented as mean ± SEM. N 
= 8 per group. Analysis with Two-way ANOVA with Sidak’s post-hoc test. * represent 
significant effect of time, $ represent significant effect of treatment. All statistical 
significance indicated at P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) and P < 0.0001 (****). 
ZT2 is repeated for visualisation purposes.       
 
The secretion of corticosterone in rodent from the adrenal gland is in response to a cascade 
of hormone production originating from the release of CRH from the PVN. The PVN is 
activated primarily from direct contact with the SCN and therefore is driven predominantly 
by circadian cues. However, the PVN is also activated in the presence of a stressor. Before 
assessing the expression of clock genes within the SCN, it was important to assess the 
circulating levels of GCs in the blood to confirm that the data were a result of circadian 
drive, and not one of a stressor. While the SCN is reported to be unaffected by acute stress, 
we nevertheless wanted to ensure all rats used in the experiment exhibited the expected 


























CORT circadian profile. It was also important to ensure that all MPL treated rats were 
suppressed at this dose, as previously reported (Spiga et al. 2011).  
 
In the control animals there was a clear and significant circadian release of GCs into the 
circulating blood (F6,49 = 4.48, p<0.0001). The levels of CORT were expectantly low during 
the early periods of inactivity (ZT2 – 9.4ng/mL) (ZT6 – 32.5ng/mL) before a clear and 
robust increase in CORT levels was observed (ZT10 – 241.9ng/mL, P=0.0001), 2 hours 
prior to the onset of activity/dark phase, in preparation for the active period. The levels of 
CORT decreased throughout the active period (ZT14 – 213.5ng/mL, P=0.0001), (ZT18 – 
169.6ng/mL, P=0.0001) (ZT22 – 92.3ng/mL, P=0.0344) in preparation for low levels of 
CORT during the early phase of inactivity/sleep phase. Following MPL treatment, the 
secretion of CORT was no longer in a circadian rhythm, with a significant effect of time 
(F6,95 = 20.83, P < 0.0001) and treatment (F1,95 = 163.2, P < 0.0001) observed between 
groups, (ZT10 – P < 0.0001), (ZT14 – P < 0.0001), (ZT18 – P < 0.0001), (ZT22– P=0.001).  
It should be noted that both of these profiles were expected based on previous findings and 
based upon the known activity and feedback circuitry of the HPA axis.  
 
3.3.2 The expression of Per1 in the SCN is altered with MPL treatment 
 
Following confirmation of the expected CORT profile in the control group and suppressed 
CORT in the MPL group, I assessed the effects of time of day and MPL treatment on SCN 
Per1 mRNA expression with reasonable confidence that I had minimised the possibility of 
a potentially confounding stress response.  
 
The rhythmic expression of Per1 mRNA has been extensively studied, both in the SCN 
and in many peripheral tissues. As a major repressor of the molecular clock, PER1’s 
importance in maintaining rhythms has been widely researched with a range of techniques 
including luciferase reporter assays, in situ hybridisation histochemistry and qPCR all 
showing a robust circadian profile. The highest levels of expression are evident prior to the 
active period. Following this high level of expression, the Per1 mRNA is translated to PER 
protein to repress its own activation, as described previously. Therefore, as the day 
progresses further into the active period, the level of Per1 decreases until low levels are 
recorded prior to the sleep period (Peirson et al. 2006; Schwartz et al. 2011).  
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Balsalobre et al. 2000 looked at the expression of core clock genes in the SCN, liver, kidney 
and heart following glucocorticoid treatment, using the potent GR agonist DEX. No effects 
on expression of the SCN clock components were observed following DEX treatment, but 
a shift in phase was observed in the tissues peripheral to the SCN. At the time, the presence 
of the glucocorticoid response element upstream of the Per1 transcriptional start site was 
unknown, however it was recently shown that glucocorticoids can regulate the expression 
of Per1 through this site. The GR is known to be abundantly expressed in the peripheral 
tissues that were sensitive to glucocorticoid-induced phase shift but has not been detected 
in the SCN. Therefore, SCN Per1 mRNA was expected to be unaffected by MPL treatment, 
























































Figure 3.2 Treatment with MPL alters the circadian expression of Per1 mRNA in the 
SCN. In control rats (A), a clear and robust circadian rhythm of Per1 expression is 
observed, with peak expression prior to the onset of the dark, or active phase. Following 
MPL treatment (B), the circadian expression of Per1 mRNA expression is inverted, 
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compared to controls. When assessing the relative levels between groups (C), a significant 
increase in expression of Per1 mRNA in the MPL group was evident at ZT2, compared to 
controls, but no significant difference was observed at any other time point. All data 
represented as mean ± SEM. N = 8 per group. One-way ANOVA with Dunnett’s post-hoc 
test was used, with all comparisons to ZT2 in graphs (A) and (B). Two-way ANOVA with 
Sidak’s post-hoc test was used in (C). All statistical significance indicated at P < 0.05 (*), 
P < 0.01 (**), P < 0.001 (***) and P < 0.0001 (****). ZT2 is repeated for visualisation 
purposes.            
 
The mRNA expression of Per1 has been well characterised in the SCN. In the control group 
(A), an obvious and robust circadian variation in expression was reported (One-way 
ANOVA F6,49 = 6.286, p<0.0001). Low levels of Per1 mRNA were measured during the 
inactive period before a significant increase in expression was shown prior to the animals 
entering the active phase (ZT10 – P=0.0176). The level of Per1 mRNA remained 
significantly elevated four hours later (ZT14 – P=0.0028) before returning to baseline 
levels during the most active period (ZT18 – P=0.2529), (ZT22 – P=0.9996).  
 
Following treatment with MPL (B), the expression profile of Per1 remained significant 
across time (One-way ANOVA F6,48 = 8.006, p<0.0001). The level of Per1 mRNA was 
most abundant at ZT2, with a repression in expression observed at all other time points 
throughout the day (ZT6 – P=0.0073), (ZT10 – P=0.0062), (ZT14 – P=0.0006), (ZT18 – 
P=0.0256), (ZT22 – P=0.0154).  
 
However, when assessing the relative levels of Per1 mRNA expression between treatment 
and across time by Two Way ANOVA (C), a significant effect was observed across time 
(F6,97 = 6.537, p<0.0001), treatment (F1,97 = 155.8, p<0.0001) and an interaction between 
both (F6,97 = 9.537, p<0.0001). A surprising and significant increase in Per1 mRNA 
expression was observed in the MPL treated group at ZT2, when compared to its control 
counterpart (P<0.0001). However, following this rapid increase, which occurred shortly 
after the onset of lights, no other time point was significantly different from controls (ZT6 
– P=0.5136), (ZT10 – P=0.9985), (ZT14 – P=0.4771), (ZT18 – P=0.8872), (ZT22 – 




3.3.3 The expression of Per2 mRNA in the SCN is altered with MPL treatment 
 
Clock gene expression in the SCN has been extensively studied. However, in previous 
studies, the only way that the SCN clock components have been altered is either by changes 
to the light/dark cycle or by using a targeted gene approach. Examples of this include 
Bmal1(-/-), Per(-/-) and Cry(-/-) mice (Bae et al. 2001; Horst et al. 1999; Kondratov et al. 2006).  
 
I have shown that the synthetic glucocorticoid MPL can change the expression of Per1, a 
major component of the primary transcriptional loop of the molecular clock. However 
importantly, Bmal1(-/-) mice become arrhythmic, whereas Per1(-/-) mice present with a 
shorter free-running period. Bmal1 is also a major component of the clock, being a 
transcriptional activator, however no other gene has been shown to compensate for its loss, 
leading to the arrhythmic phenotype. Per1(-/-) mice however, were shown to be 
compensated by Per2, retaining rhythm, albeit slightly shorter in period length. Therefore, 
following the result that MPL treatment significantly affected the expression of Per1 in the 
SCN, it was important to assess the expression of Per2 in these animals, as a compensatory 
effect of the altered expression of Per1 may occur, and therefore retain rhythmicity of 



































































Per2 mRNA expression in SCN Vehicle
*





















Per2 expression in control rats 
Per2 expression in MPL treated rats 
Relative expression of Per2  




















Figure 3.3 Per2 does not compensate for Per1 in the SCN following MPL treatment. 
The expression of Per2 in control animals (A) exhibited clear circadian rhythm, with a 
delay in peak expression observed between Per1 and Per2, where peak expression occurred 
at ZT18, rather than ZT10 in Per1. Following MPL treatment, a significant effect of 
treatment was observed (B). The expression of Per2 was altered, with peak expression 
occurring at ZT2, and a repression of expression evident between ZT6 and ZT14. The 
relative expression of Per2 between treatments was assessed (C) and showed a strikingly 
similar result to that seen in the Per1 data. A significant increase was observed at ZT2 in 
the MPL group only. All data represented as mean ± SEM. N = 8 per group. One-way 
ANOVA with Dunnett’s post-hoc test was used, with all comparisons to ZT2 in graphs (A) 
and (B). Two-way ANOVA with Sidak’s post-hoc test was used in (C). All statistical 
significance indicated at P < 0.05 (*). ZT2 is repeated for visualisation purposes.  
 
Per2, which has previously been shown to compensate for Per1 expression in Per1(-/-) mice 
keeping animals in rhythm was also shown to be significantly affected by glucocorticoid 
treatment. In the control group (A), circadian variation was evident by (One Way ANOVA 
F6,47 = 4.276, p = 0.0016), although significance was only found at ZT18 (P = 0.0311), but 
a trend to significance was also found at ZT14 (P = 0.0863).  
 
Following MPL treatment (B), the expression of Per2 across the day was significantly 
altered by One Way ANOVA (F6,49 = 2.872, p = 0.0177), with peak expression occurring 
at ZT2, and a repression of expression evident at ZT6 (P = 0.0262) and ZT14 (0.0498).  
 
However, when assessing the relative expression between treatments (C), a significant 
effect of treatment over time was observed by Two Way ANOVA (F6,98 = 3.961, p = 
0.0014), where a robust increase in expression was observed at ZT2 in the MPL group (P 
= 0.0224), indicating that the expression of Per2 remains elevated through the active period 
and into the most inactive period, before returning to low expression levels observed in the 







3.3.4 The expression of Bmal1 mRNA in the SCN is altered with MPL treatment 
 
Bmal1 is one of the major components of the molecular clock that drives the transcription 
of Per1, dimerising with CLOCK and binding to E-box elements upstream of the Per1 
TSS. Bmal1 has been a major target of gene manipulation to affect the clock, with Bmal1(-
/-) mice exhibiting a loss of circadian rhythmicity in activity periods. A GRE has not been 
described for this gene, and it is not reported to be directly regulated by glucocorticoids. Its 
expression is controlled predominantly through the secondary loop of the molecular clock 
and the expression of REV-ERBs and RORs, with BMAL1 in turn regulating the 
expression of RORs and REV-ERBs.  
 
As Bmal1 has currently not been shown to contain a GRE or be driven by glucocorticoid 
exposure, the levels of Bmal1 mRNA in control and MPL treated animals may be expected 
to remain the same. However, an alteration in Per1 expression may in turn affect the timing 
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Figure 3.4 Treatment with MPL shifts the expression pattern of Bmal1 mRNA in the 
SCN. In control rats (A), a clear and robust circadian expression of Bmal1 mRNA 
expression was observed, with peak expression evident at ZT2, and a decrease in 
expression leading up to the most active period of the rat. Following MPL treatment (B), 
Bmal1 expression was phase shifted with steady expression observed through to the most 
active period before a decrease is observed. Assessment of the relative levels between 
control and MPL treatment confirmed the effect of an elevated level of expression in the 
MPL group at ZT14 (C). All data represented as mean ± SEM. N = 8 per group. One-way 
ANOVA with Dunnett’s post-hoc test was used, with all comparisons to ZT2 in graphs (A) 
and (B). Two-way ANOVA with Sidak’s post-hoc test was used in (C). All statistical 
significance indicated at P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) and P < 0.0001 (****). 
ZT2 is repeated for visualisation purposes.             
 
The transcriptional activator of the molecular clock BMAL1 exhibits robust Bmal1 
circadian expression pattern as expected in the control group (A), being in clear antiphase 
with the Per1 expression pattern of the control group (Figure 3.2a). The most abundant 
levels of Bmal1 expression occur during the lowest levels of Per1, and vice versa. There is 
a significant effect of time of day in the expression of Bmal1 (One Way ANOVA F6,49 = 
9.44, p<0.0001), with the highest levels occurring at ZT2, during the most inactive period, 
before a decrease in expression is observed with significance noted just prior to, and during 
the most active period (ZT10 – P=0.0011), (ZT14 – P=0.0001), (ZT18 – P=0.0006).  
 
Following treatment with MPL (B), the expression profile altered, however significant 
variation was detected across time (One Way ANOVA F6,49 = 4.58, p = 0.0009). The 
mRNA level in this group remained consistently high during the inactive period and largely 
into the active period, with no significant difference observed. However, a decrease in 
expression was observed at ZT18 (P=0.0078).  
 
When assessing the relative levels of Bmal1 mRNA expression between control and MPL 
treated groups by Two Way ANOVA (C), significant effects of time (F6,98 = 8.608, 
p<0.0001) and treatment (F1,98 = 3.71, p = 0.0023) were detected. Sidak’s post tests 
indicated that the significant difference between control and MPL treated rats was found at 
ZT14 (P=0.0213). At ZT14, the control animals had a significant decrease in expression 
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relative to ZT2, whereas the MPL group was not significantly different from its highest 
level of expression observed at ZT2.    
 
3.3.5. Glucocorticoid receptor mRNA is expressed in the SCN and exhibits an altered 
pattern with MPL treatment  
 
Although previous data described no effect of glucocorticoid treatment on the clock 
machinery in the SCN due to the absence of GRs in this region, it was important to assess 
whether the glucocorticoid receptor mRNA was present following the striking effect that 
was observed in Per1 expression following MPL treatment, as this could account for the 
effect observed with Per1 mRNA.   
 
The expression of Gr mRNA has not been described in the SCN, however it has been 
published in other brain regions, notably in the hippocampus, a brain region known to 
abundantly express the receptor. Different regions of the hippocampus were assessed over 
a day, with the expression of Gr mRNA published in all sub regions of the hippocampus 
proper (CA1-3) and the cortex, describing a clear daily rhythm (Herman et al. 1993). 
Therefore, based on those data, if the receptor mRNA was to be present in the SCN, a 















































Figure 3.5 Gr mRNA is expressed in the SCN. In control rats (A), a clear and robust 
expression profile of Gr was observed, with peak levels of expression occurring at ZT2 and 
ZT14, with a significant decrease in expression observed at ZT6, ZT10 and ZT18. 
Following MPL treatment (B), Gr mRNA exhibited a similar pattern to the control group 
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at ZT6, however the biphasic expression was not present in this group, as at ZT14, Gr 
mRNA was still repressed. Relative expression (C) confirmed an expected significant 
difference at ZT14, where the expression of Gr in the control group returned to levels 
similar to ZT2, whereas the MPL group did not. All data represented as mean ± SEM. N = 
8 per group. One-way ANOVA with Dunnett’s post-hoc test was used, with all 
comparisons to ZT2 in graphs (A) and (B). Two-way ANOVA with Sidak’s post-hoc test 
was used in (C). All statistical significance indicated at P < 0.05 (*), P < 0.01 (**) and P < 
0.001 (***). ZT2 is repeated for visualisation purposes.            
 
The expression of Gr has previously been shown to be rhythmic, made of a biphasic profile 
across the daily cycle. The control group exhibited a significant effect of time on Gr levels 
(F6,42 = 5.348, p = 0.0004) in the SCN (A), with the highest levels of expression at ZT2 and 
ZT14. A significant decrease of expression was observed at ZT6 (P=0.0007) and ZT10 
(P=0.0222) before returning to non-significant baseline levels at ZT14 (P=0.8411). The 
second decrease in expression was observed at ZT18 (P=0.0207), before returning to non-
significant baseline levels at ZT22 (P=0.4260).  
 
With MPL treatment (B), the expression profile of Gr was altered in its expression profile, 
although still significant across time (F6,46 = 3.348, p = 0.0080). The biphasic activity of 
the mRNA which was shown in the control is no longer represented. A significant decrease 
in expression was observed at ZT6 (P=0.0224), similarly to that of the control group. 
However, whereas in the control group it remained low before returning to non-significant 
levels at ZT14, with MPL treatment, the mRNA levels returned to non-significant levels at 
ZT10 (P=0.6343), before a significant repression of expression reoccurred at ZT14 
(P=0.0122), significantly altered compared to the control. The levels of GR mRNA 
returned to non-significant levels at ZT18 (P=0.5852) and ZT22 (P=0.1643).  
 
This alteration in Gr mRNA expression was confirmed by Two way ANOVA (C), with a 
significant effect of time (F6,86 = 5.93, p<0.0001) and an interaction between time and 
treatment (F6,86 = 2.845, p = 0.0142) observed. Sidaks post hoc tests revealed a significant 
difference between control and MPL at ZT14 (P=0.0466), where Gr mRNA was at its 




3.3.6. The expression of the housekeeping gene Actb in the SCN in control and MPL 
treated animals 
 
Following the data presented above, it was important to show the expression of Actb across 
all tested samples in the SCN, to ensure that the expression changes observed were of 






Figure 3.6. Actb mRNA levels remained consistent across samples independent of time 
of day or exposure to MPL treatment. No circadian expression was observed in control 
rats across one day (A) or rats treated with MPL (B). The relative expression of Actb 
between treatments was not affected (C) and the stability of Actb was consistent across all 
samples tested (D). All data represented as mean ± SEM. N = 8 per group. One-way 
ANOVA with Dunnett’s post-hoc test was used, with all comparisons to ZT2 in graphs (A) 
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and (B). Two-way ANOVA with Sidak’s post-hoc test was used in (C). ZT2 is repeated for 
visualisation purposes.                   
 
It was important to assess the expression of Actb across time and treatment to ensure that 
the expression of the genes of interest were not influenced by changing levels of the 
endogenous control. In control rats (A), the expression of Actb did not change across time 
points and therefore no significant difference across the day was observed (F6,49 = 1.411, p 
= 0.4034). This was also evident in the MPL treated group (B) (F6,49 = 1.062, p = 0.8219).  
 
Although no effect was observed in Actb expression across the day in both control and 
MPL treatment, it was further important to assess the relative expression of Actb to ensure 
that MPL did not alter the overall expression levels between groups. The relative levels 
between treatments were found to be non-significant (C), with two-way ANOVA 
indicating no effect of time (P = 0.6476), treatment (P = 0.2172) or an interaction between 
both (P = 0.5339).   
 
These data therefore provide confirmation that the effects observed in clock gene 
expression in this chapter are either an effect of time and treatment, and therefore are not 
influenced by changing expression in the endogenous control.  
 
3.4 Discussion  
 
In this chapter, the mRNA expression profiles of core clock genes Per1, Per2 and Bmal1 
were assessed within the SCN following treatment with the synthetic glucocorticoid, MPL. 
Previously, no effect on the core clock components within the SCN was reported when 
using the potent glucocorticoid agonist DEX, with the core clock machinery retaining a 
robust daily rhythm in timing with the light/dark cycle (Balsalobre et al. 2000). Therefore, 
this study was designed to provide a robust control for circadian regulated genes 
synchronised to a standard 12:12 light/dark cycle. 
 
Glucocorticoids are secreted from the adrenal gland in a circadian manner, driven by SCN 
activation of the HPA axis. Internal HPA axis feedback maintains CORT at optimum 
levels, targeting the anterior pituitary and PVN to suppress the secretion of ACTH and 
CRH, respectively. The circadian levels of CORT were measurable in these data (Figure 
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3.1). In the control group, a clear circadian rhythm of CORT secretion was evident, with 
the highest levels observed prior to waking and during the active period. With MPL 
treatment, the HPA axis was significantly suppressed. This was expected based on 
previously published data (Spiga et al. 2011).  
 
The expression profile of Per1 in the control group exhibited clear rhythmicity in timing 
with the circadian period. Per1 expression has been extensively studied, both its profile 
within the SCN, as well as in peripheral tissues including the heart, liver and skeletal muscle 
(Peirson et al. 2006; Marcheva et al. 2010). In these data, Per1 accumulated during the 
inactive phase (Figure 3.2A), with absolute levels decreasing through the active period as 
they are translated to PER proteins, where they act to inhibit the transcription of Per1.  
 
Similarly to Per1, the circadian profile of Bmal1 expression has been published in the SCN 
and peripheral tissues (Peirson et al. 2006; Barca-Mayo et al. 2017). BMAL1, along with 
CLOCK, act as transcriptional activators, driving the expression of Per and Cry. In the 
control group, Per1 expression peaked during the nadir of Bmal1 expression, whilst peak 
levels of Bmal1 were evident during the nadir of Per1 expression (Figure 3.4A). Therefore, 
Bmal1 expression is in antiphase to Per1, and an alteration to either of these could push the 
other to a new rhythm (Oishi et al. 1998a).  
 
In this chapter, I have shown for the first time that MPL can alter these core clock 
components of the primary loop. It is well known that glucocorticoids can induce the Per1 
transcript via a receptor dependent mechanism, where GR and/or MR binds to GREs 
located upstream of the transcriptional start site of Per1, driving transcriptional output. 
However, this has only been described in areas that abundantly express these receptors, for 
example the GR rich liver, and the GR/MR rich hippocampus (Reddy et al. 2007; Conway-
Campbell et al. 2010). The SCN was deemed devoid of GR and MR following the inability 
to detect either (Reul & Kloet 1985; Reul & de Kloet 1986), and therefore the Per1 gene 
was not expected to be modulated by glucocorticoid exposure here. 
 
However, under normal light/dark cycles, the expression of Per1 in the SCN following 
MPL treatment was significantly altered. MPL acts via the GR and MR, and so this may 
indicate that the receptors are present in the SCN to drive Per1 expression to desynchronise 
the molecular clock (Figure 3.2C). The MPL group presented with prolonged Per1 
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expression throughout the inactive period. The elevated expression at the onset of the 
inactive period, and expression level similar to peak levels in the control group, could 
indicate an underlying mechanistic cause for disturbances to the sleep/wake cycle, as seen 
in patients with Cushing’s disease, where elevated glucocorticoid levels are evident (Van 
den Berg et al. 1995). Per2 expression was also assessed following this result. In Per1(-/-) 
mice, a compensatory effect was observed, with activity rhythm shortened 0.5h due to Per2 
retaining clock rhythm, whereas in Per1/Per2(-/-) mice, they become arrhythmic (Bae et al. 
2001; Zheng et al. 2001). In these data, the circadian expression of Per2 was also 
significantly affected with MPL treatment, indicating that a compensatory effect did not 
occur here. Bmal1 expression in the presence of MPL treatment resulted in a phase delay 
(Figure 3.4B), further supporting the notion that MPL affects the synchrony between these 
core components of the clock.  
 
Fundamentally, to affect the molecular clock in this way, MPL treatment would need to 
target the expression of Per1 through the GR and/or MR, leading to the revised hypothesis 
that the GR and MR are present in this brain area. In previous studies, affecting the clock 
components within the SCN has required either gene manipulation or alterations to the 
light/dark cycle, as no previous study targeting the clock machinery was altered with drug 
treatment in vivo (Balsalobre et al. 2000). DEX is a potent GR agonist and failed to alter 
expression of the core clock genes, whereas MPL binds both GR and MR, therefore 
suggesting a requirement for the co-activation of the GR and MR to alter the expression of 
the core clock machinery. The identification of Gr in the SCN further supported that the 
effects observed following MPL treatment in the SCN were due to the presence and 
activation of GRs. Gr mRNA was robustly expressed here, the first time this has been 
shown.  
    
The altered expression of Per1 and Bmal1, and the presence of Gr expression in the SCN 
was not expected. However, these findings are the first to provide evidence that 
glucocorticoids can target the clock machinery of the SCN. These data suggest that 
treatment with synthetic glucocorticoids can adversely affect the central clock, leading to 
a dissociation between the light/dark cycle and the internal clock rhythm. Classically, a 
dissociation between central and peripheral pacemakers have been suggested as a root 
cause for illness, in particular, in patients with depression and/or sleep disturbances 
(Sequeira et al. 2012; Bunney et al. 2015). Patients receiving glucocorticoid therapy often 
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complain of alterations to the sleep/wake period following steroid treatment (Vázquez-
Palacios et al. 2001; Antonijevic & Steiger 2003). A dissociation between the master and 
peripheral clocks has been suggested for this, as glucocorticoid treatment failed to show an 
effect on the master clock. However, the robust effect presented here reveals that MPL can 
target and alter the expression of the clock mechanism.   
 
Following on from these data, it was important to assess the clock machinery peripheral to 
the SCN, but within the brain. Glucocorticoid therapy has been shown to affect memory 
and the sleep/wake cycle (Keenan et al. 1996; Coluccia et al. 2008). The hippocampus is 
instrumental in regulating both of these processes and is a regulator of negative feedback 
of HPA axis activity (Walker & Stickgold 2004). Patients with Cushing’s disease, who 
present with an elevated level of glucocorticoids, complain of memory impairment, 
disturbances to sleep and in post mortem, often present with hippocampal atrophy 
(Starkman et al. 1992). Therefore, in the following chapter I have assessed the effect of 
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The hippocampus is a brain structure which is a major part of the limbic system that plays 
a key role in spatial navigation and sleep processing (Girardeau et al. 2009; Jones & Wilson 
2005; O’Keefe & Speakman 1987). Lesions to the hippocampus significantly impair 
memory consolidation (Zola-Morgan et al. 1986; Morris et al. 1982). CORT can also impair 
or enhance the consolidation of memories, depending upon the level of glucocorticoids 
present (Sandi et al. 1997; Schaaf et al. 2000; Hui et al. 2004; Roozendaal et al. 1998; 
McLay et al. 1998). However, high levels and low levels of glucocorticoid exposure can 
impair the memory processing of certain tasks, indicating an optimum level of 
glucocorticoid exposure to enhance memory formation (Diamond et al. 1992; Rey et al. 
1994; Pavlides et al. 1996; de Kloet et al. 1999; Joëls et al. 2011).  
 
The HC is indirectly driven by the master clock in the SCN to regulate neurogenesis by 
controlling the timing of a large proportion of molecular processes to ~24hr (Schibler & 
Sassone-Corsi 2002; Phan et al. 2011; Eckel-Mahan et al. 2008). Gene expression of the 
components of the molecular clock within the hippocampus has been published, with all 
major elements of the molecular clock expressed in the sub regions of the HC, displaying 
clear circadian timing, albeit with a slight delay in peak expression compared to the SCN 
(Bouchard-Cannon et al. 2013; Conway-Campbell et al. 2010; L. M.-C. Wang et al. 2009; 
Summa et al. 2015). The CA1 region of the HC has been extensively studied, mainly for 
its role in memory processing. Per1 mRNA expression in the CA1 region has been shown, 
and is susceptible to external stimuli, such as a restricted feeding paradigm, which 
increased baseline expression (Conway-Campbell et al. 2010; Yamamoto et al. 2001). The 
CA1, CA3 and DG highly express the molecular clock components Per1, Per2, Clock and 
Bmal1 and are circadian rhythmic (Feillet et al. 2008), however following a mild stress 
paradigm, in which glucocorticoids are subsequently released and target the HC, the 
expression of Per1, Per2 and Bmal1 are altered in the CA1 region (Christiansen et al. 
2016), reinforcing that GCs target and alter the expression of these glucocorticoid sensitive 
clock genes.  
 
The SCN drives the sleep/wake cycle. Its projection to the medial septal nuclei directly acts 
on the HC to regulate theta-burst firing in neurons driving theta oscillations in the HC, 
controlling REM and NREM sleep periods, as well as ensuring the timing of the molecular 
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clock within the HC (Kang et al. 2015). Lesions to the SCN alter the sleep period, due to a 
lack of circadian timing (Ibuka & Kawamura 1975), driving the HC but also because the 
projection from the SCN to the medial septal nuclei is abolished (Eastman et al. 1984), 
therefore affecting neuron firing and REM and NREM sleep architecture.   
 
Although memory consolidation processes in the HC are significantly affected by the 
amount, and quality of sleep attained, the cellular and molecular processes driving sleep-
enhancing memories are still not fully understood, or even what parameters of sleep, or 
what molecular processes within the HC are targeted for optimal memory consolidation 
(Rasch & Born 2013; Abel et al. 2013; Wilhelm et al. 2011; Gais et al. 2002; Siegel 2001; 
Born 2010; Bliss & Collingridge 1993). However, it is clear that the molecular clock, or at 
least components of the molecular clock are instrumental in driving memory consolidation 
and sleep processes, as using a targeted gene approach, Per1(-/-) mice exhibited altered 
sleep/wake rhythms, and deficits to memory (Rawashdeh et al. 2016; Husse et al. 2012).    
 
The glucocorticoid and mineralocorticoid receptors are abundantly expressed in the 
hippocampus, with distinct differences in the levels of expression exhibited across the 
different sub regions. The dorsal subiculum and CA1 region express the MR 7-fold greater 
than the GR whereas the dentate gyrus, CA3 and ventral hippocampus express the receptors 
equally (Reul & Kloet 1985). The presence of the receptors allows for the HC to modulate 
the negative inhibition of the HPA axis during the circadian variation and stress induction 
of GCs (Herman et al. 1989).  
 
Glucocorticoid steroids are a commonly prescribed class of drugs, used to combat illnesses 
from asthma to lupus, indicating their broad spectrum of use and therefore accounting for 
the large number of users and long prescription periods (Overman et al. 2013). MPL, a 
synthetic glucocorticoid steroid variant of Prednisolone was synthetised from endogenous 
CORT. Being a derivative of CORT, it binds to the GR and MR with similar efficacy (Ye 
et al. 2014; Andrews et al. 2012). Once activated by ligand, both GR and MR can bind to 
glucocorticoid response elements on the DNA, promoting the transcription of 
glucocorticoid regulated genes (Herman & Spencer 1998; George et al. 2017; Paskitti et al. 
2000). However, the dynamics of endogenous and synthetic glucocorticoids differ greatly. 
Endogenous GCs transiently activate the GR to facilitate the transcription of GC target 
genes for short periods of time, and only when sufficient levels of GCs are present. For 
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example, during the inactive period when circulating glucocorticoids are low, GC regulated 
gene transcription is stalled, but when circulating glucocorticoids are high, gene 
transcription readily occurs. As endogenous GCs transiently bind the GR to facilitate 
transcription, one would expect the same from synthetic GCs prescribed to patients. 
However, the timing of glucocorticoid binding differs significantly, with endogenous 
binding occurring for ~20 minutes, whereas the synthetic glucocorticoid binds for ~3h (Earl 
et al. 2018).  
 
Almost half of the protein coding transcriptome is circadian rhythmic, and in the liver, 
glucocorticoids have been shown to affect almost 60% of these (Reddy et al. 2007), 
indicating the GCs ability to act on a large proportion of circadian regulated genes. In the 
HC, glucocorticoids target an array of genes, upregulating glucocorticoid regulated targets 
such as Serum Glucocorticoid Kinase 1 (Sgk1) and Glucocorticoid Induced Leucine Zipper 
(Gilz) to induce and regulate neuron excitability, inflammation, apoptosis and a range of 
other processes (Anacker et al. 2013; Lang et al. 2010; Kajiyama et al. 2010). A reduced 
expression of Sgk1 and Gilz during high interleukin 6 (Il6) levels reduced hippocampal 
volume (Frodl et al. 2012). However, as well as these glucocorticoid targets, the clock gene 
Per1 contains a GRE upstream of the transcriptional start site which facilitates the 
transcription of Per1. As the glucocorticoid receptor is abundantly expressed in the HC, 
the expression of Per1 can be driven independently of SCN control, through glucocorticoid 
action independent of the classically known light/dark cycle (Conway-Campbell et al. 
2010).       
 
Glucocorticoid therapy often leads to alterations to sleep patterns and an effect of memory 
processing (Keenan et al. 1996). Therefore, following the results of chapter 3, where I 
showed a significant change to major components of the primary loop of the molecular 
clock, it was important to assess the effects of the glucocorticoid steroid MPL, on a 
peripheral target of the SCN, and as the HC has been extensively studied for its role in 
glucocorticoid regulation, sleep processing and the consolidation of memory, it was an 
obvious target brain region to assess, to see if this synthetic GC affects the molecular clock 
within this area as well as other glucocorticoid regulated targets. In this chapter, I have used 
RNAseq, a deep sequencing technology to profile the whole transcriptome in a sample. 
RNAseq not only provides data on the whole transcriptome, it is also a far more precise 
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measurement of levels of transcripts and their isoforms than any other method (Z. Wang et 




4.2.1 Animal housing and Home Office  
 
48 adult male Lister Hooded rats (250-300g; 9-11 weeks) were obtained from Harlan 
Laboratories, now Envigo (Bicester, UK) and maintained under standard housing 
conditions with a 12:12 light/dark cycle. Food and water were available ad libitum. Rats 
were given an initial period to acclimatise to the facility. All procedures were carried out 
in accordance with the UK Home Office guidelines and the UK Animals (Scientific 
Procedures) Act under PPL 30/3114 and PIL I04092F5F. 
    
4.2.2 Experimental design 
 
Rats were housed in fours for experimental purposes and were habituated to the 
experimenter for five days prior to the start of experimental procedures and during to 
eliminate effects of stress. Methylprednisolone (1mg/ml in drinking water (Demski-Allen 
2014) (20mg/per day)) lasted five days. Following five days treatment, the animals (n=4 
per time and treatment) were killed at zeitgeber (ZT) times 2, 6, 10, 14, 18 and 22. Whole 
hippocampus was immediately dissected and snap frozen in liquid nitrogen before storage 
at -80C for subsequent RNA expression studies. Trunk blood was collected to assess the 
levels of circulating endogenous glucocorticoid in the blood at the time of kill. Group size 
was determined by literature review.  
 
4.2.3 RNA extraction and qPCR 
 
Whole hippocampi were dissected as per an in-house technique. Total RNA was extracted 
from individual whole hippocampi using miRNeasy mini reagents (Qiagen, USA). RNA 
quality and concentration was assessed for each sample on a Tapestation RNA screentape 
(Agilent Technologies, USA). RNA Integrity Number (RIN) of < 8, to a maximum of 10 
was recorded for all samples. cDNA was synthesised using the iScript cDNA synthesis kit 
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(Biorad, USA). All gene expression assays were carried out using in-house designed 
primers (NCBI BLAST and Sigma, USA) using a 7500 thermal cycler (ABI systems, USA) 
to assay expression.  
 
4.2.4 RNAseq  
 
High throughput RNA sequencing was carried out across all time points and over both 
treatments using TruSeq Stranded Total RNA sequencing (Illumina, USA). 16 samples 
were run per lane (total read 560 million), average reads per sample 33 million. Following 
quality control checks, the samples were analysed using the open access high throughput 
sequencing portal, UseGalaxy.org. Significantly different genes were further analysed 
using supraHex.   
 
4.2.5 Radioimmunoassay (RIA) 
 
Trunk blood was collected at all time points and treatment immediately following 
decapitation. Corticosterone levels were measured following an in-house corticosterone 





4.3.1 Assessment of corticosterone levels in blood in control and MPL treated  
 
The PVN of the hypothalamus releases CRH in the presence of a circadian cue from the 
SCN or in response to stress which activates the release of ACTH from the pituitary gland. 
The release of ACTH in turn acts on the adrenal gland to secret CORT. As the PVN is 
activated in the presence of a circadian cue or the presence of a stressor, the secretion profile 
of CORT in circulating blood is circadian in rhythm in a non-stressed animal. The secretion 
of CORT in this way is vital for many processes, in particular in the hippocampus, where 
it is instrumental in the mechanisms involved in memory processing and sleep. 
Glucocorticoids have been shown to regulate gene expression, both in a circadian manner 
but also following a stress response. Glucocorticoids targeting of the hippocampus should 
affect gene transcription. However, it was still important to assess the circulating levels of 
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CORT in the animals used for the RNAseq studies, to confirm that in the control group, 
expectant levels of circulating CORT were measured (based on data from our lab and 
others), and that the MPL treated animals were HPA axis suppressed, as expected following 
















Figure 4.1 RIA of the circadian secretion of corticosterone in control animals and the 
loss of circadian CORT secretion with MPL treatment. In control animals, the secretion 
of CORT increases in preparation for the active period, with clear circadian rhythm evident. 
Circulating CORT levels in the MPL treated group are significantly blunted, with no 
circadian profile evident. All data represented as mean ± SEM. N = 4 per group. Analysis 
with Two-way ANOVA with Sidak’s post-hoc test. * represent significant effect of time, 
$ represent significant effect of treatment. All statistical significance indicated at P < 0.05 
(*), P < 0.01 (**), P < 0.001 (***) and P < 0.0001 (****). ZT2 repeated for visualisation 
purposes.        
 
The secretion of CORT in control animals exhibit a clear circadian profile with no elevated 
levels observed in individual animals. The secretion of CORT is significantly blunted in 
the MPL treated group, with no evidence of a circadian rhythm evident. All data 
represented as mean ± SEM. N = 4 per group. Two-way ANOVA with Sidak’s post-hoc 















































test was used in (d). All statistical significance indicated at P < 0.05 (*), P < 0.01 (**), P < 
0.001 (***) and P < 0.0001 (****).   
 
Corticosterone is secreted from the adrenal gland following the activation of the HPA axis. 
The PVN is activated in the presence of circadian cues from the SCN, as well as in the 
presence of a stressor. Prior to assessing the whole transcriptome for gene expression 
changes in the presence of synthetic glucocorticoid treatment, it was important to assess 
the circulating levels of endogenous glucocorticoids in the blood, to confirm that gene 
expression changes did not occur due to a stressor. In control rats, there was a clear and 
significant circadian rhythm of CORT in the blood. The levels of CORT were low during 
the inactive period (ZT2 – 34.00ng/mL) (ZT6 – 20.00ng/mL), as expected, before reaching 
its circadian peak just prior to, and during the onset of activity (ZT10 – 366.40ng/mL – 
P=0.0001) (ZT14 – 477.56ng/mL – P=0.0001) and then returning to low levels in 
preparation for the inactive period (ZT18 – 165.65ng/mL) (ZT22 – 108.06ng/mL). 
Following treatment with MPL, the secretion of CORT is no longer circadian with no 
significant difference observed across time points (ZT2 – 23.50ng/mL) (ZT6 – 15.04ng/mL 
– P = 0.8281) (ZT10 – 21.16ng/mL – P = 0.9996) (ZT14 – 36.21ng/mL – P = 0.5753) 
(ZT18 – 12.38ng/mL – P = 0.6255) (ZT22 – 7.948ng/mL – P = 0.3123). Two-way ANOVA 
identified a significant effect of treatment at (ZT10 – P<0.0001) (ZT14 – P<0.0001) (ZT18 
– P = 0.0069).        
  
4.3.2 Profiling of mRNA in hippocampus using RNA sequencing 
 
Following assessment of circulating CORT in the blood of control and MPL treated 
animals, with a circadian profile evident in the controls and a suppression of CORT in the 
MPL treated group, I assessed gene expression in the hippocampus, focusing on circadian 
regulated genes and genes that were controlled by glucocorticoid exposure, in the absence 
of a stress.  
 
The hippocampus is a major structure of the limbic system that plays a vital role in spatial 
navigation and sleep processing. Stress paradigms can impair hippocampal dependent 
memory tasks, as well as a lack of the stress hormone, altering the optimal synaptic 
plasticity and firing properties of neurons of the CA1 region of the hippocampus (Benoit 
et al. 2015).  
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The GR and MR are abundantly expressed in the HC; however, their expression varies 
depending on the sub region of the HC itself. Circulating glucocorticoids target the HC 
promoting gene expression of glucocorticoid regulated genes, including Per1. The HC also 
modulates the response to stress and circadian variations in GCs forming negative feedback 
inhibition of the HPA axis, preventing further secretion of GCs. Blocking the GR in the 
HC reduces the HC’s inhibitory influence on the HPA axis, and therefore increases CORT 
levels (Boyle et al. 2005).  
 
Here, whole transcriptomic gene expression has been characterised from the whole HC, 
rather than individual sub regions. Using whole transcriptomic sequencing enabled me to 
assess the effects of the glucocorticoid steroid, as well as the changes in gene expression 
of control animals, across the whole genome for significant changes rather than a subset of 
genes of interest. Here I have presented the significantly regulated gene targets as 
characterised by RNAseq analysis, DAVID pathway analysis and further looked at the 
expression of the core clock components in the HC. qPCR analysis of these targets was 
















































Figure 4.2 supraHEX analysis of high throughput RNA sequencing data comparing control and MPL treated rats. supraHEX is a 
suprahexagonal map that utilises hierarchical clustering to place significantly regulated genes into smaller hexagons based on basal expression 
(A). Expression profiles based on basal expression (B). Genes are further clustered into larger groups of similar expressing values (C). The number 
of genes clustered into each hexagon (D). A suprahexagonal hierarchical clustering heatmap mapping gene expression changes through time (E), 
where RED = high expression and BLUE = low expression. RNAseq data from control and MPL treated animals over 6 time points throughout 
the day were analysed using Galaxy (methods) with differential expression. CuffDiff revealed 946 genes that were significantly differentially 
expressed. Significance in CuffDiff is calculated using Benjamini-Hochberg correction for multiple testing of P-values less than the false discovery 
rate set by the program at P < 0.05.  
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4.3.2.1 supraHex analysis of high throughput RNA sequencing data 
 
948 significantly regulated genes were found using the Galaxy Next-Generation 
sequencing portal and were analysed further using supraHex, a bioinformatics program that 
places gene expression data using a hierarchical clustering paradigm, of which 517 genes 
were identified to be significantly regulated in the control group and 663 genes were 
identified to be significant regulated in the MPL treated group. supraHex arranges genome-
wide data into groups of similar gene expression profiles, and position them into either the 
same, or nearby small hexagons that make up the supraHex. This analysis program allows 
for the hierarchical clustering of a large dataset to place gene patterns into specific 
hexagons based upon their basal expression, with the heatmap indicating the change in 
expression over time and across treatments. Control ZT2, ZT6, ZT10, ZT14, ZT18 and 
ZT22, as well as MPL treated animals at equivalent time points were assessed. Significantly 
regulated genes are positioned based upon basal expression of control ZT2, and at each 
time point following, the heatmap distinguishes their relative expression, either induction 
(shown in red) or repression (shown in blue). Gene expression changes can be visualised 
in (E), where changes in expression of genes in each node is shown by a change in colour 
of that particular hexagon. Darkest red contains the highest expressing genes, with darkest 
blue representing the lowest expressing genes. The colour gradient represents the 
intermediate expression levels, with the colour key representing log2 data.  
 
Each sub-hexagon is numbered according to the layout shown (A) with the number of genes 
assigned to each sub-hexagon denoted (D). The gene expression profiles that correspond 
to each sub-hexagon are shown in (B), with a simple colour key to denote control or MPL 
treatment and time. The sub-hexagons are further clustered into 5 meta-clusters, 
representing larger groups of similar expression (C). 111 genes were located in cluster 1, 
62 genes in cluster 2, 394 in cluster 3, 246 in cluster 4 and 132 in cluster 5. A selection of 
genes from each cluster are shown in table 4.1. The meta-cluster that represents circadian 
rhythmic genes are located in meta-cluster 5 such as Per1 in sub-hexagon 105 and Per2 in 
sub-hexagon 106 along with glucocorticoid regulated gene targets Sgk1 and Gilz, located 
in sub-hexagon 147. A selection of genes and the meta-cluster in which they fall can be 




Table 4.1. Selection of genes identified in each metacluster and the expression profile 
associated with each metacluster. 
Metacluster Gene Expression profile 
1 Ddit4, NeuroD4, Tph1, Fos, Ptgds, Kif19, 
Hspb1, Eno2, Cdkn1a, Pear1, Grk1 
 
2 Igf2, Igfbp2, Pla2g5, Mmp2, Glycam1, 
Slc2a12, Dsg2, Mfrp, Tmem27, Lect1 
 
3 Egr1, Grin2a, Rgs9, Il1r1, Fkbp4, Kif26b, 
Wnt4, Camk2a, Fnbp1, Notch1, Fkbp8, Sox2 
 
4 Dbp, Gh1, Klf13, Camk2d, Olfm2, Grm2, 
Klf9, Per3, Nr4a2, Mt2A, Vapb, Lhx2, Mt1m 
 
5 Nfkbiz, Gpd1, Sgk1, Tsc22d3, Dusp5, Cryab, 




4.3.2.2 Assessment of changes in gene expression using supraHex 
 
Basal expression of genes in each hexagon is shown in the ZT2 control group, where 
expression is forced to 1, with all other hexagons expressed as an induction or repression 
of that number. As each gene is maintained in the same sub-hexagon in the defined supra-
hexagonal map, differences in expression between control and MPL treated, as well as 
differences in time can be observed as differences in the colour of corresponding sub-
hexagons in a direct comparison to either ZT2 control, or its equivalent time, between 
treatments. 
 
A robust example to show the change in expression can be observed in sub-hexagon 105, 
where PER1 is placed, in the top left corner of the supraHex. In control animals over time, 
a steady increase in expression is evident, with the highest levels occurring at ZT10-18, 
before returning close to baseline at ZT22. In the MPL group however, where it is placed 
in the same sub-hexagonal position, the expression of Per1 at ZT2 is significantly different 
from control, with an increase evident, before lowering to similar levels at ZT6, as what is 
seen at ZT2 in control. The elevated level of expression of Per1 in MPL appears to be 
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highest at ZT14-22, eluding to a possible phase shift in expression of Per1 in the presence 
of MPL.  
 
4.3.2.3 Navigating the supraHex model 
 
The dataset is ‘trained’ in a highly specific manner and is therefore unique to this particular 
dataset. The central sub-hexagon (1) represents genes with a median level of expression. 
To the right of the central sub-hexagon are genes that decrease in overall expression, where 
sub-hexagon 128 contains low abundant but significant regulated genes such as NeuroD4 
and Tph1, and the left of the central sub-hexagon (149) that contains genes that are the most 
abundant and significantly regulated in overall expression, such as Calcium/Calmodulin 
Dependent Protein Kinase II Delta (Camk2) and Solute Carrier family 19 member 3 
(SLC19A3).   
 
The supraHex map shows overall that a large number of genes are under circadian control 
and in the presence of the glucocorticoid steroid MPL, the expression profile of those genes 
become dysregulated. For instance, the expression of Per1, Per2 and Cry1 are all 
significantly altered in the presence of MPL. Glucocorticoid target genes such as Sgk1 and 
Gilz are also significantly dysregulated in the presence of this long acting glucocorticoid 
steroid.  
 
4.3.2.4 Pathway analysis of RNAseq data using DAVID 
 
RNA sequencing allows for the identification of the transcriptome and to accurately 
measure the levels of transcripts and their isoforms far more precisely than any other 
technique. It therefore also provides the experimenter with a large dataset to analyse. 
DAVID (Database for Annotation, Visualisation and Integrated Discovery) (Huang, Brad 
T. Sherman, et al. 2009; Huang, Brad T Sherman, et al. 2009) is an open access program 
that clusters related groups of genes and identifies pathways affected, gene-disease 
association and uses KEGG, which is a collection of biological pathways, diseases and 
drugs databases to understand what effect individual gene transcripts may have.  
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Further analysis of the supraHEX dataset in DAVID identified multiple pathways involved 
as displayed in table 4.2 and figures 4.3 - 4.7.  
 
























































































Figure 4.6 Long-term potentiation pathway
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Figure 4.7 Phototransduction pathway 
 
A number of pathways were identified using DAVID as shown in table 4.2 and expanded 
further with a selection of pathways in figures 4.3-7. DAVID provides a useful overview 
of pathways targeted from this experimental design, however further analysis would need 
to be carried out to identify if these individual pathways are affected. Importantly, DAVID 
did provide pathway identification for circadian entrainment (Figure 4.3) and rhythms 
(Figure 4.4) as well as calcium signalling (Figure 4.5) and long-term potentiation (Figure 
4.6), both of which are important for learning and memory processes. Following supraHex 
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and DAVID pathway analysis, it was important to confirm the gene expression profiles as 
confirmation of data analysis.        
 
4.3.3 Clock gene expression analysis from supraHex using qPCR     
 
The supraHex model of high throughput RNA sequencing data analysis carried out using 
Galaxy yielded hypothesised results and expectant results based on the literature and gene 
expression studies previously carried out, albeit in different tissues. However, it was still 
important to validate the results collected using an independent method assessing the gene 
expression using the same samples ran to analyse from RNAseq. Following the RNAseq 
analysis, it was clear that the clock mechanism was a major target, with it showing robust 
changes throughout the day in control, but also because glucocorticoids target the major 
transcriptional repressor of the clock system, Per1. Therefore, based upon this and the data 
shown in the SCN shown in chapter 3, I have assessed using qPCR, the levels of mRNA in 
control and MPL treated animals over the circadian period.  
 
4.3.3.1 Per1 mRNA expression  
 
Following analysis of the RNAseq data using CuffDiff and visualization with supraHex, 
assessment of the expression of Per1 mRNA in the HC over one circadian cycle in control 
and following treatment with MPL was carried out. The expression of Per1 in the HC has 
previously been shown, with a circadian rhythm evident, and notably delayed in peak 
expression compared to the master clock, located in the SCN, where peak expression occurs 
during the light phase, and in the hippocampus, peak expression occurs at the onset of 
activity, in the dark period. Also, following the expression changes observed of Per1 in the 
SCN following MPL treatment in chapter 3, it was important to see if it affected the 





















Figure 4.8 Per1 mRNA expression is altered in the HC with MPL treatment. Analysis 
from RNAseq and qPCR show Per1 mRNA expression is altered following MPL treatment. 
From RNAseq, in control animals (A), mRNA expression is circadian with the highest 
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levels occurring during the most active period of the animal between ZT10-18. qPCR of 
this target validated the RNAseq data (B). Following MPL treatment, the circadian profile 
of Per1 expression was lost, with a flattening evident in both the RNAseq dataset (C) and 
qPCR (D). Assessment of the relative levels of Per1 expression between controls and MPL 
treated presented a significant elevation in expression at ZT2 in the MPL treated group only 
in the RNAseq dataset (E), whereas there was an additional significant difference at ZT10 
in the qPCR dataset (F). RNAseq data represented as mean. N = 4 per group. One-way 
ANOVA with Benjamini-Hochberg post-hoc test was used, with all comparisons to ZT2 in 
graphs (A) and (C). Two-way ANOVA with Benjamini-Hochberg post-hoc was used in 
graph (E). qPCR data represented as mean ± SEM. N = 4 per group. One-way ANOVA 
with Dunnett’s post-hoc test was used, with all comparisons to ZT2 in graphs (B) and (D). 
Two-way ANOVA with Sidak’s post-hoc test was used in (F). All statistical significance 
indicated at P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) and P < 0.0001 (****). ZT2 repeated 
for visualisation purposes.              
 
The expression of Per1 in the hippocampus is robust in these data. In the RNAseq analysis, 
Per1 mRNA expression in controls (A) was robustly circadian, with P value and Q value 
significance reported at ZT10 (P < 0.00005, Q = 0.0158), ZT14 (P < 0.00005, Q = 0.0066) 
and ZT18 (P < 0.00005, Q = 0.0133). A trend to P value significance was calculated at 
ZT22 (P = 0.0511), however the false discovery rate indicated that no effect of time was 
observed here (Q = 0.623). qPCR validation of Per1 (B) also confirmed the expected 
significant circadian rhythm of expression, with the expression profiles nearly identical 
between RNAseq and qPCR analysis (F6,21 = 7.151, p = 0.0003). A significant increase in 
gene expression was observed at ZT10 (P = 0.0008), ZT14 (P = 0.0034), ZT18 (P = 0.0038) 
and ZT22 (P = 0.0329). Following MPL treatment, analysis from RNAseq (C) and qPCR 
(D) produced a consistent result, with no significant change in expression observed across 
any time point, and a flattening of the circadian profile observed. When the relative 
expression was assessed using these techniques, a significant effect of Per1 expression was 
evident in the RNAseq analysis (E) at ZT2 (P < 0.00005, Q = 0.0130). P value significance 
was also observed at ZT10 (P = 0.0215), ZT14 (P = 0.0062) and ZT18 (P = 0.01535), 
however the FDR calculated these differences to be non-significant ZT10 (Q = 0.6626), 
ZT14 (Q = 0.3208) and ZT18 (Q = 0.2607). Analysis of relative expression from qPCR 
data (F) also exhibited a significant effect of time (F6,42 = 3.283, p = 0.0097), treatment 
(F1,42 = 8.512, p = 0.0056) and interaction between time and treatment (F6,42 = 6.668, p 
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<0.0001). Post hoc analysis showed the robust and significant increase in expression of 
Per1 at ZT2 (P = 0.0005), but also at ZT10 (P = 0.0408).  
 
4.3.3.2 Per2 mRNA expression  
 
Per2 expression in the HC has been assessed, with the expression shown to increase as the 
day progresses into the active period (Moriya et al. 2014). In Per1(-/-) mice, Per2 will 
compensate for Per1 and act to regulate the clock mechanism. Therefore, the rhythm of 
Per2 would be expected to be similar to that of Per1 in the HC. Conflicting evidence of a 
GRE driving Per2 expression have been published, however this is still unknown (Cheon 
et al. 2013). Like Per1 in the HC, the expression of Per2 is delayed in peak expression to 
the master clock in the SCN. Following the effect of Per1 alteration in the HC, and due to 
the literature eluding to a compensatory mechanism of Per2, it was important to see if Per2 
mRNA expression remained circadian and in timing with controls, following treatment 



























Figure 4.9 Per2 mRNA exhibits a similar profile to Per1 in the HC with MPL 
treatment. Similarly, to the expression of Per1, Per2 mRNA was characterised from 
RNAseq data and qPCR data. From RNAseq, in control animals (A), Per2 mRNA was 
significantly circadian in rhythm with the highest levels of expression evident during the 
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most active period, like Per1 at ZT14 and ZT18. qPCR confirmed this result (B). Following 
MPL treatment, the circadian profile of Per2 expression was blunted, with no significant 
difference observed in both RNAseq (C) and qPCR (D) techniques. Relative levels of 
mRNA expression were assessed between control and MPL treated rats, with neither 
RNAseq (C) nor qPCR (F) exhibiting significant differences between expression at 
individual time points. RNAseq data represented as mean. N = 4 per group. One-way 
ANOVA with Benjamini-Hochberg post-hoc test was used, with all comparisons to ZT2 in 
graphs (A) and (C). Two-way ANOVA with Benjamini-Hochberg post-hoc was used in 
graph (E). qPCR data represented as mean ± SEM. N = 4 per group. One-way ANOVA 
with Dunnett’s post-hoc test was used, with all comparisons to ZT2 in graphs (B) and (D). 
Two-way ANOVA with Sidak’s post-hoc test was used in (F). All statistical significance 
indicated at P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) and P < 0.0001 (****). ZT2 repeated 
for visualisation purposes.              
 
Similarly, to Per1 mRNA expression in the HC, the expression of Per2 is robust and 
circadian in pattern. RNAseq analysis of Per2 expression in controls (A) exhibited a clear 
circadian rhythm, with peak significant expression evident between ZT14 (P < 0.00005, Q 
= 0.0066) and ZT18 (P < 0.00005, Q = 0.01334). P value significance was also quantified 
at ZT10 (P = 0.00335), however the FDR deemed this non-significant (Q = 0.303161). 
Validation of the RNAseq data using qPCR also showed the expected circadian profile (B), 
with qPCR analysis accentuating this rhythm, showing a clear significant effect of time on 
Per2 expression (F6,19 = 9.816, p < 0.0001). A significant increase in expression was 
observed at ZT6 (P = 0.0118), ZT10 (P = 0.0007), ZT14 (P = 0.0018), ZT18 (P = 0.0001) 
and ZT22 (0.0173). The expression of Per2 following MPL treatment was similar to that 
shown of Per1 expression following MPL treatment. RNAseq data analysis (C), showed 
the circadian profile was blunted, with no significant difference observed across time 
points. This was also matched following qPCR analysis (D), however the spread of data at 
ZT2 in qPCR may have accounted for the lack of difference seen here. Differences in 
expression between treatments were assessed. RNAseq analysis (E) showed no significant 
difference between treatments, ZT2 was deemed P value significant (P = 0.00465), the FDR 
deemed this difference non-significant (Q = 0.339815). qPCR analysis (F) also did not 




4.3.3.3 Cry1 mRNA expression  
 
The expression profiles of Per1 and Per2 being significantly altered following MPL 
treatment in the HC, led to the assessment of Cry1 in the HC. As CRY proteins dimerise 
with PER proteins to prevent their own transcription, it was important to assess the 
expression of Cry1 to see if the glucocorticoid effect through Per1 would cause secondary 
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Figure 4.10 Cry1 mRNA expression is blunted in the HC with MPL treatment. The 
expression of Cry1 was firstly assessed using RNAseq and further using qPCR. From 
RNAseq, the expression of Cry1 mRNA in the control group (A) was circadian, with 
significant increase in expression observed at ZT14. A significant increase in expression 
was also observed following qPCR (B), however it was noted at ZT18. With MPL 
treatment, the expression of Cry1 was significantly altered, with no circadian expression 
evident, from RNAseq (C) and qPCR (D) analyses. Relative levels of mRNA showed a 
significant increase in expression from the RNAseq dataset (E) at ZT6, however this was 
not confirmed with qPCR (F). RNAseq data represented as mean. N = 4 per group. One-
way ANOVA with Benjamini-Hochberg post-hoc test was used, with all comparisons to 
ZT2 in graphs (A) and (C). Two-way ANOVA with Benjamini-Hochberg post-hoc was 
used in graph (E). qPCR data represented as mean ± SEM. N = 4 per group. One-way 
ANOVA with Dunnett’s post-hoc test was used, with all comparisons to ZT2 in graphs (B) 
and (D). Two-way ANOVA with Sidak’s post-hoc test was used in (F). All statistical 
significance indicated at P < 0.05 (*), P < 0.01 (**), P < 0.001 (***) and P < 0.0001 (****). 
ZT2 repeated for visualisation purposes.              
 
PER and CLOCK proteins dimerise and bind at the E-box element of their genes to prevent 
transcription from occurring. Following the significant effect that was observed in both 
Per1 and Per2 mRNA expression following treatment, Cry1 expression was assessed. 
RNAseq data in controls (A) exhibited the clear circadian rhythm of expression that was 
expected, with significant increase in expression evident at ZT14 (P < 0.00005, Q = 
0.00665). No other time point passed significance thresholds in controls, even though at 
ZT18 and ZT22, P value significance passed the minimum threshold (P = 0.00285) and (P 
= 0.0019), however the FDR deemed these changes non-significant (Q = 0.234888) and (Q 
= 0.111477), respectively. Again, this was validated with qPCR (B), with a significant 
effect of time observed in Cry1 mRNA expression (F6,19 – 2.822, p = 0.0389). A significant 
increase was observed at ZT18 (P = 0.0376). Cry1 mRNA assessed following MPL 
treatment significantly affected the circadian profile of expression in both RNAseq (C) and 
qPCR (D) analyses, with the profile flattening and resembling a similar profile to that of 
Per1 (Fig. 4.3 C/D) and Per2 (Fig. 4.4 C/D). Relative expression between control and MPL 
treated animals showed a significant effect of treatment of ZT6 (P = 0.0001, Q = 
0.0191257), where Cry1 mRNA was elevated in the MPL treatment group, as shown from 
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the RNAseq (E). qPCR analysis (F) however did not show a significant difference between 
treatments at any time point, with only a trend of significance observed at ZT22 (P = 
0.1190).       
 
4.3.3.4 Cry2 mRNA expression  
 
Cry2 expression was assessed in the HC using RNAseq and qPCR data. The expression 
profile of Cry2 is delayed compared to the expression of Cry1, however this was shown in 
liver, and although it is peripheral to the master clock, the delay may not be evident in the 
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Figure 4.11 Cry2 mRNA expression in the HC with MPL treatment displays circadian 
rhythm. The expression of Cry2 in the hippocampus did not exhibit a significant circadian 
profile from RNAseq (A) and qPCR (B) in control animals. Following MPL treatment, a 
similar response was shown to controls, with a non-significant change in expression 
observed across all time points, in the RNAseq data analysis (C). However, qPCR (D) 
exhibited a robust a circadian rhythmicity of expression with a significant increase 
observed at ZT14 and ZT22. Relative levels between treatment groups showed no 
significant difference at any time point in RNAseq (E) or qPCR (F). RNAseq data 
represented as mean. N = 4 per group. One-way ANOVA with Benjamini-Hochberg post-
hoc test was used, with all comparisons to ZT2 in graphs (A) and (C). Two-way ANOVA 
with Benjamini-Hochberg post-hoc was used in graph (F). qPCR data represented as mean 
± SEM. N = 4 per group. One-way ANOVA with Dunnett’s post-hoc test was used, with 
all comparisons to ZT2 in graphs (B) and (D). Two-way ANOVA with Sidak’s post-hoc 
test was used in (F). All statistical significance indicated at P < 0.05 (*), P < 0.01 (**). ZT2 
repeated for visualisation purposes.        
 
 
Analysis of Cry2 mRNA in the HC yielded some surprising results. Although no significant 
effect of time was observed in the RNAseq data (A), nor following qPCR analysis (B), a 
trend of significance was observed using qPCR (F6,19 – 2.281, p = 0.0793), however the 
spread of data at each time point meant that no time point was significant (ZT18 – P = 
0.1424). With MPL treatment, the expression profile from RNAseq (C) was similar to its 
control equivalent, with no significance reported across time points. However, qPCR 
analysis (D) of Cry2 mRNA following MPL treatment showed a clear, significant circadian 
profile of expression (F6,16 – 8.018, p = 0.0004), with a significant effect observed at ZT14 
(P = 0.0142) and ZT22 (P = 0.0029), and a trend of significance at ZT18 (P = 0.0603). 
Assessment of relative expression however, showed no significant difference between 
treatments using both RNAseq (E) and qPCR (F) paradigms. A trend of significance was 







4.3.3.5 Bmal1 mRNA expression  
 
Following RNAseq and qPCR assessment of the transcriptional repressors of the molecular 
clock, it was important to assess the transcriptional activators of the molecular clock, to 
evaluate if the alteration observed to the primary clock components would affect the 
transcriptional output of these important components. Bmal1, the transcriptional activator 


































Figure 4.12 Bmal1 mRNA expression is elevated with MPL treatment. Bmal1 mRNA 
expression was assessed using RNAseq and qPCR. A non-significant decrease in 
expression was observed in the control group from RNAseq (A) and qPCR (B). MPL 
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treatment flattened the mRNA expression of Bmal1 in both RNAseq (C) and qPCR (D) 
data. No significant difference was observed when looking at the relative levels of 
expression in the RNAseq analysis (E), however a significant difference was observed 
following qPCR (F) at ZT10, where mRNA decreased in the control group but remained 
elevated in the MPL group. RNAseq data represented as mean. N = 4 per group. One-way 
ANOVA with Benjamini-Hochberg post-hoc test was used, with all comparisons to ZT2 in 
graphs (A) and (C). Two-way ANOVA with Benjamini-Hochberg post-hoc was used in 
graph (F). qPCR data represented as mean ± SEM. N = 4 per group. One-way ANOVA 
with Dunnett’s post-hoc test was used, with all comparisons to ZT2 in graphs (D) and (D). 
Two-way ANOVA with Sidak’s post-hoc test was used in (F). All statistical significance 
indicated at P < 0.05 (*) and P < 0.01 (**). ZT2 repeated for visualisation purposes.             
 
RNAseq analysis showed differential expression of Bmal1 in control animals to be non-
significant (A), however P value significance was evident at ZT6 (P = 0.02035, Q = 
0.723869), ZT10 (P = 0.00225, Q = 0.231868), ZT14 (P = 0.00355, Q = 0.166757) and 
ZT18 (P = 0.00705, Q = 0.40783), yet the FDR for each time point deemed those results 
non-significant. qPCR analysis of control (B) indicated a trend of significance (F6,20 – 
1.996, p = 0.1141), with a trend of significance observed at ZT14 (P = 0.0846).  
 
Although a circadian profile was not significantly shown in controls, with MPL treatment 
the profile was flattened further, with no significant difference observed at any time point 
from RNAseq (C) and qPCR (D) analyses. Relative expression assessment of Bmal1 
expression showed no significant difference between treatments at any time based on FDR 
values (E), however qPCR analysis (F) showed a significant effect of time (F6,34 – 2.537, p 
= 0.0388), treatment (F1,34 – 4.427, p = 0.0429) and an interaction between both (F6,34 – 
3.246, p = 0.0125), with ZT10 exhibiting clear significance between treatments (P = 
0.0088).      
 
4.3.3.6 Clock mRNA expression  
 
The transcriptional activator CLOCK was assessed in the HC following MPL treatment. 
Clock mRNA has previously been shown in tissues to be constitutively expressed 
(Ripperger & Merrow 2011), and although that could be expected here, it was still 
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Figure 4.13 Clock mRNA expression remained constitutively expressed in the HC 
irrespective of MPL treatment. In control animals, Clock mRNA remained constitutively 
expressed throughout, with no significant difference observed following RNAseq (A) and 
qPCR (B) analyses. MPL treatment did not affect the expression of Clock with both 
RNAseq (C) and qPCR (D) showing non-significant changes throughout. The relative 
levels of expression remained unchanged and non-significant from RNAseq (E) and qPCR 
(F). RNAseq data represented as mean. N = 4 per group. One-way ANOVA with 
Benjamini-Hochberg post-hoc test was used, with all comparisons to ZT2 in graphs (A) 
and (C). Two-way ANOVA with Benjamini-Hochberg post-hoc was used in graph (F). 
qPCR data represented as mean ± SEM. N = 4 per group. One-way ANOVA with Dunnett’s 
post-hoc test was used, with all comparisons to ZT2 in graphs (B) and (D). Two-way 
ANOVA with Sidak’s post-hoc test was used in (F). All statistical significance indicated 
at P < 0.05 (*). ZT2 repeated for visualisation purposes.        
 
Based upon published data, the mRNA expression of Clock was expected to remain at a 
steady state level, as it has been shown to be constitutively expressed. RNAseq (A) and 
qPCR (B) analysis confirmed this, as no significant effect of time was evident, and although 
there appeared to be a repression in expression in the RNAseq analysis, neither P value, 
nor Q value were deemed significant (ZT14, P = 0.32865, Q = 0.915714) (ZT18, P = 
0.37515, Q = 0.995783). Like the control group, no effect of MPL was observed on Clock 
mRNA expression following RNAseq (C) and qPCR (D) analyses, with the large variation 
in the RNAseq time points not passing FDR parameters. The relative levels of expression 
between control and MPL were assessed. No effect was observed in the individual control 
and MPL analyses, and no effect was observed in the RNAseq analysis (E), however an 
effect of treatment was found when assessing between groups and across time (F1,38 – 15.88, 
p = 0.0003) as well as a significant interaction (F6,38 – 2.442, p = 0.0427), using qPCR (F) 
however no significant effect was observed between time points, with a trend of an effect 
observed at ZT2 (P = 0.0547).        
 
4.3.3.7 Npas2 mRNA expression  
 
The expression of Npas2, which replaces CLOCK to bind to BMAL1 and promote the 
transcription of Per and Cry genes was assessed. The expression of Npas2 would also be 
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expected to express constitutively through the day, however profiling of this target in the 
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Figure 4.14 No effect was observed on Npas2 mRNA expression in the HC with MPL 
treatment. RNAseq (A) and qPCR (B) analysis of Npas2 in control animals showed no 
significant difference at any time point, with the levels of mRNA remaining constant 
throughout the day. Following MPL treatment, no effect of glucocorticoids was observed 
from RNAseq (C) or qPCR (D), with the levels of mRNA remaining the same as the 
controls. This was shown further when looking at the relative levels of expression, with 
neither RNAseq (E) or qPCR (F) exhibiting a significant change. RNAseq data represented 
as mean. N = 4 per group. One-way ANOVA with Benjamini-Hochberg post-hoc test was 
used, with all comparisons to ZT2 in graphs (A) and (C). Two-way ANOVA with 
Benjamini-Hochberg post-hoc was used in graph (E). qPCR data represented as mean ± 
SEM. N = 4 per group. One-way ANOVA with Dunnett’s post-hoc test was used, with all 
comparisons to ZT2 in graphs (B) and (D). Two-way ANOVA with Sidak’s post-hoc test 
was used in (F). All statistical significance indicated at P < 0.05 (*). ZT2 repeated for 
visualisation purposes.        
 
Like Clock gene expression, the expression of Npas2 in control animals following RNAseq 
(A) and qPCR (B) analyses were non-significant and remained constitutively active 
throughout the day. Treatment with MPL did not affect the expression profile from RNAseq 
data (C), however qPCR showed a significant effect of time (D) (F6,17 – 3.494, p = 0.0195), 
however only a trend of significance was observed at ZT14 (P = 0.0826). Relative levels 
of Npas2 mRNA expression were also assessed. RNAseq analysis (E) showed no 
difference between treatments across time points. qPCR analysis (F) showed no significant 
effect of time, treatment or an interaction of both.    
 
4.3.3.8 Rev-erb mRNA expression  
 
REV-ERB, a major component of the molecular clock, in the accessory loop drives the 
transcription of Bmal1, which in turn promotes the transcription of Per1, which is be 
targeted by glucocorticoids. Rev-erb is also known to contain a glucocorticoid response 
element, and it was therefore important to assess the regulation of this gene in control and 
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Figure 4.15 Rev-erb mRNA expression following treatment with MPL is blunted. 
Although the pattern of expression detected between RNAseq and qPCR in controls was 
highly similar, RNAseq analysis did not detect any significant circadian variation in control 
animals (A). However, a robust significant circadian profile was observed using qPCR (B), 
with a significant increase in expression observed at ZT10.  The circadian rhythmicity 
observed in controls, was lost following MPL treatment using both RNAseq (C) and qPCR 
(D) techniques. However, when assessing the relative expression, no significant difference 
was observed in the RNAseq data set (E), however a trend of a significance was observed 
following qPCR (F), at ZT10. RNAseq data represented as mean. N = 4 per group. One-
way ANOVA with Benjamini-Hochberg post-hoc test was used, with all comparisons to 
ZT2 in graphs (A) and (C). Two-way ANOVA with Benjamini-Hochberg post-hoc was 
used in graph (E). qPCR data represented as mean ± SEM. N = 4 per group. One-way 
ANOVA with Dunnett’s post-hoc test was used, with all comparisons to ZT2 in graphs (B) 
and (D). Two-way ANOVA with Sidak’s post-hoc test was used in (F). All statistical 
significance indicated at P < 0.05 (*) and P < 0.01 (**). ZT2 repeated for visualisation 
purposes.             
 
The expression of Rev-erb  has been shown in multiple tissues of the body, and 
consistently is shown to express highly during the inactive/light period before levels lower 
during the active/dark period. RNAseq analysis (A) did not yield a significant effect of time 
in Rev-erb  expression, however qPCR analysis of the same samples (B) showed a 
significant effect of time (F6,21 – 5.608, p = 0.0013), with a significant effect observed at 
ZT10 (P = 0.0059), consistent with published data indicating an increase in expression 
during the inactive/light period. MPL treatment blunted the circadian pattern of expression 
in both RNAseq (C) and qPCR (D) analyses, with no significant difference observed across 
time. Relative expression was assessed between treatments, with an effect of time (F6,42 – 
3.4, p = 0.0080) and an interaction (F6,42 – 3.507, p = 0.0067) observed (F), however no 
significant difference was observed between treatment at individual time points (ZT6, P = 







4.3.3.9 Ror mRNA expression  
 
Assessment of the transcriptional repressor of Bmal1 was important to assess following the 
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Figure 4.16 Ror mRNA expression was not affected following MPL treatment. In 
control animals, the mRNA levels of ROR remained constant throughout, with no change 
observed at any time point in the RNAseq (A) and qPCR (B) analyses. MPL treatment did 
not affect mRNA expression as shown by RNAseq (C) and qPCR (D). The relative levels 
of mRNA expression were assessed, with no significant difference observed from RNAseq 
(E), however a trend to significance was observed from qPCR analysis (F) at ZT18.  
RNAseq data represented as mean. N = 4 per group. One-way ANOVA with Benjamini-
Hochberg post-hoc test was used, with all comparisons to ZT2 in graphs (A) and (C). Two-
way ANOVA with Benjamini-Hochberg post-hoc was used in graph (F). qPCR data 
represented as mean ± SEM. N = 4 per group. One-way ANOVA with Dunnett’s post-hoc 
test was used, with all comparisons to ZT2 in graphs (B) and (D). Two-way ANOVA with 
Sidak’s post-hoc test was used in (c). All statistical significance indicated at P < 0.05 (*). 
ZT2 repeated for visualisation purposes.        
 
Ror mRNA expression in RNAseq (A) and qPCR (B) was not affected by time, with no 
significant changes observed across the circadian period. Although no significance was 
calculated from the RNAseq set (C), a significant effect of time was evident following 
qPCR analysis (D) (F6,18 – 3.428, p = 0.0193). Assessment of control and MPL treatment 
exhibited significance in the RNAseq data (E), however the FDR deemed these non-
significant (ZT10, P = 0.0119, Q = 0.459648) (ZT18, P = 0.03645, Q = 0.486015). qPCR 
analysis (F) did not yield a significant effect, with only a trend observed (F6,33 – 1.888, p = 




The hippocampus is a brain region that has been extensively studied for its role in memory 
processing and sleep regulation. Since the role of the hippocampus in spatial navigation 
and episodic memory was established, a huge amount of research followed, looking into 
the molecular mechanisms that account for these processes. However, to this day, although 
significant advancements have been made, there is still a huge void in the knowledge of 
what mechanisms control these processes.  
 
Basic research looking at mechanisms that control memory and sleep in the HC have 
focused largely on the long-term potentiation (LTP) and long-term depression (LTD) 
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phenomena, where neuronal synapses are strengthened or weakened for an extended period 
of time following a stimulus, respectively (Bliss & Lomo 1973; Collingridge et al. 1983; 
Bannerman et al. 1995; Stevens 1998; Muller et al. 2002). This synaptic activity can affect 
memory consolidation and is altered in neurological disorders, with long-term potentiation-
like plasticity disrupted in Alzheimer’s disease (Di Lorenzo et al. 2016). However, this 
process accounts for a small cog in a large system, as memory and sleep are affected by a 
magnitude of other molecular and physiological processes, including HPA axis activity and 
the release of hormones, and the interconnectivity between sleep and memory itself, as 
sleep is required to consolidate long-term memories (Aisa et al. 2007; Stickgold 2005; 
Marshall et al. 2006; Born 2010).  
 
The molecular clock, has proved in recent years to be fundamental to regulating our daily 
rhythms, including controlling the sleep/wake cycle, metabolic processes and being 
instrumental in controlling, to an extent, memory processing (Jin et al. 1999; Kondratova 
et al. 2010). Glucocorticoids, endogenous and synthetic, have been shown to affect these 
processes (Keenan et al. 1996; Rebuffé-Scrive et al. 1992). However, although 
glucocorticoids are known to entrain peripheral clocks, little has been shown of the link 
between the molecular clock and glucocorticoid activity in the brain, in particular in the 
HC, an area fundamental for memory and sleep processing and what becomes significantly 
affected in patients with elevated glucocorticoid levels, either through endogenous or 
exogenous means.    
 
In this chapter, I show that the mRNA expression of the major components of the molecular 
clock within the HC become dysregulated following synthetic glucocorticoid treatment 
using high throughput RNA sequencing, DAVID pathway analysis, supraHEX gene 
expression clustering and validation using qPCR. A primary target of glucocorticoids to 
the molecular clock is Per1. The GRE upstream of the Per1 gene specifically regulates the 
expression of Per1 in the HC (Conway-Campbell et al. 2010), as well as the expression of 
other circadian regulated genes, although this was shown in A549 cells and with DEX 
treatment (Reddy et al. 2012). Clock gene expression is also affected with Prednisolone 
treatment, with the glucocorticoid treatment repressing the circadian oscillations in HepG2 





The expression of the core components of the molecular clock, circadian regulated genes 
and glucocorticoid regulated genes were assessed using RNAseq over one circadian cycle. 
Consistent with the RNAseq analysis, the expression profiles and quantity using qPCR 
analysis were strikingly similar, indicating the robustness of the techniques, and enabling 
me to assess further the expression of multiple components of the molecular clock, firstly 
looking at the expression in RNAseq, and later confirming with qPCR analysis.         
 
The Per1 gene has been extensively studied, with peripheral expression of this gene 
remaining circadian, although peak expression is delayed when compared to the master 
clock in the SCN (Jilg et al. 2009). Targeting the Per1 gene using a knockout model, results 
in a shorter free-running period, however Per2 compensates and retains the circadian 
rhythm in the clock (Bae et al. 2001). In my data, in the control group, clear circadian 
rhythm with peak mRNA expression occurring prior to the onset of activity was evident, 
indicating no delay in expression compared to that of the SCN, possibly eluding to 
peripheral clocks within the brain remaining in rhythm and timing with the master clock, 
and that other peripheral clocks, such as the liver and skeletal muscle may be delayed due 
to other clock controlling factors, such as feeding and exercise affecting the liver and 
skeletal clock transcriptome (Gatfield & Schibler 2008; Zhou et al. 2014). Assessment of 
Per1, Per2, Rev-erb and Bmal1 following subcutaneous administration of Prednisolone 
for 7 days in liver and skeletal muscle showed striking results to the expression profiles of 
these genes (Koyanagi et al. 2006). The expression of Per1 in the liver and skeletal muscle 
in controls exhibited clear circadian rhythm, with peak expression occurring at ZT14, 
reinforcing the delay between peripheral and central clocks. However, in that study the 
expression of Per1 mRNA lost its circadian oscillation, with elevated levels during the 
light/inactive phase, and non-significant changes during the active period when compared 
to controls (Koyanagi et al. 2006). In these data shown here, the expression of Per1 in the 
HC following MPL treatment exhibited remarkably similar results with the expression of 
Per1 significantly elevated at ZT2 compared to controls. DAVID analysis may elude to a 
mechanistic role of the phototransduction pathway which is targeted in the presence of 
glucocorticoid treatment at ZT2, however this would need to be assessed further.   
 
 139 
As Per1(-/-) mice are protected by the incumbent compensatory mechanism of Per2, it was 
important to assess Per2 expression in the HC following MPL treatment, as it could keep 
the peripheral clock components in rhythm, independent of Per1 expression. The 
expression of Per2, following RNAseq and qPCR analysis showed robust circadian 
oscillations, as expected, with peak expression occurring 4 hours later than that of Per1 
expression. However, as in the Per1(-/-) mouse where Per2 takes over, following MPL 
treatment I show that the expression of Per2 is also significantly altered, and exhibited a 
similar pattern to that of Per1 following MPL treatment. The expression of Per1 can be 
explained by the presence of the GRE that is known to drive transcription, however 
evidence of a GRE, either upstream of the TSS or through long ranging interactions is 
limited for Per2 data (Segall et al. 2006; Cheon et al. 2013). But, these data suggest that 
glucocorticoids are able to alter the expression of the Per2 gene, at least within the HC.  
 
The molecular clock genes Cry1 and Cry2 were assessed. The Cryptochrome genes drive 
multiple processes, and interestingly were recently shown to mediate the rhythmic 
expression of the glucocorticoid receptor in HEK293T cells, and mouse liver (Lamia et al. 
2011). In this dataset, rhythmic expression of Cry1 in control was observed, with peak 
expression occurring during the active/dark phase, consistent with other published data 
(Peirson et al. 2006; Soták et al. 2016). However following MPL treatment, the expression 
was significantly altered with an elevated level of expression occurring in the early 
light/inactive phase, again linking to a phase shift in clock gene expression in the HC 
following MPL administration, most likely driven by the dysregulation of the 
transcriptional repressor Per1. The expression of Cry2 in controls, showed similar 
expression to Cry1, with no significant differences observed across the day. However 
surprisingly, following MPL treatment, although the RNAseq data did not show a 
significant difference over time in Cry2 transcript expression, the qPCR exhibited a robust 
circadian profile, with a significant increase in transcript observed during the most active 
period of the rat, providing evidence for glucocorticoid regulation or a compensatory 
mechanism of Cry2 in the HC.   
 
Following the significant effects observed in the transcriptional repressors of the molecular 
clock, led to the assessment of the transcriptional activators BMAL1, CLOCK and NPAS2. 
Classically in circadian biology research, BMAL1, the major transcriptional activator of 
the molecular clock, has been a dominant target to affect and assess for altered downstream 
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processes. Bmal1(-/-) mice become circadian arrhythmic (Rakai et al. 2014), indicating its 
importance in regulating circadian oscillations and driving circadian rhythms in biology. 
BMAL1 and CLOCK dimerise and promote the transcription of Per1 through binding at 
E-box elements upstream of the Per1 TSS. The expression of Per1 in the HC following 
glucocorticoid treatment was significantly altered, and with MPL treatment a significant 
effect was observed in Bmal1 transcript expression, as Bmal1 expression should be in 
antiphase to the expression of Per1 (Oishi et al. 1998a), as shown in controls. Following 
MPL treatment this was not evident, indicating an effect on the molecular clock. Yet, 
although with RNAseq the expression of Bmal1 was not significant across time points, this 
could be explained, in part, to the stringency of the false discovery rate in the RNAseq 
analysis, where the Benjamini-Hochberg post hoc test was used to calculate the false 
discovery rates (Benjamini & Hochberg 1995). However, if only looking at the P value, the 
expression of Bmal1 was significantly repressed at ZT6-18, as expected based upon 
previously published data, and the robustness of the SCN Bmal1 data that I showed in 
chapter 3.  Again however, following qPCR no significant difference was observed but this 
could be an example of where the effect size was too small, and that a larger group was 
needed for each time point and treatment to show clear significance. This was evident also 
with Rev-erb expression, where P-value significance was observed, however the variation 
across samples lead to the data being non-significant, although significance was observed 
following qPCR analysis.  
 
REV-ERB was the first nuclear receptor (NR) to provide a mechanistic link for direct NR 
regulation of the clock, as Rev-erb(-/-) mice showed constitutively elevated Bmal1 
transcript levels (Preitner et al. 2002). Mechanistically, REV-ERB binds to the C-terminal 
portion of heat shock protein 90 (HSP90), with GR binding to the N-terminal portion and 
influences the stability and nuclear localisation of the GR, therefore affecting gene 
expression of target GR responsive genes (Okabe et al. 2016). Because of this, the delay 
observed in the Rev-erb expression could again account for the phase shift observed in 
the components of the primary loop, as GR stability is necessary and required for the GR 
to bind to PER1 and promote Per1 gene transcription.  
 
Following MPL treatment, Per1, Per2, Cry1, Cry2, Bmal1, components of the primary loop 
of the molecular clock exhibited varying changes to expression when compared to controls. 
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Of the accessory loop, no clock components became dysregulated, with only Rev-erb 
offering a trend to a phase shift in peak expression caused by treatment.  
 
The well-established glucocorticoid target Per1 (Conway-Campbell et al. 2010) was 
significantly affected by synthetic glucocorticoid treatment, with the levels of mRNA 
expression remaining elevated through the inactive and active periods. Such the intricacy 
of the molecular clock circuitry, the overexpression during the inactive period could act to 
drive the other clock components out of rhythm, as observed in the primary loop 
components Per2, Bmal1, Cry1, but also in the accessory loop, where a delay in expression 
was observed in Rev-erb. That being said, the primary loop of the clock appeared to be 
the major target of glucocorticoid action, specifically through Per1 expression driving the 
primary loop to fall out of synchronisation, driving the dysregulation of other clock targets. 
 
These data indicate that the synthetic glucocorticoid MPL significantly alters the 
expression of major components of the molecular clock, most likely through binding of the 
glucocorticoid receptor to the Per1 GRE, driving the transcription of this gene and 
overriding the dominant light/dark cycling. As the hippocampus is a major component 
involved in memory consolidation and sleep processing, an alteration of the clock, as 
shown here with glucocorticoid treatment, could provide evidence for the mechanism that 
drives glucocorticoid-determined sleep and memory related processing in patients (Keenan 
et al. 1996; Pivonello et al. 2015; Antonijevic & Steiger 2003; Sonino & Fava 2001), and 
could offer a potential mechanism for dysregulating the timing of the molecular processes 
in the hippocampus, which would affect the optimum timing and activity of the 
hippocampus to increase memory consolidation and enter the appropriate sleep stages to 
enhance and store memories during the sleep period.  
 
The following two chapters will explore physiological outcomes arising from the 




















Locomotor activity and core body 
temperature recordings following 
MPL treatment and in the presence of 















The molecular clock within the SCN and peripheral clocks within tissue are instrumental 
in retaining physiological, chemical and metabolic processes to a periodicity of ~24h, in 
timing with the daily cycle of light and dark. Locomotor activity (LA) and core body 
temperature (cBT) are just two examples which are under the control of daily rhythms 
through central and peripheral clock processes.  
 
The master clock in the SCN drives 24h rhythmicity through the activation of 
photosensitive retinal ganglion cells in the eye, which transmit signal down the 
retinohypothalamic tract directly to the SCN, initiating the components of the molecular 
clock in hypothalamic nuclei to entrain to the light/dark cycle. Lesions to the SCN ablate 
the circadian oscillations observed in LA and cBT (Eastman et al. 1984; Refinetti et al. 
1994; Waite et al. 2012). Similarly, animals placed in constant light exhibit a loss of 
circadian rhythmicity in LA and cBT (Ohta et al. 2005; Waite et al. 2012). Gene knockouts 
of core components of the clock significantly affect the activity period, with Bmal1(-/-) and 
Per2(ldc) mice exhibiting arrhythmic activity periods (Mieda & Sakurai 2011; Bae et al. 
2001).  
 
The SCN projects to the ventral lateral preoptic nucleus (VLPO) and dorsomedial 
hypothalamus (DMH) to control core body temperature (Zhao et al. 2017). The 
subparaventricular zone (sPVZ) also relays signals to the SCN to further regulate cBT and 
LA, as well as sleep regulation (Lu et al. 2001; Saper et al. 2005).  LA and cBT can be 
further regulated by peripheral clock systems in liver and skeletal muscle (Cornu et al. 
2014; Stokkan et al. 2001), as restricted feeding or running wheel access can produce 
significantly different patterns of activity when compared to ad libitum food or no cage 
enrichment, irrespective of the light cycle (Damiola et al. 2000; Reebs & Mrosovsky 1989).       
 
Patients prescribed glucocorticoid treatment often complain of changes to their activity 
periods, with increased sleep noted in the day and a lack of sleep in the night (Antonijevic 
& Steiger 2003). MPL binds to the glucocorticoid and mineralocorticoid receptors and is 
commonly prescribed in the clinic (Overman et al. 2013). In chapters 3 and 4, I showed 
that glucocorticoid sensitive genes can be dysregulated in the presence of this long acting 
steroid, in particular in genes fundamental to the molecular clock that drive daily rhythms. 
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The action of glucocorticoids can be blocked in the presence of GR and MR antagonists, 
Mifepristone and Spironolactone, respectively. Mifepristone (RU-486), is a GR antagonist 
that specifically antagonises cortisol (or similar) action competitively at the receptor level 
(Zhang et al. 2007; Chu et al. 2001) with its binding affinity 3x the potent GR agonist DEX, 
and 10x that of CORT (Gagne et al. 1985). Spironolactone is medically used as a diuretic 
to block the effects of Aldosterone, primarily in the kidney. It binds to the MR in tissues 
inhibiting the action of aldosterone and cortisol (Rupprecht et al. 1993).      
 
Previously, it has been reported that treatment with MPL significantly altered the 
periodicity of LA and cBT (Figure 5.1). However, no further analysis characterised the 
period length in control or MPL treated animals. Rhythms are commonly assessed in 
biology, with varying analysis packages and techniques to understand rhythmic periods in 
a dataset. Classically, actograms of locomotor activity are presented in research articles 
(Leise et al. 2013), which visually show animals entraining to light/dark cycles, their 
activity during constant darkness as well as during constant light (Chen et al. 2008). 
Wavelet transform has been used for many years in the field of physical sciences but is 
relatively new to the field of circadian biology. It is a technique that processes rhythmic 
signals, or wavelets, in a dataset. This is a unique property to this signal processing 
technique, as these signals can be symmetric or non-symmetric, high or low frequency, and 
be identified in regular or irregular datasets (Hoang Dang 2014). It allows for discrete 
identification of rhythms, or independent frequencies within a dataset, and in conjunction 
with using the Lomb-Scargle periodogram, which detects rhythmic signals based upon a 
least squares fit of sinusoidal data (Hocke 1998) from sample data with zero mean, allows 
for period length to be measured.        
 
In this chapter, I have analysed the periodicity exhibited in control and MPL treated 
animals. Additionally, following the results shown in chapter 3, where treatment with MPL 
dysregulated the pivotal clock gene Per1 in the SCN, I have assessed if blocking the activity 
of the glucocorticoid receptor and the mineralocorticoid receptor, therefore preventing 
MPL from binding to the receptors and prevent GC regulated transcription of the Per1 











Figure 5.1 Locomotor activity and core body temperature are dysregulated following 
MPL treatment. Locomotor activity (A) and core body temperature (B) in controls 
showed circadian oscillations across three days of recordings. During MPL treatment, 
locomotor activity (C) and core body temperature (D) showed a lack of rhythm (Demski-





5.2.1 Animal housing and Home Office  
 
32 adult male Lister Hooded rats (250-300g; 9-11 weeks) were obtained from Harlan 
Laboratories, now Envigo (Bicester, UK) and maintained under standard housing 
conditions with a 12:12 light/dark cycle. Food and water were available ad libitum. Rats 
were given an initial period to acclimatise to the facility. All procedures were carried out 
A B 
C D 
3 days control locomotor activity 
3 days MPL locomotor activity 
3 days control body temperature 
3 days MPL body temperature 
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in accordance with the UK Home Office guidelines and the UK Animals (Scientific 
Procedures) Act under PPL 30/3114 and PIL I04092F5F. Group size was determined by 
literature review and previous experience in Prof. Stafford Lightman’s laboratory.   
 
5.2.2 Experimental design 
 
During the experimental period, rats were individually housed for technical purposes. 
Methylprednisolone (1mg/ml in drinking water (Demski-Allen 2014) (20mg/per day)) 
lasted five days. Telemetry recordings of locomotor activity and body temperature were 
measured throughout the course of MPL treatment and in the presence of a subcutaneous 
pellet containing either Mifepristone, Spironolactone or placebo. In the repeated data, all 
MPL treated animals received either a combination of GR and MR antagonism, GR or MR 




Surgery was performed under balanced anaesthesia (veterinary isoflurane; Merial Animal 
Health Ltd., UK). Post-surgery, rats received subcutaneous injections (SC) of 0.2mg/mL 
Rimadyl (Carprofen 5% w/v, Benzyl alcohol 1% w/v; Pfizer., UK) diluted in sterile 10 
IU/mL heparinised saline and 2.5mL s/c glucose saline (Sodium chloride 0.45% w/v and 
Glucose 2.5% w/v solution for infusion BP; Baxter Healthcare Ltd., UK) to aid recovery. 
 
5.2.3.1 Locomotor activity and body temperature recordings 
 
Intraperitoneal implantation of a PDT-4000 E-Mitter radiotelemetry probe (Respironics, 
US) was performed with subcutaneous implantation of a slow release pellet containing 
either Mifepristone, Spironolactone or Placebo (5mg/day (Nasca et al. 2015)) (Innovative 
Research of America, USA). Following surgical recovery, animals were housed in 
individual cages for telemetry recording in soundproof rooms. Radiotelemetry data 
collection began 2 days following surgery. Sample collection frequency of 10 minutes was 
set and viewed using Respironics VitalView software (Mini Mitter Co. USA). Activity 
counts are generated when the E-Mitter changes position relative to the charging signal 
received from any of 3 concentric charge/receive grids inside the ER-4000 Receiver. 
Position change can be in any plane or from place to cause activity counts to be recorded. 
One cannot determine how far a given movement is in terms of precise distances based on 
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number of counts. There is not a specific distance that must be moved in order to generate 
a count. These data are simply a relative measure of gross motor activity level over time.  
   
5.2.4 Analysis using Wavelet Transform and Lomb-Scargle periodogram  
 
Locomotor activity and core body temperature were analysed using computer program 
MATLAB v2016b (MathWorks, USA). In house scripts for wavelet spectrum analysis and 
Lomb-Scargle periodogram were provided by Dr. Amitesh Pratap. Full script available in 




5.3.1 Locomotor activity and core body temperature with wavelet spectral analysis 
 
Previously, it was shown that MPL significantly altered the periodicity of LA and cBT 
(Figure 5.1). Here, using the same raw data, I have reanalysed this dataset using wavelet 
spectral analysis with the Lomb-Scargle periodogram to assess underlying frequencies in 
the LA and cBT datasets of control and MPL treated animals. Following the results of 
chapter 3, where SCN clock genes were dysregulated with MPL treatment, I hypothesised 
that there should be a relationship between dysregulating the master clock in the SCN, and 
dysregulation of peripheral clocks driving these two physiological processes. For instance, 
similar to what has been shown in LA and cBT following constant light and constant dark 














Figure 5.2 Wavelet analysis of locomotor activity and core body temperature. LA (A) 
and cBT (B) in control animals exhibited a clear circadian rhythm using this analysis 
technique. Following MPL treatment, LA (C) and cBT (D) were significantly affected, with 
a loss of circadian oscillation but a dominant ultradian rhythm evident. The frequency 
periods of LA (E) and cBT (F) are shown, comparing controls with MPL treated animals.  
N = 8 per group. Detrended data and representative plot. Black bars indicate period of dark. 
Wavelet spectral analysis with Lomb-Scargle periodogram (a - raw, detrended data; b – 
wavelet spectral analysis; c – Lomb-Scargle periodogram). Red dotted line indicates 
P<0.05. Bar graphs – mean ± SEM. Analysed with unpaired t-test, P < 0.05, P < 0.01, P < 


































Locomotor activity - control Body temperature - control 
Locomotor activity - MPL Body temperature - MPL 
Hr Hr Power (ActCt2) 
Power (ActCt2) 
Power (degC2) 
Hr Hr Power (degC2) 
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Locomotor activity and core body temperature are known to be under circadian control. 
Here, three days of locomotor activity and core body temperature are presented. In the 
control group, a clear and robust circadian oscillation was observed in locomotor activity 
(A/E 23.96 ± 0.06) and core body temperature (B/F 23.99 ± 0.04) output. Visually, an 
ultradian rhythm was evident in these control animals, however the dominance of the 
circadian rhythm rendered the underlying ultradian rhythm non-significant. Following 
MPL treatment, the circadian rhythm of locomotor activity (C/E 7.372 ± 1.432) and core 
body temperature (D/F 7.083 ± 1.989) was ablated, with the ultradian rhythm becoming 
the dominant rhythm in these animals. Analysis of the Lomb-Scargle periodicity output 
showed a significant effect of MPL treatment on LA (E – t(8) = 12.82, p < 0.0001) and 
cBT (F – t(8) = 12.67, p < 0.0001).  
 
5.3.2 Locomotor activity and core body temperature during MPL treatment with GR 
and MR antagonists  
 
Previous work in our group identified a striking effect of MPL treatment on the circadian 
rhythm of LA and cBT, which I have gone on to quantify using wavelet analysis. The 
predominant rhythm of LA (Figure 5.2E) and cBT (Figure 5.2F) were calculated at 24h in 
controls, consistent with published entraining rhythms data (Stenvers et al. 2016). In 
contrast, MPL treated rats exhibited a significantly different frequency period of 7h. In 
chapter 3, I showed significant MPL dependent alteration of the circadian expression 
profiles of core clock genes Per1, Per2 and Bmal1 in the SCN. As Per1 is a well-
established glucocorticoid target gene and is known to be induced via glucocorticoid 
receptor dependent regulation at a conserved binding site in the Per1 proximal promoter, I 
hypothesised that blocking the activity of either the glucocorticoid receptor or 
mineralocorticoid receptor would block the MPL effects on LC and cBT. With MPL 
dysregulation blocked, I hypothesised that LC and cBT should cycle at a dominant 24h 
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Figure 5.3 The effects of the GR and MR antagonists Mifepristone and Spironolactone 
on locomotor activity and body temperature during MPL treatment. Circadian 
oscillations in locomotor activity (A) and core body temperature (B) were observed in MPL 
treated rats following combined GR and MR antagonism. MPL treated rats cotreated with 
the GR antagonist Mifepristone also exhibited circadian oscillations of locomotor activity 
(C) and core body temperature (D). MPL treated rats cotreated with Spironolactone, which 
targets the MR, also exhibited circadian oscillations of locomotor activity (E) and core 
body temperature (F). However, when assessing the locomotor activity (G) and body 
temperature (H) of MPL treated rats cotreated with a vehicle pellet, circadian oscillations 
were observed. N = 4 per group. Detrended data and representative plot. Wavelet spectral 
analysis with Lomb-Scargle periodogram (a - raw, detrended data; b – wavelet spectral 
analysis; c – Lomb-Scargle periodogram). Red dotted line indicating P<0.05.   
  
Treatment with MPL was previously found to significantly alter the rhythm of locomotor 
activity and core body temperature in rats (Figure 1.1) (Demski-Allen 2014). Treatment 
with the GR and MR antagonists Mifepristone and Spironolactone appeared to reverse the 
effect of MPL treatment on locomotor activity and core body temperature, with the 
frequency significantly lengthening from 7h to ~24h. The combination of the GR and MR 
antagonists drove locomotor activity (A 25.66 ± 0.3735) and core body temperature (B 
24.83 ± 0.3522) to a dominant free running period. Assessment of the effect of the GR 
specific antagonist, Mifepristone during MPL treatment, also resulted in a similar effect to 
GR/MR treatment, with a return of the free running period length of locomotor activity (C 
25.00 ± 0.1477) and core body temperature (D 23.95 ± 0.4684) apparent. This surprising 
effect was also observed in the presence of the MR specific antagonist, Spironolactone, 
where the periodicity of locomotor activity (E 25.00 ± 0.1447) and core body temperature 
(F 25.26 ± 0.1938) was circadian rhythmic. However, implantation of a vehicle pellet into 
MPL treated rats resulted in a similar periodicity in locomotor activity (G – 24.87 ± 0.211) 










Figure 5.4 Analysis of locomotor activity and core body temperature period length 
following GR and MR antagonism. Locomotor activity (A) in the presence of GR, MR 
or both showed an increase in period length compared to the control group. This effect was 
also observed in core body temperature (B) for GR and MR combined, and MR only. But 
with GR antagonism, core body temperature exhibited circadian oscillations similar to 
control. Animals given the placebo pellet presented with similar periodicity to that of the 
antagonists. N = 4 per group. Bar graphs – mean ± SEM from Lomb-Scargle periodogram 
(Figure 5.3). One-way ANOVA with Dunnett’s multiple comparison post-hoc test, P < 
0.05, P < 0.01, P < 0.001 and P < 0.0001.      
 
Using the Lomb-Scargle periodogram with wavelet spectral analysis allowed for the 
assessment of periodicity in these animals following MPL treatment with either GR, MR 
or both GR/MR antagonists to block the effect that was previously observed with MPL 
treatment alone. Locomotor activity in the control group robustly entrained to the light/dark 
cycle (A – 23.96 ± 0.05), as did core body temperature (B – 23.99 ± 0.04). MPL treatment 
with placebo pellet resulted in an increase in period length in both locomotor activity (A – 
P = 0.0108), and core body temperature (B – P = 0.0250). Co-treatment with the GR and 
MR antagonists exhibited an increase in periodicity similar to what is observed in free 
running in locomotor activity and was significantly different from the control group (A – 
25.67 ± 0.37, P < 0.0001). However, no difference was observed in body temperature (B – 
24.83 ± 0.35, P = 0.0549). The effects of GR and MR antagonism were further assessed 
alone. Locomotor activity with GR antagonism resulted in a similar effect to that observed 
with GR and MR antagonism, exhibiting a significant increase in periodicity for LA (25 ± 
A B 
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0.15, P = 0.0037), however cBT retained rhythm similar to the control group (23.95 ± 0.04). 
Locomotor activity with MPL treatment and MR antagonism was significantly different 
from control (25 ± 0.15, P = 0.0037). cBT was also significantly elongated in rhythm 
compared to the control group (25.26 ± 0.19, P = 0.0030). The findings here clearly show 
that MPL, in the presence of a placebo pellet, did not induce the predominant ultradian 
periodicity analysed in Figure 5.2 (7.372 ± 1.432 (LA) and 7.083 ± 1.989 (cBT)). 
Therefore, this led to the reassessment of LA and cBT with MPL treatment only.    
 
5.3.3 Reproducibility of the effect of MPL treatment on locomotor activity and core 
body temperature  
 
The initial findings showing that the GR and MR antagonists Mifepristone and 
Spironolactone, respectively, could prevent the circadian dysregulation observed in MPL 
treated animals was exciting. Combined with the results that I showed in chapter 3, where 
Per1 expression was altered and Gr was expressed in the SCN, this supported the notion 
that glucocorticoids may target this area and significantly affect its output. However, MPL 
treated rats implanted with placebo pellet exhibited a vastly different rhythm to that of the 
original MPL treated rats. The MPL treated group was now more similar to the control 
group, with only a small albeit significant difference in rhythm compared to control. 
Therefore, based upon these findings, it was important to repeat the initial experiment of 











Figure 5.5 A repeated experiment looking at the locomotor activity and core body 
temperature in rats treated with MPL showed a different periodicity to that shown 
previously. Following MPL treatment, the rhythmicity of locomotor activity (A) and core 
body temperature (B) exhibited a different profile than what was previously shown, with 
rhythmicity no longer dominant to a ~7h frequency but instead, more similar to that shown 
in the control group. The periodicity of LA (C) and cBT (D) are shown between control 
and MPL treated animals. A significant increase in period length was observed in the MPL 
treated group for LA (C) and cBT (D). N = 8 per group. Detrended data and representative 
plot. Wavelet spectral analysis with Lomb-Scargle periodogram (a - raw, detrended data; 
b – wavelet spectral analysis; c – Lomb-Scargle periodogram). Red dotted line indicating 
P<0.05. Bar graphs; Mean ± SEM. Unpaired t-tests. P < 0.05, P < 0.01, P < 0.001 and P < 
0.0001. 
 
Based on previous data, the expectant rhythm was anticipated to lack circadian rhythmicity 
with a dominant ultradian rhythm present. However, locomotor activity (A/C - 24.59 ± 
0.1114), although not 24h, exhibited a periodicity much more similar to that of controls, 
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temperature, similarly to locomotor activity was also more similar to controls than the 
previous experiment, but again with a lengthening of the period, similar to what is seen in 
free running (B/D - 24.9 ± 0.1056). The periodicity was assessed between groups in LA 
(C) and cBT (D), with a significant increase in period length observed in both LA (C) and 
cBT (D) in the MPL treated group (C – t(8) – 4.992, p = 0.0005) (D – t(8) – 8.98, p < 




Locomotor activity (LA) and core body temperature (cBT) are tightly regulated to remain 
in rhythm with the light/dark cycle, maintaining a 24h periodicity (Stenvers et al. 2016). In 
a 12:12 light cycle, rats entrain to this rhythm, with both robustly synchronized by the 
external stimuli (Panda et al. 2002). In constant dark, rats revert to a free running rhythm 
with a lengthened period of 24.5h observed (Chen et al. 2008), resulting in a daily shift in 
phase continuing over time. In constant light, which acts as both a circadian disruptor and 
a chronic stressor, rats become arrhythmic (Waite et al. 2012). Analysis of these data using 
wavelet spectral analysis showed a similar periodicity to what was evident in the original 
MPL treated LA and cBT (Figure 5.7) providing evidence that MPL treatment could 
robustly and rapidly dysregulate the clock mechanism at the level of the SCN, an effect 
that took 4 weeks of constant light to evoke.  
 
 
Figure 5.6 Actogram data of 12:12 light/dark 
schedule, free running during constant 
darkness and arrhythmic activity during 
constant light. These data show rats entrained to 
the 12:12 light/dark cycle, with LA rhythm 
entrained to 24h. However, during constant dark, 
mice free run, whereas during constant light they 
present with arrhythmic activity periods (Adapted 






Patients who are prescribed glucocorticoid steroids often report altered activity periods, 
including sleep disruption. However, this has been difficult to evaluate, as differences in 
dosage and disease per patient makes it hard to analyse for a significant effect.  Previously, 
it was shown that the glucocorticoid steroid MPL significantly affects the periodicity of LA 
and cBT in rats (Figure 1.1), however no further analysis was carried out, with only an 
observational effect noted. However, the rapid effect observed in those data, were similar 
to the effect observed in rats following 6 weeks of constant light, indicating that MPL 
rapidly targets the master clock, whereas constant light exposure requires 4 weeks to induce 









Figure 5.7 Constant light evokes free running in rats followed by arrhythmic activity 
after four weeks in actogram data and wavelet spectral analysis. During the first four 
weeks of constant light exposure, rats exhibit a free running LA behavior that is similar to 
rats kept in constant dark (A). However, after five weeks of constant light the rats become 
arrhythmic (shown with arrow) (Waite et al. 2012). Using wavelet spectral analysis and the 
Lomb-Scargle periodogram (B), the arrhythmic activity is evident over the three-day period 
analysed. Output of the wavelet analysis and Lomb-Scargle periodogram (C) showed that 
in constant light, the rats entered a free running periodicity (24.38 ± 0.06843) compared to 
the light/dark entrained group (23.96 ± 0.05545). Following four weeks of constant light, 
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the rats became arrhythmic, with the periodicity of activity sharply falling (7.486 ± 0.493). 
N = 8 per group. Detrended data and representative plot. Wavelet spectral analysis with 
Lomb-Scargle periodogram (a - raw, detrended data; b – wavelet spectral analysis; c – 
Lomb-Scargle periodogram). Red dotted line indicating P<0.05. Bar graphs; Mean ± SEM. 
Unpaired t-tests. P < 0.05, P < 0.01, P < 0.001 and P < 0.0001.  
 
Here, I used wavelet spectral analysis with a Lomb-Scargle periodogram to assess the 
periodicity of these data. Continuous wavelet spectral analysis, used previously to assess 
body temperature (Leise 2013) and PER2:LUC oscillations (Price et al. 2008) finds a 
correlation between a time series across specific points in a dataset with a scaled version of 
the wavelet function to define the frequency that best describes the dataset analysed. 
Further, using the Lomb-Scargle periodogram, which although is well-known for its 
algorithm to detect and characterize periodic signals from unevenly sampled data (Ruf 
1999), can be utilized here, in particular in conjunction with the wavelet analysis to assess 
dominant and/or hidden frequencies within these data (Mallat 2009). It estimates the 
Fourier power, which decomposes a function of time, as a function of period oscillation, 
and therefore reads the oscillation as a period of time (Abramovich et al. 2000). Using this 
analysis technique allowed for the assessment of periodicity across a short period of time. 
Actogram data of LA in particular, is usually assessed following a significant period of 
recording, i.e. regularly 2+ weeks (Ben-Hamo et al. 2016; Sabbar et al. 2017; Chabot et al. 
2012; Riccio & Goldman 2000). However, I was unable to do this due to experimental 
constraints, and therefore an adaptation to the analysis program was required. Using two 
analysis programs built into one, provided the most suitable option for this.   
 
Clear daily rhythm in LA and cBT in the control group was observed using the wavelet 
analysis, as expected, with a light/dark entrainment evident, and further with the Lomb-
Scargle periodogram which identified the same periodicity. Assessment of the MPL 
periodicity presented an exciting result, with an ultradian rhythm dominant in both LA and 
cBT. The ultradian rhythm showed here is not the first time LA and cBT have been shown 
to exhibit a dominant ultradian rhythm. Lesioning the SCN results in arrhythmic locomotor 
activity and core body temperature rhythms as well as rats kept in constant light for 6 weeks 
(Waite et al. 2012). However, in the MPL experiments, the SCN remained intact, and the 
light cycle remained on a 12:12 light/dark cycle, indicating that the effect observed was 
through the action of the glucocorticoid steroid, MPL.     
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Following on from this, and the results of chapter 3 where I showed that MPL dysregulated 
clock genes Per1, Per2 and Bmal1 in the SCN, assessment of LA and cBT in the presence 
of GR and MR antagonists was carried out.  A rhythm close to 24h was observed in all 
antagonist datasets, however this was also observed in the placebo dataset, and therefore 
significantly differed from the original MPL treated dataset from 2013 (Demski-Allen 
2014). It was therefore important to return to the original experiment and repeat to confirm 
that I could match the initial result. The outcome was that I couldn't replicate those findings, 
however the periodicity of LA and cBT remained significantly different from control. 
Interestingly, the effect that I observed was one of an elongation to the period length. The 
extended period was consistent with that detected in free running animals (Verwey et al. 
2013).      
 
The latest rhythmic periodicity shown in the MPL treated group (Figure 5.5) would indicate 
that the GR and MR antagonist study was unable to inhibit the effect of the glucocorticoid 
MPL on LA and cBT, as the periodicity in the GR, MR and GR/MR combined antagonist 
study also produced a longer periodicity than the 24h profile (Figure 5.4). The dose given 
to antagonize GR and MR was not assessed in house but was taken from an experiment 
shown to block the effects of stress during a behavioural task (Nasca et al. 2015). Therefore, 
I cannot conclude with certainty that the GR and MR were effectively inhibited in my 
experiment. The potential role of GR and MR in the MPL-dependent rhythm changes 
would need to be assessed further, after optimization and characterisation of antagonist 
doses.   
 
Furthermore, it is also important to address the differences between my experimental 
findings and the previous data. In an ideal world, we would want to be able to understand 
and find the cause of the rhythm disturbance that was observed previously. Reproducibility 
is vital in scientific research and therefore understanding what could account for the 
differences observed between the two sets of experiments are paramount.  There were a 
number of factors that might account for the differences observed between MPL groups. 
Firstly, although the animals (male Lister hooded rat, Harlan, UK) were purchased from 
the same supplier, the initial experiments were carried out in mid 2013, whereas the most 
recent experiments were carried out in early 2018. During this five-year period, the genetic 
lineage may have changed and could have resulted in increased or decreased susceptibility 
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to GC treatment (Charmandari et al. 2008). Others have previously shown differential 
effects of using the same animal but with different genetic backgrounds (Ceolin et al. 2011; 
Wood et al. 2017). Secondly, my experiments were conducted on rats with surgically 
implanted IP telemeters. Whereas the previous experiment was conducted on rats with a 
combination of surgically implanted IP telemeters and jugular vein cannulation for 
continuous blood sampling with a spring and swivel tethering system (Windle et al. 1997). 
It may be possible that the combination of the extra surgical procedures and tethering 
induced a different physiological outcome during MPL treatment.  
 
Despite the caveats detailed in this chapter, the results from my own series of experiments 
are both robust and reproducible. Taken together my data are internally consistent, with an 
alteration of the central clock at both the molecular and physiological level.  MPL treatment 
induced an elongation in LA and cBT period length along with disrupted expression 
profiles of core clock genes in the SCN. The prolonged elevation of Per1 mRNA 
expression – i.e. high expression from ZT10 through to ZT2 on the following day - could 
account for the prolonged period observed in LA and cBT in the MPL treated group.  
 
Using wavelet analysis on actogram data from a previous constant light experiment (Figure 
5.7), I detected a four-week duration of free running rhythm that is similar to rats kept in 
constant dark. After the fourth week of constant light, the rats displayed arrhythmic 
behaviour that was similar to SCN lesioned rats. The data that I have presented here 
indicated that treatment with MPL also induced a free running periodicity in animals 
without manipulating light/dark cues. This may imply a disconnect between the light/dark 
entraining rhythm of the SCN, with MPL being able to significantly override the dominant 
light/dark entraining signal to induce free running behaviour in these animals. In the 
following chapter, I explore how this alteration in circadian activity may also affect sleep 






















The effects of MPL on hippocampal 


















Treatment with MPL impacts cognitive function, with hippocampal specific memory 
significantly affected (Figure 6.1). Glucocorticoids are known to target the hippocampus 
through the abundantly expressed GR and MR (Reul & Kloet 1985; Conway-Campbell et 
al. 2010). Hippocampal specific memory consolidation, routinely assessed using the novel 
object location (NOL) task in rodents, has previously been reported to be impaired by 
glucocorticoid administration during the sleep period (Lupien & Lepage 2001; Kelemen et 
al. 2014), and memory impairments have been detected in patients during chronic 
prednisolone treatment (Keenan et al. 1996). Furthermore, the most commonly reported 
cognitive side effects associated with high dose intravenous MPL are memory loss and 
sleep disturbances (Kupersmith et al. 1994). However, these effects appear to be reversible, 
as memory processing and the sleep cycle recover after 60 days following treatment 


















Figure 6.1 MPL treatment significantly affected memory performance in the novel 
object location task. Following a 1h delay between sample and test phases (A), both 
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locations. However, following a 6h delay (B), only the control group could discriminate 
between novel and familiar object locations. In contrast, the MPL group spent equal time 
at each object. Total exploration time was assessed at both time points, 1h (C) and 6h (D), 
showing no significant difference between treatments. Discrimination ratio equation (N – 
F)/, where  = time,  = sum, N = novel and F = familiar. Figure adapted from Demski-
Allen 2014.  
 
In ‘normal’ healthy animals, there is a large variation in endogenous glucocorticoid levels 
between the circadian active and inactive phases. The highest circulating CORT levels 
occur prior to wakening, with levels falling throughout the night in nocturnal animals in 
anticipation of the sleep period (Weitzman et al. 1983; Henley et al. 2009), stabilising the 
sleep/wake cycle to the photoperiod (Sage et al. 2004). Exogenous glucocorticoid treatment 
has been shown to profoundly affect the sleep/wake cycle, dependent upon the time of 
administration (Born et al. 1991; Xie et al. 2015). Interestingly, there is a striking 
concentration dependent differential effect of glucocorticoids on sleep. Low dose 
hydrocortisone increases SWS, while high dose hydrocortisone decreases SWS (Vázquez-
Palacios et al. 2001; Bradbury et al. 1998).  Consistent with this, HPA axis alterations to 
corticotropin-releasing hormone can affect REM and SWS sleep (Holsboer et al. 1988). 
There are also reciprocal interactions between these systems, as alterations in sleep can 
significantly impact the secretion of CORT (Mirescu et al. 2006).  
 
Sleep can be separated into rapid eye movement sleep (REM) and non-rapid eye movement 
sleep (NREM). NREM sleep, which comprises slow wave sleep (SWS) predominantly 
occurs during the first half of the sleep period, during which glucocorticoid levels are low 
(Born et al. 1988; Bierwolf et al. 2003; Plihal & Born 1999b; Henley et al. 2009) (Figure 
6.2). Long-term memories are consolidated during SWS (Marshall et al. 2006; Rasch et al. 
2007). Slow wave activity is evident in neuronal firing in the hippocampus, during which 
time the reactivation of recently encoded neuronal memory representations occur and are 
transformed for integration into long term memories (Wilson & McNaughton 1994; Skaggs 
& McNaughton 1996; Rasch & Born 2013). Therefore, timing of exposure to elevated 
glucocorticoid levels during the sleep period may have functionally significant effects on 
memory consolidation. 
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Figure 6.2 Cortisol secretion from continuous blood sampling during the different 
stages of sleep. During the early period of sleep, cortisol levels are low and SWS 
dominates, with small bouts of REM sleep evident. However, as the sleep period 
progresses, cortisol begins to rise in preparation for wakening where REM sleep dominates, 
with less SWS. W - wake, REM – Rapid Eye Movement, N1 – Non-REM1, N2 – Non-
REM2, N3 – Non-REM3. N1-3 are collectively referred to as NREM sleep, N3 – Slow 
wave sleep.  Circulating cortisol profile – black dotted line. (Adapted from Henley et al. 
2009; Rasch & Born 2013)   
 
In the previous chapters I showed a dysregulation to major components of the primary loop 
of the molecular clock in the SCN, a concomitant change in circadian activity period, and 
an alteration to the hippocampal circadian clock transcriptional machinery following MPL 
treatment. Therefore, I hypothesised that an MPL-induced sleep impairment may be 
responsible for impaired memory during the hippocampal specific NOL task. However, the 
NOL memory task was performed during the rats active phase, and impaired memory was 
detected at the 6h timepoint, which was also within the rats active phase. Therefore, the 
consolidation mechanism affected by MPL treatment must occur prior to the sleep phase 
(inactive period). However, rats sleep for short periods within the active phase, where 
during these bouts of sleep, characteristic sleep architecture is evident, with both REM and 
NREM sleep detected (Figure. 6.3).   
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Figure 6.3 A representative hypnogram displaying periods of sleep across the active 
and inactive phase in the rat. During the active period (shaded), rats exhibit short periods 
of NREM (SWS) sleep with short bursts of REM sleep, interspersed with long periods of 
wake. During the inactive period (non-shaded), rats exhibit long periods of NREM (SWS) 
sleep and bursts of REM sleep, with only short periods of wake. Shaded region – active 
period. W – wake, S – slow-wave sleep, R – REM. (Adapted from Simasko & Mukherjee 
2009).        
 
Therefore, we hypothesised that we would see altered sleep architecture in the MPL treated 




6.2.1 Animal housing and Home Office  
 
5 adult male Lister Hooded rats (250-300g; 9-11 weeks) were obtained from Harlan 
Laboratories, now Envigo (Bicester, UK) and maintained under standard housing 
conditions with a 12:12 light/dark cycle. Food and water were available ad libitum. Rats 
were given an initial period of at least one week to acclimatise to the facility. All procedures 
were carried out in accordance with the UK Home Office guidelines and the UK Animals 
(Scientific Procedures) Act under PIL I04092F5F. Sample size was generated based upon 
known effect size in Prof. Matt Jones’ laboratory.     
 
6.2.2 Experimental design 
 
During the experimental period, rats were individually housed for technical purposes. Rats 
were handled by the experimenter for 5 days prior to the start of experiments to eliminate 
effects of stress on memory processing during sleep. Rats were placed into a sleep box for 
2hr prior to the NOL sample phase. Following the 4-minute NOL sample phase, the rats 
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were placed into the sleep box for 6 hours. The NOL test phase was then carried out (3-
minute). Methylprednisolone (1mg/ml in drinking water (Demski-Allen 2014) (20mg/per 
day)) lasted five days. Sleep experiments were carried out on day 5 of treatment. N = 5 per 




Surgery was performed under balanced anaesthesia (veterinary isoflurane; Merial Animal 
Health Ltd., UK). Post-surgery, rats received subcutaneous injections (SC) of 0.2mg/mL 
Rimadyl (Carprofen 5% w/v, Benzyl alcohol 1% w/v; Pfizer., UK) diluted in sterile 10 
IU/mL heparinised saline and 2.5mL s/c glucose saline (Sodium chloride 0.45% w/v and 
Glucose 2.5% w/v solution for infusion BP; Baxter Healthcare Ltd., UK) to aid recovery. 
 
6.2.3.2 In vivo electrophysiology recordings of sleep 
 
Rats were implanted with multi-site electrode arrays targeting the Prelimbic (PrL) area of 
the prefrontal cortex and the dorsal CA1 area of the hippocampus. The animals were 
handled daily and habituated to the behavioural arena and recording environment 5 days 
prior to experiment start. Electrical signal was acquired using a Digital Lynx 4 SX system 
(Neuralynx, USA) and recording using the PC software Cheetah (Neuralynx, USA). All 
behavioural and sleep recordings were carried out during the rats' active phase. The rats 
were placed in a sound-attenuating chamber for a 2hr recording, followed by a 4min object 
location sample phase experiment in a behavioural arena. The rats were placed back into 
the sound-attenuating chamber for a further 6hr recording. Following the 6hr delay period, 
the rats were replaced into the behavioural arena with one of the objects moved to a novel 
location. In order to measure the rats movement, a video recording was captured above the 
sound-attenuating chamber and above the behavioural arena. These movement data were 
used alongside the electrophysiology data to manually score arousal state in 10sec epochs. 
Epochs was scored as wake if movement was high. REM sleep was scored during periods 
of low movement combined with the presence of short wave activity (Theta frequency – 6-
10Hz) on the local field potential (LFP) drive. Non-rapid eye movement (NREM) was 
scored if there was low movement and ripples and slow-waves (Delta frequency – 0.5-2Hz) 




6.2.4 Novel object location task 
 
The task comprised of an acquisition phase and a test phase separated by a 6h delay. In the 
acquisition phase, each rat was placed into the arena (wall facing) opposite to where 
duplicate objects were placed. The rats were allowed to investigate the objects for a total 
of 4 minutes before being placed into the sleep box. Six hours later, the rats were placed 
back into the arena but with one object now moved into the opposite corner (Figure 6.4). 
Exploration behaviour was recorded via a camera placed directly above the arena. 






   
 




6.3.1 Recordings during the memory consolidation period reveal a significant effect 
of MPL treatment 
 
Hippocampal specific memory was impaired by MPL treatment when the rats were tested 
with a 6h delay, but not following a 1h delay. Here, I have recorded brain activity for 6h 
following the sample phase of the NOL task to assess if MPL treatment altered 











Figure 6.5 In vivo electrophysiology recordings of hippocampal activity for 6h 
following the NOL sample phase. Hippocampal activity in the control group (A) showed 
dominant periods of wake activity, as expected, with small bouts of REM and NREM sleep 
across each of the 1h epochs. In the MPL treated group (B), the rats were also active across 
all hours following the NOL sample phase, however a significant increase in NREM sleep 
was observed. Data represented as mean as a percentage of time.  N = 5 per group.     
 
In vivo electrophysiology recordings of hippocampal activity showed the expected level of 
wake activity, REM and NREM periods of sleep in the control group (A). No REM sleep 
was evident in the first hour following the NOL sample phase, with REM sleep occurring 
across the following five hours. NREM sleep occurred across all hours assessed, stabilised 
in hours 3, 4 and 5 then reached maximal levels during the final hour prior to the NOL test 
phase. In the MPL treated group (B), REM sleep was observed during all time periods. A 
significant portion of each hour was spent in NREM sleep, and similarly to the control 
group, maximal levels of NREM sleep were observed in the final hour.  
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6.3.2 REM sleep following the NOL sample phase  
 
Figure 6.3 showed differences in hippocampal activity between treatment groups and 







Figure 6.6 REM sleep was unchanged following MPL treatment. In the first hour (A) 
following NOL sample phase, the control group did not go into REM sleep but the MPL 
treated group did. In the second (B), third (C), fourth (D), fifth (E) and sixth (F) hour 
following the NOL sample phase, both treatment groups exhibited REM sleep, but no 
difference was observed between groups. N = 5. Data represented as mean ± SEM. Paired 
t-test. Significance set at P < 0.05.       
 
Assessment of REM sleep between control and MPL was carried out. During the first hour 
following the NOL sample phase, the control group did not go into REM sleep at any point, 
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– 0%, MPL – 0.46%, or 28secs of the hour), no significant difference was observed here. 
No significant difference was observed across any other hour, with REM sleep during the 
total assessment period not increasing over 2.47% of total time in control, and 2.87% in the 
MPL group, observed at 3h.   
 
6.3.3 NREM sleep following the NOL sample phase  
 
Although no significant difference was observed in REM sleep over the assessed period, 
an obvious increase in NREM sleep was evident. Therefore, individual assessment of each 





Figure 6.7 NREM sleep was affected following the NOL sample phase with MPL 
treatment. NREM sleep was evident within 1h (A), 2h (B), 3h (C), 4h (D), 5h (E) and 6h 
(F) following the NOL sample phase in both treatment groups. However, a significant 
increase in NREM sleep was observed in the MPL group at 1h, 2h and 6h, with a trend of 
significance observed at 5h. N = 5. Data represented as mean ± SEM. Paired t-test. 
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The total percentage of time spent in NREM sleep was significantly greater than that 
observed in the REM sleep period. In the first hour following the NOL sample phase (A), 
a significant increase in NREM sleep was observed in the MPL treated group (A (t(5) = 
4.266, p = 0.013)). This significant increase persisted into the second hour (B (t(5) = 2.788, 
p = 0.0494)). No significant difference in NREM sleep was observed between groups for 
the following three hours, with only a trend of significance observed in the fifth hour (E 
(t(5) = 2.592, p = 0.0606). However, 6h following the NOL sample phase, a significant 
increase in NREM sleep was observed in the MPL group (F t(5) = 2.954, p = 0.0418).  
 




Figure 6.8 No difference was observed in memory performance between treatments 
in the novel object location task. Following a 6h delay in the NOL task (A), the control 
group were able to discriminate between novel and familiar objects, however the MPL 
group could not. However, no significant difference was observed between treatment. No 
significant difference was observed in exploration time between treatments (B). N = 4. * is 
comparison to hypothetical 0 using a t-test. Further analysed using Two-way ANOVA. 
Discrimination ratio equation (N – F)/, where  = time,  = sum, N = novel and F = 
familiar.  
 
Following on from previous published work, it was important to assess the NOL test phase 
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these animals. Using a hypothetical 0 to assess if both the control and MPL treated groups 
could discriminate between novel and familiar objects, the control group could (P = 
0.0329), whereas the MPL group could not (P = 0.8478). Using a two-way ANOVA to 
assess for an interaction between treatments, no significant difference was observed (P = 




MPL has previously been shown to significantly impair memory processing during a 
hippocampal dependent memory task (Figure 6.1). In that experiment, short term memory 
remained intact, but memory was significantly impaired when tested 6h and 24h after the 
sample phase (Demski-Allen 2014). In those experiments, the sample phase of the 
behavioural test was carried out in the early active phase, when circulating glucocorticoids 
in the control rats were high. Therefore, the following 6h would still be within the active 
period, when circulating glucocorticoids remained elevated. In this chapter, I have looked 
at hippocampal activity during the 6h memory consolidation period of the NOL task, to 
assess for differences that could account for the memory impairment in the MPL treated 
rats.  
 
A significant increase in NREM sleep was identified in the MPL treated group during the 
time period in which a deficit to hippocampal dependent memory was observed. Disrupted 
NREM sleep is known to impair hippocampal dependent memory (Mander et al. 2013), so 
an increase in NREM sleep was unexpected. However, as my recordings were carried out 
during the active phase, studies reporting associations between disrupted NREM sleep and 
impaired memory were conducted during the inactive phase, it is therefore difficult to draw 
further comparisons between the two sets of studies. 
 
Assessment of the novel object location task yielded no effect of memory impairment 
between treatments. Although this result is not consistent with previously published data, 
it could be due to a number of factors. That being said, a significant difference was observed 
between a hypothetical 0 and control and MPL. However, the variability in the treatment 
group rendered further testing non-significant. To note, the sample size in this particular 
study was potentially underpowered, as in this cohort, 5 animals were used compared to 12 
in the published study. Therefore, making conclusions based on these specific data may be 
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difficult and to identify a significant effect in behavioural analysis may have required a 
larger sample size.   
 
However, although the behavioural data may be underpowered, it is still important to 
further analyse the NREM sleep data which may reveal important functional differences 
between the control and MPL treated rats. NREM sleep is composed of slow wave activity 
and sharp-wave ripples, which haven’t yet been analysed in my dataset. In particular, ripple 
density during the first episodes of SWS after learning has been reported to be the more 
important for memory consolidation (Eschenko et al. 2008). As well as ripple density, 
magnitude and duration have been shown to increase during learning. Therefore, while the 
bouts of NREM sleep may be increased, the quality of sleep may be altered/decreased by 
MPL treatment.  
 
While there is good evidence for interactions between sleep state, memory consolidation 
and the HPA axis, most of these studies are performed during the inactive phase. LFP and 
EEG recording are usually performed during the inactive phase in the rat, and memory 
testing is performed following a true period of sleep (Plihal & Born 1999a; Plihal & Born 
1997; Wagner & Born 2008). However, here I show that discrete episodes of NREM sleep, 
with brain wave activity such as sharp-wave ripples and slow waves normally associated 
with memory consolidation processes, also occur during the rats’ active phase. The findings 
in this chapter highlight the importance of these types of brain waves during memory 
consolidation processes at this time of day. Future characterisation of ripple density, 
magnitude and duration within the episodes of NREM sleep during memory consolidation, 
as well as assessing differences in sleep bouts between treatment groups, will hopefully 
elucidate mechanisms that may become dysregulated with MPL treatment.  






































7.1 Summary of findings 
 
In this thesis, I have for the first time demonstrated that treatment with the synthetic 
glucocorticoid Methylprednisolone targets the gene expression of the core clock 
component, Period1 in the suprachiasmatic nucleus, dysregulating other clock components 
and altering the rhythmic output of the master circadian oscillator. I have demonstrated that 
MPL targets the peripheral clock oscillator in the hippocampus, significantly dysregulating 
core clock genes throughout the day. Further to dysregulating the molecular clock both 
centrally and peripherally, I have presented altered physiological output, in the form of 
locomotor activity and core body temperature. Previously published data showed that 
methylprednisolone significantly affected memory following a novel object location task. 
Here, I have showed that altering the molecular clock with MPL resulted in altered 
hippocampal activity following the novel object location task which may account for the 
memory deficits observed.     
 
7.2 The role of glucocorticoids in circadian physiology 
 
Circadian rhythms are intrinsic ~24h cycles that persist in the absence of external cues 
(Rosenwasser et al. 2005). The SCN acts as the master clock in the brain, entraining 
peripheral clocks in the body to remain in rhythm (Chen et al. 2008) with light input via 
photosensitive retinal ganglion cells retaining this rhythm to the photoperiod (Hattar et al. 
2002), as rats in constant dark free run to a period of ~24.5h (Nakamura et al. 2005). 
Neuroendocrine circadian function is under the control of the SCN, as circadian variation 
in glucocorticoid secretion is abolished in SCNx studies (Moore & Eichler 1972; Silver et 
al. 1996; Waite et al. 2012).  
 
In the brain, glucocorticoids target multiple areas where the GR and MR are expressed 
(Reul & Kloet 1985). The GR and MR were estimated to be located throughout most brain 
areas based on findings from in vitro [3H]CORT binding assays, identifying such areas as 
the hippocampus, amygdala, lateral septum, locus coeruleus, and dorsal raphe.  The 
hippocampus, which is particularly rich in GR and MR expression, has been extensively 
studied due to its importance for stress, and memory and learning. However, the receptors 
were not detected in the SCN in these studies (Reul & Kloet 1985; Reul & de Kloet 1986). 
Further experimentation assessing glucocorticoid action on the SCN failed to exhibit an 
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effect on the clock components using the potent GR specific agonist, DEX, whereas 
peripheral clocks were altered (Balsalobre et al. 2000).  
 
CORT, DEX and MPL differ considerably in their activities. CORT rapidly binds to the 
GR in short pulses of 20 minutes every hour, whereas it binds to the MR far longer 
(Conway-Campbell et al. 2010; Mifsud & Reul 2016). DEX is a potent GR specific agonist 
whose activity is considerably different to that of CORT and MPL. A single injection of 
DEX into ADX animals results in GR binding for 6h in the HC. MPL on the other hand, 
binds to both the GR and MR in similar affinities to that of endogenous CORT. Again, in 
ADX animals, a single injection of MPL results in GR binding for 3h in the HC (Emma 
Earl et al. 2018). Although DEX binds to the GR far longer than MPL in the brain, it doesn’t 
bind the MR, whereas MPL binds both receptors.  
 
The prolonged half-life of MPL in vivo effectively maintains extremely low levels of 
circulating endogenous glucocorticoids whilst the synthetic glucocorticoid levels remained 
high. Importantly though, in untreated animals, corticosterone binds to the glucocorticoid 
receptor in a circadian manner (Kitchener et al. 2004) whereas MR is bound at both the 
circadian peak and nadir (Reul & Kloet 1985; Mifsud & Reul 2016). GR monomers and 
dimers mediate transcriptional processes in vivo (Lim et al. 2015) and GR:MR interactions 
have been observed at the DNA, suggesting a transcriptional role (Pooley 2015).  
 
With MPL treatment, the GR was bound to the synthetic glucocorticoid far longer and in 
absence of a circadian pattern, keeping the receptor active and facilitating increased gene 
expression of Per1 (Figure 7.1) (Earl et al. 2018). However, although this was expected, it 
has only been shown in tissues that express the GR, and as the SCN was a brain area where 
the GR or MR had not previously been identified, the expression of glucocorticoid 













Figure 7.1 Hippocampal GR binding at the Per1 gene distal GRE. Glucocorticoid 
receptor binding in control animals exhibit clear circadian rhythmic binding, with the 
binding at the Per1 glucocorticoid response element significantly upregulated during peak 
CORT secretion. In the MPL treated group, endogenous glucocorticoids were suppressed, 
however GR binding persists in this group with the rhythmic binding lost. Data represented 
as mean ± SEM. N = 7 per group. Two-way ANOVA with Tukey’s post-hoc test was used. 
All statistical significance indicated at P < 0.05 (*/$). * represents effect of time, $ 
represents effect of treatment. ZT2 repeated for visualisation purposes (Birnie 2018).   
 
As DEX did not alter the core clock genes in the SCN, the data presented showing 
dysregulation in the SCN, potentially indicates a requirement of the activation of both the 
GR and MR to mediate the effects observed. Figure 7.2 potentially supports this hypothesis. 
Although I did not include these data in my results because it is only preliminary data, using 
RNAscope (ACDBio, US), which detects RNA using a novel in situ hybridisation 
technique, I identified the presence of Gr, Mr, and Per1 in nuclei of the SCN.   
 


























Figure 7.2 The colocalization of Gr, Mr and Per1 mRNA in individual neurons within 
the SCN using RNAscope. A wide field view of the neurons in the SCN shows abundant 
expression of Per1, Gr and Mr in the perinuclear area of individual neurons (a). Enlarged 
images of an individual nucleus indicate the perinuclear expression of Gr, Mr and Per1. 
(b) For visualisation purposes, only channels for Gr and Mr are shown in this image (c). 
Interestingly, another neuron is shown to lack MR expression, with only Gr and Per1 
expression evident (d). For visualisation purposes, only channels for Gr and Mr are shown 
in this image (e). Gr – green, Mr – red, Per1 – pink, Nuclear Stain DAPI – blue. Scale bar 
– 10m. 
 
Further to the identification of Gr, Mr and Per1 in SCN neurons, the effect observed in 
gene expression was most likely due to the use of a synthetic glucocorticoid that differs in 
temporal activation to its endogenous counterpart. GR activation with CORT is transient, 
lasting ~20 minutes during the highest levels of GC secretion, facilitating GC sensitive 








GR for over 3h, which would ultimately prolong GR activation and binding to DNA 
response elements to facilitate transcription, for example Per1. This prolonged activation 
of the receptor and transcriptional output of Per1 would result in a dysregulation to the 
molecular clock shown.   
 
However, SCN clock timing is also regulated by other brain areas such as the raphe nucleus 
as serotonergic projections from here to the SCN affect light entrainment of the clock. 
Adrenalectomy abolishes the circadian transcription of the serotonin rate limiting enzyme, 
Tryptophan hydroxylase-2 (Tph2) in the raphe nucleus, indicating an indirect mechanism 
for glucocorticoid feedback (Malek et al. 2007; Meyer-Bernstein & Morin 1999). However, 
as Balsalobre et al. 2000 failed to report a change in clock gene expression in the SCN with 
DEX in vivo, it indicates that the raphe nuclei did not drive an indirect rhythmic change 
here, at least via a GR only mediated effect, again supporting the role for the activation of 
both GR and MR to bring about this effect.  
 
However, I do not believe these results are limited to this synthetic GC, as Cushing’s 
disease, in which patients exhibit elevated circulating GCs levels with an undefined 
circadian rhythm, complain of altered sleep periods and memory deficits (Keenan et al. 
1996), leading to the hypothesis that elevated levels of endogenous GCs, may evoke a 
similar response in the SCN.      
 
SCN expression of Per1, Per2 and Bmal1 exhibited the rhythmic expression profile in 
agreement with previously published data (Peirson et al. 2006). Per1 and Per2 expression 
increased prior to the onset of the active phase (Figure 3.2A and 3.4A), with Bmal1 
transcript expression in antiphase. The expression of the Per1 gene following MPL 
treatment was robust and showed that glucocorticoids are able to target this brain region. 
In Per1(-/-) mice, a compensatory mechanism has been observed, with Per2 regulating the 
clock (Bae et al. 2001) and so was tested to assess if this mechanism was evident. 
Interestingly, Per2 expression was similar to Per1, indicating that either Per1 was able to 
significantly dysregulate Per2, or that Per2 in the SCN is also a glucocorticoid target, as it 
has been shown in vivo in the BNST and CeA (Amir et al. 2004; Lamont et al. 2005). The 
significant induction of Per1 and Per2 at ZT2 in the MPL group also raises the question of 
whether this effect would be observed in constant dark experimentation, as this effect could 
be due to a hypersensitivity to light following chronic treatment with glucocorticoid 
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therapy, although there is currently no clinical evidence for this. However the 
glucocorticoid and mineralocorticoid receptors are expressed in the retina (Zhao et al. 2010; 
Gallina et al. 2014), and therefore could potentially exert direct retinal to SCN input effects, 
and is certainly an area that is of importance to explore.   
 
Peripheral to the SCN in the HC, ligand-activated GR can directly induce increased 
transcription of Per1 irrespective of the time of day (Conway-Campbell et al. 2010) and in 
the liver and skeletal muscle, activated GR has been shown to phase shift clock genes 
(Balsalobre et al. 2000). The prolonged activation of the GR on the Per1 gene (Figure 7.1) 
results in increased output of Per1 transcription, which in turn could drive the dysregulation 
of peripheral clocks, in particular altering other core components of the primary loop such 
as Cry1, Cry2, Bmal1 and Clock, to desynchronise internal clocks from external stimuli. 
Although I haven’t shown this in the SCN, this is a mechanism that could be expected 
based upon these data.  
  
Interestingly, the expression of Per1 in the HC in the MPL group was similar to Per1 
expression in the SCN, with a significant increase in transcript observed at ZT2, in both the 
RNA sequencing and qPCR data. However, as the SCN drives peripheral clocks to remain 
in rhythm, one could say this was unsurprising, however as the SCN was not expected to 
be altered with GC treatment, this provides further evidence that glucocorticoids can target 
the SCN.   
 
That being said, further assessment of Per1 and Bmal1 expression in the HC following 
MPL treatment provided evidence of a 4h phase shift (Figure 7.3) in a manner similar to 


















Figure 7.3 Phase shifting the expression of Per1 and Bmal1 in the MPL group by 4h 
results in no effect of treatment in the HC. A significant effect of MPL treatment on Per1 
expression was observed in the HC, with a significant increase in transcript expression 
observed at ZT2, followed by a repression of expression at ZT10 (A). However, replotting 
the data after shifting the phase of expression of the MPL group 4h back, resulted in no 
significant difference between groups (B). Bmal1 expression was affected by MPL treated 
(C), however, replotting the data after shifting the phase by 4h in the MPL group, resulted 
in no significant difference between treatments. MPL – dotted line. qPCR data represented 
as mean ± SEM. N = 4 per group. Two-way ANOVA with Sidak’s post-hoc test was used. 
All statistical significance indicated at P < 0.05 (*). ZT2 repeated for visualisation 
purposes. 
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This phase delay in clock gene expression here, may have resulted in the extended phase 
of locomotor activity and core body temperature identified in these animals. In the 12:12 
light/dark cycle, they should retain rhythm to the photoperiod, similarly to controls (Riccio 
& Goldman 2000). However, the alteration to the master clock and peripheral clocks may 
account for the extended period length in these animals. The light/dark cycle may still act 
as a zeitgeiber in these animals, to retain a circadian rhythm. Therefore, assessing these 
animals in constant dark with MPL treatment would provide further understanding of the 
effect MPL has on the master clock to affect physiological output.   
 
Similarly, hippocampal activity was assessed following a novel object location task. 
Although the behavioural data did not yield a significant effect of treatment as shown 
previously, this could be due to the sample size used. However, the neural activity data 
indicated an increase in slow wave activity in the MPL treated group, further supporting 
the notion that MPL can target central and peripheral clocks to alter the sleep phase in 
relation to the light/dark cycle, which may account for this increase in hippocampal slow 
wave activity during the active period. The underlying mechanism that accounted for the 
memory disturbances in those animals remains unknown and although differences were 
observed in the neural activity of these animals, no difference was observed in the ability 
to consolidate memories at this stage, and therefore indicates that these two events may 
occur independently of one another. However, hippocampal plasticity is vital for 
consolidating new memories, and importantly, exhibits a striking time-of-day difference, 
indicating that timing is key to forming new memories (Jilg et al. 2009).  
 
I have showed in this thesis that MPL significantly dysregulates the core clock gene Per1. 
The rhythmic phosphorylation of CREB is critically regulated by Per1 (Rawashdeh et al. 
2016) and CREB is central to learning and memory (Kida & Serita 2014). Further evidence 
of a requirement of Per1 in memory processing was evident with Per1(-/-) mice, who exhibit 
reduced LTP, a marker of long-term memory in electrophysiology experiments 
(Rawashdeh et al. 2014b), whilst also testing poorly in the hippocampal specific radial arm 
maze (Jilg et al. 2009).  
 
Although these data provide a novel role in which glucocorticoids can target the SCN, there 
are a number of limitations that were noted. Firstly, the metabolic effects of glucocorticoid 
treatment render this experimental design to a maximum of five days treatment, which 
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limits the ability to assess long term effects on activity and temperature recordings. The 
method of delivery too, via ad libitum oral treatment, which although is medically relevant 
to the clinic, limits the known dose that each rat received during each experimental study. 
To combat this, future studies employing direct infusions to the brain areas of interest 
would certainly be a method to combat these limitations.        
 
Glucocorticoids are one of the most commonly prescribed classes of drugs today, with 2% 
of the UK adult population prescribed oral glucocorticoid therapy at any given time 
(Overman et al. 2013). Reports of depression and psychiatric illness have been reported 
following synthetic glucocorticoid use (Muzyk & Holt 2010), as well as in patients with 
Cushing’s disease and Cushing’s syndrome, who present with elevated levels of 
glucocorticoid hormones throughout the day (Pereira et al. 2010; Pivonello et al. 2015). 
Sleep disturbances are commonly reported in the clinic and studies have revealed that 
memory is significantly impaired with long-term Prednisolone treatment (Keenan et al. 
1996; Brown 2009; Judd et al. 2014). In this thesis, I believe I have identified a novel 
mechanism that will increase the understanding of glucocorticoid action on circadian 
biology, with particular relevance to glucocorticoid related sleep disturbances, memory 
impairment and mental health in patients treated chronically with long-acting synthetic 



























Abarca, C., Albrecht, U. & Spanagel, R., 2002. Cocaine sensitization and reward are 
under the influence of circadian genes and rhythm. Proceedings of the National 
Academy of Sciences of the United States of America, 99(13), pp.9026–30. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/12084940. 
Abe, M. et al., 2002. Circadian rhythms in isolated brain regions. The Journal of 
neuroscience : the official journal of the Society for Neuroscience, 22(1), pp.350–6. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/11756518. 
Abel, T. et al., 2013. Sleep, Plasticity and Memory from Molecules to Whole-Brain 
Networks. Current Biology, 23(17), pp.R774–R788. Available at: 
https://www.sciencedirect.com/science/article/pii/S0960982213008488. 
Abraham, U. et al., 2005. Independent circadian oscillations of Period1 in specific brain 
areas in vivo and in vitro. Soc Neuroscience. Available at: 
http://www.jneurosci.org/content/25/38/8620.short. 
Abrahamson, E.E. & Moore, R.Y., 2001. Suprachiasmatic nucleus in the mouse: retinal 
innervation, intrinsic organization and efferent projections. Brain research, 916(1–
2), pp.172–91. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11597605. 
Abramovich, F., Bailey, T.C. & Sapatinas, T., 2000. Wavelet Analysis and its Statistical 
Applications. Journal of the Royal Statistical Society: Series D (The Statistician), 
49(1), pp.1–29. Available at: http://doi.wiley.com/10.1111/1467-9884.00216. 
Adelmant, G. et al., 1996. A functional Rev-erb alpha responsive element located in the 
human Rev-erb alpha promoter mediates a repressing activity. Proceedings of the 
National Academy of Sciences of the United States of America, 93(8), pp.3553–8. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/8622974. 
Aggleton, J.P. & Brown, M.W., 1999. Episodic memory, amnesia, and the hippocampal-
anterior thalamic axis. The Behavioral and brain sciences, 22(3), pp.425-44; 
discussion 444-89. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11301518. 
Ahima, R.S. & Harlan, R.E., 1990. Charting of Type II glucocorticoid receptor-like 
immunoreactivity in the rat central nervous system. Neuroscience, 39(3), pp.579–
604. Available at: 
https://www.sciencedirect.com/science/article/pii/030645229090244X. 
Ahmad, M. & Cashmore, A.R., 1993. HY4 gene of A. thaliana encodes a protein with 
characteristics of a blue-light photoreceptor. Nature, 366(6451), pp.162–166. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/8232555. 
Ahmed, T. & Frey, J.U., 2005. Plasticity-specific phosphorylation of CaMKII, MAP-
kinases and CREB during late-LTP in rat hippocampal slices in vitro. 
Neuropharmacology, 49(4), pp.477–492. Available at: 
https://www.sciencedirect.com/science/article/pii/S0028390805001498. 
Aisa, B. et al., 2007. Cognitive impairment associated to HPA axis hyperactivity after 
maternal separation in rats. Psychoneuroendocrinology, 32(3), pp.256–266. 
Available at: 
https://www.sciencedirect.com/science/article/pii/S030645300700008X. 
Akashi, M. & Takumi, T., 2005. The orphan nuclear receptor RORα regulates circadian 
transcription of the mammalian core-clock Bmal1. Nature Structural & Molecular 
Biology, 12(5), pp.441–448. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15821743. 
Akhtar, R.A. et al., 2002. Circadian cycling of the mouse liver transcriptome, as revealed 
by cDNA microarray, is driven by the suprachiasmatic nucleus. Current biology : 
 184 
CB, 12(7), pp.540–50. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11937022. 
Al-Habet, S.M. & Rogers, H.J., 1989. Methylprednisolone pharmacokinetics after 
intravenous and oral administration. British journal of clinical pharmacology, 27(3), 
pp.285–90. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2655680. 
Albers, H.E. & Ferris, C.F., 1984. Neuropeptide Y: role in light-dark cycle entrainment of 
hamster circadian rhythms. Neuroscience letters, 50(1–3), pp.163–8. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/6548555. 
Amaral, D.G. & Dent, J.A., 1981. Development of the mossy fibers of the dentate gyrus: 
I. A light and electron microscopic study of the mossy fibers and their expansions. 
The Journal of Comparative Neurology, 195(1), pp.51–86. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/7204652. 
Amaral, D.G. & Lavenex, P., 2007. The dentate gyrus: fundamental neuroanatomical 
organization (dentate gyrus for dummies). Progress in Brain Research, 163, pp.3–
790. Available at: 
https://www.sciencedirect.com/science/article/pii/S0079612307630015. 
Amato, M.P. et al., 2004. Neocortical volume decrease in relapsing-remitting MS patients 
with mild cognitive impairment. Neurology, 63(1), pp.89–93. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15249616. 
Amir, S. et al., 2004. A Circadian Rhythm in the Expression of PERIOD2 Protein 
Reveals a Novel SCN-Controlled Oscillator in the Oval Nucleus of the Bed Nucleus 
of the Stria Terminalis. Journal of Neuroscience, 24(4), pp.781–790. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/14749422. 
Anacker, C. et al., 2013. Role for the kinase SGK1 in stress, depression, and 
glucocorticoid effects on hippocampal neurogenesis. Proceedings of the National 
Academy of Sciences of the United States of America, 110(21), pp.8708–13. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/23650397. 
Anand, S.N. et al., 2013. Distinct and Separable Roles for Endogenous CRY1 and CRY2 
within the Circadian Molecular Clockwork of the Suprachiasmatic Nucleus, as 
Revealed by the Fbxl3Afh Mutation. Journal of Neuroscience, 33(17), pp.7145–
7153. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23616524. 
Andersen, P., Holmqvist, B. & Voorhoeve, P.E., 1966. Excitatory Synapses on 
Hippocampal Apical Dendrites Activated by Entorhinal Stimulation. Acta 
Physiologica Scandinavica, 66(4), pp.461–472. Available at: 
http://doi.wiley.com/10.1111/j.1748-1716.1966.tb03224.x. 
André, E. et al., 1998. Disruption of retinoid-related orphan receptor β changes circadian 
behavior, causes retinal degeneration and leads to vacillans phenotype in mice. The 
EMBO Journal, 17(14), pp.3867–3877. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/9670004. 
Andrews, M.H. et al., 2012. Acute glucocorticoid administration rapidly suppresses basal 
and stress-induced hypothalamo-pituitary-adrenal axis activity. Endocrinology, 
153(1), pp.200–11. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22087024. 
Antle, M.C. & Silver, R., 2005. Orchestrating time: arrangements of the brain circadian 
clock. Trends in Neurosciences, 28(3), pp.145–151. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15749168. 
Antonijevic, I.A. & Steiger, A., 2003. Depression-like changes of the sleep-EEG during 
high dose corticosteroid treatment in patients with multiple sclerosis. , 28, pp.780–
795. 
Archer, S.N. et al., 2003. A length polymorphism in the circadian clock gene Per3 is 
linked to delayed sleep phase syndrome and extreme diurnal preference. Sleep, 
 185 
26(4), pp.413–5. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12841365. 
Arens, D. et al., 2007. Seasonal changes in bone metabolism in sheep. The Veterinary 
Journal, 174(3), pp.585–591. Available at: 
https://www.sciencedirect.com/science/article/pii/S1090023306001985. 
Arriza, J.L. et al., 1987. Cloning of Human Mineralocorticoid Receptor Complementary 
DNA: Structural and Functional Kinship with the Glucocorticoid Receptor Cloning 
of Human Mineralocorticoid Receptor Complementary DNA: Structural and 
Functional IKinship with the Glucocorticoid Receptor. Source: Science, New Series, 
237222117(17), pp.268–275. Available at: http://www.jstor.org/stable/1699970. 
Asher, G. et al., 2008. SIRT1 Regulates Circadian Clock Gene Expression through PER2 
Deacetylation. Cell, 134(2), pp.317–328. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18662546. 
Azcue, M. et al., 1997. Energy expenditure and body composition in children with 
Crohn’s disease: effect of enteral nutrition and treatment with prednisolone. Gut, 
41(2), pp.203–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9301499. 
Bae, K. et al., 2001. Differential functions of mPer1, mPer2, and mPer3 in the SCN 
circadian clock. Neuron, 30(2), pp.525–36. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11395012. 
Baldock, N.M., Sibly, R.M. & Penning, P.D., 1988. Behaviour and seasonal variation in 
heart rate in domestic sheep, Ovis aries. Animal Behaviour, 36(1), pp.35–43. 
Available at: 
https://www.sciencedirect.com/science/article/pii/S0003347288802471. 
Balsalobre, A. et al., 2000. Resetting of Circadian Time in Peripheral Tissues by 
Glucocorticoid Signaling. Science , 289(5488), pp.2344–2347. 
Bannerman, D.M. et al., 1995. Distinct components of spatial learning revealed by prior 
training and NMDA receptor blockade. Nature, 378(6553), pp.182–186. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/7477320. 
Barca-Mayo, O. et al., 2017. Astrocyte deletion of Bmal1 alters daily locomotor activity 
and cognitive functions via GABA signalling. Nature Communications, 8. 
Barrow, J.G. et al., 1951. DECUBITUS ULCER IN RHEUMATIC FEVER TREATED 




Baver, S.B. et al., 2008. Two types of melanopsin retinal ganglion cell differentially 
innervate the hypothalamic suprachiasmatic nucleus and the olivary pretectal 
nucleus. European Journal of Neuroscience, 27(7), pp.1763–1770. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18371076. 
van der Beek, E.M., 1996. Circadian control of reproduction in the female rat. Progress 
in brain research, 111, pp.295–320. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/8990922. 
van der Beek, E.M. et al., 1997. Synaptic contacts between gonadotropin-releasing 
hormone-containing fibers and neurons in the suprachiasmatic nucleus and 
perichiasmatic area: an anatomical substrate for feedback regulation? Brain 
research, 755(1), pp.101–11. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/9163545. 
Belden, W.J. & Dunlap, J.C., 2008. SIRT1 Is a Circadian Deacetylase for Core Clock 
Components. Cell, 134(2), p.212. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18662537. 
Bellanti, F. et al., 2017. Alterations of Clock Gene RNA Expression in Brain Regions of a 
 186 
Triple Transgenic Model of Alzheimer’s Disease. Journal of Alzheimer’s disease : 
JAD, 59(2), pp.615–631. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/28671110. 
Ben-Hamo, M. et al., 2016. Circadian Forced Desynchrony of the Master Clock Leads to 
Phenotypic Manifestation of Depression in Rats. eneuro, 3(6), p.ENEURO.0237-
16.2016. Available at: http://eneuro.sfn.org/lookup/doi/10.1523/ENEURO.0237-
16.2016. 
Benedict, R.H.B. et al., 2006. Neocortical Atrophy, Third Ventricular Width, and 
Cognitive Dysfunction in Multiple Sclerosis. Archives of Neurology, 63(9), p.1301. 
Available at: 
http://archneur.jamanetwork.com/article.aspx?doi=10.1001/archneur.63.9.1301. 
Benjamini, Y. & Hochberg, Y., 1995. Controlling the False Discovery Rate: A Practical 
and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. 
Series B (Methodological), 57, pp.289–300. Available at: 
https://www.jstor.org/stable/2346101. 
Benoit, J.D., Rakic, P. & Frick, K.M., 2015. Prenatal stress induces spatial memory 
deficits and epigenetic changes in the hippocampus indicative of heterochromatin 
formation and reduced gene expression. Behavioural Brain Research, 281, pp.1–8. 
Available at: 
https://www.sciencedirect.com/science/article/pii/S0166432814007864. 
Van den Berg, G. et al., 1995. Combined amplification of the pulsatile and basal modes 
of adrenocorticotropin and cortisol secretion in patients with Cushing’s disease: 
Evidence for decreased responsiveness of the adrenal glands. Journal of Clinical 
Endocrinology and Metabolism, 80(12), pp.3750–3757. 
Berk, M.L. & Finkelstein, J.A., 1981. An autoradiographic determination of the efferent 
projections of the suprachiasmatic nucleus of the hypothalamus. Brain Research, 
226(1–2), pp.1–13. Available at: 
https://www.sciencedirect.com/science/article/pii/0006899381910799. 
Bernardis, L.L., 1973. Disruption of diurnal feeding and weight gain cycles in weanling 
rats by ventromedial and dorsomedial hypothalamic lesions. Physiology & behavior, 
10(5), pp.855–61. Available at: http://www.ncbi.nlm.nih.gov/pubmed/4715812. 
Berson, D.M., Dunn, F.A. & Takao, M., 2002. Phototransduction by Retinal Ganglion 
Cells That Set the Circadian Clock. Science, 295(5557). Available at: 
http://science.sciencemag.org/content/295/5557/1070. 
Berson, D.M., Dunn, F.A. & Takao, M., 2002. Phototransduction by Retinal Ganglion 
Cells That Set the Circadian Clock. Science, 295(5557), pp.1070–1073. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11834835. 
Bierwolf, C. et al., 2003. Slow Wave Sleep Drives Inhibition of Pituitary-
AdrenalSecretion in Humans. Journal of Neuroendocrinology, 9(6), pp.479–484. 
Available at: http://doi.wiley.com/10.1046/j.1365-2826.1997.00605.x. 
Billon, C., Sitaula, S. & Burris, T.P., 2017. Metabolic Characterization of a Novel RORα 
Knockout Mouse Model without Ataxia. Frontiers in Endocrinology, 8, p.141. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/28744254. 
Birnie, M.T., 2018. Chronic synthetic glucocorticoid treatment induces circadian 
disturbances and memory impairments. Acad. Med. Sci. 
Bisset, G.W., Errington, M.L. & Richards, C.D., 1973. The distribution of vasopressin 
and oxytocin in the hypothalamoneurohypophysial system of the guinea-pig. Br. J. 




Björefeldt, A., 2015. Neuromodulation of hippocampal single cell-and network activity 
by human cerebrospinal fluid. Thesis. Available at: 
https://gupea.ub.gu.se/bitstream/2077/40445/1/gupea_2077_40445_1.pdf. 
Blandina, P. et al., 2012. Histamine neurons in the tuberomamillary nucleus: a whole 
center or distinct subpopulations? Frontiers in systems neuroscience, 6, p.33. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/22586376. 
Bliss, T. V & Lomo, T., 1973. Long-lasting potentiation of synaptic transmission in the 
dentate area of the anaesthetized rabbit following stimulation of the perforant path. 
The Journal of physiology, 232(2), pp.331–56. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/4727084. 
Bliss, T.V.P. & Collingridge, G.L., 1993. A synaptic model of memory: long-term 
potentiation in the hippocampus. Nature, 361(6407), pp.31–39. Available at: 
http://www.nature.com/doifinder/10.1038/361031a0. 
Bolton, J.L. et al., 2018. Anhedonia Following Early-Life Adversity Involves Aberrant 
Interaction of Reward and Anxiety Circuits and Is Reversed by Partial Silencing of 
Amygdala Corticotropin-Releasing Hormone Gene. Biological Psychiatry, 83(2), 
pp.137–147. Available at: http://www.ncbi.nlm.nih.gov/pubmed/29033027. 
Bone, R.C. et al., 1987. A Controlled Clinical Trial of High-Dose Methylprednisolone in 
the Treatment of Severe Sepsis and Septic Shock. New England Journal of 
Medicine, 317(11), pp.653–658. Available at: 
http://www.nejm.org/doi/abs/10.1056/NEJM198709103171101. 
Born, J. et al., 1991. Gluco- and antimineralocorticoid effects on human sleep: a role of 
central corticosteroid receptors. American Journal of Physiology-Endocrinology and 
Metabolism, 260(2), pp.E183–E188. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/1996621. 
Born, J., 2010. Slow-wave sleep and the consolidation of long-term memory. The World 
Journal of Biological Psychiatry, 11(sup1), pp.16–21. Available at: 
http://www.tandfonline.com/doi/full/10.3109/15622971003637637. 
Born, J., Muth, S. & Fehm, H.L., 1988. The significance of sleep onset and slow wave 
sleep for nocturnal release of growth hormone (GH) and cortisol. 
Psychoneuroendocrinology, 13(3), pp.233–43. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/3406323. 
Bouchard-Cannon, P. et al., 2013. The Circadian Molecular Clock Regulates Adult 
Hippocampal Neurogenesis by Controlling the Timing of Cell-Cycle Entry and Exit. 
Cell Reports, 5(4), pp.961–973. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/24268780. 
Boyle, M.P. et al., 2005. Acquired deficit of forebrain glucocorticoid receptor produces 
depression-like changes in adrenal axis regulation and behavior. Proceedings of the 
National Academy of Sciences, 102(2), pp.473–478. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15623560. 
Bradbury, M.J., Dement, W.C. & Edgar, D.M., 1998. Effects of adrenalectomy and 
subsequent corticosterone replacement on rat sleep state and EEG power spectra. 
The American journal of physiology, 275(2 Pt 2), pp.R555-65. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/9688693. 
Brown, E.S., 2009. Effects of Glucocorticoids on Mood, Memory, and the Hippocampus. 
Annals of the New York Academy of Sciences, 1179(1), pp.41–55. Available at: 
http://doi.wiley.com/10.1111/j.1749-6632.2009.04981.x. 
Brown, E.S. & Chandler, P.A., 2001. Mood and Cognitive Changes During Systemic 
Corticosteroid Therapy. Primary care companion to the Journal of clinical 
psychiatry, 3(1), pp.17–21. Available at: 
 188 
http://www.ncbi.nlm.nih.gov/pubmed/15014624. 
Buchanan, T.W. et al., 2004. Circadian regulation of cortisol after hippocampal damage 
in humans. Biological Psychiatry, 56(9), pp.651–656. Available at: 
https://www.sciencedirect.com/science/article/pii/S0006322304009011. 
Bugge, A. et al., 2012. Rev-erbα and Rev-erbβ coordinately protect the circadian clock 
and normal metabolic function. Genes & development, 26(7), pp.657–67. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/22474260. 
Buller, K.M., Xu, Y. & Day, T.A., 1998. Indomethacin attenuates oxytocin and 
hypothalamic-pituitary-adrenal axis responses to systemic interleukin-1 beta. 
Journal of neuroendocrinology, 10(7), pp.519–28. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/9700679. 
Bunney, B.G. et al., 2015. Circadian dysregulation of clock genes: clues to rapid 
treatments in major depressive disorder. Molecular psychiatry, 20(1), pp.48–55. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/25349171. 
Bush, G., Luu, P. & Posner, M.I., 2000. Cognitive and emotional influences in anterior 
cingulate cortex. Trends in Cognitive Sciences, 4(6), pp.215–222. Available at: 
https://www.sciencedirect.com/science/article/pii/S1364661300014832. 
Buzsáki, G., 2010. Neural Syntax: Cell Assemblies, Synapsembles, and Readers. Neuron, 
68(3), pp.362–385. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21040841. 
Buzsáki, G., 2002. Theta Oscillations in the Hippocampus. Neuron, 33(3), pp.325–340. 
Available at: 
https://www.sciencedirect.com/science/article/pii/S089662730200586X. 
Canteras, N.S. & Swanson, L.W., 1992. Projections of the ventral subiculum to the 
amygdala, septum, and hypothalamus: A PHAL anterograde tract-tracing study in 
the rat. The Journal of Comparative Neurology, 324(2), pp.180–194. Available at: 
http://doi.wiley.com/10.1002/cne.903240204. 
Card, J.P. & Moore, R.Y., 1988. Neuropeptide Y localization in the rat suprachiasmatic 
nucleus and periventricular hypothalamus. Neuroscience letters, 88(3), pp.241–6. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/3386869. 
CARSON-JURICA, M.A., SCHRADER, W.T. & O’MALLEY, B.W., 1990. Steroid 
Receptor Family: Structure and Functions. Endocrine Reviews, 11(2), pp.201–220. 
Available at: http://press.endocrine.org/doi/abs/10.1210/edrv-11-2-201. 
Casady, R.L. & Taylor, A.N., 1976. Effect of electrical stimulation of the hippocampus 
upon corticosteroid levels in the freely-behaving, non-stressed rat. 
Neuroendocrinology, 20(1), pp.68–78. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/934426. 
Castel, M. & Morris, J.F., 2000. Morphological heterogeneity of the GABAergic network 
in the suprachiasmatic nucleus, the brain’s circadian pacemaker. Journal of anatomy, 
196 ( Pt 1), pp.1–13. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10697283. 
Catani, M., Dell’Acqua, F. & Thiebaut de Schotten, M., 2013. A revised limbic system 
model for memory, emotion and behaviour. Neuroscience & Biobehavioral Reviews, 
37(8), pp.1724–1737. Available at: 
https://www.sciencedirect.com/science/article/pii/S0149763413001711. 
Van Cauter, E., Leproult, R. & Plat, L., 2000. Age-Related Changes in Slow Wave Sleep 
and REM Sleep and Relationship With Growth Hormone and Cortisol Levels in 
Healthy Men. JAMA, 284(7), p.861. Available at: 
http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.284.7.861. 
Van Cauter, E. & Refetoff, S., 1985. Evidence for Two Subtypes of Cushing’s Disease 
Based on the Analysis of Episodic Cortisol Secretion. New England Journal of 
Medicine, 312(21), pp.1343–1349. Available at: 
 189 
http://www.nejm.org/doi/abs/10.1056/NEJM198505233122102. 
Ceolin, L. et al., 2011. Study of Novel Selective mGlu2 Agonist in the Temporo-
Ammonic Input to CA1 Neurons Reveals Reduced mGlu2 Receptor Expression in a 
Wistar Substrain with an Anxiety-Like Phenotype. Journal of Neuroscience, 31(18), 
pp.6721–6731. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21543601. 
Cermakian, N. et al., 2001. Altered behavioral rhythms and clock gene expression in mice 
with a targeted mutation in the Period1 gene. The EMBO journal, 20(15), pp.3967–
74. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11483500. 
Chabot, C.C., Connolly, D.M. & Waring, B.B., 2012. The effects of lighting conditions 
and food restriction paradigms on locomotor activity of common spiny mice, 
Acomys cahirinus. Journal of Circadian Rhythms, 10(0), p.6. Available at: 
https://www.jcircadianrhythms.com/article/10.1186/1740-3391-10-6/. 
Charmandari, E. et al., 2008. Generalized Glucocorticoid Resistance: Clinical Aspects, 
Molecular Mechanisms, and Implications of a Rare Genetic Disorder. The Journal of 
Clinical Endocrinology & Metabolism, 93(5), pp.1563–1572. Available at: 
https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2008-0040. 
Chen, C.-Y. et al., 2016. Effects of aging on circadian patterns of gene expression in the 
human prefrontal cortex. Proceedings of the National Academy of Sciences, 113(1), 
pp.206–211. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26699485. 
Chen, Q.H., Haywood, J.R. & Toney, G.M., 2003. Sympathoexcitation by PVN-Injected 
Bicuculline Requires Activation of Excitatory Amino Acid Receptors. Hypertension, 
42(4), pp.725–731. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12900439. 
Chen, R. et al., 2008. Strong resetting of the mammalian clock by constant light followed 
by constant darkness. The Journal of neuroscience : the official journal of the 
Society for Neuroscience, 28(46), pp.11839–47. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/19005049. 
Chen, S.-T. et al., 2005. Deregulated expression of the PER1 , PER2 and PER3 genes in 
breast cancers. Carcinogenesis, 26(7), pp.1241–1246. Available at: 
http://academic.oup.com/carcin/article/26/7/1241/2390900/Deregulated-expression-
of-the-PER1-PER2-and-PER3. 
Cheon, S. et al., 2013. Glucocorticoid-mediated Period2 induction delays the phase of 
circadian rhythm. Nucleic Acids Research, 41(12), pp.6161–6174. Available at: 
http://academic.oup.com/nar/article/41/12/6161/1028125/Glucocorticoidmediated-
Period2-induction-delays. 
CHILDS, G. V., WESTLUND, K.N. & UNABIA, G., 1989. Characterization of Anterior 
Pituitary Target Cells for Arginine Vasopressin: Including Cells that Store 
Adrenocorticotropin, Thyrotropin-β, and Both Hormones*. Endocrinology, 125(1), 
pp.554–559. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2544413. 
Cho, H. et al., 2012. Regulation of circadian behaviour and metabolism by REV-ERB-α 
and REV-ERB-β. Nature, 485(7396), pp.123–127. Available at: 
http://www.nature.com/articles/nature11048. 
Christiansen, S. et al., 2016. Altered Expression Pattern of Clock Genes in a Rat Model of 
Depression. International Journal of Neuropsychopharmacology, 19(11), p.pyw061. 
Available at: https://academic.oup.com/ijnp/article-lookup/doi/10.1093/ijnp/pyw061. 
Chu, J.W. et al., 2001. Successful Long-Term Treatment of Refractory Cushing’s Disease 
with High-Dose Mifepristone (RU 486). The Journal of Clinical Endocrinology & 
Metabolism, 86(8), pp.3568–3573. Available at: 
https://academic.oup.com/jcem/article-lookup/doi/10.1210/jcem.86.8.7740. 
Collingridge, G.L., Kehl, S.J. & McLennan, H., 1983. Excitatory amino acids in synaptic 
transmission in the Schaffer collateral-commissural pathway of the rat hippocampus. 
 190 
The Journal of physiology, 334, pp.33–46. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/6306230. 
Coluccia, D. et al., 2008. Glucocorticoid therapy-induced memory deficits: acute versus 
chronic effects. The Journal of neuroscience : the official journal of the Society for 
Neuroscience, 28(13), pp.3474–3478. 
Conn, D.L., 2001. Resolved: Low-dose prednisone is indicated as a standard treatment in 
patients with rheumatoid arthritis. Arthritis and rheumatism, 45(5), pp.462–7. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/11642646. 
Conrad, C. et al., 2004. Influence of chronic corticosterone and glucocorticoid receptor 
antagonism in the amygdala on fear conditioning. Neurobiology of Learning and 
Memory, 81(3), pp.185–199. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15082020 [Accessed July 14, 2018]. 
Conrad, C.D. et al., 1996. Chronic stress impairs rat spatial memory on the Y maze, and 
this effect is blocked by tianeptine pretreatment. Behavioral neuroscience, 110(6), 
pp.1321–34. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8986335. 
Conrad, C.D. et al., 1999. Repeated restraint stress facilitates fear conditioning 
independently of causing hippocampal CA3 dendritic atrophy. Behavioral 
neuroscience, 113(5), pp.902–13. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10571474. 
Conway-Campbell, B.L. et al., 2010. Glucocorticoid ultradian rhythmicity directs cyclical 
gene pulsing of the clock gene period 1 in rat hippocampus. Journal of 
neuroendocrinology, 22(10), pp.1093–100. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/20649850. 
Conway-Campbell, B.L. et al., 2012. Molecular dynamics of ultradian glucocorticoid 
receptor action. Molecular and Cellular Endocrinology, 348(2), pp.383–393. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/21872640. 
Coomans, C.P. et al., 2013. The suprachiasmatic nucleus controls circadian energy 
metabolism and hepatic insulin sensitivity. Diabetes, 62(4), pp.1102–8. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/23274903. 
Cornu, M. et al., 2014. Hepatic mTORC1 controls locomotor activity, body temperature, 
and lipid metabolism through FGF21. Proceedings of the National Academy of 
Sciences, 111(32), pp.11592–11599. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/25082895. 
Crumbley, C. & Burris, T.P., 2011. Direct Regulation of CLOCK Expression by REV-
ERB I. Hansen, ed. PLoS ONE, 6(3), p.e17290. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/21479263. 
Cui, Z., Gerfen, C.R. & Young, W.S., 2013. Hypothalamic and other connections with 
dorsal CA2 area of the mouse hippocampus. Journal of Comparative Neurology, 
521(8), pp.1844–1866. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/23172108. 
Cunningham, E.T., Bohn, M.C. & Sawchenko, P.E., 1990. Organization of adrenergic 
inputs to the paraventricular and supraoptic nuclei of the hypothalamus in the rat. 
The Journal of Comparative Neurology, 292(4), pp.651–667. Available at: 
http://doi.wiley.com/10.1002/cne.902920413. 
Damiola, F. et al., 2000. Restricted feeding uncouples circadian oscillators in peripheral 
tissues from the central pacemaker in the suprachiasmatic nucleus. Genes & 
development, 14(23), pp.2950–61. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11114885. 
Davidson, A.J. et al., 2003. Is the food-entrainable circadian oscillator in the digestive 
system? Genes, Brain and Behavior, 2(1), pp.32–39. Available at: 
 191 
http://doi.wiley.com/10.1034/j.1601-183X.2003.00005.x. 
Dayas, C. V., Buller, K.M. & Day, T.A., 1999. Neuroendocrine responses to an emotional 
stressor: evidence for involvement of the medial but not the central amygdala. 
European Journal of Neuroscience, 11(7), pp.2312–2322. Available at: 
http://doi.wiley.com/10.1046/j.1460-9568.1999.00645.x. 
DeBruyne, J.P. et al., 2006. A Clock Shock: Mouse CLOCK Is Not Required for 
Circadian Oscillator Function. Neuron, 50(3), pp.465–477. Available at: 
https://www.sciencedirect.com/science/article/pii/S0896627306002674?via%3Dihub
. 
DeBruyne, J.P., Weaver, D.R. & Reppert, S.M., 2007. CLOCK and NPAS2 have 
overlapping roles in the suprachiasmatic circadian clock. Nature Neuroscience, 
10(5), pp.543–545. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17417633. 
DeFronzo, R.A. & Tripathy, D., 2009. Skeletal muscle insulin resistance is the primary 
defect in type 2 diabetes. Diabetes care, 32 Suppl 2(suppl 2), pp.S157-63. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/19875544. 
Delerive, P., Chin, W.W. & Suen, C.S., 2002. Identification of Reverbα as a Novel RORα 
Target Gene. Journal of Biological Chemistry, 277(38), pp.35013–35018. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/12114512. 
Demski-Allen, R., 2014. Characterisation of the Molecular and Cognitive Effects of 
synthetic glucocorticoid treatment. 
Diamond, D.M. et al., 1992. Inverted-U relationship between the level of peripheral 
corticosterone and the magnitude of hippocampal primed burst potentiation. 
Hippocampus, 2(4), pp.421–430. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/1308198. 
Díaz-Muñoz, M. et al., 2000. Anticipatory changes in liver metabolism and entrainment 
of insulin, glucagon, and corticosterone in food-restricted rats. American Journal of 
Physiology-Regulatory, Integrative and Comparative Physiology, 279(6), 
pp.R2048–R2056. Available at: 
http://www.physiology.org/doi/10.1152/ajpregu.2000.279.6.R2048. 
Diorio, D., Viau, V. & Meaney, M.J., 1993. The role of the medial prefrontal cortex 
(cingulate gyrus) in the regulation of hypothalamic-pituitary-adrenal responses to 
stress. The Journal of neuroscience : the official journal of the Society for 
Neuroscience, 13(9), pp.3839–47. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/8396170. 
Doi, M., Hirayama, J. & Sassone-Corsi, P., 2006. Circadian Regulator CLOCK Is a 
Histone Acetyltransferase. Cell, 125(3), pp.497–508. Available at: 
https://www.sciencedirect.com/science/article/pii/S0092867406004442. 
Drevets, W.C. et al., 1992. A functional anatomical study of unipolar depression. The 
Journal of neuroscience : the official journal of the Society for Neuroscience, 12(9), 
pp.3628–41. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1527602. 
Dubrovsky, Y. V., Samsa, W.E. & Kondratov, R. V., 2010. Deficiency of circadian 
protein CLOCK reduces lifespan and increases age-related cataract development in 
mice. Aging, 2(12), pp.936–944. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/21149897. 
Dudley, T.E., Dinardo, L.A. & Glass, J.D., 1999. In Vivo Assessment of the Midbrain 
Raphe Nuclear Regulation of Serotonin Release in the Hamster Suprachiasmatic 
Nucleus. Journal of Neurophysiology, 81(4), pp.1469–1477. Available at: 
http://www.physiology.org/doi/10.1152/jn.1999.81.4.1469. 
Dumont, J.R. et al., 2012. Anterior thalamic nuclei lesions in rats disrupt markers of 
neural plasticity in distal limbic brain regions. Neuroscience, 224, pp.81–101. 
 192 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/22917615. 
Dyar, K.A. et al., 2014. Muscle insulin sensitivity and glucose metabolism are controlled 
by the intrinsic muscle clock. Molecular Metabolism, 3(1), pp.29–41. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/24567902. 
Earl, E. et al., 2018. Characterisation of glucocorticoid receptor activation profiles in rat 
brain and pituitary during treatment with the synthetic glucocorticoids 
methylprednisolone and dexamethasone. Journal of Psychopharmacology, (In 
review. 
Earl, E., Stubbs, F.. & Conway-Campbell, B.L., 2018. Dynamics of endogenous and 
synthetic glucocorticoid binding. In review. 
Eastman, C. & Rechtschaffen, A., 1983. Circadian temperature and wake rhythms of rats 
exposed to prolonged continuous illumination. Physiology & behavior, 31(4), 
pp.417–27. Available at: http://www.ncbi.nlm.nih.gov/pubmed/6657763. 
Eastman, C.I., Mistlberger, R.E. & Rechtschaffen, A., 1984. Suprachiasmatic nuclei 
lesions eliminate circadian temperature and sleep rhythms in the rat. Physiology & 
Behavior, 32(3), pp.357–368. Available at: 
https://www.sciencedirect.com/science/article/pii/0031938484902488. 
Ebling, F.J.P. et al., 1992. Circadian and Photoperiodic Time Measurement in Male 
Syrian Hamsters Following Lesions of the Melatonin-Binding Sites of the 
Paraventricular Thalamus. Journal of Biological Rhythms, 7(3), pp.241–254. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/1330085. 
Eckel-Mahan, K.L. et al., 2008. Circadian oscillation of hippocampal MAPK activity and 
cAmp: implications for memory persistence. Nature neuroscience, 11(9), pp.1074–
82. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19160506. 
Edelstein, K. & Amir, S., 1999. The role of the intergeniculate leaflet in entrainment of 
circadian rhythms to a skeleton photoperiod. The Journal of neuroscience : the 
official journal of the Society for Neuroscience, 19(1), pp.372–80. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/9870966. 
Edmonds, S.C. & Adler, N.T., 1977. Food and light as entrainers of circadian running 
activity in the rat. Physiology & Behavior, 18(5), pp.915–919. Available at: 
https://www.sciencedirect.com/science/article/pii/0031938477902013. 
Edwards, C.R.W. et al., 1988. LOCALISATION OF 11β-HYDROXYSTEROID 
DEHYDROGENASE—TISSUE SPECIFIC PROTECTOR OF THE 
MINERALOCORTICOID RECEPTOR. The Lancet, 332(8618), pp.986–989. 
Available at: 
https://www.sciencedirect.com/science/article/pii/S0140673688907428. 
Van Eekelen, J.A.M. et al., 1988. Distribution of the mineralocorticoid and the 
glucocorticoid receptor mRNAs in the rat hippocampus. Journal of Neuroscience 
Research, 21(1), pp.88–94. Available at: 
http://doi.wiley.com/10.1002/jnr.490210113. 
Ehlers, C.L., Reed, T.K. & Henriksen, S.J., 1986. Effects of corticotropin-releasing factor 
and growth hormone-releasing factor on sleep and activity in rats. 
Neuroendocrinology, 42(6), pp.467–74. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/3084988. 
Eliava, M. et al., 2016. A New Population of Parvocellular Oxytocin Neurons Controlling 
Magnocellular Neuron Activity and Inflammatory Pain Processing. Neuron, 89(6), 
pp.1291–1304. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26948889. 
Emery, P. et al., 1998. CRY, a Drosophila clock and light-regulated cryptochrome, is a 
major contributor to circadian rhythm resetting and photosensitivity. Cell, 95(5), 
pp.669–79. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9845369. 
 193 
Erkut, Z.A., Pool, C. & Swaab, D.F., 1998. Glucocorticoids Suppress Corticotropin-
Releasing Hormone and Vasopressin Expression in Human Hypothalamic Neurons. 
The Journal of Clinical Endocrinology & Metabolism, 83(6), pp.2066–2073. 
Available at: http://press.endocrine.org/doi/10.1210/jcem.83.6.4881. 
Eschenko, O. et al., 2008. Sustained increase in hippocampal sharp-wave ripple activity 
during slow-wave sleep after learning. Learning & memory (Cold Spring Harbor, 
N.Y.), 15(4), pp.222–8. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18385477. 
Etchegaray, J.-P. et al., 2009. Casein kinase 1 delta regulates the pace of the mammalian 
circadian clock. Molecular and cellular biology, 29(14), pp.3853–66. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/19414593. 
Etchegaray, J.-P. et al., 2003. Rhythmic histone acetylation underlies transcription in the 
mammalian circadian clock. Nature, 421(6919), pp.177–182. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/12483227. 
Eun, B. et al., 2011. Induction of Per1 expression following an experimentally induced 
epilepsy in the mouse hippocampus. Neuroscience Letters, 498(2), pp.110–113. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/21420468. 
Fang, H. & Gough, J., 2014. SupraHex: An R/Bioconductor package for tabular omics 
data analysis using a supra-hexagonal map. Biochemical and Biophysical Research 
Communications, 443(1), pp.285–289. 
Fanselow, M.S. & LeDoux, J.E., 1999. Why we think plasticity underlying Pavlovian fear 
conditioning occurs in the basolateral amygdala. Neuron, 23(2), pp.229–32. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/10399930. 
Feillet, C.A. et al., 2008. Forebrain oscillators ticking with different clock hands. 
Molecular and Cellular Neuroscience, 37(2), pp.209–221. Available at: 
https://www.sciencedirect.com/science/article/pii/S1044743107002217. 
Feldman, S., Conforti, N. & Saphier, D., 1990. The preoptic area and bed nucleus of the 
stria terminalis are involved in the effects of the amygdala on adrenocortical 
secretion. Neuroscience, 37(3), pp.775–779. Available at: 
https://www.sciencedirect.com/science/article/pii/030645229090107F. 
FENDLER, K., KARMOS, G. & TELEGDY, G., 1961. The effect of hippocampal lesion 
on pituitary-adrenal function. Acta physiologica Academiae Scientiarum 
Hungaricae, 20, pp.293–7. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/13892267. 
Field, M.D. et al., 2000. Analysis of clock proteins in mouse SCN demonstrates 
phylogenetic divergence of the circadian clockwork and resetting mechanisms. 
Neuron, 25(2), pp.437–47. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10719897 [Accessed July 12, 2018]. 
Fields, H.L. et al., 2007. Ventral Tegmental Area Neurons in Learned Appetitive 
Behavior and Positive Reinforcement. Annual Review of Neuroscience, 30(1), 
pp.289–316. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17376009. 
Filiano, A.N. et al., 2013. Chronic Ethanol Consumption Disrupts the Core Molecular 
Clock and Diurnal Rhythms of Metabolic Genes in the Liver without Affecting the 
Suprachiasmatic Nucleus W. Schwartz, ed. PLoS ONE, 8(8), p.e71684. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/23951220. 
Fischette, C.T. et al., 1980. Differential fornix ablations and the circadian rhythmicity of 
adrenal corticosteroid secretion. Brain Research, 195(2), pp.373–387. Available at: 
https://www.sciencedirect.com/science/article/pii/0006899380900736. 
Foster, R.G. & Hankins, M.W., 2007. Circadian vision. Current Biology, 17(17), 
pp.R746–R751. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17803920. 
 194 
Frank, L.M., Brown, E.N. & Wilson, M., 2000. Trajectory Encoding in the Hippocampus 
and Entorhinal Cortex. Neuron, 27(1), pp.169–178. Available at: 
https://www.sciencedirect.com/science/article/pii/S0896627300000180. 
Frédéric, F. et al., 2006. Enhanced endocrine response to novel environment stress and 
lack of corticosterone circadian rhythm instaggerer (Rora sg/sg) mutant mice. 
Journal of Neuroscience Research, 83(8), pp.1525–1532. Available at: 
http://doi.wiley.com/10.1002/jnr.20843. 
Frey, S., Bergado, J.. & Frey, J.., 2003. Modulation of late phases of long-term 
potentiation in rat dentate gyrus by stimulation of the medial septum. Neuroscience, 
118(4), pp.1055–1062. Available at: 
https://www.sciencedirect.com/science/article/pii/S0306452203000290. 
Frodl, T. et al., 2012. Reduced expression of glucocorticoid-inducible genes GILZ and 
SGK-1: high IL-6 levels are associated with reduced hippocampal volumes in major 
depressive disorder. Translational Psychiatry, 2(3), pp.e88–e88. Available at: 
http://www.nature.com/articles/tp201214. 
Frotscher, M., 1985. Mossy fibres form synapses with identified pyramidal basket cells in 
the CA3 region of the guinea-pig hippocampus: a combined Golgi-electron 
microscope study. Journal of Neurocytology, 14(2), pp.245–259. Available at: 
http://link.springer.com/10.1007/BF01258450. 
Fuhrmann, F. et al., 2015. Locomotion, Theta Oscillations, and the Speed-Correlated 
Firing of Hippocampal Neurons Are Controlled by a Medial Septal Glutamatergic 
Circuit. Neuron, 86(5), pp.1253–1264. Available at: 
https://www.sciencedirect.com/science/article/pii/S0896627315004080. 
Gagne, D., Pons, M. & Philibert, D., 1985. RU 38486: a potent antiglucocorticoid in vitro 
and in vivo. Journal of steroid biochemistry, 23(3), pp.247–51. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/2864478. 
Gais, S. et al., 2002. Learning-dependent increases in sleep spindle density. The Journal 
of neuroscience : the official journal of the Society for Neuroscience, 22(15), 
pp.6830–4. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12151563. 
Gais, S. et al., 2007. Sleep transforms the cerebral trace of declarative memories. 
Proceedings of the National Academy of Sciences, 104(47), pp.18778–18783. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/18000060. 
Gallina, D., Zelinka, C. & Fischer, A.J., 2014. Glucocorticoid receptors in the retina, 
Muller glia and the formation of Muller glia-derived progenitors. Development, 
141(17), pp.3340–3351. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/25085975. 
Gamble, K.L. et al., 2007. Gastrin-Releasing Peptide Mediates Light-Like Resetting of 
the Suprachiasmatic Nucleus Circadian Pacemaker through cAMP Response 
Element-Binding Protein and Per1 Activation. Journal of Neuroscience, 27(44), 
pp.12078–12087. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17978049. 
Garfinkel, D. et al., 1995. Improvement of sleep quality in elderly people by controlled-
release melatonin. The Lancet, 346(8974), pp.541–544. Available at: 
https://www.sciencedirect.com/science/article/pii/S0140673695913823. 
Gatfield, D. & Schibler, U., 2008. Circadian glucose homeostasis requires compensatory 
interference between brain and liver clocks. Proceedings of the National Academy of 
Sciences of the United States of America, 105(39), pp.14753–4. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18812506. 
Gekakis, N. et al., 1998. Role of the CLOCK protein in the mammalian circadian 
mechanism. Science (New York, N.Y.), 280(5369), pp.1564–9. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/9616112. 
 195 
George, C.L. et al., 2017. Ultradian glucocorticoid exposure directs gene-dependent and 
tissue-specific mRNA expression patterns in vivo. Molecular and cellular 
endocrinology, 439, pp.46–53. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/27769714. 
Giguere, V. et al., 1986. Functional Domains of the Human Glucocorticoid Receptor. 
Cell, 46, pp.645–652. 
Gilhooley, M.J., Pinnock, S.B. & Herbert, J., 2011. Rhythmic expression of per1 in the 
dentate gyrus is suppressed by corticosterone: Implications for neurogenesis. 
Neuroscience Letters, 489(3), pp.177–181. Available at: 
https://www.sciencedirect.com/science/article/pii/S0304394010015454. 
Gillette, M.U. & Tischkau, S.A., 1999. Suprachiasmatic nucleus: the brain’s circadian 
clock. Recent progress in hormone research, 54, pp.33-58; discussion 58–9. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/10548871. 
Girardeau, G. et al., 2009. Selective suppression of hippocampal ripples impairs spatial 
memory. Nature Neuroscience, 12(10), pp.1222–1223. Available at: 
http://www.nature.com/articles/nn.2384. 
Gomez, F. et al., 1997. Arginine vasopressin (AVP) depletion in neurons of the 
suprachiasmatic nuclei affects the AVP content of the paraventricular neurons and 
stimulates adrenocorticotrophic hormone release. Journal of Neuroscience Research, 
50(4), pp.565–574. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9404718. 
Goto, S.G. & Denlinger, D.L., 2002. Short-day and long-day expression patterns of genes 
involved in the flesh fly clock mechanism: period, timeless,cycle and cryptochrome. 
Journal of Insect Physiology, 48(8), pp.803–816. Available at: 
https://www.sciencedirect.com/science/article/pii/S0022191002001087. 
Gottlieb, D.I. & Cowan, W.M., 1973. Autoradiographic studies of the commissural and 
ipsilateral association connections of the hippocampus and dentate gyrus. I. The 
commissural connections. The Journal of Comparative Neurology, 149(4), pp.393–
421. Available at: http://doi.wiley.com/10.1002/cne.901490402. 
Granados-Fuentes, D. et al., 2004. Olfactory bulb neurons express functional, entrainable 
circadian rhythms. The European journal of neuroscience, 19(4), pp.898–906. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/15009137. 
Granados-Fuentes, D., Tseng, A. & Herzog, E.D., 2006. A Circadian Clock in the 
Olfactory Bulb Controls Olfactory Responsivity. Journal of Neuroscience, 26(47), 
pp.12219–12225. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17122046. 
Graves, L.A. et al., 2003. Sleep deprivation selectively impairs memory consolidation for 
contextual fear conditioning. Learning & memory (Cold Spring Harbor, N.Y.), 
10(3), pp.168–76. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12773581. 
Gray, T.S., Carney, M.E. & Magnuson, D.J., 1989. Direct Projections from the Central 
Amygdaloid Nucleus to the Hypothalamic Paraventricular Nucleus: Possible Role in 
Stress-Induced Adrenocorticotropin Release. Neuroendocrinology, 50(4), pp.433–
446. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2554178. 
Grol, M.J. et al., 2006. Cerebral changes during performance of overlearned arbitrary 
visuomotor associations. The Journal of neuroscience : the official journal of the 
Society for Neuroscience, 26(1), pp.117–25. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16399678. 
Grønli, J. et al., 2006. Chronic mild stress inhibits BDNF protein expression and CREB 
activation in the dentate gyrus but not in the hippocampus proper. Pharmacology 
Biochemistry and Behavior, 85(4), pp.842–849. Available at: 
https://www.sciencedirect.com/science/article/pii/S009130570600387X. 
Gruart, A., Muñoz, M.D. & Delgado-García, J.M., 2006. Involvement of the CA3-CA1 
 196 
Synapse in the Acquisition of Associative Learning in Behaving Mice. Journal of 
Neuroscience, 26(4), pp.1077–1087. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16436593. 
Guillaumond, F. et al., 2005. Differential Control of Bmal1 Circadian Transcription by 
REV-ERB and ROR Nuclear Receptors. Journal of Biological Rhythms, 20(5), 
pp.391–403. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16267379. 
Guo, H. et al., 2005. Differential control of peripheral circadian rhythms by 
suprachiasmatic-dependent neural signals. Proceedings of the National Academy of 
Sciences of the United States of America, 102(8), pp.3111–6. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15710878. 
Habib, K.E., Gold, P.W. & Chrousos, G.P., 2001. Neuroendocrinology of stress. 
Endocrinology and metabolism clinics of North America, 30(3), p.695–728; vii–viii. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/11571937. 
Hall, J.C., 1983. Complex brain and behavioral functions disrupted by mutations in 
Drosophila. Developmental Genetics, 4(4), pp.355–378. Available at: 
http://doi.wiley.com/10.1002/dvg.1020040411. 
Hamani, C. et al., 2011. The Subcallosal Cingulate Gyrus in the Context of Major 
Depression. Biological Psychiatry, 69(4), pp.301–308. Available at: 
https://www.sciencedirect.com/science/article/pii/S0006322310010036. 
Han, F. et al., 2005. Colocalization of mineralocorticoid receptor and glucocorticoid 
receptor in the hippocampus and hypothalamus. Neuroscience research, 51(4), 
pp.371–81. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15740800. 
Hara, R. et al., 2001. Restricted feeding entrains liver clock without participation of the 
suprachiasmatic nucleus. Genes to cells : devoted to molecular & cellular 
mechanisms, 6(3), pp.269–78. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11260270. 
Hargreaves, E.L. et al., 2005. Major Dissociation Between Medial and Lateral Entorhinal 
Input to Dorsal Hippocampus. Science, 308(5729), pp.1792–1794. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15961670. 
Harper, R.M., Woo, M.A. & Alger, J.R., 2000. Visualization of sleep influences on 
cerebellar and brainstem cardiac and respiratory control mechanisms. Brain 
Research Bulletin, 53(1), pp.125–131. Available at: 
https://www.sciencedirect.com/science/article/pii/S0361923000003178. 
Harrington, M.E., 1997. The ventral lateral geniculate nucleus and the intergeniculate 
leaflet: interrelated structures in the visual and circadian systems. Neuroscience and 
biobehavioral reviews, 21(5), pp.705–27. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/9353800. 
Harrington, M.E., Nance, D.M. & Rusak, B., 1987. Double-labeling of neuropeptide Y-
immunoreactive neurons which project from the geniculate to the suprachiasmatic 
nuclei. Brain research, 410(2), pp.275–82. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/2439175. 
Hasan, S. et al., 2011. Altered sleep and behavioral activity phenotypes in PER3-deficient 
mice. American Journal of Physiology-Regulatory, Integrative and Comparative 
Physiology, 301(6), pp.R1821–R1830. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/21957163. 
Hattar, S. et al., 2002. Melanopsin-containing retinal ganglion cells: architecture, 
projections, and intrinsic photosensitivity. Science (New York, N.Y.), 295(5557), 
pp.1065–70. Available at: 
http://www.sciencemag.org/cgi/doi/10.1126/science.1069609. 
Hayreh, S.S. & Zimmerman, B., 2003. Visual deterioration in giant cell arteritis patients 
 197 
while on high doses of corticosteroid therapy. Ophthalmology, 110(6), pp.1204–
1215. Available at: 
https://www.sciencedirect.com/science/article/pii/S0161642003002288. 
Heath, R.G. et al., 1978. Cerebellar stimulation: effects on septal region, hippocampus, 
and amygdala of cats and rats. Biological psychiatry, 13(5), pp.501–29. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/728506. 
Heath, R.G. & Harper, J.W., 1974. Ascending projections of the cerebellar fastigial 
nucleus to the hippocampus, amygdala, and other temporal lobe sites: Evoked 
potential and histological studies in monkeys and cats. Experimental Neurology, 
45(2), pp.268–287. Available at: 
https://www.sciencedirect.com/science/article/pii/0014488674901186. 
Henley, D.E. et al., 2009. Development of an automated blood sampling system for use in 
humans. Journal of Medical Engineering & TechnologyOnline) Journal Journal of 
Medical Engineering & Technology, 333, pp.309–1902. Available at: 
http://www.tandfonline.com/action/journalInformation?journalCode=ijmt20. 
Hensler, J.G., 2006. Serotonergic modulation of the limbic system. Neuroscience & 
Biobehavioral Reviews, 30(2), pp.203–214. Available at: 
https://www.sciencedirect.com/science/article/pii/S0149763405001181. 
Herman, J.P. et al., 2003. Central mechanisms of stress integration: hierarchical circuitry 
controlling hypothalamo–pituitary–adrenocortical responsiveness. Frontiers in 
Neuroendocrinology, 24(3), pp.151–180. Available at: 
https://www.sciencedirect.com/science/article/pii/S0091302203000293. 
Herman, J.P. et al., 1995. Contribution of the Ventral Subiculum to Inhibitory Regulation 
of the Hypothalamo-Pituitary-Adrenocortical Axis. Journal of Neuroendocrinology, 
7(6), pp.475–482. Available at: http://doi.wiley.com/10.1111/j.1365-
2826.1995.tb00784.x. 
Herman, J.P. et al., 1993. Diurnal Regulation of Glucocorticoid Receptor and 
Mineralocorticoid Receptor mRNAs in Rat Hippocampus. Molecular and Cellular 
Neuroscience, 4(2), pp.181–190. Available at: 
https://www.sciencedirect.com/science/article/pii/S1044743183710225?via%3Dihub
. 
Herman, J.P. et al., 1989. Evidence for hippocampal regulation of neuroendocrine 
neurons of the hypothalamo-pituitary-adrenocortical axis. The Journal of 
neuroscience : the official journal of the Society for Neuroscience, 9(9), pp.3072–82. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/2795152. 
Herman, J.P. et al., 2016. Regulation of the Hypothalamic-Pituitary-Adrenocortical Stress 
Response. In Comprehensive Physiology. Hoboken, NJ, USA: John Wiley & Sons, 
Inc., pp. 603–621. Available at: http://www.ncbi.nlm.nih.gov/pubmed/27065163. 
Herman, J.P. & Cullinan, W.E., 1997. Neurocircuitry of stress: central control of the 
hypothalamo–pituitary–adrenocortical axis. Trends in Neurosciences, 20(2), pp.78–
84. Available at: 
https://www.sciencedirect.com/science/article/pii/S0166223696100692. 
Herman, J.P. & Spencer, R., 1998. Regulation of hippocampal glucocorticoid receptor 
gene transcription and protein expression in vivo. The Journal of neuroscience : the 
official journal of the Society for Neuroscience, 18(18), pp.7462–73. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/9736665. 
Hida, A. et al., 2015. Screening of Clock Gene Polymorphisms Demonstrates Association 
of a PER3 Polymorphism with Morningness–Eveningness Preference and Circadian 
Rhythm Sleep Disorder. Scientific Reports, 4(1), p.6309. Available at: 
http://www.nature.com/articles/srep06309. 
 198 
Hirayama, J. et al., 2007. CLOCK-mediated acetylation of BMAL1 controls circadian 
function. Nature, 450(7172), pp.1086–1090. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18075593. 
Hirose, T., Smith, R.J. & Jetten, A.M., 1994. ROR-γ: The Third Member of ROR/RZR 
Orphan Receptor Subfamily That Is Highly Expressed in Skeletal Muscle. 
Biochemical and Biophysical Research Communications, 205(3), pp.1976–1983. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/7811290. 
Hitti, F.L. & Siegelbaum, S.A., 2014. The hippocampal CA2 region is essential for social 
memory. Nature, 508(7494), pp.88–92. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/24572357. 
Hoang Dang, V., 2014. Wavelet-based spectral analysis. Analytical Chemistry, 62, 
pp.144–153. 
Hocke, K., 1998. Phase estimation with the Lomb-Scargle periodogram method. 
Geophysicis, 16, pp.356–358. Available at: 
https://www.researchgate.net/publication/283359043. 
Hodge, B.A. et al., 2015. The endogenous molecular clock orchestrates the temporal 
separation of substrate metabolism in skeletal muscle. Skeletal Muscle, 5(1), p.17. 
Available at: http://www.skeletalmusclejournal.com/content/5/1/17. 
Hofstetter, J.R., Grahame, N.J. & Mayeda, A.R., 2003. Circadian activity rhythms in 
high-alcohol-preferring and low-alcohol-preferring mice. Alcohol, 30(1), pp.81–85. 
Available at: 
https://www.sciencedirect.com/science/article/pii/S0741832903000958#FIG1. 
Hogenesch, J.B. et al., 1997. Characterization of a subset of the basic-helix-loop-helix-
PAS superfamily that interacts with components of the dioxin signaling pathway. 
The Journal of biological chemistry, 272(13), pp.8581–93. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/9079689. 
Holsboer, F., von Bardeleben, U. & Steiger, A., 1988. Effects of Intravenous 
Corticotropin-Releasing Hormone upon Sleep-Related Growth Hormone Surge and 
Sleep EEG in Man. Neuroendocrinology, 48(1), pp.32–38. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/3262835. 
Honma, S. et al., 1988. Rhythms in behaviors, body temperature and plasma 
corticosterone in SCN lesioned rats given methamphetamine. Physiology & 
Behavior, 44(2), pp.247–255. Available at: 
https://www.sciencedirect.com/science/article/pii/0031938488901461. 
Ter Horst, G.J. et al., 1991. Projections from the rostral parvocellular reticular formation 
to pontine and medullary nuclei in the rat: Involvement in autonomic regulation and 
orofacial motor control. Neuroscience, 40(3), pp.735–758. Available at: 
https://www.sciencedirect.com/science/article/pii/030645229190009D. 
Horst, G.T.J. van der et al., 1999. Mammalian Cry1 and Cry2 are essential for 
maintenance of circadian rhythms. Nature, 398(6728), pp.627–630. Available at: 
http://www.nature.com/articles/19323. 
Hosp, J.A. et al., 2011. Dopaminergic projections from midbrain to primary motor cortex 
mediate motor skill learning. The Journal of neuroscience : the official journal of the 
Society for Neuroscience, 31(7), pp.2481–7. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/21325515. 
Huang, D.W., Sherman, B.T. & Lempicki, R.A., 2009. Bioinformatics enrichment tools: 
paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids 
Research, 37(1), pp.1–13. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/19033363. 
Huang, D.W., Sherman, B.T. & Lempicki, R.A., 2009. Systematic and integrative 
 199 
analysis of large gene lists using DAVID bioinformatics resources. Nature 
Protocols, 4(1), pp.44–57. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/19131956. 
Huang, W. et al., 2011. Circadian rhythms, sleep, and metabolism. The Journal of clinical 
investigation, 121(6), pp.2133–41. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/21633182. 
Hui, G.K. et al., 2004. Memory enhancement of classical fear conditioning by post-
training injections of corticosterone in rats. Neurobiology of Learning and Memory, 
81(1), pp.67–74. Available at: 
https://www.sciencedirect.com/science/article/pii/S1074742703001126. 
Huikuri, H. V. et al., 1992. Circadian rhythm of heart rate variability in survivors of 
cardiac arrest. The American Journal of Cardiology, 70(6), pp.610–615. Available 
at: https://www.sciencedirect.com/science/article/pii/000291499290200I. 
Hurlbert, R.J., 2000. Methylprednisolone for acute spinal cord injury: an inappropriate 
standard of care. Journal of Neurosurgery: Spine, 93(1), pp.1–7. Available at: 
http://thejns.org/doi/10.3171/spi.2000.93.1.0001. 
Hurley, K.M. et al., 1991. Efferent projections of the infralimbic cortex of the rat. The 
Journal of Comparative Neurology, 308(2), pp.249–276. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/1716270. 
Husse, J. et al., 2012. Circadian Clock Genes Per1 and Per2 Regulate the Response of 
Metabolism-Associated Transcripts to Sleep Disruption K. L. Gamble, ed. PLoS 
ONE, 7(12), p.e52983. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/23285241. 
Ibata, Y. et al., 1989. Vasoactive intestinal peptide (VIP)-like immunoreactive neurons 
located in the rat suprachiasmatic nucleus receive a direct retinal projection. 
Neuroscience Letters, 97(1–2), pp.1–5. Available at: 
https://www.sciencedirect.com/science/article/pii/0304394089901298. 
Ibuka, N. & Kawamura, H., 1975. Loss of circadian rhythm in sleep-wakefulness cycle in 
the rat by suprachiasmatic nucleus lesions. Brain Research, 96(1), pp.76–81. 
Available at: https://www.sciencedirect.com/science/article/pii/0006899375905740. 
Ikeda, M. & Nomura, M., 1997. cDNA Cloning and Tissue-Specific Expression of a 
Novel Basic Helix–Loop–Helix/PAS Protein (BMAL1) and Identification of 
Alternatively Spliced Variants with Alternative Translation Initiation Site Usage. 
Biochemical and Biophysical Research Communications, 233(1), pp.258–264. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/9144434. 
Inagaki, N. et al., 1988. Organization of histaminergic fibers in the rat brain. The Journal 
of Comparative Neurology, 273(3), pp.283–300. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/3062046. 
Inoue, H. et al., 2004. Role of STAT-3 in regulation of hepatic gluconeogenic genes and 
carbohydrate metabolism in vivo. Nature Medicine, 10(2), pp.168–174. Available at: 
http://www.nature.com/articles/nm980. 
Inouye, S.T. & Kawamura, H., 1982. Characteristics of a circadian pacemaker in the 
suprachiasmatic nucleus. Journal of Comparative Physiology ? A, 146(2), pp.153–
160. Available at: http://link.springer.com/10.1007/BF00610233. 
Ishizuka, N., Weber, J. & Amaral, D.G., 1990. Organization of intrahippocampal 
projections originating from CA3 pyramidal cells in the rat. The Journal of 
Comparative Neurology, 295(4), pp.580–623. Available at: 
http://doi.wiley.com/10.1002/cne.902950407. 
Itowi, N. et al., 1990. Effects of histamine and alpha-fluoromethylhistidine injections on 
circadian phase of free-running rhythms. Physiology & behavior, 47(3), pp.549–54. 
 200 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/2359768. 
Ivry, R.B., Keele, S.W. & Diener, H.C., 1988. Dissociation of the lateral and medial 
cerebellum in movement timing and movement execution. Experimental Brain 
Research, 73(1), pp.167–180. Available at: 
http://link.springer.com/10.1007/BF00279670. 
Jagannath, A., Peirson, S.N. & Foster, R.G., 2013. Sleep and circadian rhythm disruption 
in neuropsychiatric illness. Current Opinion in Neurobiology, 23(5), pp.888–894. 
Available at: 
https://www.sciencedirect.com/science/article/pii/S0959438813000858. 
Jiang, C. & Salton, S., 2013. The role of neurotrophins in major depressive disorder. 
Translational Neuroscience, 4(1), pp.46–58. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/23691270. 
Jilg, A. et al., 2009. Temporal dynamics of mouse hippocampal clock gene expression 
support memory processing. Hippocampus, 20(3), p.NA-NA. Available at: 
http://doi.wiley.com/10.1002/hipo.20637. 
Jin, X. et al., 1999. A Molecular Mechanism Regulating Rhythmic Output from the 
Suprachiasmatic Circadian Clock. Cell, 96(1), pp.57–68. Available at: 
https://www.sciencedirect.com/science/article/pii/S0092867400809599. 
Joëls, M., Fernandez, G. & Roozendaal, B., 2011. Stress and emotional memory: a matter 
of timing. Trends in Cognitive Sciences, 15(6), pp.280–288. Available at: 
https://www.sciencedirect.com/science/article/pii/S136466131100074X. 
Jones, C.R. et al., 1999. Familial advanced sleep-phase syndrome: A short-period 
circadian rhythm variant in humans. Nature Medicine, 5(9), pp.1062–1065. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/10470086. 
Jones, M.W. & Wilson, M.A., 2005. Theta Rhythms Coordinate Hippocampal–Prefrontal 
Interactions in a Spatial Memory Task R. Morris, ed. PLoS Biology, 3(12), p.e402. 
Available at: http://dx.plos.org/10.1371/journal.pbio.0030402. 
Judd, L.L. et al., 2014. Adverse Consequences of Glucocorticoid Medication: 
Psychological, Cognitive, and Behavioral Effects. American Journal of Psychiatry, 
171(10), pp.1045–1051. Available at: 
http://psychiatryonline.org/doi/abs/10.1176/appi.ajp.2014.13091264. 
Kajiyama, Y. et al., 2010. Prednisolone causes anxiety- and depression-like behaviors and 
altered expression of apoptotic genes in mice hippocampus. Progress in Neuro-
Psychopharmacology and Biological Psychiatry, 34(1), pp.159–165. Available at: 
https://www.sciencedirect.com/science/article/pii/S0278584609003765#fig2. 
Kalin, N., 2018. HPA and Amygdala CRH Alterations Associated With Primate Anxiety. 
Biological Psychiatry, 83(9), p.S53. Available at: 
https://www.sciencedirect.com/science/article/pii/S000632231830249X. 
Kalsbeek, A. et al., 2008. Circadian Control of the Daily Plasma Glucose Rhythm: An 
Interplay of GABA and Glutamate J. A. L. Calbet, ed. PLoS ONE, 3(9), p.e3194. 
Available at: http://dx.plos.org/10.1371/journal.pone.0003194. 
Kalsbeek, A. et al., 1999. GABA release from suprachiasmatic nucleus terminals is 
necessary for the light-induced inhibition of nocturnal melatonin release in the rat. 
Neuroscience, 91(2), pp.453–61. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10366002. 
Kalsbeek, A. & Buijs, R.M., 2002. Output pathways of the mammalian suprachiasmatic 
nucleus: coding circadian time by transmitter selection and specific targeting. Cell 
and Tissue Research, 309(1), pp.109–118. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/12111541. 
Kamphuis, W. et al., 2005. Circadian expression of clock genes and clock-controlled 
 201 
genes in the rat retina. Biochemical and Biophysical Research Communications, 
330(1), pp.18–26. Available at: 
https://www.sciencedirect.com/science/article/pii/S0006291X05003943#fig3. 
Kaneko, K. et al., 2009. Obesity alters circadian expressions of molecular clock genes in 
the brainstem. Brain Research, 1263, pp.58–68. Available at: 
https://www.sciencedirect.com/science/article/pii/S0006899309000031. 
Kang, D. et al., 2015. Theta-rhythmic drive between medial septum and hippocampus in 
slow-wave sleep and microarousal: a Granger causality analysis. Journal of 
Neurophysiology, 114(5), pp.2797–2803. Available at: 
http://www.physiology.org/doi/10.1152/jn.00542.2015. 
van de Kar, L.D. & Lorens, S.A., 1979. Differential serotonergic innervation of 
individual hypothalamic nuclei and other forebrain regions by the dorsal and median 
midbrain raphe nuclei. Brain research, 162(1), pp.45–54. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/761086. 
Karolczak, M. et al., 2004. Clock gene mRNA and protein rhythms in the pineal gland of 
mice. European Journal of Neuroscience, 19(12), pp.3382–3388. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15217395. 
Katada, S. & Sassone-Corsi, P., 2010. The histone methyltransferase MLL1 permits the 
oscillation of circadian gene expression. Nature Structural & Molecular Biology, 
17(12), pp.1414–1421. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/21113167. 
Kawano, H. & Daikoku, S., 1981. Immunohistochemical demonstration of LHRH 
neurons and their pathways in the rat hypothalamus. Neuroendocrinology, 32(3), 
pp.179–86. Available at: https://www.karger.com/Article/FullText/123153. 
Keenan, P. et al., 1996. The effect on memory of chronic prednisone treatment in patients 
with systemic disease. American Academy of Neurology, 47, pp.1396–1402. 
Kelemen, E. et al., 2014. Hippocampal corticosterone impairs memory consolidation 
during sleep but improves consolidation in the wake state. Hippocampus, 24(5), 
pp.510–5. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24596244. 
Khan, S.H., Ling, J. & Kumar, R., 2011. TBP Binding-Induced Folding of the 
Glucocorticoid Receptor AF1 Domain Facilitates Its Interaction with Steroid 
Receptor Coactivator-1 A. J. Cooney, ed. PLoS ONE, 6(7), p.e21939. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/21760925. 
Kida, S. & Serita, T., 2014. Functional roles of CREB as a positive regulator in the 
formation and enhancement of memory. Brain Research Bulletin, 105, pp.17–24. 
Available at: 
https://www.sciencedirect.com/science/article/pii/S0361923014000653. 
King, D.P. et al., 1997. Positional cloning of the mouse circadian clock gene. Cell, 89(4), 
pp.641–53. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9160755. 
Kiss, J. et al., 2008. Synaptic contacts of vesicular glutamate transporter 2 fibres on 
chemically identified neurons of the hypothalamic suprachiasmatic nucleus of the 
rat. European Journal of Neuroscience, 28(9), pp.1760–1774. Available at: 
http://doi.wiley.com/10.1111/j.1460-9568.2008.06463.x. 
Kitchener, P. et al., 2004. Differences between brain structures in nuclear translocation 
and DNA binding of the glucocorticoid receptor during stress and the circadian 
cycle. The European journal of neuroscience, 19(7), pp.1837–46. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15078557. 
de Kloet, E.R., Oitzl, M.S. & Joëls, M., 1999. Stress and cognition: are corticosteroids 
good or bad guys? Trends in Neurosciences, 22(10), pp.422–426. Available at: 
https://www.sciencedirect.com/science/article/pii/S0166223699014381#bib0225. 
 202 
Knierim, J.J., Neunuebel, J.P. & Deshmukh, S.S., 2014. Functional correlates of the 
lateral and medial entorhinal cortex: objects, path integration and local-global 
reference frames. Philosophical transactions of the Royal Society of London. Series 
B, Biological sciences, 369(1635), p.20130369. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/24366146. 
Knigge, K.M., 1961. Adrenocortical Response to Stress in Rats with Lesions in 
Hippocampus and Amygdala. Experimental Biology and Medicine, 108(1), pp.18–
21. Available at: http://ebm.sagepub.com/lookup/doi/10.3181/00379727-108-26832. 
Knutson, K.L., 2007. Impact of sleep and sleep loss on glucose homeostasis and appetite 
regulation. Sleep medicine clinics, 2(2), pp.187–197. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18516218. 
Ko, C.H. & Takahashi, J.S., 2006. Molecular components of the mammalian circadian 
clock. Human Molecular Genetics, 15(suppl_2), pp.R271–R277. Available at: 
http://academic.oup.com/hmg/article/15/suppl_2/R271/624758/Molecular-
components-of-the-mammalian-circadian. 
Köhler, C., 1990. Subicular projections to the hypothalamus and brainstem: some novel 
aspects revealed in the rat by the anterogradePhaseolus vulgaris leukoagglutinin 
(PHA-L) tracing method. Progress in Brain Research, 83, pp.59–69. Available at: 
https://www.sciencedirect.com/science/article/pii/S0079612308612418. 
Koike, N. et al., 2012. Transcriptional Architecture and Chromatin Landscape of the Core 
Circadian Clock in Mammals. Science, 338(6105), pp.349–354. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/22936566. 
Kondratov, R. V et al., 2006. Early aging and age-related pathologies in mice deficient in 
BMAL1, the core componentof the circadian clock. Genes & development, 20(14), 
pp.1868–73. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16847346. 
Kondratova, A.A. et al., 2010. Circadian clock proteins control adaptation to novel 
environment and memory formation. Aging, 2(5), pp.285–97. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/20519775. 
Koyanagi, S. et al., 2006. Chronic Treatment with Prednisolone Represses the Circadian 
Oscillation of Clock Gene Expression in Mouse Peripheral Tissues. Molecular 
Endocrinology, 20(3), pp.573–583. 
Kramer, A. et al., 2005. A Screen for Secreted Factors of the Suprachiasmatic Nucleus. In 
Methods in enzymology. pp. 645–663. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15817317. 
KRIEGER, D.T., 1980. Ventromedial Hypothalamic Lesions Abolish Food-Shifted 
Circadian Adrenal and Temperature Rhythinicity*. Endocrinology, 106(3), pp.649–
654. Available at: https://academic.oup.com/endo/article-lookup/doi/10.1210/endo-
106-3-649. 
Kriegsfeld, L.J., Korets, R. & Silver, R., 2003. Expression of the circadian clock gene 
Period 1 in neuroendocrine cells: an investigation using mice with a Per1::GFP 
transgene. The European journal of neuroscience, 17(2), pp.212–20. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/12542657. 
Kruisbrink, J. et al., 1987. Effects of enhanced cerebrospinal fluid levels of vasopressin, 
vasopressin antagonist or vasoactive intestinal polypeptide on circadian sleep-wake 
rhythm in the rat. Brain research, 419(1–2), pp.76–86. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/3676743. 
Kuhn, H.G., Dickinson-Anson, H. & Gage, F.H., 1996. Neurogenesis in the dentate gyrus 
of the adult rat: age-related decrease of neuronal progenitor proliferation. The 
Journal of neuroscience : the official journal of the Society for Neuroscience, 16(6), 
pp.2027–33. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8604047. 
 203 
Kumar, R. & Thompson, E.B., 2005. Gene regulation by the glucocorticoid receptor: 
structure:function relationship. The Journal of steroid biochemistry and molecular 
biology, 94, pp.383–394. 
Kumar, R. & Thompson, E.B., 1999. The structure of the nuclear hormone receptors. 
Steroids, 64(5), pp.310–9. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10406480. 
Kume, K. et al., 1999. mCRY1 and mCRY2 Are Essential Components of the Negative 
Limb of the Circadian Clock Feedback Loop. Cell, 98(2), pp.193–205. Available at: 
https://www.sciencedirect.com/science/article/pii/S0092867400810144. 
Kupersmith, M.J. et al., 1994. Megadose corticosteroids in multiple sclerosis. Neurology, 
44(1), pp.1–4. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8290041. 
Kuruvilla, M. V & Ainge, J.A., 2017. Lateral Entorhinal Cortex Lesions Impair Local 
Spatial Frameworks. Frontiers in systems neuroscience, 11, p.30. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/28567006. 
de la Iglesia, H.O., Meyer, J. & Schwartz, W.J., 2003. Lateralization of circadian 
pacemaker output: Activation of left- and right-sided luteinizing hormone-releasing 
hormone neurons involves a neural rather than a humoral pathway. The Journal of 
neuroscience : the official journal of the Society for Neuroscience, 23(19), pp.7412–
4. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12917377.  
Lacaille, J.C. et al., 1987. Local circuit interactions between oriens/alveus interneurons 
and CA1 pyramidal cells in hippocampal slices: electrophysiology and morphology. 
The Journal of neuroscience : the official journal of the Society for Neuroscience, 
7(7), pp.1979–93. Available at: http://www.ncbi.nlm.nih.gov/pubmed/3612227. 
Lamacz, M. et al., 1991. [The intermediate lobe of the pituitary, model of neuroendocrine 
communication]. Archives internationales de physiologie, de biochimie et de 
biophysique, 99(3), pp.205–19. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/1717055. 
Lamia, K.A. et al., 2011. Cryptochromes mediate rhythmic repression of the 
glucocorticoid receptor. Nature, 480. 
Lammel, S. et al., 2012. Input-specific control of reward and aversion in the ventral 
tegmental area. Nature, 491(7423), pp.212–217. Available at: 
http://www.nature.com/articles/nature11527. 
Lamont, E.W. et al., 2005. The central and basolateral nuclei of the amygdala exhibit 
opposite diurnal rhythms of expression of the clock protein Period2. Proceedings of 
the National Academy of Sciences, 102(11), pp.4180–4184. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15746242. 
Landgraf, D. et al., 2016. NPAS2 Compensates for Loss of CLOCK in Peripheral 
Circadian Oscillators A. Kramer, ed. PLOS Genetics, 12(2), p.e1005882. Available 
at: http://dx.plos.org/10.1371/journal.pgen.1005882. 
Landolt, H.-P. et al., 1996. Effect of age on the sleep EEG: slow-wave activity and 
spindle frequency activity in young and middle-aged men. Brain Research, 738(2), 
pp.205–212. Available at: 
https://www.sciencedirect.com/science/article/pii/S0006899396007706. 
Lang, F. et al., 2010. Significance of SGK1 in the regulation of neuronal function. The 
Journal of Physiology, 588(18), pp.3349–3354. Available at: 
http://doi.wiley.com/10.1113/jphysiol.2010.190926 [Accessed July 12, 2018]. 
Laposky, A. et al., 2005. Deletion of the mammalian circadian clock gene BMAL1/Mop3 
alters baseline sleep architecture and the response to sleep deprivation. Sleep, 28(4), 
pp.395–409. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16171284. 
Lee, H. et al., 2011. The period of the circadian oscillator is primarily determined by the 
 204 
balance between casein kinase 1 and protein phosphatase 1. Proceedings of the 
National Academy of Sciences of the United States of America, 108(39), pp.16451–6. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/21930935. 
Lee, I. & Kesner, R.P., 2004. Encoding versus retrieval of spatial memory: Double 
dissociation between the dentate gyrus and the perforant path inputs into CA3 in the 
dorsal hippocampus. Hippocampus, 14(1), pp.66–76. Available at: 
http://doi.wiley.com/10.1002/hipo.10167. 
Lee, J. et al., 2008. Dual Modification of BMAL1 by SUMO2/3 and Ubiquitin Promotes 
Circadian Activation of the CLOCK/BMAL1 Complex. Molecular and Cellular 
Biology, 28(19), pp.6056–6065. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18644859. 
LeGates, T.A., Fernandez, D.C. & Hattar, S., 2014. Light as a central modulator of 
circadian rhythms, sleep and affect. Nature Reviews Neuroscience, 15(7). 
Lei, S. & McBain, C.J., 2004. Two Loci of Expression for Long-Term Depression at 
Hippocampal Mossy Fiber-Interneuron Synapses. Journal of Neuroscience, 24(9), 
pp.2112–2121. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14999062. 
Leise, T.L., 2013. Wavelet analysis of circadian and ultradian behavioral rhythms. 
Journal of Circadian Rhythms, 11(1), p.5. Available at: 
http://www.jcircadianrhythms.com/content/11/1/5. 
Leise, T.L. et al., 2013. Wavelet Meets Actogram. Journal of Biological Rhythms, 28(1), 
pp.62–68. Available at: 
http://journals.sagepub.com/doi/10.1177/0748730412468693. 
Leutgeb, S. et al., 2005. Independent Codes for Spatial and Episodic Memory in 
Hippocampal Neuronal Ensembles. Science, 309(5734), pp.619–623. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16040709. 
Levine, J.D. et al., 1986. Circadian activity rhythms in rats with midbrain raphe lesions. 
Brain Research, 384(2), pp.240–249. Available at: 
https://www.sciencedirect.com/science/article/pii/0006899386911601. 
Lévy, B. et al., 2003. [Topical methylprednisolone vs lidocaïne for the prevention of 
postoperative sore throat]. Annales francaises d’anesthesie et de reanimation, 22(7), 
pp.595–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12946491. 
Levy, O. et al., 2007. Light-responsive cryptochromes from a simple multicellular animal, 
the coral Acropora millepora. Science (New York, N.Y.), 318(5849), pp.467–70. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/17947585. 
Li, X.-G. et al., 1994. The hippocampal CA3 network: An in vivo intracellular labeling 
study. Journal of Comparative Neurology, 339(2), pp.181–208. Available at: 
http://doi.wiley.com/10.1002/cne.903390204. 
Lightman, S.L. & Conway-Campbell, B.L., 2010. The crucial role of pulsatile activity of 
the HPA axis for continuous dynamic equilibration. Nat Rev Neurosci, 11(10), 




Lim, H.-W. et al., 2015. Genomic redistribution of GR monomers and dimers mediates 
transcriptional response to exogenous glucocorticoid in vivo. Genome research, 
25(6), pp.836–44. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25957148. 
Di Lorenzo, F. et al., 2016. Long-term potentiation-like cortical plasticity is disrupted in 
Alzheimer’s disease patients independently from age of onset. Annals of Neurology, 
80(2), pp.202–210. Available at: http://www.ncbi.nlm.nih.gov/pubmed/27255833. 
Loving, R.T., Kripke, D.F. & Glazner, L.K., 1996. Circadian rhythms in the human pupil 
 205 
and eyelid. American Journal of Physiology-Regulatory, Integrative and 
Comparative Physiology, 271(2), pp.R320–R324. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/8770129. 
Lu, J. et al., 2001. Contrasting effects of ibotenate lesions of the paraventricular nucleus 
and subparaventricular zone on sleep-wake cycle and temperature regulation. The 
Journal of neuroscience : the official journal of the Society for Neuroscience, 
21(13), pp.4864–74. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11425913. 
Lu, J. et al., 2000. Effect of lesions of the ventrolateral preoptic nucleus on NREM and 
REM sleep. The Journal of neuroscience : the official journal of the Society for 
Neuroscience, 20(10), pp.3830–42. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10804223. 
Lu, J. et al., 2002. Selective activation of the extended ventrolateral preoptic nucleus 
during rapid eye movement sleep. The Journal of neuroscience : the official journal 
of the Society for Neuroscience, 22(11), pp.4568–76. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/12040064. 
Lupien, S.J. & Lepage, M., 2001. Stress, memory, and the hippocampus: can’t live with 
it, can’t live without it. Behavioural brain research, 127(1–2), pp.137–58. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/11718889. 
Malek, Z.S. et al., 2007. Daily Rhythm of Tryptophan Hydroxylase-2 Messenger 
Ribonucleic Acid within Raphe Neurons Is Induced by Corticoid Daily Surge and 
Modulated by Enhanced Locomotor Activity. Endocrinology, 148(11), pp.5165–
5172. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17595225. 
Mallat, S., 2009. A Wavelet Tour of Signal Processing: The Sparse Way. Academic 
Press, San Diego. 
Mander, B.A. et al., 2013. Prefrontal atrophy, disrupted NREM slow waves and impaired 
hippocampal-dependent memory in aging. Nature Neuroscience, 16(3), pp.357–364. 
Available at: http://www.nature.com/articles/nn.3324. 
Marchal, C. & Mulle, C., 2004. Postnatal maturation of mossy fibre excitatory 
transmission in mouse CA3 pyramidal cells: a potential role for kainate receptors. 
The Journal of Physiology, 561(1), pp.27–37. Available at: 
http://doi.wiley.com/10.1113/jphysiol.2004.069922. 
Marcheva, B. et al., 2010. Disruption of the clock components CLOCK and BMAL1 
leads to hypoinsulinaemia and diabetes. Nature, 466(7306), pp.627–631. Available 
at: http://www.nature.com/articles/nature09253. 
Markus, E.J. et al., 1995. Interactions between location and task affect the spatial and 
directional firing of hippocampal neurons. The Journal of neuroscience : the official 
journal of the Society for Neuroscience, 15(11), pp.7079–94. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/7472463. 
Marrosu, F. et al., 1990. Corticotropin-releasing factor (CRF) increases paradoxical sleep 
(PS) rebound in PS-deprived rats. Brain Research, 515(1–2), pp.315–318. Available 
at: https://www.sciencedirect.com/science/article/pii/000689939090614H. 
Marshall, L. et al., 2006. Boosting slow oscillations during sleep potentiates memory. 
Nature, 444(7119), pp.610–613. Available at: 
http://www.nature.com/articles/nature05278. 
Le Martelot, G. et al., 2012. Genome-Wide RNA Polymerase II Profiles and RNA 
Accumulation Reveal Kinetics of Transcription and Associated Epigenetic Changes 
During Diurnal Cycles A. Kramer, ed. PLoS Biology, 10(11), p.e1001442. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/23209382. 
Martin, R.A., Handel, S.F. & Aldama, A.E., 1991. Inability to sneeze as a manifestation 
of medullary neoplasm. Neurology, 41(10), pp.1675–6. Available at: 
 206 
http://www.ncbi.nlm.nih.gov/pubmed/1922817. 
Massin, M.M. et al., 2000. Circadian rhythm of heart rate and heart rate variability. 
Archives of disease in childhood, 83(2), pp.179–82. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10906034. 
Mayberg, H.S. et al., 2000. Regional metabolic effects of fluoxetine in major depression: 
serial changes and relationship to clinical response. Biological psychiatry, 48(8), 
pp.830–43. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11063978. 
Maywood, E.S. et al., 1999. Rapid down-regulation of mammalian period genes during 
behavioral resetting of the circadian clock. Proceedings of the National Academy of 
Sciences of the United States of America, 96(26), pp.15211–6. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10611364. 
Mcarthur, A.J. et al., 2000. Gastrin-Releasing Peptide Phase-Shifts Suprachiasmatic 




McGrath, R.E. & Yahia, M., 1993. Preliminary data on seasonally related alcohol 
dependence. The Journal of clinical psychiatry, 54(7), pp.260–2. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/8335652. 
McKinley, M.J. et al., 2015. The median preoptic nucleus: front and centre for the 
regulation of body fluid, sodium, temperature, sleep and cardiovascular homeostasis. 
Acta Physiologica, 214(1), pp.8–32. Available at: 
http://doi.wiley.com/10.1111/apha.12487. 
McLay, R.N., Freeman, S.M. & Zadina, J.E., 1998. Chronic Corticosterone Impairs 
Memory Performance in the Barnes Maze. Physiology & Behavior, 63(5), pp.933–
937. Available at: 
https://www.sciencedirect.com/science/article/pii/S0031938497005295. 
Medvedev, A. et al., 1996. Cloning of a cDNA encoding the murine orphan receptor 
RZR/ROR gamma and characterization of its response element. Gene, 181(1–2), 
pp.199–206. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8973331. 
Megías, M. et al., 2001. Total number and distribution of inhibitory and excitatory 
synapses on hippocampal CA1 pyramidal cells. Neuroscience, 102(3), pp.527–40. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/11226691. 
Meijer, J.H. & De Vries, M.J., 1995. Light-Induced Phase Shifts in Onset and Offset of 
Running-Wheel Activity in the Syrian Hamster. Journal of Biological Rhythms, 
10(1), pp.4–16. Available at: 
http://journals.sagepub.com/doi/10.1177/074873049501000101. 
Menet, J.S., Pescatore, S. & Rosbash, M., 2014. CLOCK:BMAL1 is a pioneer-like 
transcription factor. Genes & development, 28(1), pp.8–13. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/24395244. 
Meng, N.H., Wang, T.G. & Lien, I.N., 2000. Dysphagia in patients with brainstem stroke: 
incidence and outcome. American journal of physical medicine & rehabilitation, 
79(2), pp.170–5. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10744192. 
Meng, Q.-J. et al., 2008. Setting Clock Speed in Mammals: The CK1ɛ tau Mutation in 
Mice Accelerates Circadian Pacemakers by Selectively Destabilizing PERIOD 
Proteins. Neuron, 58(1), pp.78–88. Available at: 
https://www.sciencedirect.com/science/article/pii/S0896627308001049. 
Merzenich, M.M. & Reid, M.D., 1974. Representation of the cochlea within the inferior 
colliculus of the cat. Brain Research, 77(3), pp.397–415. Available at: 
https://www.sciencedirect.com/science/article/pii/0006899374906301. 
 207 
Meyer-Bernstein, E.L. & Morin, L.P., 1996. Differential serotonergic innervation of the 
suprachiasmatic nucleus and the intergeniculate leaflet and its role in circadian 
rhythm modulation. The Journal of neuroscience : the official journal of the Society 
for Neuroscience, 16(6), pp.2097–111. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/8604054. 
Meyer-Bernstein, E.L. & Morin, L.P., 1999. Electrical stimulation of the median or dorsal 
raphe nuclei reduces light-induced FOS protein in the suprachiasmatic nucleus and 
causes circadian activity rhythm phase shifts. Neuroscience, 92(1), pp.267–79. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/10392849. 
Mieda, M. et al., 2015. Cellular Clocks in AVP Neurons of the SCN Are Critical for 
Interneuronal Coupling Regulating Circadian Behavior Rhythm. Neuron, 85(5), 
pp.1103–1116. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25741730. 
Mieda, M. & Sakurai, T., 2011. Bmal1 in the nervous system is essential for normal 
adaptation of circadian locomotor activity and food intake to periodic feeding. The 
Journal of neuroscience : the official journal of the Society for Neuroscience, 
31(43), pp.15391–6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22031885. 
Mifsud, K.R. & Reul, J.M.H.M., 2016. Acute stress enhances heterodimerization and 
binding of corticosteroid receptors at glucocorticoid target genes in the 
hippocampus. Proceedings of the National Academy of Sciences of the United States 
of America, 113(40), pp.11336–11341. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/27655894. 
Mikkelsen, J.D., 1990. Projections from the lateral geniculate nucleus to the 
hypothalamus of the mongolian gerbil (Meriones unguiculatus): An anterograde and 
retrograde tracing study. The Journal of Comparative Neurology, 299(4), pp.493–
508. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1700802. 
Mikkelsen, J.D. & Vrang, N., 1994. A direct pretectosuprachiasmatic projection in the 
rat. Neuroscience, 62(2), pp.497–505. Available at: 
https://www.sciencedirect.com/science/article/pii/0306452294903824. 
Miles, R. et al., 1996. Differences between Somatic and Dendritic Inhibition in the 
Hippocampus. Neuron, 16(4), pp.815–823. Available at: 
https://www.sciencedirect.com/science/article/pii/S0896627300801014. 
Miller, B.H. et al., 2007. Circadian and CLOCK-controlled regulation of the mouse 
transcriptome and cell proliferation. Proceedings of the National Academy of 
Sciences, 104(9), pp.3342–3347. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/17360649. 
Miller, M.A. et al., 2015. Photoperiod is associated with hippocampal volume in a large 
community sample. Hippocampus, 25(4), pp.534–43. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/25394737. 
Mirescu, C. et al., 2006. Sleep deprivation inhibits adult neurogenesis in the hippocampus 
by elevating glucocorticoids. Proceedings of the National Academy of Sciences of 
the United States of America, 103(50), pp.19170–5. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/17135354. 
Mitra, R., Ferguson, D. & Sapolsky, R.M., 2009. Mineralocorticoid Receptor 
Overexpression in Basolateral Amygdala Reduces Corticosterone Secretion and 
Anxiety. Biological Psychiatry, 66(7), pp.686–690. Available at: 
https://www.sciencedirect.com/science/article/pii/S0006322309004570. 
Moga, M.M. & Moore, R.Y., 1997. Organization of neural inputs to the suprachiasmatic 
nucleus in the rat. The Journal of comparative neurology, 389(3), pp.508–34. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/9414010. 
Moga, M.M. & Saper, C.B., 1994. Neuropeptide-immunoreactive neurons projecting to 
 208 
the paraventricular hypothalamic nucleus in the rat. The Journal of Comparative 
Neurology, 346(1), pp.137–150. Available at: 
http://doi.wiley.com/10.1002/cne.903460110. 
Moga, M.M., Weis, R.P. & Moore, R.Y., 1995. Efferent projections of the paraventricular 
thalamic nucleus in the rat. The Journal of Comparative Neurology, 359(2), pp.221–
238. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7499526. 
Moore, R.Y., 1995. Neural control of the pineal gland. Behavioural Brain Research, 
73(1–2), pp.125–130. Available at: 
https://www.sciencedirect.com/science/article/pii/0166432896000836. 
Moore, R.Y. & Eichler, V.B., 1972. Loss of a circadian adrenal corticosterone rhythm 
following suprachiasmatic lesions in the rat. Brain research, 42(1), pp.201–6. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/5047187. 
Moore, R.Y. & Klein, D.C., 1974. Visual pathways and the central neural control of a 
circadian rhythm in pineal serotonin N-acetyltransferase activity. Brain research, 
71(1), pp.17–33. Available at: http://www.ncbi.nlm.nih.gov/pubmed/4595289. 
Moore, R.Y., Speh, J.C. & Leak, R.K., 2002. Suprachiasmatic nucleus organization. Cell 
and Tissue Research, 309(1), pp.89–98. Available at: 
http://link.springer.com/10.1007/s00441-002-0575-2. 
Moriya, S. et al., 2014. Effect of quetiapine on Per1, Per2, and Bmal1 clock gene 
expression in the mouse amygdala and hippocampus. Journal of pharmacological 
sciences, 125(3), pp.329–32. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/24965164. 
Morris, K.A. & Gold, P.E., 2012. Age-related impairments in memory and in CREB and 
pCREB expression in hippocampus and amygdala following inhibitory avoidance 
training. Mechanisms of Ageing and Development, 133(5), pp.291–299. Available at: 
https://www.sciencedirect.com/science/article/pii/S0047637412000395. 
Morris, R., 2008. Morris water maze. Scholarpedia, 3(8), p.6315. Available at: 
http://www.scholarpedia.org/article/Morris_water_maze. 
Morris, R.G.M. et al., 1982. Place navigation impaired in rats with hippocampal lesions. 
Nature, 297(5868), pp.681–683. Available at: 
http://www.nature.com/articles/297681a0. 
Muller, D. et al., 2002. LTP, Memory and Structural Plasticity. Current Molecular 
Medicine, 2(7), pp.605–611. Available at: 
http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1566-
5240&volume=2&issue=7&spage=605. 
Murakami, N. et al., 1991. Long-term cultured neurons from rat suprachiasmatic nucleus 
retain the capacity for circadian oscillation of vasopressin release. Brain research, 
545(1–2), pp.347–50. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1860057. 
Mure, L.S. et al., 2018. Diurnal transcriptome atlas of a primate across major neural and 
peripheral tissues. Science, 359(6381), p.eaao0318. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/29439024. 
Muzyk, A.J. & Holt, S., 2010. Corticosteroid psychosis: Stop therapy or add 
psychotropics? Current Psychiatry, 9(1). Available at: http://currentpsychiatry.. 
Naber, D., Sand, P. & Heigl, B., 1996. Psychopathological and neuropsychological 
effects of 8-days’ corticosteroid treatment. A prospective study. 
Psychoneuroendocrinology, 21(1), pp.25–31. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/8778901. 
Nakahata, Y. et al., 2008. The NAD+-Dependent Deacetylase SIRT1 Modulates CLOCK-
Mediated Chromatin Remodeling and Circadian Control. Cell, 134(2), pp.329–340. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/18662547. 
 209 
Nakamura, W. et al., 2005. Cellular/Molecular Differential Response of Period 1 
Expression within the Suprachiasmatic Nucleus. Neuroscience, 25(23), pp.5481–
5487. Available at: http://www.jneurosci.org/content/jneuro/25/23/5481.full.pdf. 
Nasca, C. et al., 2015. Mind the gap: glucocorticoids modulate hippocampal glutamate 
tone underlying individual differences in stress susceptibility. Molecular psychiatry, 
20(6), pp.755–63. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25178162. 
Naylor, E. et al., 2000. The circadian clock mutation alters sleep homeostasis in the 
mouse. The Journal of neuroscience : the official journal of the Society for 
Neuroscience, 20(21), pp.8138–43. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11050136. 
Neunuebel, J.P. et al., 2013. Conflicts between Local and Global Spatial Frameworks 
Dissociate Neural Representations of the Lateral and Medial Entorhinal Cortex. 
Journal of Neuroscience, 33(22), pp.9246–9258. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/23719794. 
Newell-Price, J. et al., 2006. Cushing’s syndrome Epidemiology and prognosis. 
www.thelancet.com, 367. 
Nieman, L.K. et al., 2008. The Diagnosis of Cushing’s Syndrome: An Endocrine Society 
Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 
93(5), pp.1526–1540. Available at: 
http://press.endocrine.org/doi/abs/10.1210/jc.2008-0125. 
De Novellis, V. et al., 1995. Hypothalamic sites mediating cardiovascular effects of 
microinjected bicuculline and EAAs in rats. American Journal of Physiology-
Regulatory, Integrative and Comparative Physiology, 269(1), pp.R131–R140. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/7631885. 
O’Callaghan, E.K. et al., 2012. Long-lasting effects of sepsis on circadian rhythms in the 
mouse. PloS one, 7(10), p.e47087. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/23071720. 
O’Keefe, J. & Speakman, A., 1987. Single unit activity in the rat hippocampus during a 
spatial memory task. Experimental Brain Research, 68(1), pp.1–27. Available at: 
http://link.springer.com/10.1007/BF00255230. 
Ohta, H., Yamazaki, S. & Mcmahon, D.G., 2005. Constant light desynchronizes 
mammalian clock neurons. NATURE NEUROSCIENCE, 8(3). Available at: 
https://search.proquest.com/openview/44f63cf4c808d84ebc2d5f70bc59eaf3/1?pq-
origsite=gscholar&cbl=44706. 
Oishi, K. et al., 1998a. Antiphase Circadian Expression 
betweenBMAL1andperiodHomologue mRNA in the Suprachiasmatic Nucleus and 
Peripheral Tissues of Rats. Biochemical and Biophysical Research Communications, 
253(2), pp.199–203. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9878515. 
Oishi, K. et al., 2003. Genome-wide expression analysis of mouse liver reveals CLOCK-
regulated circadian output genes. The Journal of biological chemistry, 278(42), 
pp.41519–27. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12865428. 
Oishi, K. et al., 1998b. Humoral signals mediate the circadian expression of rat period 
homologue (rPer2) mRNA in peripheral tissues. Neuroscience Letters, 256(2), 
pp.117–119. Available at: 
http://linkinghub.elsevier.com/retrieve/pii/S0304394098007654. 
Oitzl, M.S. & de Kloet, E.R., 1992. Selective corticosteroid antagonists modulate specific 
aspects of spatial orientation learning. Behavioral neuroscience, 106(1), pp.62–71. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/1313244. 
Okabe, T. et al., 2016. REV-ERBα influences the stability and nuclear localization of the 
glucocorticoid receptor. Journal of cell science, 129(21), pp.4143–4154. Available 
 210 
at: http://www.ncbi.nlm.nih.gov/pubmed/27686098. 
Oliva, D. et al., 1982. VIP stimulates ACTH release and adenylate cyclase in human 
ACTH-secreting pituitary adenomas. European Journal of Pharmacology, 83(1–2), 
pp.101–105. Available at: 
https://www.sciencedirect.com/science/article/pii/0014299982902916. 
Oliveri, R.L. et al., 1998. Pulsed methylprednisolone induces a reversible impairment of 
memory in patients with relapsing-remitting multiple sclerosis. Acta neurologica 
Scandinavica, 97(6), pp.366–369. 
Olsen, L., Knigge, U. & Warberg, J., 1992. Gastrin-releasing peptide stimulation of 
corticotropin secretion in male rats. Endocrinology, 130(5), pp.2710–2716. 
Available at: https://academic.oup.com/endo/article-
lookup/doi/10.1210/en.130.5.2710. 
Ono, D., Honma, K. & Honma, S., 2015. Circadian and ultradian rhythms of clock gene 
expression in the suprachiasmatic nucleus of freely moving mice. Scientific Reports, 
5(1), p.12310. Available at: http://www.nature.com/articles/srep12310. 
Overman, R.A., Yeh, J.-Y. & Deal, C.L., 2013. Prevalence of Oral Glucocorticoid Usage 
in the United States: A General Population Perspective. Arthritis Care & Research, 
65(2), pp.294–298. Available at: 
http://onlinelibrary.wiley.com/store/10.1002/acr.21796/asset/21796_ftp.pdf?v=1&t=
j6hzb2ei&s=e130ea85cb69ea590f5223cecac8dfa9d4fb6d1f. 
PALCHYKOVA, S. et al., 2006. Sleep deprivation impairs object recognition in mice. 
Neurobiology of Learning and Memory, 85(3), pp.263–271. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16423541. 
Pan, W.-X. & McNaughton, N., 2002. The role of the medial supramammillary nucleus in 
the control of hippocampal theta activity and behaviour in rats. European Journal of 
Neuroscience, 16(9), pp.1797–1809. Available at: 
http://doi.wiley.com/10.1046/j.1460-9568.2002.02267.x. 
Pan, W.-X. & McNaughton, N., 2004. The supramammillary area: its organization, 
functions and relationship to the hippocampus. Progress in Neurobiology, 74(3), 
pp.127–166. Available at: 
https://www.sciencedirect.com/science/article/pii/S0301008204001613. 
Panda, S. et al., 2002. Melanopsin (Opn4) Requirement for Normal Light-Induced 
Circadian Phase Shifting. Science, 298(5601), pp.2213–2216. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/12481141. 
Panula, P. et al., 1989. Histamine-immunoreactive nerve fibers in the rat brain. 
Neuroscience, 28(3), pp.585–610. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/2710333. 
Partonen, T. et al., 2007. Three circadian clock genes Per2, Arntl, and Npas2 contribute to 
winter depression. Annals of Medicine, 39(3), pp.229–238. Available at: 
http://www.tandfonline.com/doi/full/10.1080/07853890701278795. 
Paskitti, M.., McCreary, B.. & Herman, J.., 2000. Stress regulation of 
adrenocorticosteroid receptor gene transcription and mRNA expression in rat 
hippocampus: time-course analysis. Molecular Brain Research, 80(2), pp.142–152. 
Available at: 
https://www.sciencedirect.com/science/article/pii/S0169328X00001212. 
Patel, S.A. et al., 2016. Calorie restriction regulates circadian clock gene expression 
through BMAL1 dependent and independent mechanisms. Scientific Reports, 6(1), 
p.25970. Available at: http://www.nature.com/articles/srep25970. 
Patke, A. et al., 2017. Mutation of the Human Circadian Clock Gene CRY1 in Familial 
Delayed Sleep Phase Disorder. Cell, 169(2), p.203–215.e13. Available at: 
 211 
https://www.sciencedirect.com/science/article/pii/S009286741730346X. 
Pavlides, C. et al., 1996. Role of adrenal steroid mineralocorticoid and glucocorticoid 
receptors in long-term potentiation in the CA1 field of hippocampal slices. Brain 
research, 738(2), pp.229–35. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/8955517. 
Paxinos, G. & Watson, C.R., 2007. The Rat Brain in Stereotaxic Coordinates. Academic 
Press, San Diego, 3rd. 
Peek, C.B. et al., 2017. Circadian Clock Interaction with HIF1α Mediates Oxygenic 
Metabolism and Anaerobic Glycolysis in Skeletal Muscle. Cell Metabolism, 25(1), 
pp.86–92. Available at: 
https://www.sciencedirect.com/science/article/pii/S1550413116304909#fig1. 
Peirson, S.N. et al., 2006. Comparison of clock gene expression in SCN, retina, heart, and 
liver of mice. Biochemical and Biophysical Research Communications, 351(4), 
pp.800–807. Available at: 
http://www.sciencedirect.com/science/article/pii/S0006291X06023035. 
Pereira, A.M., Tiemensma, J. & Romijn, J.A., 2010. Neuropsychiatric disorders in 
Cushing’s syndrome. Neuroendocrinology, 92 Suppl 1(Suppl. 1), pp.65–70. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/20829621. 
Perreau-Lenz, S. et al., 2003. Suprachiasmatic control of melatonin synthesis in rats: 
inhibitory and stimulatory mechanisms. The European journal of neuroscience, 
17(2), pp.221–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12542658. 
Peters, A., 1971. Stellate cells of the rat parietal cortex. The Journal of Comparative 
Neurology, 141(3), pp.345–373. Available at: 
http://doi.wiley.com/10.1002/cne.901410306. 
Phan, T.H. et al., 2011. The Diurnal Oscillation of MAP (Mitogen-Activated Protein) 
Kinase and Adenylyl Cyclase Activities in the Hippocampus Depends on the 
Suprachiasmatic Nucleus. Journal of Neuroscience, 31(29), pp.10640–10647. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/21775607. 
Pinnock, S.B. et al., 2009. Synergistic effects of dehydroepiandrosterone and fluoxetine 
on proliferation of progenitor cells in the dentate gyrus of the adult male rat. 
Neuroscience, 158(4), pp.1644–1651. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/19068226. 
Pivonello, R. et al., 2015. Neuropsychiatric disorders in Cushing’s syndrome. Frontiers in 
Neuroscience, 9, p.129. Available at: 
http://journal.frontiersin.org/article/10.3389/fnins.2015.00129/abstract. 
Plihal, W. & Born, J., 1997. Effects of Early and Late Nocturnal Sleep on Declarative and 
Procedural Memory. Journal of Cognitive Neuroscience, 9(4), pp.534–547. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/23968216. 
Plihal, W. & Born, J., 1999a. Effects of early and late nocturnal sleep on priming and 
spatial memory. Psychophysiology, 36(5), pp.571–82. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10442025. 
Plihal, W. & Born, J., 1999b. Memory consolidation in human sleep depends on 
inhibition of glucocorticoid release. Neuroreport, 10(13), pp.2741–7. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10511433. 
Van den Pol, A.N., 1980. The hypothalamic suprachiasmatic nucleus of rat: intrinsic 
anatomy. The Journal of comparative neurology, 191(4), pp.661–702. Available at: 
http://doi.wiley.com/10.1002/cne.901910410. 
Pooley, J.R., 2015. Interaction of the MR and GR in the Nucleus and at DNA. 
Preitner, N. et al., 2002. The orphan nuclear receptor REV-ERBalpha controls circadian 
transcription within the positive limb of the mammalian circadian oscillator. Cell, 
 212 
110(2), pp.251–60. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12150932. 
Prewitt, C.M. & Herman, J.P., 1998. Anatomical interactions between the central 
amygdaloid nucleus and the hypothalamic paraventricular nucleus of the rat: a dual 
tract-tracing analysis. Journal of chemical neuroanatomy, 15(3), pp.173–85. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/9797074. 
Price, T.S. et al., 2008. WAVECLOCK: wavelet analysis of circadian oscillation. 
Bioinformatics (Oxford, England), 24(23), pp.2794–5. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18931366. 
Qian, X. et al., 2012. Circadian and Ultradian Rhythms of Free Glucocorticoid Hormone 
Are Highly Synchronized between the Blood, the Subcutaneous Tissue, and the 
Brain. Endocrinology, 153(9), pp.4346–4353. Available at: 
https://academic.oup.com/endo/article-lookup/doi/10.1210/en.2012-1484. 
Quirk, G.J., Armony, J.L. & LeDoux, J.E., 1997. Fear Conditioning Enhances Different 
Temporal Components of Tone-Evoked Spike Trains in Auditory Cortex and Lateral 
Amygdala. Neuron, 19(3), pp.613–624. Available at: 
https://www.sciencedirect.com/science/article/pii/S089662730080375X. 
Rakai, B.D. et al., 2014. Survival of Adult Generated Hippocampal Neurons Is Altered in 
Circadian Arrhythmic Mice N. Cermakian, ed. PLoS ONE, 9(6), p.e99527. Available 
at: http://dx.plos.org/10.1371/journal.pone.0099527. 
Rasch, B. et al., 2007. Odor Cues During Slow-Wave Sleep Prompt Declarative Memory 
Consolidation. Science, 315(5817), pp.1426–1429. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/17347444. 
Rasch, B. & Born, J., 2013. About sleep’s role in memory. Physiological reviews, 93(2), 
pp.681–766. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23589831. 
Raspé, E. et al., 2002. Identification of Rev-erbalpha as a physiological repressor of 
apoC-III gene transcription. Journal of lipid research, 43(12), pp.2172–9. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/12454280. 
Rath, M.F., Rovsing, L. & Møller, M., 2014. Circadian oscillators in the mouse brain: 
molecular clock components in the neocortex and cerebellar cortex. Cell and Tissue 
Research, 357(3), pp.743–755. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/24842045. 
Rawashdeh, O. et al., 2014a. PERIOD1 coordinates hippocampal rhythms and memory 
processing with daytime. Hippocampus, 24(6), pp.712–723. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/24550127. 
Rawashdeh, O. et al., 2014b. PERIOD1 coordinates hippocampal rhythms and memory 
processing with daytime. Hippocampus, 24(6), pp.712–723. Available at: 
http://doi.wiley.com/10.1002/hipo.22262. 
Rawashdeh, O. et al., 2016. Period1 gates the circadian modulation of memory-relevant 
signaling in mouse hippocampus by regulating the nuclear shuttling of the CREB 
kinase pP90RSK. Journal of neurochemistry. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/27246400. 
Rea, M.A., Buckley, B. & Lutton, L.M., 1993. Local administration of EAA antagonists 
blocks light-induced phase shifts and c-fos expression in hamster SCN. The 
American journal of physiology, 265(5 Pt 2), pp.R1191-8. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/7902017. 
Rea, M.A., Glass, J.D. & Colwell, C.S., 1994. Serotonin Modulates Photic Responses in 
the Hamster Suprachiasmatic Nuclei. The Journal of Neuroscience, 74(6), pp.3635–
3642. Available at: http://www.jneurosci.org/content/jneuro/14/6/3635.full.pdf. 
Rebuffé-Scrive, M. et al., 1992. Effect of chronic stress and exogenous glucocorticoids on 
regional fat distribution and metabolism. Physiology & Behavior, 52(3), pp.583–
 213 
590. Available at: 
https://www.sciencedirect.com/science/article/pii/0031938492903512. 
Reddy, A.B. et al., 2007. Glucocorticoid signaling synchronizes the liver circadian 
transcriptome. Hepatology, 45(6), pp.1478–1488. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/17538967. 
Reddy, T.E. et al., 2012. The hypersensitive glucocorticoid response specifically 
regulates period 1 and expression of circadian genes. Molecular and cellular 
biology, 32(18), pp.3756–67. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/22801371. 
Reebs, S.G. & Mrosovsky, N., 1989. Effects of Induced Wheel Running on the Circadian 
Activity Rhythms of Syrian Hamsters: Entrainment and Phase Response Curve. 
Journal of Biological Rhythms, 4(1), pp.39–48. Available at: 
http://journals.sagepub.com/doi/10.1177/074873048900400103. 
Reeth, O. Van & Turek, F.W., 1989. Stimulated activity mediates phase shifts in the 
hamster circadian clock induced by dark pulses or benzodiazepines. Nature, 
339(6219), pp.49–51. Available at: 
http://www.nature.com/doifinder/10.1038/339049a0. 
Refinetti, R., Kaufman, C.M. & Menaker, M., 1994. Complete suprachiasmatic lesions 
eliminate circadian rhythmicity of body temperature and locomotor activity in 
golden hamsters. Journal of Comparative Physiology A, 175(2), pp.223–232. 
Available at: http://link.springer.com/10.1007/BF00215118. 
Refinetti, R. & Menaker, M., 1992. The circadian rhythm of body temperature. 
Physiology & Behavior, 51(3), pp.613–637. Available at: 
https://www.sciencedirect.com/science/article/pii/0031938492901888. 
Rekers, N. V. et al., 2016. Mechanisms and risk assessment of steroid resistance in acute 
kidney transplant rejection. Transplant Immunology, 38, pp.3–14. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/27480047. 
Relles, D. et al., 2013. Circadian Gene Expression and Clinicopathologic Correlates in 
Pancreatic Cancer. Journal of Gastrointestinal Surgery, 17(3), pp.443–450. 
Available at: http://link.springer.com/10.1007/s11605-012-2112-2. 
Reppert, S.M. & Weaver, D.R., 2002. Coordination of circadian timing in mammals. 
Nature, 418(6901), pp.935–941. Available at: 
http://www.nature.com/articles/nature00965. 
Reul, J.M. & de Kloet, E.R., 1986. Anatomical resolution of two types of corticosterone 
receptor sites in rat brain with in vitro autoradiography and computerized image 
analysis. Journal of steroid biochemistry, 24(1), pp.269–72. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/3702410. 
Reul, J.M.H.M. & Kloet, E.R. DE, 1985. Two Receptor Systems for Corticosterone in 
Rat Brain: Microdistribution and Differential Occupation. Endocrinology, 117(6), 
pp.2505–2511. Available at: http://press.endocrine.org/doi/abs/10.1210/endo-117-6-
2505. 
Rey, M. et al., 1994. Corticosterone Effects on Long-Term Potentiation in Mouse 
Hippocampal Slices. Neuroendocrinology, 60(1), pp.36–41. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/8090280. 
Riccio, A.P. & Goldman, B.D., 2000. Circadian rhythms of locomotor activity in naked 
mole-rats (Heterocephalus glaber). Physiology & Behavior, 71(1–2), pp.1–13. 
Available at: 
https://www.sciencedirect.com/science/article/pii/S003193840000281X. 
Ripperger, J.A. et al., 2000. CLOCK, an essential pacemaker component, controls 
expression of the circadian transcription factor DBP. Genes & development, 14(6), 
 214 
pp.679–89. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10733528. 
Ripperger, J.A. & Merrow, M., 2011. Perfect timing: Epigenetic regulation of the 
circadian clock. FEBS Letters, 585(10), pp.1406–1411. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/21536041. 
Ripperger, J.A. & Schibler, U., 2006. Rhythmic CLOCK-BMAL1 binding to multiple E-
box motifs drives circadian Dbp transcription and chromatin transitions. Nature 
Genetics, 38(3), pp.369–374. Available at: http://www.nature.com/articles/ng1738. 
Risold, P.. & Swanson, L.., 1997. Connections of the rat lateral septal complex. Brain 
Research Reviews, 24(2–3), pp.115–195. Available at: 
https://www.sciencedirect.com/science/article/pii/S016501739700009X. 
Roelink, H., 2000. Hippocampus formation: An intriguing collaboration. Current 
Biology, 10(7), pp.R279–R281. Available at: 
https://www.sciencedirect.com/science/article/pii/S0960982200004073. 
Roozendaal, B., de Quervain, D.J.-F. & McGaugh, J.L., 1998. Stress and glucocorticoids 
impair retrieval of long-term spatial memory. Nature, 394(6695), pp.787–790. 
Available at: http://www.nature.com/doifinder/10.1038/29542. 
Rosbash, M. & Hall, J.C., 1985. Biological Clocks in Drosophila: Finding the Molecules 
That Make Them Tick. Cell, 43(0), pp.3–4. Available at: 
http://www.bio.brandeis.edu/rosbash-lab/PublishedPapers/1982-
1986/Rosbash.Cell.1985.pdf. 
Rosenwasser, A.M. et al., 2005. Circadian activity rhythms in selectively bred ethanol-
preferring and nonpreferring rats. Alcohol, 36(2), pp.69–81. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16396740. 
Rozwaha, T., 2017. Circadian rhythmicity in Hippocampus and Perirhinal Cortex is 
Dysregulated during chronic Methyl-Prednisolone treatment. 
Ruby, N.F. et al., 2008. Hippocampal-dependent learning requires a functional circadian 
system. Proceedings of the National Academy of Sciences, 105(40), pp.15593–
15598. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18832172. 
Ruby, N.F. et al., 2002. The suprachiasmatic nucleus is essential for circadian body 
temperature rhythms in hibernating ground squirrels. The Journal of neuroscience : 
the official journal of the Society for Neuroscience, 22(1), pp.357–64. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11756519. 
Rudic, R.D. et al., 2004. BMAL1 and CLOCK, Two Essential Components of the 
Circadian Clock, Are Involved in Glucose Homeostasis Steve O’Rahilly, ed. PLoS 
Biology, 2(11), p.e377. Available at: 
http://dx.plos.org/10.1371/journal.pbio.0020377. 
Rudolf Thal, D. et al., 2000. Alzheimer-Related τ-Pathology in the Perforant Path Target 
Zone and in the Hippocampal Stratum Oriens and Radiatum Correlates with Onset 




Ruf, T., 1999. The Lomb-Scargle Periodogram in Biological Rhythm Research: Analysis 
of Incomplete and Unequally Spaced Time-Series. Biological Rhythm Research, 
30(2), pp.178–201. Available at: 
https://www.tandfonline.com/doi/full/10.1076/brhm.30.2.178.1422. 
Rupprecht, R. et al., 1993. Pharmacological and functional characterization of human 
mineralocorticoid and glucocorticoid receptor ligands. European Journal of 
Pharmacology: Molecular Pharmacology, 247(2), pp.145–154. Available at: 
https://www.sciencedirect.com/science/article/pii/092241069390072H. 
 215 
Rushworth, M.F.S. et al., 2011. Frontal Cortex and Reward-Guided Learning and 
Decision-Making. Neuron, 70(6), pp.1054–1069. Available at: 
https://www.sciencedirect.com/science/article/pii/S0896627311003953. 
Sabbar, M. et al., 2017. Circadian Clock Protein Content and Daily Rhythm of 
Locomotor Activity Are Altered after Chronic Exposure to Lead in Rat. Frontiers in 
Behavioral Neuroscience, 11, p.178. Available at: 
http://journal.frontiersin.org/article/10.3389/fnbeh.2017.00178/full. 
Sage, D. et al., 2004. Influence of the Corticosterone Rhythm on Photic Entrainment of 
Locomotor Activity in Rats. Journal of Biological Rhythms, 19(2), pp.144–156. 
Available at: http://journals.sagepub.com/doi/10.1177/0748730403261894. 
Sainio, E.-L., Lehtola, T. & Roininen, P., 1988. Radioimmunoassay of total and free 
corticosterone in rat plasma: Measurement of the effect of different doses of 
corticosterone. Steroids, 51(5–6), pp.609–622. Available at: 
https://www.sciencedirect.com/science/article/pii/0039128X88900566?via%3Dihub. 
Sakai, T. et al., 2004. A clock gene, period, plays a key role in long-term memory 
formation in Drosophila. National Acad Sciences. Available at: 
http://www.pnas.org/content/101/45/16058.short. 
Sancar, A., 2004. Regulation of the mammalian circadian clock by cryptochrome. The 
Journal of biological chemistry, 279(33), pp.34079–82. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15123698. 
Sandborn, W.J. et al., 2012. Adalimumab Induces and Maintains Clinical Remission in 
Patients With Moderate-to-Severe Ulcerative Colitis. Gastroenterology, 142(2), 
p.257–265.e3. Available at: 
https://www.sciencedirect.com/science/article/pii/S001650851101506X. 
Sandi, C., Loscertales, M. & Guaza, C., 1997. Experience-dependent Facilitating Effect 
of Corticosterone on Spatial Memory Formation in the Water Maze. European 
Journal of Neuroscience, 9(4), pp.637–642. Available at: 
http://doi.wiley.com/10.1111/j.1460-9568.1997.tb01412.x. 
Saper, C.B. et al., 2005. The hypothalamic integrator for circadian rhythms. Trends in 
Neurosciences, 28(3), pp.152–157. Available at: 
http://www.sciencedirect.com/science/article/pii/S0166223604003959. 
Sato, T.K. et al., 2004. A Functional Genomics Strategy Reveals Rora as a Component of 
the Mammalian Circadian Clock. Neuron, 43(4), pp.527–537. Available at: 
https://www.sciencedirect.com/science/article/pii/S089662730400460X. 
Sawchenko, P.E., Arias, C.A. & Mortrud, M.T., 1993. Local Tetrodotoxin Blocks 
Chronic Stress Effects on Corticotropin-Releasing Factor and Vasopressin 
Messenger Ribonucleic Acids in Hypophysiotropic Neurons. Journal of 
Neuroendocrinology, 5(4), pp.341–348. Available at: 
http://doi.wiley.com/10.1111/j.1365-2826.1993.tb00493.x. 
Schaaf, M.J.M., De Kloet, E.R. & Vreugdenhil, E., 2000. Corticosterone Effects on 
BDNF Expression in the Hippocampus Implications for Memory Formation. Stress, 
3(3), pp.201–208. Available at: 
http://www.tandfonline.com/doi/full/10.3109/10253890009001124. 
Scharfman, H.E., Goodman, J.H. & Sollas, A.L., 2000. Granule-like neurons at the 
hilar/CA3 border after status epilepticus and their synchrony with area CA3 
pyramidal cells: functional implications of seizure-induced neurogenesis. The 
Journal of neuroscience : the official journal of the Society for Neuroscience, 
20(16), pp.6144–58. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10934264. 
Schibler, U. & Sassone-Corsi, P., 2002. A Web of Circadian Pacemakers. Cell, 111(7), 
pp.919–922. Available at: 
 216 
http://www.sciencedirect.com/science/article/pii/S0092867402012254. 
Schlessinger, A.R., Cowan, W.M. & Gottlieb, D.I., 1975. An autoradiographic study of 
the time of origin and the pattern of granule cell migration in the dentate gyrus of the 
rat. The Journal of Comparative Neurology, 159(2), pp.149–175. Available at: 
http://doi.wiley.com/10.1002/cne.901590202. 
Schmahmann, J.D., 1991. An emerging concept. The cerebellar contribution to higher 
function. Archives of neurology, 48(11), pp.1178–87. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/1953406. 
Schmahmann, J.D., 2004. Disorders of the Cerebellum: Ataxia, Dysmetria of Thought, 
and the Cerebellar Cognitive Affective Syndrome. The Journal of Neuropsychiatry 
and Clinical Neurosciences, 16(3), pp.367–378. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15377747. 
Schmutz, I., Albrecht, U. & Ripperger, J.A., 2012. The role of clock genes and 
rhythmicity in the liver. Molecular and Cellular Endocrinology, 349(1), pp.38–44. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/21664421. 
Schroeder, A. et al., 2011. Circadian regulation of cardiovascular function: a role for 
vasoactive intestinal peptide. American Journal of Physiology-Heart and 
Circulatory Physiology, 300(1), pp.H241–H250. Available at: 
http://www.physiology.org/doi/10.1152/ajpheart.00190.2010. 
Schultz, C. & Engelhardt, M., 2014. Anatomy of the hippocampal formation. Frontiers of 
neurology and neuroscience, 34, pp.6–17. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/24777126. 
Schwartz, W.J. et al., 2011. Distinct patterns of Period gene expression in the 
suprachiasmatic nucleus underlie circadian clock photoentrainment by advances or 
delays. Proceedings of the National Academy of Sciences of the United States of 
America, 108(41), pp.17219–24. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/21969555. 
Schwartz, W.J. et al., 1983. In vivo metabolic activity of the suprachiasmatic nuclei: a 
comparative study. Brain Research, 274(1), pp.184–187. Available at: 
https://www.sciencedirect.com/science/article/pii/0006899383905383. 
Segall, L.A. et al., 2006. Glucocorticoid rhythms control the rhythm of expression of the 
clock protein, Period2, in oval nucleus of the bed nucleus of the stria terminalis and 
central nucleus of the amygdala in rats. Neuroscience, 140(3), pp.753–757. 
Available at: 
https://www.sciencedirect.com/science/article/pii/S0306452206004076. 
Segall, L.A. & Amir, S., 2010. Glucocorticoid Regulation of Clock Gene Expression in 
the Mammalian Limbic Forebrain. Journal of Molecular Neuroscience, 42(2), 
pp.168–175. Available at: http://link.springer.com/10.1007/s12031-010-9341-1. 
Senft, R.A. et al., 2016. Distribution and Abundance of Glucocorticoid and 
Mineralocorticoid Receptors throughout the Brain of the Great Tit (Parus major) M. 
J. Coleman, ed. PLOS ONE, 11(2), p.e0148516. Available at: 
http://dx.plos.org/10.1371/journal.pone.0148516. 
Sequeira, A. et al., 2012. Gene Expression Changes in the Prefrontal Cortex, Anterior 
Cingulate Cortex and Nucleus Accumbens of Mood Disorders Subjects That 
Committed Suicide B. J. Harrison, ed. PLoS ONE, 7(4), p.e35367. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/22558144. 
Sherin, J.E. et al., 1996. Activation of ventrolateral preoptic neurons during sleep. Science 
(New York, N.Y.), 271(5246), pp.216–9. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/8539624. 
SHIBLEY, H.L., MALCOLM, R.J. & VEATCH, L.M., 2008. Adolescents with Insomnia 
 217 
and Substance Abuse: Consequences and Comorbidities. Journal of Psychiatric 
Practice, 14(3), pp.146–153. Available at: 
https://insights.ovid.com/crossref?an=00131746-200805000-00003. 
Shieh, K.-R., 2003. Distribution of the rhythm-related genes rPERIOD1, rPERIOD2, and 
rCLOCK, in the rat brain. Neuroscience, 118(3), pp.831–843. Available at: 
https://www.sciencedirect.com/science/article/pii/S0306452203000046. 
Shinohara, K. et al., 1994. Circadian rhythms in the release of vasoactive intestinal 
polypeptide and arginine-vasopressin in organotypic slice culture of rat 
suprachiasmatic nucleus. Neuroscience letters, 170(1), pp.183–6. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/8041503. 
Short, D., El Masry, W. & Jones, P., 2000. High dose methylprednisolone in the 
management of acute spinal cord injury – a systematic review from a clinical 
perspective. Spinal Cord, 38(5), pp.273–286. Available at: 
http://www.nature.com/articles/3100986. 
Siegel, J.M., 2001. The REM sleep-memory consolidation hypothesis. Science (New 
York, N.Y.), 294(5544), pp.1058–63. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11691984. 
Silver, R. et al., 1996. A diffusible coupling signal from the transplanted suprachiasmatic 
nucleus controlling circadian locomotor rhythms. Nature, 382(6594), pp.810–813. 
Available at: http://www.nature.com/doifinder/10.1038/382810a0. 
Simasko, S.M. & Mukherjee, S., 2009. Novel analysis of sleep patterns in rats separates 
periods of vigilance cycling from long-duration wake events. Behavioural brain 
research, 196(2), pp.228–36. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18835301. 
Skaggs, W.E. & McNaughton, B.L., 1996. Replay of neuronal firing sequences in rat 
hippocampus during sleep following spatial experience. Science (New York, N.Y.), 
271(5257), pp.1870–3. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8596957. 
Slusher, M., 1966. Effects of cortisol implants in the brainstem and ventral hippocampus 
on diurnal corticosteroid levels. Experimental Brain Research, 1(2), pp.184–194. 
Available at: http://link.springer.com/10.1007/BF00236870. 
Smith, S.M. & Vale, W.W., 2006. The role of the hypothalamic-pituitary-adrenal axis in 
neuroendocrine responses to stress. Dialogues in clinical neuroscience, 8(4), 
pp.383–95. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17290797. 
Sonino, N. & Fava, G., 2001. Psychiatric disorders associated with Cushing’s syndrome. 
CNS drugs, 15(5), pp.361–373. Available at: 
http://link.springer.com/10.2165/00023210-200115050-00003. 
Soria, V. et al., 2010. Differential Association of Circadian Genes with Mood Disorders: 
CRY1 and NPAS2 are Associated with Unipolar Major Depression and CLOCK and 
VIP with Bipolar Disorder. Neuropsychopharmacology, 35(6), pp.1279–1289. 
Available at: http://www.nature.com/articles/npp2009230. 
Soták, M. et al., 2016. Peripheral circadian clocks are diversely affected by 
adrenalectomy. Chronobiology International, 0528(April). 
Spanagel, R. et al., 2005. The clock gene Per2 influences the glutamatergic system and 
modulates alcohol consumption. Nature Medicine, 11(1), pp.35–42. Available at: 
http://www.nature.com/articles/nm1163. 
Spiga, F. et al., 2011. ACTH-dependent ultradian rhythm of corticosterone secretion. 
Endocrinology, 152(4), pp.1448–57. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/21303945. 
Sprague, J.M., 1966. Interaction of cortex and superior colliculus in mediation of visually 
guided behavior in the cat. Science (New York, N.Y.), 153(3743), pp.1544–7. 
 218 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/5917786. 
van Staa, T.P. et al., 2000. Use of oral corticosteroids in the United Kingdom. QJM : 
monthly journal of the Association of Physicians, 93(2), pp.105–11. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10700481. 
Stanewsky, R. et al., 1998. The cryb mutation identifies cryptochrome as a circadian 
photoreceptor in Drosophila. Cell, 95(5), pp.681–92. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/9845370. 
Starkman, M.N. et al., 1992. Hippocampal Formation Volume, Memory Dysfunction, and 
Cortisoi Levels in Patients with Cushing’s Syndrome. BIOL PSYCHIATRY, 32, 
pp.756–765. 
Stenvers, D.J. et al., 2016. Dim light at night disturbs the daily sleep-wake cycle in the 
rat. Scientific Reports, 6(1), p.35662. Available at: 
http://www.nature.com/articles/srep35662. 
Stephan, F.K., Swann, J.M. & Sisk, C.L., 1979. Entrainment of circadian rhythms by 
feeding schedules in rats with suprachiasmatic lesions. Behavioral and Neural 
Biology, 25(4), pp.545–554. Available at: 
https://www.sciencedirect.com/science/article/pii/S0163104779903327. 
Stephan, F.K. & Zucker, I., 1972. Circadian rhythms in drinking behavior and locomotor 
activity of rats are eliminated by hypothalamic lesions. Proceedings of the National 
Academy of Sciences of the United States of America, 69(6), pp.1583–6. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/4556464. 
Steriade, M. & McCarley, R.W., 1990. Brainstem Control of Wakefulness and Sleep, 




Stevens, C.F., 1998. A million dollar question: does LTP = memory? Neuron, 20(1), 
pp.1–2. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9459434. 
Steward, O., 1976. Topographic organization of the projections from the entorhinal area 
to the hippocampal formation of the rat. The Journal of Comparative Neurology, 
167(3), pp.285–314. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1270625. 
Stickgold, R., 2005. Sleep-dependent memory consolidation. Nature, 437(7063), 
pp.1272–1278. Available at: http://www.nature.com/doifinder/10.1038/nature04286. 
Stickgold, R., James, L. & Hobson, J.A., 2000. Visual discrimination learning requires 
sleep after training. Nature Neuroscience, 3(12), pp.1237–1238. Available at: 
http://www.nature.com/articles/nn1200_1237. 
Stojkovic, K., Wing, S.S. & Cermakian, N., 2014. A central role for ubiquitination within 
a circadian clock protein modification code. Frontiers in molecular neuroscience, 7, 
p.69. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25147498. 
Stokkan, K.-A. et al., 2001. Entrainment of the Circadian Clock in the Liver by Feeding. 
Science, 291(5503), pp.490–493. Available at: 
http://www.sciencemag.org/cgi/doi/10.1126/science.291.5503.490. 
Suh, J. et al., 2011. Entorhinal Cortex Layer III Input to the Hippocampus Is Crucial for 
Temporal Association Memory. Science, 334(6061), pp.1415–1420. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/22052975. 
Sukhotinsky, I. et al., 2005. Movement suppression during anesthesia: Neural projections 
from the mesopontine tegmentum to areas involved in motor control. The Journal of 
Comparative Neurology, 489(4), pp.425–448. Available at: 
http://doi.wiley.com/10.1002/cne.20636. 
Summa, K.C. et al., 2015. Chronic Alcohol Exposure and the Circadian Clock Mutation 
 219 
Exert Tissue-Specific Effects on Gene Expression in Mouse Hippocampus, Liver, 
and Proximal Colon. Alcoholism: Clinical and Experimental Research, 39(10), 
pp.1917–1929. Available at: http://doi.wiley.com/10.1111/acer.12834. 
Swanson, L.W. & Petrovich, G.D., 1998. What is the amygdala? Trends in 
Neurosciences, 21(8), pp.323–331. Available at: 
https://www.sciencedirect.com/science/article/pii/S016622369801265X. 
Takahashi, H. & Magee, J.C., 2009. Pathway Interactions and Synaptic Plasticity in the 
Dendritic Tuft Regions of CA1 Pyramidal Neurons. Neuron, 62(1), pp.102–111. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/19376070. 
Takekida, S. et al., 2000. Differential adrenergic regulation of the circadian expression of 
the clock genes Period1 and Period2 in the rat pineal gland. European Journal of 
Neuroscience, 12(12), pp.4557–4561. Available at: 
http://doi.wiley.com/10.1046/j.0953-816X.2000.01324.x. 
Tam, S.K.E. et al., 2017. Constant Light Desynchronizes Olfactory versus Object and 
Visuospatial Recognition Memory Performance. The Journal of neuroscience : the 
official journal of the Society for Neuroscience, 37(13), pp.3555–3567. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/28264977. 
Tambe, K. et al., 2010. The Role of Intravenous Methylprednisolone Immunosuppression 
in the Management of Active Thyroid Eye Disease. Orbit, 29(5), pp.227–231. 
Available at: http://www.tandfonline.com/doi/full/10.3109/01676831003660663. 
Tatomir, A., Micu, C. & Crivii, C., 2014. The impact of stress and glucocorticoids on 
memory. Clujul medical (1957), 87(1), pp.3–6. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/26527987. 
Terazono, H. et al., 2003. Adrenergic regulation of clock gene expression in mouse liver. 
Proceedings of the National Academy of Sciences, 100(11), pp.6795–6800. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/12754374. 
Thompson, C.L. et al., 2003. Expression of the Blue-Light Receptor Cryptochrome in the 
Human Retina. Investigative Opthalmology & Visual Science, 44(10), p.4515. 
Available at: http://iovs.arvojournals.org/article.aspx?doi=10.1167/iovs.03-0303. 
Thompson, R.H., Canteras, N.S. & Swanson, L.W., 1996. Organization of projections 
from the dorsomedial nucleus of the hypothalamus: a PHA-L study in the rat. The 
Journal of comparative neurology, 376(1), pp.143–73. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/8946289. 
Toh, K.L. et al., 2001. An hPer2 phosphorylation site mutation in familial advanced sleep 
phase syndrome. Science (New York, N.Y.), 291(5506), pp.1040–3. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11232563. 
Tong, X. & Yin, L., 2013. Circadian Rhythms in Liver Physiology and Liver Diseases. In 
Comprehensive Physiology. Hoboken, NJ, USA: John Wiley & Sons, Inc., pp. 917–
40. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23720334. 
Turek, F.W. et al., 2005. Obesity and Metabolic Syndrome in Circadian Clock Mutant 
Mice. Science, 308(5724), pp.1043–1045. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15845877. 
Udoh, U. et al., 2015. The Molecular Circadian Clock and Alcohol-Induced Liver Injury. 
Biomolecules, 5(4), pp.2504–2537. Available at: http://www.mdpi.com/2218-
273X/5/4/2504. 
Ueda, H.R. et al., 2002. A transcription factor response element for gene expression 
during circadian night. Nature, 418(6897), pp.534–539. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/12152080. 
Uhl, A. et al., 2002. Pharmacokinetics and pharmacodynamics of methylprednisolone 
after one bolus dose compared with two dose fractions. Journal of clinical pharmacy 
 220 
and therapeutics, 27(4), pp.281–7. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/12174030. 
Ulrich-Lai, Y.M., Arnhold, M.M. & Engeland, W.C., 2006. Adrenal splanchnic 
innervation contributes to the diurnal rhythm of plasma corticosterone in rats by 
modulating adrenal sensitivity to ACTH. American Journal of Physiology-
Regulatory, Integrative and Comparative Physiology, 290(4), pp.R1128–R1135. 
Available at: http://www.physiology.org/doi/10.1152/ajpregu.00042.2003. 
Ulrich-Lai, Y.M. & Herman, J.P., 2009. Neural regulation of endocrine and autonomic 
stress responses. Nature Reviews Neuroscience, 10(6), pp.397–409. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/19469025. 
Uz, T. et al., 2005. Effect of fluoxetine and cocaine on the expression of clock genes in 
the mouse hippocampus and striatum. Neuroscience, 134(4), pp.1309–1316. 
Available at: 
https://www.sciencedirect.com/science/article/pii/S0306452205005166. 
Valekunja, U.K. et al., 2013. Histone methyltransferase MLL3 contributes to genome-
scale circadian transcription. Proceedings of the National Academy of Sciences, 
110(4), pp.1554–1559. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/23297224. 
Vanselow, K. et al., 2006. Differential effects of PER2 phosphorylation: molecular basis 
for the human familial advanced sleep phase syndrome (FASPS). Genes & 
development, 20(19), pp.2660–72. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16983144. 
Vázquez-Palacios, G. et al., 2001. Further definition of the effect of corticosterone on the 
sleep-wake pattern in the male rat. Pharmacology, biochemistry, and behavior, 
70(2–3), pp.305–10. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11701201. 
Verner, T.A., Goodchild, A.K. & Pilowsky, P.M., 2004. A mapping study of 
cardiorespiratory responses to chemical stimulation of the midline medulla 
oblongata in ventilated and freely breathing rats. American Journal of Physiology-
Regulatory, Integrative and Comparative Physiology, 287(2), pp.R411–R421. 
Available at: http://www.physiology.org/doi/10.1152/ajpregu.00019.2004. 
Verwey, M., Robinson, B. & Amir, S., 2013. Recording and analysis of circadian 
rhythms in running-wheel activity in rodents. Journal of visualized experiments : 
JoVE, (71). Available at: http://www.ncbi.nlm.nih.gov/pubmed/23380887. 
Vinson, G.P., 2016. Functional Zonation of the Adult Mammalian Adrenal Cortex. 
Frontiers in Neuroscience, 10, p.238. Available at: 
http://journal.frontiersin.org/Article/10.3389/fnins.2016.00238/abstract. 
Wagner, U. & Born, J., 2008. Memory consolidation during sleep: Interactive effects of 
sleep stages and HPA regulation. Stress, 11(1), pp.28–41. Available at: 
http://www.tandfonline.com/doi/full/10.1080/10253890701408822. 
Waite, E.J. et al., 2012. Ultradian corticosterone secretion is maintained in the absence of 
circadian cues. European Journal of Neuroscience, 36(8), pp.3142–3150. Available 
at: http://doi.wiley.com/10.1111/j.1460-9568.2012.08213.x. 
Walker, M.P. & Stickgold, R., 2004. Sleep-dependent learning and memory 
consolidation. Neuron, 44(1), pp.121–33. Available at: 
http://www.sciencedirect.com/science/article/pii/S0896627304005409. 
Wang, L.M.-C. et al., 2009. Expression of the Circadian Clock Gene Period2 in the 
Hippocampus: Possible Implications for Synaptic Plasticity and Learned Behaviour. 
ASN Neuro, 1(3), p.AN20090020. Available at: 
http://journals.sagepub.com/doi/10.1042/AN20090020. 
Wang, Z., Gerstein, M. & Snyder, M., 2009. RNA-Seq: a revolutionary tool for 
 221 
transcriptomics. Nature reviews. Genetics, 10(1), pp.57–63. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/19015660. 
Watanabe, K. et al., 1993. Circadian rhythms of vasopressin release in primary cultures of 
rat suprachiasmatic nucleus. Brain research, 624(1–2), pp.115–20. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/8252382. 
Watts, A.G. & Swanson, L.W., 1987. Efferent projections of the suprachiasmatic nucleus: 
II. Studies using retrograde transport of fluorescent dyes and simultaneous peptide 
immunohistochemistry in the rat. The Journal of comparative neurology, 258(2), 
pp.230–52. Available at: http://doi.wiley.com/10.1002/cne.902580205. 
Weger, M. et al., 2013. Real-time in vivo monitoring of circadian E-box enhancer 
activity: A robust and sensitive zebrafish reporter line for developmental, chemical 
and neural biology of the circadian clock. Developmental Biology, 380(2), pp.259–
273. Available at: 
https://www.sciencedirect.com/science/article/pii/S0012160613002303#f0005. 
Weitzman, E.D., 1976. Circadian rhythms and Episodic memory hormone secretion in 
man. Available at: 
https://www.annualreviews.org/doi/pdf/10.1146/annurev.me.27.020176.001301. 
WEITZMAN, E.D. et al., 1983. Cortisol Secretion Is Inhibited during Sleep in Normal 
Man*. The Journal of Clinical Endocrinology & Metabolism, 56(2), pp.352–358. 
Available at: https://academic.oup.com/jcem/article-lookup/doi/10.1210/jcem-56-2-
352. 
WEITZMAN, E.D. et al., 1971. Twenty-four Hour Pattern of the Episodic Secretion of 
Cortisol in Normal Subjects. The Journal of Clinical Endocrinology & Metabolism, 
33(1), pp.14–22. Available at: http://www.ncbi.nlm.nih.gov/pubmed/4326799. 
Welsh, D.K. et al., 1995. Individual neurons dissociated from rat suprachiasmatic nucleus 
express independently phased circadian firing rhythms. Neuron, 14(4), pp.697–706. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/7718233. 
Welsh, D.K., Richardson, G.S. & Dement, W.C., 1985. A circadian rhythm of 
hippocampal theta activity in the mouse. Physiology & Behavior, 35(4), pp.533–538. 
Available at: https://www.sciencedirect.com/science/article/pii/0031938485901362. 
Whitnall, M.H., Kiss, A. & Aguilera, G., 1993. Contrasting effects of central alpha-1-
adrenoreceptor activation on stress-responsive and stress-nonresponsive 
subpopulations of corticotropin-releasing hormone neurosecretory cells in the rat. 
Neuroendocrinology, 58(1), pp.42–8. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/8264854. 
Wilhelm, I. et al., 2011. Sleep Selectively Enhances Memory Expected to Be of Future 
Relevance. Journal of Neuroscience, 31(5), pp.1563–1569. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/21289163. 
Williams, C.M. et al., 2008. Blueberry-induced changes in spatial working memory 
correlate with changes in hippocampal CREB phosphorylation and brain-derived 
neurotrophic factor (BDNF) levels. Free Radical Biology and Medicine, 45(3), 
pp.295–305. Available at: 
https://www.sciencedirect.com/science/article/pii/S0891584908002098. 
Wilson, M.A. & McNaughton, B.L., 1994. Reactivation of hippocampal ensemble 
memories during sleep. Science (New York, N.Y.), 265(5172), pp.676–9. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/8036517. 
Windle, R.J. et al., 1997. Central Oxytocin Administration Reduces Stress-Induced 
Corticosterone Release and Anxiety Behavior in Rats 1. Endocrinology, 138(7), 
pp.2829–2834. Available at: https://academic.oup.com/endo/article-
lookup/doi/10.1210/endo.138.7.5255. 
 222 
Wisor, J.P. et al., 2002. A role for cryptochromes in sleep regulation. BMC neuroscience, 
3, p.20. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12495442. 
Witkovsky, P. et al., 2003. Cellular location and circadian rhythm of expression of the 
biological clock gene Period 1 in the mouse retina. The Journal of neuroscience : the 
official journal of the Society for Neuroscience, 23(20), pp.7670–6. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/12930806. 
Witter, M.P. et al., 2000. Cortico-hippocampal communication by way of parallel 
parahippocampal-subicular pathways. Hippocampus, 10(4), pp.398–410. Available 
at: http://doi.wiley.com/10.1002/1098-
1063%282000%2910%3A4%3C398%3A%3AAID-HIPO6%3E3.0.CO%3B2-K. 
Witter, M.P., 2007. The perforant path: projections from the entorhinal cortex to the 
dentate gyrus. Progress in Brain Research, 163, pp.43–61. Available at: 
https://www.sciencedirect.com/science/article/pii/S0079612307630039. 
Wood, C.M. et al., 2017. Prevalence and influence of cys407* Grm2 mutation in 
Hannover-derived Wistar rats: mGlu2 receptor loss links to alcohol intake, risk 
taking and emotional behaviour. Neuropharmacology, 115, pp.128–138. Available 
at: https://www.sciencedirect.com/science/article/pii/S0028390816300922. 
Wood, E.R. et al., 2000. Hippocampal Neurons Encode Information about Different 
Types of Memory Episodes Occurring in the Same Location. Neuron, 27(3), pp.623–
633. Available at: 
https://www.sciencedirect.com/science/article/pii/S0896627300000714. 
Woon, P.Y. et al., 2007. Aryl hydrocarbon receptor nuclear translocator-like (BMAL1) is 
associated with susceptibility to hypertension and type 2 diabetes. Proceedings of 
the National Academy of Sciences, 104(36), pp.14412–14417. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/17728404. 
Xie, M. et al., 2015. Short-term sleep deprivation impairs spatial working memory and 
modulates expression levels of ionotropic glutamate receptor subunits in 
hippocampus. Behavioural Brain Research, 286, pp.64–70. Available at: 
https://www.sciencedirect.com/science/article/pii/S0166432815001199. 
Xiong, W. et al., 2016. BMAL1 regulates transcription initiation and activates circadian 
clock gene expression in mammals. Biochemical and Biophysical Research 
Communications, 473(4), pp.1019–1025. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/27055591. 
Xu, Y. et al., 2007. Modeling of a Human Circadian Mutation Yields Insights into Clock 
Regulation by PER2. Cell, 128(1), pp.59–70. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/17218255. 
Yabaluri, N. & Bashyam, M.D., 2010. Hormonal regulation of gluconeogenic gene 
transcription in the liver. Journal of biosciences, 35(3), pp.473–84. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/20826956. 
Yamaguchi, S. et al., 2000. Role of DBP in the circadian oscillatory mechanism. 
Molecular and cellular biology, 20(13), pp.4773–81. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10848603. 
Yamaguchi, S. et al., 2003. Synchronization of Cellular Clocks in the Suprachiasmatic 
Nucleus. Science, 302(5649). Available at: 
http://science.sciencemag.org/content/302/5649/1408/tab-pdf. 
Yamamoto, S. et al., 2001. Expression of thePer1 gene in the hamster: Brain atlas and 
circadian characteristics in the suprachiasmatic nucleus. The Journal of Comparative 




Yang, G. et al., 2016. Timing of expression of the core clock gene Bmal1 influences its 
effects on aging and survival. Science Translational Medicine, 8(324), p.324ra16-
324ra16. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26843191. 
Yang, X. et al., 2006. Nuclear Receptor Expression Links the Circadian Clock to 
Metabolism. Cell, 126(4), pp.801–810. Available at: 
https://www.sciencedirect.com/science/article/pii/S0092867406009780. 
Yang, X. et al., 2009. THE CIRCADIAN CLOCK GENE PER1 SUPPRESSES 
CANCER CELL PROLIFERATION AND TUMOR GROWTH AT SPECIFIC 
TIMES OF DAY. Chronobiology International, 26(7), pp.1323–1339. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/19916834. 
Ye, L. et al., 2014. Blocking the Mineralocorticoid Receptor Improves Effectiveness of 




Yeh, K.-T. et al., 2005. Abnormal expression of period 1 (PER1) in endometrial 
carcinoma. The Journal of Pathology, 206(1), pp.111–120. Available at: 
http://doi.wiley.com/10.1002/path.1756. 
Yoshitane, H. et al., 2009. Roles of CLOCK phosphorylation in suppression of E-box-
dependent transcription. Molecular and cellular biology, 29(13), pp.3675–86. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/19414601. 
Young, M.E., Razeghi, P. & Taegtmeyer, H., 2001. Clock genes in the heart: 
characterization and attenuation with hypertrophy. Circulation research, 88(11), 
pp.1142–50. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11397780. 
Young, M.W. et al., 1985. A biological clock in Drosophila. Cold Spring Harbor 
symposia on quantitative biology, 50, pp.865–75. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/3868509. 
Zhang, R. et al., 2014. A circadian gene expression atlas in mammals: implications for 
biology and medicine. Proceedings of the National Academy of Sciences of the 
United States of America, 111(45). 
Zhang, S., Jonklaas, J. & Danielsen, M., 2007. The glucocorticoid agonist activities of 
mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor 
levels but not on EC50 values. Steroids, 72(6–7), pp.600–608. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/17509631. 
Zhao, M. et al., 2010. The neuroretina is a novel mineralocorticoid target: aldosterone up-
regulates ion and water channels in Müller glial cells. The FASEB Journal, 24(9), 
pp.3405–3415. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20466875. 
Zhao, Q. et al., 2016. The clock gene PER1 plays an important role in regulating the 
clock gene network in human oral squamous cell carcinoma cells. Oncotarget, 7(43), 
pp.70290–70302. Available at: http://www.ncbi.nlm.nih.gov/pubmed/27602964. 
Zhao, Z.-D. et al., 2017. A hypothalamic circuit that controls body temperature. 
Proceedings of the National Academy of Sciences of the United States of America, 
114(8), pp.2042–2047. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/28053227. 
Zheng, B. et al., 2001. Nonredundant roles of the mPer1 and mPer2 genes in the 
mammalian circadian clock. Cell, 105(5), pp.683–94. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11389837. 
Zheng, X. et al., 2014. Casein Kinase 1 Promotes Synchrony of the Circadian Clock 
Network. Molecular and Cellular Biology, 34(14), pp.2682–2694. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/24820422. 
 224 
Zhou, Q.-Y. & Cheng, M.Y., 2005. Prokineticin 2 and circadian clock output. FEBS 
Journal, 272(22), pp.5703–5709. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16279936. 
Zhou, Y.D. et al., 1997. Molecular characterization of two mammalian bHLH-PAS 
domain proteins selectively expressed in the central nervous system. Proceedings of 
the National Academy of Sciences of the United States of America, 94(2), pp.713–8. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/9012850. 
Zhou, Z., Chadt, A. & Al-Hasani, H., 2014. Tuning in to the rhythm of clock genes in 
skeletal muscle. Molecular metabolism, 3(1), pp.1–2. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/24567898. 
Zmrzljak, U.P. et al., 2013. Inducible cAMP early repressor regulates the Period 1 gene 
of the hepatic and adrenal clocks. The Journal of biological chemistry, 288(15), 
pp.10318–27. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23443664. 
Zola-Morgan, S., Squire, L.R. & Amaral, D.G., 1986. Human amnesia and the medial 
temporal region: enduring memory impairment following a bilateral lesion limited to 
field CA1 of the hippocampus. The Journal of neuroscience : the official journal of 
the Society for Neuroscience, 6(10), pp.2950–67. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/3760943. 
Zorzon, M. et al., 2005. Long-term effects of intravenous high dose methylprednisolone 
pulses on bone mineral density in patients with multiple sclerosis. European Journal 
of Neurology, 12(7), pp.550–556. Available at: http://doi.wiley.com/10.1111/j.1468-
1331.2005.00988. 
 
